{"PMC7118892": [["Characteristics of bioaerosolsThe characteristics of bioaerosols have been described previously.16., 17., 18.", [["bioaerosols", "CANCER", 53, 64], ["bioaerosols", "PROBLEM", 53, 64], ["bioaerosols", "OBSERVATION", 19, 30], ["bioaerosols", "OBSERVATION", 53, 64]]], ["Although the aerosol properties of bioaerosols are generally considered similar to nonbioaerosols, respirator selection and maintenance are complicated by the biologic nature.", [["bioaerosols", "SIMPLE_CHEMICAL", 35, 46], ["nonbioaerosols", "TREATMENT", 83, 97], ["respirator selection", "TREATMENT", 99, 119], ["bioaerosols", "OBSERVATION", 35, 46]]], ["Bioaerosols include bacteria, viruses, fungi, algae, and dust mites.", [["algae", "ANATOMY", 46, 51], ["bacteria", "PROBLEM", 20, 28], ["viruses", "PROBLEM", 30, 37], ["fungi", "PROBLEM", 39, 44], ["bacteria", "OBSERVATION", 20, 28], ["viruses", "OBSERVATION", 30, 37]]], ["In addition, biologic products such as pollen, endotoxins, proteins, and animal excreta form aerosols.", [["pollen", "ANATOMY", 39, 45], ["biologic products", "TREATMENT", 13, 30], ["pollen, endotoxins, proteins", "TEST", 39, 67]]], ["Both viable and nonviable forms of bioaerosols can be health hazardous.", [["bioaerosols", "DISEASE", 35, 46], ["nonviable", "OBSERVATION_MODIFIER", 16, 25], ["bioaerosols", "OBSERVATION", 35, 46]]], ["The infectious bioaerosols produce adverse health effects because of their ability to incubate, grow, multiply, and produce toxic substances.", [["The infectious bioaerosols", "PROBLEM", 0, 26], ["toxic substances", "PROBLEM", 124, 140], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["toxic substances", "OBSERVATION", 124, 140]]], ["The health effects because of inhalation of bioaerosols depend on the number of viable particles, whereas the nonbioaerosols depend mostly on the mass of particles.", [["inhalation of bioaerosols", "PROBLEM", 30, 55], ["the nonbioaerosols depend", "PROBLEM", 106, 131], ["the mass of particles", "PROBLEM", 142, 163], ["bioaerosols", "OBSERVATION", 44, 55], ["viable", "OBSERVATION_MODIFIER", 80, 86], ["particles", "OBSERVATION", 87, 96], ["mass", "OBSERVATION", 146, 150]]], ["Bioaerosols are sometimes employed in terrorism events.", [["Bioaerosols", "DISEASE", 0, 11]]], ["Terrorists utilize the unique features of microorganisms to cause psychologic shock on society and catastrophic effects.", [["shock", "DISEASE", 78, 83], ["microorganisms", "PROBLEM", 42, 56], ["psychologic shock", "PROBLEM", 66, 83], ["catastrophic effects", "PROBLEM", 99, 119], ["catastrophic effects", "OBSERVATION", 99, 119]]], ["This suggests that respirator selection, cleaning, and reuse need to be carefully considered for a better respiratory protection against bioaerosol exposures.Filter efficiency against biologic agentsSeveral studies have reviewed the role of respiratory protective devices in the control of TB in health care settings.19., 20., 21., 22.", [["respiratory", "ANATOMY", 106, 117], ["respiratory", "ANATOMY", 241, 252], ["TB", "DISEASE", 290, 292], ["bioaerosol", "SIMPLE_CHEMICAL", 137, 147], ["respirator selection", "TREATMENT", 19, 39], ["Filter efficiency", "TREATMENT", 158, 175], ["biologic agents", "TREATMENT", 184, 199], ["Several studies", "TEST", 199, 214], ["respiratory protective devices", "TREATMENT", 241, 271], ["respirator selection", "OBSERVATION", 19, 39]]], ["Studies on respiratory protection against TB were carried out with nonpathogenic bacteria having physical characteristics similar to that of M tuberculosis.", [["respiratory", "ANATOMY", 11, 22], ["TB", "DISEASE", 42, 44], ["tuberculosis", "DISEASE", 143, 155], ["M tuberculosis", "SPECIES", 141, 155], ["M tuberculosis", "SPECIES", 141, 155], ["respiratory protection", "TEST", 11, 33], ["TB", "PROBLEM", 42, 44], ["nonpathogenic bacteria", "PROBLEM", 67, 89], ["M tuberculosis", "PROBLEM", 141, 155], ["tuberculosis", "OBSERVATION", 143, 155]]], ["Two decades ago, conventional surgical masks were believed to be effective barriers for retaining large droplets expelled from patients as well as from health care workers through speaking, coughing, or sneezing.", [["coughing", "DISEASE", 190, 198], ["sneezing", "DISEASE", 203, 211], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["conventional surgical masks", "TREATMENT", 17, 44], ["retaining large droplets", "PROBLEM", 88, 112], ["coughing", "PROBLEM", 190, 198], ["sneezing", "PROBLEM", 203, 211], ["surgical masks", "OBSERVATION", 30, 44], ["large", "OBSERVATION_MODIFIER", 98, 103], ["droplets", "OBSERVATION", 104, 112]]], ["However, surgical masks were not adequate to remove submicrometer-size bioaerosols.23., 24.", [["surgical masks", "TREATMENT", 9, 23], ["size", "OBSERVATION_MODIFIER", 66, 70], ["bioaerosols", "OBSERVATION", 71, 82]]], ["The measurement of filtration efficiencies of different respirators against Mycobacterium chelonae another surrogate bacteria of M tuberculosis, showed that DMF and a HEPA were more effective than the DM and single-use submicron surgical mask under a constant flow of 46 L/min.25 Mean percentage efficiencies for viable M chelonae ranged from 97% for the DM and the surgical mask to more than 99.99% for the HEPA respirator.25", [["tuberculosis", "DISEASE", 131, 143], ["DMF", "CHEMICAL", 157, 160], ["DM", "DISEASE", 355, 357], ["DMF", "CHEMICAL", 157, 160], ["Mycobacterium chelonae", "ORGANISM", 76, 98], ["DMF", "SIMPLE_CHEMICAL", 157, 160], ["Mycobacterium chelonae", "SPECIES", 76, 98], ["M tuberculosis", "SPECIES", 129, 143], ["M chelonae", "SPECIES", 320, 330], ["Mycobacterium chelonae", "SPECIES", 76, 98], ["M tuberculosis", "SPECIES", 129, 143], ["M chelonae", "SPECIES", 320, 330], ["filtration efficiencies", "TREATMENT", 19, 42], ["different respirators", "TREATMENT", 46, 67], ["Mycobacterium chelonae", "PROBLEM", 76, 98], ["M tuberculosis", "PROBLEM", 129, 143], ["DMF", "PROBLEM", 157, 160], ["a HEPA", "TREATMENT", 165, 171], ["the DM", "PROBLEM", 197, 203], ["submicron surgical mask", "TREATMENT", 219, 242], ["a constant flow", "TREATMENT", 249, 264], ["Mean percentage efficiencies", "TREATMENT", 280, 308], ["viable M chelonae", "TEST", 313, 330], ["the DM", "PROBLEM", 351, 357], ["the surgical mask", "TREATMENT", 362, 379], ["the HEPA respirator", "TREATMENT", 404, 423], ["filtration efficiencies", "OBSERVATION", 19, 42], ["Mycobacterium chelonae", "OBSERVATION", 76, 98], ["tuberculosis", "OBSERVATION", 131, 143], ["surgical mask", "OBSERVATION", 366, 379]]]], "fcab591bcffca97c7a342d7a55cca5d47d59157f": [["The novelty and fast spread of the SARS-CoV-2, have made it impossible to 1 scientifically determine the best approach for its management and to take evidence-2 based political measures to try to tackle it 1 .", [["SARS", "DISEASE", 35, 39], ["SARS-CoV", "SPECIES", 35, 43], ["its management", "TREATMENT", 123, 137], ["political measures", "TREATMENT", 167, 185]]], ["Several countries worldwide, have adopted 3 political measures of confinement of the population and restriction of free movement 4 within their territories to mitigate the collapse of their healthcare systems 1 .", [["collapse", "OBSERVATION", 172, 180]]], ["In this 5 scenario of countries\u00b4 quarantine and of lack of healthcare resources, a potentially 6 effective and efficient alternative to provide health care for non-critical patients with a 7 confirmed SARS-COV-2 infection, is the promotion of Hospital-at-Home (HaH) 8 services.9HaH is a healthcare modality that administers specialized medical care to patients 10 within their own homes, for illnesses that usually would require a hospitalization 2-4 .11This healthcare modality has been successfully used for the treatment of acute 12 exacerbations of chronic respiratory diseases, as is the clinical presentation of a great 13 number of SARS-CoV-2 infected patients 5,6 .", [["respiratory", "ANATOMY", 561, 572], ["SARS", "DISEASE", 201, 205], ["infection", "DISEASE", 212, 221], ["HaH", "CHEMICAL", 278, 281], ["chronic respiratory diseases", "DISEASE", 553, 581], ["SARS-CoV-2 infected", "DISEASE", 639, 658], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 352, 360], ["SARS-CoV-2", "ORGANISM", 639, 649], ["patients", "ORGANISM", 659, 667], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 352, 360], ["patients", "SPECIES", 659, 667], ["SARS", "PROBLEM", 201, 205], ["COV-2 infection", "PROBLEM", 206, 221], ["illnesses", "PROBLEM", 392, 401], ["acute 12 exacerbations", "PROBLEM", 527, 549], ["chronic respiratory diseases", "PROBLEM", 553, 581], ["SARS", "PROBLEM", 639, 643], ["CoV", "TEST", 644, 647], ["infection", "OBSERVATION", 212, 221], ["acute", "OBSERVATION_MODIFIER", 527, 532], ["chronic", "OBSERVATION_MODIFIER", 553, 560], ["respiratory diseases", "OBSERVATION", 561, 581]]], ["Furthermore, it have shown at least non-14 inferiority in comparison to traditional hospital in-patient treatment options 2,5-7 .", [["patient", "ORGANISM", 96, 103], ["2,5-7", "SIMPLE_CHEMICAL", 122, 127], ["patient", "SPECIES", 96, 103], ["patient treatment options", "TREATMENT", 96, 121]]], ["In a 15 context of lack of evidence on SARS-CoV-2, and given its similarity with viral 16 infections (e.g., picornaviruses or influenza A) that are a major cause of acute 17 respiratory exacerbations 8,9 , it is reasonable to assume that HaH could be an effective 18 option for its management 5,7 .", [["SARS", "DISEASE", 39, 43], ["viral 16 infections", "DISEASE", 81, 100], ["influenza A", "DISEASE", 126, 137], ["HaH", "CHEMICAL", 238, 241], ["influenza A", "ORGANISM", 126, 137], ["HaH", "SIMPLE_CHEMICAL", 238, 241], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47], ["viral 16 infections", "PROBLEM", 81, 100], ["picornaviruses", "PROBLEM", 108, 122], ["influenza A", "PROBLEM", 126, 137], ["acute 17 respiratory exacerbations", "PROBLEM", 165, 199], ["its management", "TREATMENT", 278, 292], ["infections", "OBSERVATION", 90, 100], ["acute", "OBSERVATION_MODIFIER", 165, 170]]]], "PMC7241588": [["Two phenotypes for one pathophysiologyTwo phenotypes have recently been suggested to describe the clinical features of respiratory failure in COVID-19\u2014a low elastance (L-type) phenotype and a high elastance (H-type) phenotype.11-13 As the elastance is the inverse of the compliance, the L-type indicates high compliance, and the H-type the opposite.", [["respiratory", "ANATOMY", 119, 130], ["respiratory failure", "DISEASE", 119, 138], ["Two phenotypes", "PROBLEM", 38, 52], ["respiratory failure", "PROBLEM", 119, 138], ["COVID", "TEST", 142, 147], ["low elastance (L-type) phenotype", "PROBLEM", 153, 185], ["a high elastance (H-type) phenotype.", "PROBLEM", 190, 226], ["respiratory failure", "OBSERVATION", 119, 138], ["high elastance", "OBSERVATION_MODIFIER", 192, 206], ["high compliance", "OBSERVATION", 304, 319]]], ["The phenotype\u2019s differing presentations are based on viral load timing, comorbidities, and likely genetic determinants of the response to hypoxemia.13 The L-type is the most common phenotype (> 50%).13 Those patients present with hypoxemia and hypocapnia but without dyspnea.", [["hypoxemia", "DISEASE", 138, 147], ["hypoxemia", "DISEASE", 230, 239], ["hypocapnia", "DISEASE", 244, 254], ["dyspnea", "DISEASE", 267, 274], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["viral load timing", "TREATMENT", 53, 70], ["comorbidities", "PROBLEM", 72, 85], ["hypoxemia", "PROBLEM", 138, 147], ["hypoxemia", "PROBLEM", 230, 239], ["hypocapnia", "PROBLEM", 244, 254], ["dyspnea", "PROBLEM", 267, 274], ["hypoxemia", "OBSERVATION", 138, 147], ["most common", "OBSERVATION_MODIFIER", 169, 180], ["hypoxemia", "OBSERVATION", 230, 239], ["hypocapnia", "OBSERVATION", 244, 254], ["without", "UNCERTAINTY", 259, 266], ["dyspnea", "OBSERVATION", 267, 274]]], ["They have normal respiratory system mechanics, hence the reported term by several emergency physicians of \u201chappy hypoxic COVID\u201d because, despite significant oxygen desaturation, the patient remains alert and able to talk.", [["respiratory system", "ANATOMY", 17, 35], ["oxygen", "CHEMICAL", 157, 163], ["oxygen", "CHEMICAL", 157, 163], ["oxygen", "SIMPLE_CHEMICAL", 157, 163], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 182, 189], ["significant oxygen desaturation", "PROBLEM", 145, 176], ["normal", "OBSERVATION", 10, 16], ["respiratory system mechanics", "OBSERVATION", 17, 45], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["oxygen desaturation", "OBSERVATION", 157, 176]]], ["While some may keep a normal respiratory drive, others may exhibit a significantly increased respiratory drive, which could induce a patient self-inflicted lung injury (P-SILI).14-18 Hypoxemia in the L-type phenotype is thought to result from a ventilation-perfusion mismatch and loss of hypoxic vasoconstriction leading to shunt fraction up to 50%.11 As reported in the acute respiratory system (ARDS), the severity seems to correlate with the difference between the end-tidal carbon dioxide and the arterial partial pressure of carbon dioxide (PaCO2), which is an indirect measure of dead-space.19 The CT and chest radiographs reveal well-aerated compartments, patchy disease and ground-glass opacities with some peripheral involvement.20Two phenotypes for one pathophysiologyThe high elastance (H-type) is more consistent with a classical picture of ARDS from non-COVID-19 settings.", [["respiratory", "ANATOMY", 29, 40], ["respiratory", "ANATOMY", 93, 104], ["lung", "ANATOMY", 156, 160], ["arterial", "ANATOMY", 501, 509], ["chest", "ANATOMY", 611, 616], ["lung injury", "DISEASE", 156, 167], ["Hypoxemia", "DISEASE", 183, 192], ["acute respiratory system", "DISEASE", 371, 395], ["ARDS", "DISEASE", 397, 401], ["carbon dioxide", "CHEMICAL", 478, 492], ["carbon dioxide", "CHEMICAL", 530, 544], ["ARDS", "DISEASE", 853, 857], ["carbon dioxide", "CHEMICAL", 478, 492], ["carbon dioxide", "CHEMICAL", 530, 544], ["PaCO2", "CHEMICAL", 546, 551], ["patient", "ORGANISM", 133, 140], ["lung", "ORGAN", 156, 160], ["arterial", "MULTI-TISSUE_STRUCTURE", 501, 509], ["carbon dioxide", "SIMPLE_CHEMICAL", 530, 544], ["PaCO2", "SIMPLE_CHEMICAL", 546, 551], ["patient", "SPECIES", 133, 140], ["a significantly increased respiratory drive", "PROBLEM", 67, 110], ["a patient self-inflicted lung injury", "PROBLEM", 131, 167], ["Hypoxemia", "PROBLEM", 183, 192], ["a ventilation", "TREATMENT", 243, 256], ["perfusion mismatch", "PROBLEM", 257, 275], ["hypoxic vasoconstriction", "PROBLEM", 288, 312], ["shunt fraction", "TEST", 324, 338], ["the acute respiratory system", "PROBLEM", 367, 395], ["the end-tidal carbon dioxide", "TREATMENT", 464, 492], ["the arterial partial pressure of carbon dioxide", "TREATMENT", 497, 544], ["PaCO2", "TEST", 546, 551], ["The CT and chest radiographs", "TEST", 600, 628], ["patchy disease", "PROBLEM", 663, 677], ["ground-glass opacities", "PROBLEM", 682, 704], ["some peripheral involvement", "PROBLEM", 710, 737], ["ARDS", "PROBLEM", 853, 857], ["non-COVID", "TEST", 863, 872], ["respiratory drive", "OBSERVATION", 29, 46], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["respiratory drive", "OBSERVATION", 93, 110], ["lung", "ANATOMY", 156, 160], ["injury", "OBSERVATION", 161, 167], ["thought to result", "UNCERTAINTY", 220, 237], ["perfusion mismatch", "OBSERVATION", 257, 275], ["hypoxic vasoconstriction", "OBSERVATION", 288, 312], ["shunt fraction", "OBSERVATION", 324, 338], ["acute", "OBSERVATION_MODIFIER", 371, 376], ["respiratory system", "ANATOMY", 377, 395], ["ARDS", "OBSERVATION", 397, 401], ["arterial", "ANATOMY", 501, 509], ["partial", "OBSERVATION_MODIFIER", 510, 517], ["pressure", "OBSERVATION_MODIFIER", 518, 526], ["carbon dioxide", "OBSERVATION", 530, 544], ["chest", "ANATOMY", 611, 616], ["aerated", "OBSERVATION", 641, 648], ["patchy", "OBSERVATION_MODIFIER", 663, 669], ["disease", "OBSERVATION", 670, 677], ["ground-glass opacities", "OBSERVATION", 682, 704], ["some", "OBSERVATION_MODIFIER", 710, 714], ["peripheral", "OBSERVATION_MODIFIER", 715, 725], ["involvement", "OBSERVATION", 726, 737], ["high", "OBSERVATION_MODIFIER", 782, 786], ["elastance", "OBSERVATION", 787, 796], ["more consistent with", "UNCERTAINTY", 809, 829], ["ARDS", "OBSERVATION", 853, 857]]], ["Hypoxemia in those patients is a result of shunting through the consolidated regions of the lung, which is more important than in the L-type.", [["lung", "ANATOMY", 92, 96], ["Hypoxemia", "DISEASE", 0, 9], ["patients", "ORGANISM", 19, 27], ["lung", "ORGAN", 92, 96], ["patients", "SPECIES", 19, 27], ["Hypoxemia", "PROBLEM", 0, 9], ["shunting through the consolidated regions of the lung", "PROBLEM", 43, 96], ["shunting", "OBSERVATION", 43, 51], ["consolidated", "OBSERVATION", 64, 76], ["regions", "ANATOMY_MODIFIER", 77, 84], ["lung", "ANATOMY", 92, 96], ["more", "OBSERVATION_MODIFIER", 107, 111], ["important", "OBSERVATION_MODIFIER", 112, 121]]], ["As those clinical manifestations are different, the treatment will vary according to the predominant pattern.", [["the treatment", "TREATMENT", 48, 61], ["predominant pattern", "OBSERVATION", 89, 108]]], ["Notably, a transition from L-type to H-type may evolve because of progression of COVID-19 pneumonia, injurious mechanical ventilation, and/or P-SILI.14-18 Regression from an H-type to L-type or gradual normalization has also been observed with CT during recovery (Fig. 1).20,21Proposed management algorithmFigure 2 outlines a proposed management algorithm for a rational approach to ventilatory support of COVID-19 patients with acute respiratory failure.", [["respiratory", "ANATOMY", 435, 446], ["pneumonia", "DISEASE", 90, 99], ["acute respiratory failure", "DISEASE", 429, 454], ["patients", "ORGANISM", 415, 423], ["patients", "SPECIES", 415, 423], ["COVID", "TEST", 81, 86], ["pneumonia", "PROBLEM", 90, 99], ["injurious mechanical ventilation", "TREATMENT", 101, 133], ["P", "TEST", 142, 143], ["SILI", "TEST", 144, 148], ["CT", "TEST", 244, 246], ["Proposed management algorithmFigure", "TREATMENT", 277, 312], ["a proposed management algorithm", "TREATMENT", 324, 355], ["a rational approach", "TREATMENT", 360, 379], ["ventilatory support", "TREATMENT", 383, 402], ["acute respiratory failure", "PROBLEM", 429, 454], ["pneumonia", "OBSERVATION", 90, 99], ["injurious", "OBSERVATION_MODIFIER", 101, 110], ["mechanical ventilation", "OBSERVATION", 111, 133], ["gradual", "OBSERVATION_MODIFIER", 194, 201], ["normalization", "OBSERVATION", 202, 215], ["acute", "OBSERVATION_MODIFIER", 429, 434], ["respiratory failure", "OBSERVATION", 435, 454]]], ["Although it will need careful prospective clinical evaluation, it can be considered an \u201coutside the box\u201d perspective in this new clinical frontier.", [["careful prospective clinical evaluation", "TEST", 22, 61]]], ["Its purpose is to help clarify the importance in ventilation strategies, which will be very different for the two ARDS phenotypes seen in COVID-19.Ventilation strategies for different phenotypesWe propose that the algorithm be initiated when oxygen therapy is needed to correct symptomatic hypoxemia in COVID-19 patients with acute respiratory failure\u2014e.g., when hypoxemia occurs that is refractory to oxygen therapy with a high-flow nasal cannula (HFNC) with an increased fraction of inspired oxygen (FiO2).", [["respiratory", "ANATOMY", 332, 343], ["nasal", "ANATOMY", 434, 439], ["ARDS", "DISEASE", 114, 118], ["oxygen", "CHEMICAL", 242, 248], ["hypoxemia", "DISEASE", 290, 299], ["hypoxemia", "DISEASE", 363, 372], ["oxygen", "CHEMICAL", 402, 408], ["oxygen", "CHEMICAL", 494, 500], ["FiO2", "CHEMICAL", 502, 506], ["oxygen", "CHEMICAL", 242, 248], ["oxygen", "CHEMICAL", 402, 408], ["oxygen", "CHEMICAL", 494, 500], ["FiO2", "CHEMICAL", 502, 506], ["oxygen", "SIMPLE_CHEMICAL", 242, 248], ["patients", "ORGANISM", 312, 320], ["oxygen", "SIMPLE_CHEMICAL", 402, 408], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 434, 447], ["oxygen", "SIMPLE_CHEMICAL", 494, 500], ["FiO2", "SIMPLE_CHEMICAL", 502, 506], ["patients", "SPECIES", 312, 320], ["ventilation strategies", "TREATMENT", 49, 71], ["the two ARDS phenotypes", "PROBLEM", 106, 129], ["COVID", "TEST", 138, 143], ["Ventilation strategies", "TREATMENT", 147, 169], ["different phenotypesWe propose", "TREATMENT", 174, 204], ["the algorithm", "TREATMENT", 210, 223], ["oxygen therapy", "TREATMENT", 242, 256], ["symptomatic hypoxemia", "PROBLEM", 278, 299], ["acute respiratory failure\u2014e.g.", "PROBLEM", 326, 356], ["hypoxemia", "PROBLEM", 363, 372], ["oxygen therapy", "TREATMENT", 402, 416], ["a high-flow nasal cannula (HFNC", "TREATMENT", 422, 453], ["an increased fraction", "TREATMENT", 460, 481], ["inspired oxygen (FiO2", "TREATMENT", 485, 506], ["symptomatic", "OBSERVATION_MODIFIER", 278, 289], ["hypoxemia", "OBSERVATION", 290, 299], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["respiratory failure\u2014e.g.", "OBSERVATION", 332, 356], ["hypoxemia", "OBSERVATION", 363, 372], ["refractory", "OBSERVATION_MODIFIER", 388, 398], ["oxygen therapy", "OBSERVATION", 402, 416], ["increased", "OBSERVATION_MODIFIER", 463, 472], ["fraction", "OBSERVATION_MODIFIER", 473, 481], ["inspired oxygen", "OBSERVATION", 485, 500]]], ["Traditionally, the response to oxygen therapy is assessed with the oxygen partial pressure (PaO2)/FiO2 ratio22 or alternatively, when using peripheral pulse oximetry (SpO2), the SpO2/FiO2.23 Even though these ratios are well documented, they do not take into account the underlying respiratory workload.", [["respiratory", "ANATOMY", 282, 293], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["oxygen therapy", "TREATMENT", 31, 45], ["the oxygen partial pressure", "TREATMENT", 63, 90], ["PaO2", "TEST", 92, 96], ["FiO2", "TREATMENT", 98, 102], ["peripheral pulse oximetry", "TEST", 140, 165], ["SpO2", "TEST", 167, 171], ["the SpO2", "TEST", 174, 182], ["oxygen therapy", "OBSERVATION", 31, 45], ["respiratory workload", "OBSERVATION", 282, 302]]], ["A PaO2/FiO2 \u2264 150 mmHg is considered a severe hypoxemic state and mandates close clinical supervision and intervention.", [["FiO2", "CHEMICAL", 7, 11], ["A PaO2", "TEST", 0, 6], ["FiO2", "TEST", 7, 11], ["a severe hypoxemic state", "PROBLEM", 37, 61], ["intervention", "TREATMENT", 106, 118], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["hypoxemic", "OBSERVATION", 46, 55]]], ["The medical community is now supporting the use of HFNC as a clinically accepted adjunct approach to treating hypoxemia in COVID-19 patients.24 The literature from HFNC technology proposes a novel index, validated as a prognostic outcome of short-term HFNC therapy.", [["hypoxemia", "DISEASE", 110, 119], ["HFNC", "DISEASE", 252, 256], ["HFNC", "SIMPLE_CHEMICAL", 51, 55], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["HFNC", "TREATMENT", 51, 55], ["adjunct approach", "TREATMENT", 81, 97], ["hypoxemia", "PROBLEM", 110, 119], ["HFNC technology", "TREATMENT", 164, 179], ["short-term HFNC therapy", "TREATMENT", 241, 264], ["hypoxemia", "OBSERVATION", 110, 119]]], ["This respiratory rate and oxygenation (ROX) index is based on the traditional PaO2/FiO2 ratio, but is then coupled with the respiratory rate.23,25 For practical bedside use, PaO2 is substituted for SpO2, so the ROX index is defined as the ([SpO2/FiO2]/respiratory rate).", [["respiratory", "ANATOMY", 5, 16], ["respiratory", "ANATOMY", 124, 135], ["FiO2", "CHEMICAL", 83, 87], ["PaO2", "CHEMICAL", 174, 178], ["FiO2", "CHEMICAL", 246, 250], ["PaO2", "SIMPLE_CHEMICAL", 174, 178], ["ROX", "SIMPLE_CHEMICAL", 211, 214], ["This respiratory rate", "TEST", 0, 21], ["the traditional PaO2", "TEST", 62, 82], ["FiO2 ratio", "TEST", 83, 93], ["the respiratory rate", "TEST", 120, 140], ["PaO2", "TEST", 174, 178], ["SpO2", "TEST", 198, 202], ["the ROX index", "TEST", 207, 220], ["SpO2", "TEST", 241, 245], ["FiO2", "TEST", 246, 250], ["respiratory rate", "TEST", 252, 268], ["oxygenation", "OBSERVATION_MODIFIER", 26, 37], ["respiratory rate", "OBSERVATION", 124, 140]]], ["It can be calculated using an online tool (https://qxmd.com/calculate/calculator_724/rox-index-to-predict-risk-of-intubation).Ventilation strategies for different phenotypesAs an example, a patient with an SpO2 of 80%, an FiO2 of 0.8, and an respiratory rate of 35/min ([80/0.8]/35) will have a ROX index of 2.8.", [["patient", "ORGANISM", 190, 197], ["patient", "SPECIES", 190, 197], ["an online tool", "TEST", 27, 41], ["Ventilation strategies", "TREATMENT", 126, 148], ["an SpO2", "TEST", 203, 210], ["an FiO2", "TEST", 219, 226], ["an respiratory rate", "TEST", 239, 258], ["a ROX index", "TEST", 293, 304]]], ["As the respiratory condition deteriorates, the ROX index decreases.Ventilation strategies for different phenotypesRoca et al. have suggested various ROX index cut-off values that are associated with the need for intubation.23 Values below 2.85, 3.47, and 3.85 are the cut-off values used at two, six, and twelve hour, respectively.", [["respiratory", "ANATOMY", 7, 18], ["ROX", "CHEMICAL", 47, 50], ["ROX", "GENE_OR_GENE_PRODUCT", 47, 50], ["ROX", "SIMPLE_CHEMICAL", 149, 152], ["the respiratory condition", "PROBLEM", 3, 28], ["the ROX index", "TEST", 43, 56], ["Ventilation strategies", "TREATMENT", 67, 89], ["different phenotypesRoca et al", "PROBLEM", 94, 124], ["various ROX index cut", "TREATMENT", 141, 162], ["intubation", "TREATMENT", 212, 222], ["Values", "TEST", 226, 232], ["ROX index", "OBSERVATION", 47, 56], ["various", "OBSERVATION_MODIFIER", 141, 148], ["ROX", "OBSERVATION_MODIFIER", 149, 152], ["index", "OBSERVATION_MODIFIER", 153, 158]]], ["No predictive index is perfect, and a gray zone obviously exists between 3.85 and 4.88, in which it is difficult to firmly conclude what the optimal management should be.", [["a gray zone", "TEST", 36, 47], ["predictive", "OBSERVATION_MODIFIER", 3, 13], ["index", "OBSERVATION", 14, 19]]], ["However, monitoring the ROX index over time, with emphasis from the 12th hour onwards, suggests that if the ROX index is \u2265 4.88, then the patient has a high chance of avoiding intubation.", [["ROX", "GENE_OR_GENE_PRODUCT", 24, 27], ["ROX", "GENE_OR_GENE_PRODUCT", 108, 111], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["monitoring the ROX index", "TEST", 9, 33], ["the ROX index", "TEST", 104, 117], ["intubation", "TREATMENT", 176, 186]]], ["If the ROX index is < 3.85, then the risk of HFNC failure is high.", [["HFNC", "DISEASE", 45, 49], ["ROX", "GENE_OR_GENE_PRODUCT", 7, 10], ["HFNC", "CANCER", 45, 49], ["the ROX index", "TEST", 3, 16], ["HFNC failure", "PROBLEM", 45, 57], ["HFNC failure", "OBSERVATION", 45, 57], ["high", "OBSERVATION_MODIFIER", 61, 65]]], ["In the initial study of the ROX index23 among patients in this zone, the ROX index could be repeated one or two hours later.", [["ROX", "CHEMICAL", 28, 31], ["ROX", "CHEMICAL", 73, 76], ["ROX index23", "GENE_OR_GENE_PRODUCT", 28, 39], ["patients", "ORGANISM", 46, 54], ["ROX", "GENE_OR_GENE_PRODUCT", 73, 76], ["ROX index23", "DNA", 28, 39], ["patients", "SPECIES", 46, 54], ["the ROX index", "TEST", 69, 82]]], ["If the score has increased, the patient should be considered with a higher likelihood of avoiding intubation.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["intubation", "TREATMENT", 98, 108], ["increased", "OBSERVATION_MODIFIER", 17, 26]]], ["If it has decreased, then intubation has a higher likelihood to be necessary.", [["intubation", "TREATMENT", 26, 36], ["decreased", "OBSERVATION_MODIFIER", 10, 19]]], ["If the score is unchanged, then reassessment should be performed after one or two more hours.", [["reassessment", "TEST", 32, 44], ["unchanged", "OBSERVATION_MODIFIER", 16, 25]]], ["The ROX index has recently been implemented by one of the authors (N.P.) and is being considered, along with advice from other experts in mechanical ventilation, by the French Ministry of Health, who have arbitrarily decided to re-assess the ROX index every 30 min.26 They have chosen a change in the ROX index of 0.5 to monitor the rapid onset of symptoms in the average COVID-19 patient compared with the usual ARDS patient.", [["ROX", "CHEMICAL", 4, 7], ["ROX", "CHEMICAL", 242, 245], ["ARDS", "DISEASE", 413, 417], ["ROX", "GENE_OR_GENE_PRODUCT", 4, 7], ["patient", "ORGANISM", 381, 388], ["patient", "ORGANISM", 418, 425], ["patient", "SPECIES", 381, 388], ["patient", "SPECIES", 418, 425], ["The ROX index", "TEST", 0, 13], ["mechanical ventilation", "TREATMENT", 138, 160], ["the ROX index", "TEST", 297, 310], ["symptoms", "PROBLEM", 348, 356], ["ROX index", "OBSERVATION", 4, 13], ["mechanical ventilation", "OBSERVATION", 138, 160], ["ARDS", "OBSERVATION", 413, 417]]], ["Therefore, a reduction of the ROX index by 0.5 from baseline over 30 min is considered significant and may suggest imminent need for intubation.23,25,26 Indeed, such a strategy obviously requires a prospective evaluation.Role of lung ultrasound monitoringFollowing the initiation of mechanical ventilation, it becomes important to discriminate between type-L vs type-H ARDS phenotypes for proper ventilator strategies as proposed by Marini et al.27 This is where lung ultrasound can be useful.Role of lung ultrasound monitoringThe sensitivity and specificity of lung ultrasound findings for COVID-19 remains to be determined.", [["lung", "ANATOMY", 229, 233], ["lung", "ANATOMY", 463, 467], ["lung", "ANATOMY", 501, 505], ["lung", "ANATOMY", 562, 566], ["ROX", "CHEMICAL", 30, 33], ["ARDS", "DISEASE", 369, 373], ["ROX", "GENE_OR_GENE_PRODUCT", 30, 33], ["lung", "ORGAN", 229, 233], ["lung", "ORGAN", 463, 467], ["lung", "ORGAN", 501, 505], ["lung", "ORGAN", 562, 566], ["the ROX index", "TEST", 26, 39], ["intubation", "TREATMENT", 133, 143], ["a prospective evaluation", "TEST", 196, 220], ["lung ultrasound monitoring", "TEST", 229, 255], ["mechanical ventilation", "TREATMENT", 283, 305], ["type-H ARDS phenotypes", "PROBLEM", 362, 384], ["proper ventilator strategies", "TREATMENT", 389, 417], ["lung ultrasound", "TEST", 463, 478], ["lung ultrasound monitoring", "TEST", 501, 527], ["The sensitivity", "TEST", 527, 542], ["lung ultrasound findings", "TEST", 562, 586], ["COVID", "TEST", 591, 596], ["reduction", "OBSERVATION_MODIFIER", 13, 22], ["ROX", "OBSERVATION_MODIFIER", 30, 33], ["index", "OBSERVATION_MODIFIER", 34, 39], ["may suggest", "UNCERTAINTY", 103, 114], ["lung", "ANATOMY", 229, 233], ["lung", "ANATOMY", 463, 467], ["lung", "ANATOMY", 501, 505], ["lung", "ANATOMY", 562, 566]]], ["Nevertheless, based on several case series,7,8,28-30 editorials/commentaries,9,10,31-35 a recent narrative review,36 and the authors own experience, four basic ultrasound patterns can be observed: 1) normal pattern (A lines and < 3 B-lines); 2) mild disease: \u2265 3 B-lines with some of them being confluent (waterfall or beam like)34 (Fig. 3A) and thickened pleura suggestive of an L-type; 3) broken pleural lines (Fig. 3B) with B-lines; and 4) severe disease with subpleural consolidation (Fig. 3C,3D) and a typical ARDS picture.Role of lung ultrasound monitoringThe fourth pattern is more suggestive of an H-type.", [["A lines", "ANATOMY", 216, 223], ["B-lines", "ANATOMY", 232, 239], ["pleura", "ANATOMY", 356, 362], ["pleural lines", "ANATOMY", 398, 411], ["B-lines", "ANATOMY", 427, 434], ["subpleural", "ANATOMY", 463, 473], ["lung", "ANATOMY", 536, 540], ["ARDS", "DISEASE", 515, 519], ["A lines", "CELL", 216, 223], ["B-lines", "CELL", 232, 239], ["B-lines", "CELL", 263, 270], ["pleura", "ORGAN", 356, 362], ["pleural lines", "CELL", 398, 411], ["B-lines", "CELL", 427, 434], ["subpleural", "MULTI-TISSUE_STRUCTURE", 463, 473], ["lung", "ORGAN", 536, 540], ["B-lines", "CELL_LINE", 427, 434], ["four basic ultrasound patterns", "TEST", 149, 179], ["A lines and < 3 B-lines", "TREATMENT", 216, 239], ["mild disease", "PROBLEM", 245, 257], ["thickened pleura", "PROBLEM", 346, 362], ["an L-type; 3) broken pleural lines", "PROBLEM", 377, 411], ["B-lines", "TREATMENT", 427, 434], ["severe disease", "PROBLEM", 443, 457], ["subpleural consolidation (Fig. 3C", "PROBLEM", 463, 496], ["a typical ARDS picture", "PROBLEM", 505, 527], ["lung ultrasound monitoring", "TEST", 536, 562], ["normal", "OBSERVATION", 200, 206], ["mild", "OBSERVATION_MODIFIER", 245, 249], ["disease", "OBSERVATION", 250, 257], ["confluent", "OBSERVATION_MODIFIER", 295, 304], ["thickened", "OBSERVATION", 346, 355], ["pleura", "ANATOMY", 356, 362], ["suggestive of", "UNCERTAINTY", 363, 376], ["L", "ANATOMY_MODIFIER", 380, 381], ["pleural", "ANATOMY", 398, 405], ["lines", "OBSERVATION", 406, 411], ["severe", "OBSERVATION_MODIFIER", 443, 449], ["disease", "OBSERVATION", 450, 457], ["subpleural", "ANATOMY_MODIFIER", 463, 473], ["consolidation", "OBSERVATION", 474, 487], ["typical", "OBSERVATION_MODIFIER", 507, 514], ["ARDS", "OBSERVATION", 515, 519], ["lung", "ANATOMY", 536, 540], ["fourth", "OBSERVATION_MODIFIER", 566, 572], ["more suggestive of", "UNCERTAINTY", 584, 602], ["H-type", "OBSERVATION_MODIFIER", 606, 612]]], ["In H-type, ultrasound examination will often reveal some L-type features, such as loss of aeration and overlapping areas of peripheral or subpleural consolidation (Fig. 3C-F and Fig. 4), but pathological lesions will mostly be seen in the posterior region of the lung.7,30 Management and triage would be different in patients with more extensive disease.", [["subpleural", "ANATOMY", 138, 148], ["lesions", "ANATOMY", 204, 211], ["posterior region", "ANATOMY", 239, 255], ["lung", "ANATOMY", 263, 267], ["subpleural", "MULTI-TISSUE_STRUCTURE", 138, 148], ["lesions", "PATHOLOGICAL_FORMATION", 204, 211], ["posterior region", "MULTI-TISSUE_STRUCTURE", 239, 255], ["lung", "ORGAN", 263, 267], ["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 317, 325], ["ultrasound examination", "TEST", 11, 33], ["some L-type features", "PROBLEM", 52, 72], ["loss of aeration", "PROBLEM", 82, 98], ["peripheral or subpleural consolidation", "PROBLEM", 124, 162], ["pathological lesions", "PROBLEM", 191, 211], ["triage", "TEST", 288, 294], ["more extensive disease", "PROBLEM", 331, 353], ["-type", "OBSERVATION_MODIFIER", 58, 63], ["loss", "OBSERVATION_MODIFIER", 82, 86], ["aeration", "OBSERVATION_MODIFIER", 90, 98], ["overlapping", "OBSERVATION_MODIFIER", 103, 114], ["areas", "OBSERVATION_MODIFIER", 115, 120], ["peripheral", "ANATOMY_MODIFIER", 124, 134], ["subpleural", "ANATOMY_MODIFIER", 138, 148], ["consolidation", "OBSERVATION", 149, 162], ["Fig", "OBSERVATION_MODIFIER", 164, 167], ["pathological", "OBSERVATION_MODIFIER", 191, 203], ["lesions", "OBSERVATION", 204, 211], ["posterior", "ANATOMY_MODIFIER", 239, 248], ["region", "ANATOMY_MODIFIER", 249, 255], ["lung", "ANATOMY", 263, 267], ["extensive", "OBSERVATION_MODIFIER", 336, 345], ["disease", "OBSERVATION", 346, 353]]], ["Nevertheless, it is possible that the extent of any abnormal lung ultrasound pattern might be more important than the actual pattern or type of pathology itself.", [["lung", "ANATOMY", 61, 65], ["lung", "ORGAN", 61, 65], ["any abnormal lung ultrasound pattern", "PROBLEM", 48, 84], ["abnormal", "OBSERVATION_MODIFIER", 52, 60], ["lung", "ANATOMY", 61, 65], ["pathology", "OBSERVATION", 144, 153]]], ["A large number of abnormal regions would correlate with the severity of lung inflammation.", [["lung", "ANATOMY", 72, 76], ["lung inflammation", "DISEASE", 72, 89], ["lung", "ORGAN", 72, 76], ["A large number of abnormal regions", "PROBLEM", 0, 34], ["lung inflammation", "PROBLEM", 72, 89], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["abnormal", "OBSERVATION", 18, 26], ["lung", "ANATOMY", 72, 76], ["inflammation", "OBSERVATION", 77, 89]]], ["Pleural effusions have been uncommonly observed7,32 and were present in only 4.7% of patients in a series by Lomoro et al.28 and in 10% of patients in a separate report by Xing et al.30 The reduction or absence of a vascular Doppler signal in the areas of peripheral or subpleural consolidation (Fig. 1D,1F) is common in COVID-197 and could represent peripheral segmental lung infarction through a microangiopathy, as described recently by autopsies from the United States.37 Coronavirus disease could be associated with an increased incidence of thrombotic complications such as pulmonary embolism.38-41Role of lung ultrasound monitoringStandardization of lung ultrasound examination using a 14-region approach in COVID-19 has been recently proposed by Soldati et al.33 This would allow both diagnostic and daily monitoring of the pulmonary lesions.42 A simpler approach using six zones has also been recently proposed.43 The relevance of serial lung ultrasound has previously been reported in a small series of patients with ARDS42 unrelated to the current COVID-19 pandemic but the various scoring systems would need comparing and validating in COVID-19 patients.", [["Pleural effusions", "ANATOMY", 0, 17], ["vascular", "ANATOMY", 216, 224], ["subpleural", "ANATOMY", 270, 280], ["lung", "ANATOMY", 372, 376], ["pulmonary", "ANATOMY", 580, 589], ["lung", "ANATOMY", 612, 616], ["lung", "ANATOMY", 657, 661], ["pulmonary lesions", "ANATOMY", 832, 849], ["lung", "ANATOMY", 947, 951], ["Pleural effusions", "DISEASE", 0, 17], ["COVID-197", "CHEMICAL", 321, 330], ["peripheral segmental lung infarction", "DISEASE", 351, 387], ["microangiopathy", "DISEASE", 398, 413], ["Coronavirus disease", "DISEASE", 476, 495], ["thrombotic complications", "DISEASE", 547, 571], ["pulmonary embolism", "DISEASE", 580, 598], ["COVID-19", "CHEMICAL", 715, 723], ["pulmonary lesions", "DISEASE", 832, 849], ["Pleural effusions", "CANCER", 0, 17], ["patients", "ORGANISM", 85, 93], ["patients", "ORGANISM", 139, 147], ["vascular", "MULTI-TISSUE_STRUCTURE", 216, 224], ["subpleural", "MULTI-TISSUE_STRUCTURE", 270, 280], ["lung", "ORGAN", 372, 376], ["pulmonary", "ORGAN", 580, 589], ["lung", "ORGAN", 612, 616], ["lung", "ORGAN", 657, 661], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 832, 849], ["lung", "ORGAN", 947, 951], ["patients", "ORGANISM", 1013, 1021], ["patients", "ORGANISM", 1157, 1165], ["COVID-19", "DNA", 715, 723], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 1013, 1021], ["patients", "SPECIES", 1157, 1165], ["Pleural effusions", "PROBLEM", 0, 17], ["a vascular Doppler signal", "TEST", 214, 239], ["peripheral or subpleural consolidation", "PROBLEM", 256, 294], ["COVID", "TEST", 321, 326], ["peripheral segmental lung infarction", "PROBLEM", 351, 387], ["a microangiopathy", "PROBLEM", 396, 413], ["37 Coronavirus disease", "PROBLEM", 473, 495], ["thrombotic complications", "PROBLEM", 547, 571], ["pulmonary embolism", "PROBLEM", 580, 598], ["lung ultrasound", "TEST", 612, 627], ["lung ultrasound examination", "TEST", 657, 684], ["a 14-region approach", "TREATMENT", 691, 711], ["daily monitoring", "TEST", 808, 824], ["the pulmonary lesions", "PROBLEM", 828, 849], ["A simpler approach using six zones", "TREATMENT", 853, 887], ["serial lung ultrasound", "TEST", 940, 962], ["the current COVID", "TEST", 1047, 1064], ["pandemic", "PROBLEM", 1068, 1076], ["effusions", "OBSERVATION", 8, 17], ["reduction", "OBSERVATION_MODIFIER", 190, 199], ["vascular", "ANATOMY", 216, 224], ["areas", "OBSERVATION_MODIFIER", 247, 252], ["peripheral", "ANATOMY_MODIFIER", 256, 266], ["subpleural", "ANATOMY_MODIFIER", 270, 280], ["consolidation", "OBSERVATION", 281, 294], ["could represent", "UNCERTAINTY", 335, 350], ["peripheral", "ANATOMY_MODIFIER", 351, 361], ["segmental", "ANATOMY_MODIFIER", 362, 371], ["lung", "ANATOMY", 372, 376], ["infarction", "OBSERVATION", 377, 387], ["microangiopathy", "OBSERVATION", 398, 413], ["Coronavirus disease", "OBSERVATION", 476, 495], ["could be associated with", "UNCERTAINTY", 496, 520], ["increased", "OBSERVATION_MODIFIER", 524, 533], ["thrombotic", "OBSERVATION_MODIFIER", 547, 557], ["complications", "OBSERVATION", 558, 571], ["pulmonary", "ANATOMY", 580, 589], ["embolism", "OBSERVATION", 590, 598], ["lung", "ANATOMY", 612, 616], ["lung", "ANATOMY", 657, 661], ["pulmonary", "ANATOMY", 832, 841], ["lesions", "OBSERVATION", 842, 849], ["lung", "ANATOMY", 947, 951]]], ["In that study, the non-resolution of pulmonary lesions was associated with worse outcome.42Role of lung ultrasound monitoringAs with any patients in the intensive care unit, COVID-19 patients can also develop other pulmonary complications.", [["pulmonary lesions", "ANATOMY", 37, 54], ["lung", "ANATOMY", 99, 103], ["pulmonary", "ANATOMY", 215, 224], ["pulmonary lesions", "DISEASE", 37, 54], ["pulmonary complications", "DISEASE", 215, 238], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 37, 54], ["lung", "ORGAN", 99, 103], ["patients", "ORGANISM", 137, 145], ["patients", "ORGANISM", 183, 191], ["pulmonary", "ORGAN", 215, 224], ["patients", "SPECIES", 137, 145], ["patients", "SPECIES", 183, 191], ["that study", "TEST", 3, 13], ["pulmonary lesions", "PROBLEM", 37, 54], ["lung ultrasound monitoring", "TEST", 99, 125], ["other pulmonary complications", "PROBLEM", 209, 238], ["pulmonary", "ANATOMY", 37, 46], ["lesions", "OBSERVATION", 47, 54], ["lung", "ANATOMY", 99, 103], ["pulmonary", "ANATOMY", 215, 224], ["complications", "OBSERVATION", 225, 238]]], ["These include superimposed bacterial pneumonia, cardiogenic pulmonary edema related to myocardial dysfunction, right ventricular dysfunction and pulmonary hypertension due to pulmonary embolism, pleural effusions, and pneumothoraces.44,45 As suggested by Volpicelli et al., the bilateral patchy distribution of multiform clusters, alternating with \u201cspared areas\u201d is typical of the disease.", [["pulmonary", "ANATOMY", 60, 69], ["myocardial", "ANATOMY", 87, 97], ["right ventricular", "ANATOMY", 111, 128], ["pulmonary", "ANATOMY", 145, 154], ["pulmonary", "ANATOMY", 175, 184], ["pleural", "ANATOMY", 195, 202], ["pneumonia", "DISEASE", 37, 46], ["cardiogenic pulmonary edema", "DISEASE", 48, 75], ["myocardial dysfunction", "DISEASE", 87, 109], ["right ventricular dysfunction", "DISEASE", 111, 140], ["pulmonary hypertension", "DISEASE", 145, 167], ["pulmonary embolism", "DISEASE", 175, 193], ["pleural effusions", "DISEASE", 195, 212], ["pneumothoraces", "DISEASE", 218, 232], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 60, 75], ["myocardial", "MULTI-TISSUE_STRUCTURE", 87, 97], ["ventricular", "MULTI-TISSUE_STRUCTURE", 117, 128], ["pulmonary", "ORGAN", 145, 154], ["pulmonary", "ORGAN", 175, 184], ["pleural", "PATHOLOGICAL_FORMATION", 195, 202], ["superimposed bacterial pneumonia", "PROBLEM", 14, 46], ["cardiogenic pulmonary edema", "PROBLEM", 48, 75], ["myocardial dysfunction", "PROBLEM", 87, 109], ["right ventricular dysfunction", "PROBLEM", 111, 140], ["pulmonary hypertension", "PROBLEM", 145, 167], ["pulmonary embolism", "PROBLEM", 175, 193], ["pleural effusions", "PROBLEM", 195, 212], ["pneumothoraces", "PROBLEM", 218, 232], ["the bilateral patchy distribution of multiform clusters", "PROBLEM", 274, 329], ["the disease", "PROBLEM", 377, 388], ["superimposed", "OBSERVATION_MODIFIER", 14, 26], ["bacterial", "OBSERVATION_MODIFIER", 27, 36], ["pneumonia", "OBSERVATION", 37, 46], ["cardiogenic", "OBSERVATION_MODIFIER", 48, 59], ["pulmonary", "ANATOMY", 60, 69], ["edema", "OBSERVATION", 70, 75], ["myocardial", "ANATOMY", 87, 97], ["dysfunction", "OBSERVATION", 98, 109], ["right ventricular", "ANATOMY", 111, 128], ["dysfunction", "OBSERVATION", 129, 140], ["pulmonary", "ANATOMY", 145, 154], ["hypertension", "OBSERVATION", 155, 167], ["pulmonary", "ANATOMY", 175, 184], ["embolism", "OBSERVATION", 185, 193], ["pleural", "ANATOMY", 195, 202], ["effusions", "OBSERVATION", 203, 212], ["pneumothoraces", "OBSERVATION", 218, 232], ["bilateral", "ANATOMY_MODIFIER", 278, 287], ["patchy", "OBSERVATION_MODIFIER", 288, 294], ["distribution", "OBSERVATION_MODIFIER", 295, 307], ["multiform clusters", "OBSERVATION", 311, 329], ["spared", "OBSERVATION_MODIFIER", 349, 355], ["areas", "OBSERVATION", 356, 361], ["disease", "OBSERVATION", 381, 388]]], ["Any other ultrasound signs should be considered at intermediate probability and should lead to further testing.34Role of lung ultrasound monitoringBedside ultrasound could be useful in detecting associated pulmonary complications or non-pulmonary complications such as cardiac dysfunction that can occur in such patients.46 Combining heart, lung, deep veins examination41 and whole-body ultrasound47,48 can identify the mechanism,49 risk factors,50 and life-threatening conditions in patients with respiratory symptoms (Fig. 5).51 Lung ultrasound can also impact clinical decision-making in patients with acute respiratory failure52,53 and provide comprehensive monitoring of regional lung aeration changes that could be used to predict response to prone positioning with improved right ventricular function (Figs 6 and 7)54-56 or higher positive end-expiratory pressure strategy.57 Newer modalities such as strain and speckle tracking could eventually be used to detect early abnormal peripheral pulmonary stress.58,59 The authors strongly advocate ultrasound as the key to rapid repeated progress imaging (rather than CT, which is more expensive and has logistical difficulties) and hence a decision to intubate would clearly be influenced by a rapidly deteriorating set of ultrasound images.Role of lung ultrasound monitoringRepeated ultrasound imaging over time can allow for accurate determination of the progression of lung pathology and can strongly influence a decision to institute early mechanical ventilation.", [["lung", "ANATOMY", 121, 125], ["pulmonary", "ANATOMY", 206, 215], ["non-pulmonary", "ANATOMY", 233, 246], ["cardiac", "ANATOMY", 269, 276], ["heart", "ANATOMY", 334, 339], ["lung", "ANATOMY", 341, 345], ["deep veins", "ANATOMY", 347, 357], ["respiratory", "ANATOMY", 498, 509], ["Lung", "ANATOMY", 531, 535], ["respiratory", "ANATOMY", 611, 622], ["lung", "ANATOMY", 685, 689], ["right ventricular", "ANATOMY", 781, 798], ["pulmonary", "ANATOMY", 997, 1006], ["lung", "ANATOMY", 1302, 1306], ["lung", "ANATOMY", 1425, 1429], ["cardiac dysfunction", "DISEASE", 269, 288], ["respiratory symptoms", "DISEASE", 498, 518], ["acute respiratory failure", "DISEASE", 605, 630], ["lung", "ORGAN", 121, 125], ["pulmonary", "ORGAN", 206, 215], ["cardiac", "ORGAN", 269, 276], ["patients", "ORGANISM", 312, 320], ["heart", "ORGAN", 334, 339], ["lung", "ORGAN", 341, 345], ["deep veins", "MULTI-TISSUE_STRUCTURE", 347, 357], ["patients", "ORGANISM", 484, 492], ["Lung", "ORGAN", 531, 535], ["patients", "ORGANISM", 591, 599], ["lung", "ORGAN", 685, 689], ["right ventricular", "MULTI-TISSUE_STRUCTURE", 781, 798], ["pulmonary", "ORGAN", 997, 1006], ["lung", "ORGAN", 1302, 1306], ["lung", "ORGAN", 1425, 1429], ["patients", "SPECIES", 312, 320], ["patients", "SPECIES", 484, 492], ["patients", "SPECIES", 591, 599], ["Any other ultrasound signs", "TEST", 0, 26], ["further testing", "TEST", 95, 110], ["lung ultrasound monitoring", "TEST", 121, 147], ["Bedside ultrasound", "TEST", 147, 165], ["pulmonary complications", "PROBLEM", 206, 229], ["non-pulmonary complications", "PROBLEM", 233, 260], ["cardiac dysfunction", "PROBLEM", 269, 288], ["deep veins examination41", "TEST", 347, 371], ["whole-body ultrasound", "TEST", 376, 397], ["respiratory symptoms", "PROBLEM", 498, 518], ["Lung ultrasound", "TEST", 531, 546], ["acute respiratory failure", "PROBLEM", 605, 630], ["comprehensive monitoring", "TEST", 648, 672], ["regional lung aeration changes", "PROBLEM", 676, 706], ["Figs", "TEST", 809, 813], ["strain", "PROBLEM", 908, 914], ["speckle tracking", "TEST", 919, 935], ["early abnormal peripheral pulmonary stress", "PROBLEM", 971, 1013], ["ultrasound", "TEST", 1050, 1060], ["rapid repeated progress imaging", "TEST", 1075, 1106], ["CT", "TEST", 1120, 1122], ["ultrasound images", "TEST", 1276, 1293], ["lung ultrasound monitoring", "TEST", 1302, 1328], ["Repeated ultrasound imaging", "TEST", 1328, 1355], ["lung pathology", "PROBLEM", 1425, 1439], ["early mechanical ventilation", "TREATMENT", 1491, 1519], ["lung", "ANATOMY", 121, 125], ["pulmonary", "ANATOMY", 206, 215], ["complications", "OBSERVATION", 216, 229], ["non-pulmonary", "ANATOMY", 233, 246], ["complications", "OBSERVATION", 247, 260], ["cardiac", "ANATOMY", 269, 276], ["dysfunction", "OBSERVATION", 277, 288], ["heart", "ANATOMY", 334, 339], ["lung", "ANATOMY", 341, 345], ["deep", "ANATOMY_MODIFIER", 347, 351], ["veins", "ANATOMY", 352, 357], ["Lung", "ANATOMY", 531, 535], ["acute", "OBSERVATION_MODIFIER", 605, 610], ["respiratory failure", "OBSERVATION", 611, 630], ["regional", "ANATOMY_MODIFIER", 676, 684], ["lung", "ANATOMY", 685, 689], ["aeration", "OBSERVATION", 690, 698], ["right ventricular", "ANATOMY", 781, 798], ["expiratory pressure", "OBSERVATION", 851, 870], ["early", "OBSERVATION_MODIFIER", 971, 976], ["abnormal", "OBSERVATION_MODIFIER", 977, 985], ["peripheral", "ANATOMY_MODIFIER", 986, 996], ["pulmonary", "ANATOMY", 997, 1006], ["stress", "OBSERVATION", 1007, 1013], ["lung", "ANATOMY", 1302, 1306], ["lung", "ANATOMY", 1425, 1429], ["pathology", "OBSERVATION", 1430, 1439], ["mechanical ventilation", "OBSERVATION", 1497, 1519]]], ["Such repeated ultrasound imaging would be logistically convenient at the bedside without transporting the patient to the radiology department and would not involve any radiation dosing.", [["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113], ["Such repeated ultrasound imaging", "TEST", 0, 32], ["any radiation dosing", "TREATMENT", 164, 184]]], ["Nevertheless, although lung ultrasound outperforms chest radiograph,60,61 it cannot be as comprehensive as CT since any lung pathology not involving the surface of the lung (and therefore covered by some aerated lung) cannot be detected by ultrasound.", [["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 120, 124], ["surface", "ANATOMY", 153, 160], ["lung", "ANATOMY", 168, 172], ["lung", "ANATOMY", 212, 216], ["lung", "ORGAN", 23, 27], ["lung", "ORGAN", 120, 124], ["surface", "CELLULAR_COMPONENT", 153, 160], ["lung", "ORGAN", 168, 172], ["lung", "ORGAN", 212, 216], ["lung ultrasound outperforms chest radiograph", "TEST", 23, 67], ["CT", "TEST", 107, 109], ["any lung pathology", "TEST", 116, 134], ["some aerated lung", "PROBLEM", 199, 216], ["ultrasound", "TEST", 240, 250], ["lung", "ANATOMY", 23, 27], ["chest", "ANATOMY", 51, 56], ["lung", "ANATOMY", 120, 124], ["pathology", "OBSERVATION", 125, 134], ["surface", "ANATOMY_MODIFIER", 153, 160], ["lung", "ANATOMY", 168, 172], ["some", "OBSERVATION_MODIFIER", 199, 203], ["aerated", "OBSERVATION", 204, 211], ["lung", "ANATOMY", 212, 216], ["cannot be detected", "UNCERTAINTY", 218, 236]]], ["Lung ultrasound can be performed with a wide range of ultrasound machines, including handheld devices.62 The advantage of the handheld devices is that they can be fully enclosed in a plastic sheath, thereby reducing the risk of equipment contamination and spread of infection between patients.", [["Lung", "ANATOMY", 0, 4], ["infection", "DISEASE", 266, 275], ["Lung", "ORGAN", 0, 4], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292], ["Lung ultrasound", "TEST", 0, 15], ["ultrasound machines", "TREATMENT", 54, 73], ["handheld devices", "TREATMENT", 85, 101], ["the handheld devices", "TREATMENT", 122, 142], ["a plastic sheath", "TREATMENT", 181, 197], ["equipment contamination", "PROBLEM", 228, 251], ["infection", "PROBLEM", 266, 275], ["plastic sheath", "OBSERVATION", 183, 197], ["infection", "OBSERVATION", 266, 275]]], ["The performance and interpretation of lung ultrasound is much simpler than other imaging modalities such as transthoracic echocardiography as the images are easy to acquire and there are a limited number of patterns to interpret.63,64 Education can be scaled to meet the COVID-19 crisis through online courses (e.g., https://www.iteachu.com/courses/covid-19-lung-ultrasound/) simulation, and peer-to-peer mentoring.Other management modalities and limitationsOther important elements in deciding whether to intubate is the work of breathing.27 This can also be monitored clinically by observing the use of accessory muscles or by measuring or estimating changes in pleural pressure.13 Once mechanical ventilation is initiated, tidal volume, respiratory rate, positive-pressure ventilation, prone positioning and veno-venous extracorporeal membrane oxygenation, sedation, and neuromuscular blockade will be adjusted differently depending on the phenotype and in accordance to ARDS management guidelines.65-68Other management modalities and limitationsFinally, there are still several unanswered questions and uncertainties regarding COVID-19 respiratory infections and the role of bedside ultrasound.", [["lung", "ANATOMY", 38, 42], ["accessory muscles", "ANATOMY", 605, 622], ["pleural", "ANATOMY", 664, 671], ["respiratory", "ANATOMY", 740, 751], ["veno-venous extracorporeal membrane", "ANATOMY", 811, 846], ["neuromuscular", "ANATOMY", 874, 887], ["neuromuscular blockade", "DISEASE", 874, 896], ["ARDS", "DISEASE", 974, 978], ["respiratory infections", "DISEASE", 1140, 1162], ["lung", "ORGAN", 38, 42], ["muscles", "ORGAN", 615, 622], ["pleural", "ORGAN", 664, 671], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 823, 846], ["lung ultrasound", "TEST", 38, 53], ["other imaging modalities", "TEST", 75, 99], ["transthoracic echocardiography", "TEST", 108, 138], ["the images", "TEST", 142, 152], ["the COVID", "TEST", 267, 276], ["Other management modalities", "TREATMENT", 415, 442], ["estimating changes in pleural pressure", "PROBLEM", 642, 680], ["mechanical ventilation", "TREATMENT", 689, 711], ["tidal volume", "TEST", 726, 738], ["respiratory rate", "TEST", 740, 756], ["positive-pressure ventilation", "TREATMENT", 758, 787], ["prone positioning", "TREATMENT", 789, 806], ["veno-venous extracorporeal membrane oxygenation", "TREATMENT", 811, 858], ["sedation", "TREATMENT", 860, 868], ["neuromuscular blockade", "TREATMENT", 874, 896], ["ARDS management", "TREATMENT", 974, 989], ["COVID", "TEST", 1131, 1136], ["19 respiratory infections", "PROBLEM", 1137, 1162], ["bedside ultrasound", "TEST", 1179, 1197], ["lung", "ANATOMY", 38, 42], ["accessory muscles", "ANATOMY", 605, 622], ["pleural", "ANATOMY", 664, 671], ["pressure", "OBSERVATION", 672, 680], ["mechanical ventilation", "OBSERVATION", 689, 711], ["pressure ventilation", "OBSERVATION", 767, 787], ["veno-venous", "ANATOMY_MODIFIER", 811, 822], ["extracorporeal membrane", "OBSERVATION", 823, 846], ["respiratory", "ANATOMY", 1140, 1151], ["infections", "OBSERVATION", 1152, 1162]]], ["We are still on an ascending learning curve regarding this new medical condition.", [["an ascending learning curve", "TREATMENT", 16, 43], ["this new medical condition", "PROBLEM", 54, 80]]], ["Our proposed algorithm, which reflects the current understanding of COVID-19 respiratory failure, is likely to evolve as new information becomes available.", [["respiratory failure", "DISEASE", 77, 96], ["Our proposed algorithm", "TEST", 0, 22], ["COVID", "TEST", 68, 73], ["respiratory failure", "PROBLEM", 77, 96], ["respiratory failure", "OBSERVATION", 77, 96], ["likely to", "UNCERTAINTY", 101, 110]]], ["The Table summarizes key questions on respiratory complications and management in COVID-19 patients with the use of lung ultrasound.Other management modalities and limitationsOur understanding of COVID-19 and its effect on the respiratory system is rapidly evolving.", [["respiratory", "ANATOMY", 38, 49], ["lung", "ANATOMY", 116, 120], ["respiratory system", "ANATOMY", 227, 245], ["respiratory complications", "DISEASE", 38, 63], ["COVID-19", "CHEMICAL", 196, 204], ["patients", "ORGANISM", 91, 99], ["lung", "ORGAN", 116, 120], ["COVID-19", "GENE_OR_GENE_PRODUCT", 196, 204], ["COVID-19", "DNA", 196, 204], ["patients", "SPECIES", 91, 99], ["respiratory complications", "PROBLEM", 38, 63], ["management", "TREATMENT", 68, 78], ["lung ultrasound", "TEST", 116, 131], ["Other management modalities", "TREATMENT", 132, 159], ["COVID", "TEST", 196, 201], ["lung", "ANATOMY", 116, 120], ["respiratory system", "ANATOMY", 227, 245], ["rapidly", "OBSERVATION_MODIFIER", 249, 256]]], ["Biochemical pathways involving cardiovascular issues have recently been described by Liu et al.46 This novel knowledge might contribute to understanding more about the two suggested phenotypes described by Gattinoni et al.11,13 It might also be used to confirm or challenge the aforementioned phenotypes categorization.69,70 Bedside lung ultrasound can help identify severity of lung involvement and response to therapy, as part of evaluation for ventilation as well as during the recovery and weaning process.", [["cardiovascular", "ANATOMY", 31, 45], ["lung", "ANATOMY", 333, 337], ["lung", "ANATOMY", 379, 383], ["cardiovascular", "ANATOMICAL_SYSTEM", 31, 45], ["lung", "ORGAN", 333, 337], ["lung", "ORGAN", 379, 383], ["cardiovascular issues", "PROBLEM", 31, 52], ["Bedside lung ultrasound", "TEST", 325, 348], ["lung involvement", "PROBLEM", 379, 395], ["therapy", "TREATMENT", 412, 419], ["evaluation", "TEST", 432, 442], ["ventilation", "TREATMENT", 447, 458], ["weaning process", "TREATMENT", 494, 509], ["lung", "ANATOMY", 333, 337], ["lung", "ANATOMY", 379, 383], ["involvement", "OBSERVATION", 384, 395]]], ["With the implementation of this emerging information, clinical management may be somewhat distinct from that of other evidence-based interventions.", [["clinical management", "TREATMENT", 54, 73], ["based interventions", "TREATMENT", 127, 146]]], ["As a result, clinical trials will be required to determine the best ventilation strategies for the different lung-involvement phenotypes seen in hypoxic COVID-19 patients.", [["lung", "ANATOMY", 109, 113], ["lung", "ORGAN", 109, 113], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["the different lung-involvement phenotypes", "PROBLEM", 95, 136], ["hypoxic COVID", "TEST", 145, 158], ["lung", "ANATOMY", 109, 113]]]], "65e9d14789c7a1001947030898cd711f1697f6e0": [["IntroductionBacterial and viral respiratory diseases are a major health issue in species reared under confined conditions in large groups.", [["respiratory", "ANATOMY", 32, 43], ["viral respiratory diseases", "DISEASE", 26, 52], ["IntroductionBacterial", "TREATMENT", 0, 21], ["viral respiratory diseases", "PROBLEM", 26, 52], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["respiratory diseases", "OBSERVATION", 32, 52], ["large", "OBSERVATION_MODIFIER", 125, 130]]], ["Most often multiple infectious agents are involved in the development of these clinical conditions making unsuited the common reductionist approach of host-pathogen interactions by the study of single infection [1] .", [["infection", "DISEASE", 201, 210], ["these clinical conditions", "PROBLEM", 73, 98], ["the study", "TEST", 181, 190], ["single infection", "PROBLEM", 194, 210], ["infectious", "OBSERVATION", 20, 30]]], ["Infection by more than one type of pathogen (viruses, bacteria and parasites amongst others) is described as a mixed infection.", [["infection", "DISEASE", 117, 126], ["Infection", "PROBLEM", 0, 9], ["pathogen (viruses", "PROBLEM", 35, 52], ["bacteria", "PROBLEM", 54, 62], ["parasites", "PROBLEM", 67, 76], ["a mixed infection", "PROBLEM", 109, 126], ["more than one type", "OBSERVATION_MODIFIER", 13, 31], ["pathogen", "OBSERVATION", 35, 43], ["mixed", "OBSERVATION_MODIFIER", 111, 116], ["infection", "OBSERVATION", 117, 126]]], ["However, the term coinfection is frequently used to describe concomitant infection of a cell or a host by separate pathogens [2] .", [["cell", "ANATOMY", 88, 92], ["coinfection", "DISEASE", 18, 29], ["infection", "DISEASE", 73, 82], ["cell", "CELL", 88, 92], ["the term coinfection", "PROBLEM", 9, 29], ["concomitant infection", "PROBLEM", 61, 82], ["a cell", "PROBLEM", 86, 92], ["coinfection", "OBSERVATION", 18, 29]]], ["Since in the literature the definitions of coinfection and mixed infection have been both used to describe the same events, we will use the term \"coinfection\" in the current review.", [["coinfection", "DISEASE", 43, 54], ["infection", "DISEASE", 65, 74], ["coinfection", "DISEASE", 146, 157], ["coinfection", "PROBLEM", 43, 54], ["mixed infection", "PROBLEM", 59, 74], ["coinfection", "OBSERVATION", 43, 54], ["mixed", "OBSERVATION_MODIFIER", 59, 64], ["infection", "OBSERVATION", 65, 74]]], ["Additionally, in virology, the term superinfection is used if one virus infects the cell or the host before infection by the second superinfecting virus.", [["cell", "ANATOMY", 84, 88], ["superinfection", "DISEASE", 36, 50], ["infection", "DISEASE", 108, 117], ["cell", "CELL", 84, 88], ["the term superinfection", "PROBLEM", 27, 50], ["one virus infects the cell", "PROBLEM", 62, 88], ["infection", "PROBLEM", 108, 117], ["the second superinfecting virus", "PROBLEM", 121, 152], ["superinfection", "OBSERVATION", 36, 50]]], ["We will also use the term \"superinfection\" in the review.", [["superinfection", "DISEASE", 27, 41], ["the term \"superinfection", "TREATMENT", 17, 41], ["superinfection", "OBSERVATION", 27, 41]]], ["Finally, an opportunistic pathogen is usually considered as a pathogen that would not have infected animals in absence of the primary infection, or alternatively, \"pathogen\" that would have been asymptomatic in the absence of the primary infection.", [["primary infection", "DISEASE", 126, 143], ["primary infection", "DISEASE", 230, 247], ["an opportunistic pathogen", "PROBLEM", 9, 34], ["a pathogen", "PROBLEM", 60, 70], ["the primary infection", "PROBLEM", 122, 143], ["pathogen", "PROBLEM", 164, 172], ["asymptomatic", "PROBLEM", 195, 207], ["the primary infection", "PROBLEM", 226, 247], ["primary", "OBSERVATION_MODIFIER", 126, 133], ["infection", "OBSERVATION", 134, 143], ["primary", "OBSERVATION_MODIFIER", 230, 237], ["infection", "OBSERVATION", 238, 247]]], ["In some studies, however, the use of the terms \"coinfection\" is not suitable and \"superinfection\" should be used instead, as we will see later.", [["coinfection", "DISEASE", 48, 59], ["superinfection", "DISEASE", 82, 96], ["some studies", "TEST", 3, 15], ["superinfection", "PROBLEM", 82, 96]]], ["This semantic point is responsible for a lot of confusion and makes comparisons between studies sometimes tricky.", [["confusion", "DISEASE", 48, 57], ["confusion", "PROBLEM", 48, 57]]], ["The outcome of any coinfection or superinfection can be affected by the interactions taking place between the infectious agents, the nature of the cell/host, adverse environmental and management conditions, intestinal and respiratory microbiomes, and the triggered immune response-innate and adaptive-developed afterwards [2, 3] .", [["cell", "ANATOMY", 147, 151], ["intestinal", "ANATOMY", 207, 217], ["respiratory", "ANATOMY", 222, 233], ["coinfection", "DISEASE", 19, 30], ["superinfection", "DISEASE", 34, 48], ["cell", "CELL", 147, 151], ["intestinal", "ORGAN", 207, 217], ["any coinfection", "PROBLEM", 15, 30], ["superinfection", "PROBLEM", 34, 48], ["the infectious agents", "TREATMENT", 106, 127], ["management conditions", "TREATMENT", 184, 205], ["intestinal and respiratory microbiomes", "PROBLEM", 207, 245], ["coinfection", "OBSERVATION", 19, 30], ["superinfection", "OBSERVATION", 34, 48], ["intestinal", "ANATOMY", 207, 217], ["respiratory", "ANATOMY", 222, 233]]], ["When occurring at the same time or with a delay, infections can impact the virulence of causative pathogens with subsequent consequences on the host immune response and its ability to clear the infections [2] .", [["infections", "DISEASE", 49, 59], ["infections", "DISEASE", 194, 204], ["a delay", "PROBLEM", 40, 47], ["infections", "PROBLEM", 49, 59], ["causative pathogens", "PROBLEM", 88, 107], ["the infections", "PROBLEM", 190, 204], ["infections", "OBSERVATION", 194, 204]]], ["The first contact with a pathogen can change the cell/host response against any other second pathogen, possibly causing a more virulent infection, reducing its severity or suppressing it completely [4] .", [["cell", "ANATOMY", 49, 53], ["infection", "DISEASE", 136, 145], ["cell", "CELL", 49, 53], ["a pathogen", "PROBLEM", 23, 33], ["any other second pathogen", "PROBLEM", 76, 101], ["a more virulent infection", "PROBLEM", 120, 145], ["possibly causing", "UNCERTAINTY", 103, 119], ["virulent", "OBSERVATION_MODIFIER", 127, 135], ["infection", "OBSERVATION", 136, 145]]], ["Thus, different scenarios concerning the pathogen interactions can be observed, the first infectious agent can promote the second one, attenuate its effects or simply prevent its establishment.", [["the pathogen interactions", "PROBLEM", 37, 62]]], ["Conversely, the second pathogen may also influence the first one directly or indirectly.IntroductionCoinfections have been described in both humans and animals [1, 2] .", [["IntroductionCoinfections", "DISEASE", 88, 112], ["humans", "ORGANISM", 141, 147], ["humans", "SPECIES", 141, 147], ["humans", "SPECIES", 141, 147], ["IntroductionCoinfections", "TREATMENT", 88, 112]]], ["Moreover, bacterial and viral infections might be followed by secondary bacterial or viral infections, which in some cases are responsible for the pathology development and the observed clinical signs.", [["bacterial and viral infections", "DISEASE", 10, 40], ["infections", "DISEASE", 91, 101], ["bacterial and viral infections", "PROBLEM", 10, 40], ["secondary bacterial or viral infections", "PROBLEM", 62, 101], ["the pathology development", "PROBLEM", 143, 168], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["viral infections", "OBSERVATION", 24, 40], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["infections", "OBSERVATION", 91, 101]]], ["In this review, the current knowledge regarding frequent coinfections that occur in the porcine respiratory tract and particularly in the lungs are reviewed.", [["respiratory tract", "ANATOMY", 96, 113], ["lungs", "ANATOMY", 138, 143], ["coinfections", "DISEASE", 57, 69], ["porcine", "ORGANISM", 88, 95], ["respiratory tract", "ORGANISM_SUBDIVISION", 96, 113], ["lungs", "ORGAN", 138, 143], ["porcine", "SPECIES", 88, 95], ["frequent coinfections", "PROBLEM", 48, 69], ["coinfections", "OBSERVATION", 57, 69], ["respiratory tract", "ANATOMY", 96, 113], ["lungs", "ANATOMY", 138, 143]]], ["We especially discussed coinfections involving main bacteria and viruses associated with the so-called porcine respiratory diseases, excluding coinfections involving parasites and fungi (including their metabolites, such as mycotoxins).", [["respiratory", "ANATOMY", 111, 122], ["respiratory diseases", "DISEASE", 111, 131], ["coinfections", "DISEASE", 143, 155], ["porcine", "ORGANISM", 103, 110], ["porcine", "SPECIES", 103, 110], ["coinfections", "PROBLEM", 24, 36], ["main bacteria", "PROBLEM", 47, 60], ["viruses", "PROBLEM", 65, 72], ["the so-called porcine respiratory diseases", "PROBLEM", 89, 131], ["coinfections", "PROBLEM", 143, 155], ["parasites", "PROBLEM", 166, 175], ["fungi", "PROBLEM", 180, 185], ["viruses", "OBSERVATION", 65, 72], ["respiratory diseases", "OBSERVATION", 111, 131]]], ["Moreover, we do not discuss the impact of adverse environmental and management conditions which have been shown to be of major importance in the modulation of respiratory infections' severity [3].Porcine respiratory disease complex and the associated pathogensRespiratory diseases have been formally described in pigs as early as the 1960\u2032s [5] and several studies have been carried out to identify associated agents.", [["respiratory", "ANATOMY", 159, 170], ["respiratory", "ANATOMY", 204, 215], ["respiratory infections", "DISEASE", 159, 181], ["Porcine respiratory disease", "DISEASE", 196, 223], ["Respiratory diseases", "DISEASE", 260, 280], ["Porcine", "ORGANISM", 196, 203], ["pigs", "ORGANISM", 313, 317], ["Porcine", "SPECIES", 196, 203], ["pigs", "SPECIES", 313, 317], ["pigs", "SPECIES", 313, 317], ["management conditions", "TREATMENT", 68, 89], ["respiratory infections' severity", "PROBLEM", 159, 191], ["Porcine respiratory disease complex", "PROBLEM", 196, 231], ["the associated pathogensRespiratory diseases", "PROBLEM", 236, 280], ["several studies", "TEST", 349, 364], ["respiratory infections", "OBSERVATION", 159, 181], ["respiratory disease", "OBSERVATION", 204, 223], ["pathogens", "OBSERVATION_MODIFIER", 251, 260], ["Respiratory diseases", "OBSERVATION", 260, 280]]], ["The role of the infectious pathogens has been assessed by using two main approaches: direct research of the pathogens (by culture or Polymerase Chain Reaction-PCR for instance) from tissue samples of diseased (acute or chronic stage) and non-diseased pigs or indirect detection by serological tests to look for antibodies produced after exposure to specific pathogens.", [["tissue samples", "ANATOMY", 182, 196], ["tissue samples", "MULTI-TISSUE_STRUCTURE", 182, 196], ["pigs", "ORGANISM", 251, 255], ["antibodies", "PROTEIN", 311, 321], ["pigs", "SPECIES", 251, 255], ["pigs", "SPECIES", 251, 255], ["the infectious pathogens", "PROBLEM", 12, 36], ["the pathogens", "PROBLEM", 104, 117], ["culture", "TEST", 122, 129], ["Polymerase Chain Reaction", "TEST", 133, 158], ["PCR", "TEST", 159, 162], ["tissue samples", "TEST", 182, 196], ["diseased (acute or chronic stage)", "PROBLEM", 200, 233], ["non-diseased pigs", "PROBLEM", 238, 255], ["indirect detection", "TEST", 259, 277], ["serological tests", "TEST", 281, 298], ["antibodies", "PROBLEM", 311, 321], ["specific pathogens", "PROBLEM", 349, 367], ["infectious", "OBSERVATION", 16, 26], ["diseased", "OBSERVATION_MODIFIER", 200, 208], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["chronic", "OBSERVATION_MODIFIER", 219, 226]]], ["These studies indicated that frequently under field conditions, several infectious pathogens are simultaneously detected from lung lesions (see [6] [7] [8] Causative respiratory infectious agents can be divided into primary and secondary or opportunistic pathogens.", [["lung lesions", "ANATOMY", 126, 138], ["respiratory infectious agents", "DISEASE", 166, 195], ["primary and secondary or opportunistic pathogens", "DISEASE", 216, 264], ["lung lesions", "CANCER", 126, 138], ["These studies", "TEST", 0, 13], ["several infectious pathogens", "PROBLEM", 64, 92], ["lung lesions", "PROBLEM", 126, 138], ["Causative respiratory infectious agents", "TREATMENT", 156, 195], ["opportunistic pathogens", "PROBLEM", 241, 264], ["infectious", "OBSERVATION_MODIFIER", 72, 82], ["lung", "ANATOMY", 126, 130], ["lesions", "OBSERVATION", 131, 138], ["respiratory", "ANATOMY", 166, 177], ["infectious", "OBSERVATION", 178, 188], ["opportunistic", "OBSERVATION_MODIFIER", 241, 254], ["pathogens", "OBSERVATION", 255, 264]]], ["Primary pathogen being defined here as pathogen that can infect the animal as first unique pathogen and then facilitate secondary or opportunistic coinfection.", [["opportunistic coinfection", "DISEASE", 133, 158], ["Primary pathogen", "PROBLEM", 0, 16], ["pathogen", "PROBLEM", 39, 47], ["opportunistic coinfection", "PROBLEM", 133, 158], ["opportunistic", "OBSERVATION_MODIFIER", 133, 146], ["coinfection", "OBSERVATION", 147, 158]]], ["These primary pathogens include common bacteria such as highly virulent Actinobacillus (A.) pleuropneumoniae,Bacterium-bacterium interactions 3.4 Limitations of coinfection studies 4 Conclusion and perspectives ReferencesM. hyopneumoniae, Bordetella (B.) bronchiseptica in young piglets and common viruses such as swIAV [1] .", [["Bordetella (B.) bronchiseptica", "DISEASE", 239, 269], ["Actinobacillus (A.) pleuropneumoniae", "ORGANISM", 72, 108], ["hyopneumoniae", "ORGANISM", 224, 237], ["Bordetella (B.) bronchiseptica", "ORGANISM", 239, 269], ["piglets", "ORGANISM", 279, 286], ["Actinobacillus", "SPECIES", 72, 86], ["A.) pleuropneumoniae", "SPECIES", 88, 108], ["hyopneumoniae", "SPECIES", 224, 237], ["Bordetella", "SPECIES", 239, 249], ["B.) bronchiseptica", "SPECIES", 251, 269], ["piglets", "SPECIES", 279, 286], ["A.) pleuropneumoniae", "SPECIES", 88, 108], ["hyopneumoniae", "SPECIES", 224, 237], ["Bordetella (B.) bronchiseptica", "SPECIES", 239, 269], ["These primary pathogens", "PROBLEM", 0, 23], ["common bacteria", "PROBLEM", 32, 47], ["highly virulent Actinobacillus", "PROBLEM", 56, 86], ["pleuropneumoniae", "PROBLEM", 92, 108], ["Bacterium", "PROBLEM", 109, 118], ["bacterium interactions", "PROBLEM", 119, 141], ["coinfection studies", "TEST", 161, 180], ["hyopneumoniae", "PROBLEM", 224, 237], ["Bordetella", "PROBLEM", 239, 249], ["bronchiseptica", "PROBLEM", 255, 269], ["common viruses", "PROBLEM", 291, 305], ["virulent Actinobacillus", "OBSERVATION", 63, 86]]], ["PRRSV and PCV2 are not strictly respiratory pathogens as swIAV, however, since they also frequently affect the respiratory system and since they can act as facilitators of secondary respiratory infections, they must be considered too.", [["respiratory system", "ANATOMY", 111, 129], ["respiratory", "ANATOMY", 182, 193], ["respiratory infections", "DISEASE", 182, 204], ["PRRSV", "ORGANISM", 0, 5], ["PCV2", "ORGANISM", 10, 14], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PCV2", "SPECIES", 10, 14], ["PRRSV", "PROBLEM", 0, 5], ["PCV2", "PROBLEM", 10, 14], ["strictly respiratory pathogens", "PROBLEM", 23, 53], ["secondary respiratory infections", "PROBLEM", 172, 204], ["PCV2", "OBSERVATION", 10, 14], ["not strictly", "UNCERTAINTY", 19, 31], ["respiratory system", "ANATOMY", 111, 129], ["respiratory infections", "OBSERVATION", 182, 204]]], ["Other primary pathogens such as Aujeszky's Disease Virus (ADV) and PRCoV are reported but they are far less frequently encountered today or they have less impact on porcine health [1].", [["Aujeszky's Disease Virus", "DISEASE", 32, 56], ["Aujeszky's Disease Virus", "ORGANISM", 32, 56], ["ADV", "ORGANISM", 58, 61], ["porcine", "ORGANISM", 165, 172], ["Aujeszky", "SPECIES", 32, 40], ["Aujeszky's Disease Virus", "SPECIES", 32, 56], ["ADV", "SPECIES", 58, 61], ["PRCoV", "SPECIES", 67, 72], ["porcine", "SPECIES", 165, 172], ["Other primary pathogens", "PROBLEM", 0, 23], ["Aujeszky's Disease Virus", "PROBLEM", 32, 56]]], ["Then, some viruses like the porcine cytomegalovirus can also inhibit host immune functions-particularly the action of T lymphocytes-and promote respiratory diseases such as the porcine reproductive and respiratory syndrome [9] .", [["T lymphocytes", "ANATOMY", 118, 131], ["respiratory", "ANATOMY", 144, 155], ["porcine cytomegalovirus", "DISEASE", 28, 51], ["respiratory diseases", "DISEASE", 144, 164], ["porcine reproductive and respiratory syndrome", "DISEASE", 177, 222], ["porcine cytomegalovirus", "ORGANISM", 28, 51], ["T lymphocytes", "CELL", 118, 131], ["T lymphocytes", "CELL_TYPE", 118, 131], ["porcine", "SPECIES", 28, 35], ["porcine cytomegalovirus", "SPECIES", 28, 51], ["some viruses", "PROBLEM", 6, 18], ["the porcine cytomegalovirus", "PROBLEM", 24, 51], ["host immune functions", "PROBLEM", 69, 90], ["T lymphocytes", "PROBLEM", 118, 131], ["promote respiratory diseases", "PROBLEM", 136, 164], ["the porcine reproductive", "TREATMENT", 173, 197], ["respiratory syndrome", "PROBLEM", 202, 222], ["viruses", "OBSERVATION", 11, 18], ["porcine cytomegalovirus", "OBSERVATION", 28, 51], ["respiratory diseases", "OBSERVATION", 144, 164], ["respiratory syndrome", "OBSERVATION", 202, 222]]], ["Among the secondary pathogens common bacteria such as lower virulence strains of A. pleuropneumoniae, A. suis, Glaesserella parasuis, Pasteurella multocida, and Streptococcus (S.) suis are reported.", [["Pasteurella multocida", "DISEASE", 134, 155], ["A. pleuropneumoniae", "ORGANISM", 81, 100], ["A. suis", "ORGANISM", 102, 109], ["Glaesserella parasuis", "ORGANISM", 111, 132], ["Pasteurella multocida", "ORGANISM", 134, 155], ["Streptococcus (S.) suis", "ORGANISM", 161, 184], ["A. pleuropneumoniae", "SPECIES", 81, 100], ["A. suis", "SPECIES", 102, 109], ["Glaesserella parasuis", "SPECIES", 111, 132], ["Pasteurella multocida", "SPECIES", 134, 155], ["Streptococcus", "SPECIES", 161, 174], ["S.) suis", "SPECIES", 176, 184], ["A. pleuropneumoniae", "SPECIES", 81, 100], ["A. suis", "SPECIES", 102, 109], ["Glaesserella parasuis", "SPECIES", 111, 132], ["Pasteurella multocida", "SPECIES", 134, 155], ["Streptococcus (S.) suis", "SPECIES", 161, 184], ["the secondary pathogens common bacteria", "PROBLEM", 6, 45], ["lower virulence strains", "PROBLEM", 54, 77], ["A. pleuropneumoniae", "PROBLEM", 81, 100], ["A. suis", "TEST", 102, 109], ["Glaesserella parasuis", "PROBLEM", 111, 132], ["Pasteurella multocida", "PROBLEM", 134, 155], ["Streptococcus", "PROBLEM", 161, 174], ["suis", "PROBLEM", 180, 184], ["secondary", "OBSERVATION_MODIFIER", 10, 19], ["pathogens", "OBSERVATION_MODIFIER", 20, 29]]], ["Together primary and secondary pathogens are involved in the \"Porcine Respiratory Disease Complex\" (PRDC) [10] .Bacterium-bacterium interactions 3.4 Limitations of coinfection studies 4 Conclusion and perspectives ReferencesSeveral studies have assessed the nature of the infectious agents directly or indirectly associated with respiratory diseases in pigs [7, 8, 11, 12] .", [["respiratory", "ANATOMY", 329, 340], ["Porcine Respiratory Disease", "DISEASE", 62, 89], ["respiratory diseases", "DISEASE", 329, 349], ["pigs", "ORGANISM", 353, 357], ["Porcine", "SPECIES", 62, 69], ["pigs", "SPECIES", 353, 357], ["secondary pathogens", "PROBLEM", 21, 40], ["the \"Porcine Respiratory Disease", "PROBLEM", 57, 89], ["Bacterium", "TEST", 112, 121], ["bacterium interactions", "PROBLEM", 122, 144], ["coinfection studies", "TEST", 164, 183], ["Several studies", "TEST", 224, 239], ["the infectious agents", "TREATMENT", 268, 289], ["respiratory diseases", "PROBLEM", 329, 349], ["secondary", "OBSERVATION_MODIFIER", 21, 30], ["pathogens", "OBSERVATION", 31, 40], ["Respiratory Disease", "OBSERVATION", 70, 89], ["infectious", "OBSERVATION", 272, 282]]], ["In one of these studies involving breeding sows in five French farrow-to-finish herds [12] , results indicated that S. suis, a secondary pathogen, was quite widespread among sows-67.1% of the animals being positive using a PCR assay-and PCV2 and swIAV infections were highly prevalent (75% of the sows with antibodies against PCV2 and between 91.7% and 100% of the sows with antibodies against swIAV).", [["S. suis", "DISEASE", 116, 123], ["infections", "DISEASE", 252, 262], ["sows", "ORGANISM", 43, 47], ["S. suis", "ORGANISM", 116, 123], ["sows", "ORGANISM", 174, 178], ["animals", "ORGANISM", 192, 199], ["PCV2", "ORGANISM", 237, 241], ["swIAV", "ORGANISM", 246, 251], ["sows", "ORGANISM", 297, 301], ["PCV2", "ORGANISM", 326, 330], ["sows", "ORGANISM", 365, 369], ["antibodies", "PROTEIN", 307, 317], ["antibodies", "PROTEIN", 375, 385], ["swIAV", "PROTEIN", 394, 399], ["S. suis", "SPECIES", 116, 123], ["S. suis", "SPECIES", 116, 123], ["PCV2", "SPECIES", 237, 241], ["swIAV", "SPECIES", 246, 251], ["PCV2", "SPECIES", 326, 330], ["these studies", "TEST", 10, 23], ["S. suis", "PROBLEM", 116, 123], ["a secondary pathogen", "PROBLEM", 125, 145], ["a PCR assay", "TEST", 221, 232], ["PCV2", "PROBLEM", 237, 241], ["swIAV infections", "PROBLEM", 246, 262], ["antibodies", "TEST", 307, 317], ["PCV2", "TEST", 326, 330], ["antibodies", "TREATMENT", 375, 385]]], ["Other infectious agents such as A. pleuropneumoniae, G. parasuis and P. multocida were detected in 31%, 25%, and 23% of the sows, respectively [12] .", [["A. pleuropneumoniae", "ORGANISM", 32, 51], ["G. parasuis", "ORGANISM", 53, 64], ["P. multocida", "ORGANISM", 69, 81], ["A. pleuropneumoniae", "SPECIES", 32, 51], ["G. parasuis", "SPECIES", 53, 64], ["P. multocida", "SPECIES", 69, 81], ["A. pleuropneumoniae", "SPECIES", 32, 51], ["G. parasuis", "SPECIES", 53, 64], ["P. multocida", "SPECIES", 69, 81], ["Other infectious agents", "TREATMENT", 0, 23], ["A. pleuropneumoniae", "PROBLEM", 32, 51], ["P. multocida", "TEST", 69, 81], ["infectious", "OBSERVATION", 6, 16]]], ["In another study evaluating infectious agents associated with respiratory diseases in 125 farrow-to-finish pig herds in France, it has been shown that M. hyopneumoniae, PRRSV, and swIAV subtype H1N1 were the major pathogens involved in pneumonia-like gross lesions [8] .", [["respiratory", "ANATOMY", 62, 73], ["gross lesions", "ANATOMY", 251, 264], ["respiratory diseases", "DISEASE", 62, 82], ["pneumonia", "DISEASE", 236, 245], ["pig", "ORGANISM", 107, 110], ["M. hyopneumoniae", "ORGANISM", 151, 167], ["PRRSV", "ORGANISM", 169, 174], ["swIAV subtype H1N1", "ORGANISM", 180, 198], ["gross lesions", "PATHOLOGICAL_FORMATION", 251, 264], ["pig", "SPECIES", 107, 110], ["M. hyopneumoniae", "SPECIES", 151, 167], ["PRRSV", "SPECIES", 169, 174], ["swIAV subtype H1N1", "SPECIES", 180, 198], ["pig", "SPECIES", 107, 110], ["M. hyopneumoniae", "SPECIES", 151, 167], ["PRRSV", "SPECIES", 169, 174], ["swIAV subtype H1N1", "SPECIES", 180, 198], ["another study", "TEST", 3, 16], ["infectious agents", "TREATMENT", 28, 45], ["respiratory diseases", "PROBLEM", 62, 82], ["pig herds", "TREATMENT", 107, 116], ["M. hyopneumoniae", "PROBLEM", 151, 167], ["PRRSV", "PROBLEM", 169, 174], ["swIAV subtype H1N1", "PROBLEM", 180, 198], ["the major pathogens", "PROBLEM", 204, 223], ["pneumonia", "PROBLEM", 236, 245], ["gross lesions", "PROBLEM", 251, 264], ["hyopneumoniae", "OBSERVATION", 154, 167], ["pneumonia", "OBSERVATION", 236, 245], ["gross", "OBSERVATION_MODIFIER", 251, 256], ["lesions", "OBSERVATION", 257, 264]]], ["For extensive pleuritis, PRRSV was frequently associated with A. pleuropneumoniae [8, 12] .", [["pleuritis", "DISEASE", 14, 23], ["PRRSV", "ORGANISM", 25, 30], ["A. pleuropneumoniae", "ORGANISM", 62, 81], ["A. pleuropneumoniae", "SPECIES", 62, 81], ["PRRSV", "SPECIES", 25, 30], ["A. pleuropneumoniae", "SPECIES", 62, 81], ["extensive pleuritis", "PROBLEM", 4, 23], ["PRRSV", "PROBLEM", 25, 30], ["A. pleuropneumoniae", "PROBLEM", 62, 81], ["extensive", "OBSERVATION_MODIFIER", 4, 13], ["pleuritis", "OBSERVATION", 14, 23], ["pleuropneumoniae", "OBSERVATION", 65, 81]]], ["Regarding bacteria associated with lung lesions in 3731 French slaughter pigs [8] , a report mentioned lesions of pneumonia and pleuritis as the most frequent lesions.", [["lung lesions", "ANATOMY", 35, 47], ["lesions", "ANATOMY", 103, 110], ["lesions", "ANATOMY", 159, 166], ["lung lesions", "DISEASE", 35, 47], ["pneumonia", "DISEASE", 114, 123], ["pleuritis", "DISEASE", 128, 137], ["lung lesions", "PATHOLOGICAL_FORMATION", 35, 47], ["lesions", "PATHOLOGICAL_FORMATION", 103, 110], ["lesions", "PATHOLOGICAL_FORMATION", 159, 166], ["pigs", "SPECIES", 73, 77], ["bacteria", "PROBLEM", 10, 18], ["lung lesions", "PROBLEM", 35, 47], ["pneumonia", "PROBLEM", 114, 123], ["pleuritis", "PROBLEM", 128, 137], ["the most frequent lesions", "PROBLEM", 141, 166], ["lung", "ANATOMY", 35, 39], ["lesions", "OBSERVATION", 40, 47], ["lesions", "OBSERVATION", 103, 110], ["pneumonia", "OBSERVATION", 114, 123], ["pleuritis", "OBSERVATION", 128, 137], ["most frequent", "OBSERVATION_MODIFIER", 145, 158], ["lesions", "OBSERVATION", 159, 166]]], ["In these lesions, bacteria such as M. hyopneumoniae, P. multocida, A. pleuropneumoniae, S. suis, and G. parasuis were detected in 69.3%, 36.9%, 20.7%, 6.4%, and 0.99% of the lungs, respectively [13] .", [["lesions", "ANATOMY", 9, 16], ["lungs", "ANATOMY", 174, 179], ["lesions", "PATHOLOGICAL_FORMATION", 9, 16], ["M. hyopneumoniae", "ORGANISM", 35, 51], ["P. multocida", "ORGANISM", 53, 65], ["A. pleuropneumoniae", "ORGANISM", 67, 86], ["S. suis", "ORGANISM", 88, 95], ["G. parasuis", "ORGANISM", 101, 112], ["lungs", "ORGAN", 174, 179], ["M. hyopneumoniae", "SPECIES", 35, 51], ["P. multocida", "SPECIES", 53, 65], ["A. pleuropneumoniae", "SPECIES", 67, 86], ["S. suis", "SPECIES", 88, 95], ["G. parasuis", "SPECIES", 101, 112], ["M. hyopneumoniae", "SPECIES", 35, 51], ["P. multocida", "SPECIES", 53, 65], ["A. pleuropneumoniae", "SPECIES", 67, 86], ["S. suis", "SPECIES", 88, 95], ["G. parasuis", "SPECIES", 101, 112], ["these lesions", "PROBLEM", 3, 16], ["bacteria", "PROBLEM", 18, 26], ["M. hyopneumoniae", "PROBLEM", 35, 51], ["multocida", "PROBLEM", 56, 65], ["A. pleuropneumoniae", "TEST", 67, 86], ["S. suis", "TEST", 88, 95], ["G. parasuis", "TEST", 101, 112], ["lesions", "OBSERVATION", 9, 16], ["bacteria", "OBSERVATION_MODIFIER", 18, 26], ["M. hyopneumoniae", "OBSERVATION", 35, 51], ["lungs", "ANATOMY", 174, 179]]], ["In a retrospective analysis of the etiologic agents associated with respiratory diseases in pigs in USA, two or more infectious agents were identified in 88.2% of the analyzed cases [7] .", [["respiratory", "ANATOMY", 68, 79], ["respiratory diseases", "DISEASE", 68, 88], ["pigs", "ORGANISM", 92, 96], ["pigs", "SPECIES", 92, 96], ["pigs", "SPECIES", 92, 96], ["respiratory diseases", "PROBLEM", 68, 88], ["respiratory diseases", "OBSERVATION", 68, 88]]], ["PRRSV (35.4% of the samples), P. multocida (31.6%), M. hyopneumoniae (27%), swIAV (22.2%), G. parasuis (22.0%) and PCV2 (18.6%) were the infectious agents most frequently encountered [7] .", [["samples", "ANATOMY", 20, 27], ["P. multocida", "DISEASE", 30, 42], ["G. parasuis", "DISEASE", 91, 102], ["PRRSV", "ORGANISM", 0, 5], ["samples", "CANCER", 20, 27], ["P. multocida", "ORGANISM", 30, 42], ["M. hyopneumoniae", "ORGANISM", 52, 68], ["G. parasuis", "ORGANISM", 91, 102], ["PCV2", "ORGANISM", 115, 119], ["PRRSV", "SPECIES", 0, 5], ["P. multocida", "SPECIES", 30, 42], ["M. hyopneumoniae", "SPECIES", 52, 68], ["G. parasuis", "SPECIES", 91, 102], ["PRRSV", "SPECIES", 0, 5], ["P. multocida", "SPECIES", 30, 42], ["M. hyopneumoniae", "SPECIES", 52, 68], ["swIAV", "SPECIES", 76, 81], ["G. parasuis", "SPECIES", 91, 102], ["PCV2", "SPECIES", 115, 119], ["PRRSV", "TEST", 0, 5], ["the samples", "TEST", 16, 27], ["P. multocida", "TEST", 30, 42], ["M. hyopneumoniae", "PROBLEM", 52, 68], ["swIAV", "TEST", 76, 81], ["G. parasuis", "TEST", 91, 102], ["PCV2", "TEST", 115, 119], ["the infectious agents", "TREATMENT", 133, 154]]], ["In Korean pigs, PRRSV and PCV2 were frequently identified associated or not to various bacteria such as S. suis (25.2%), M. hyopneumoniae (20.1%), P. multocida (12.9%), and A. pleuropneumoniae (5%) [11] .Bacterium-bacterium interactions 3.4 Limitations of coinfection studies 4 Conclusion and perspectives ReferencesBelow we review the main primary pathogens as defined above, common viruses such as PRRSV, PCV2, swIAV, PRCoV and ADV as well as bacteria like A. pleuropneumoniae, M. hyopneumoniae and B. bronchiseptica.", [["P. multocida", "DISEASE", 147, 159], ["ADV", "CHEMICAL", 430, 433], ["pigs", "ORGANISM", 10, 14], ["PRRSV", "ORGANISM", 16, 21], ["PCV2", "ORGANISM", 26, 30], ["S. suis", "ORGANISM", 104, 111], ["M. hyopneumoniae", "ORGANISM", 121, 137], ["P. multocida", "ORGANISM", 147, 159], ["A. pleuropneumoniae", "ORGANISM", 173, 192], ["PRRSV", "ORGANISM", 400, 405], ["PCV2", "ORGANISM", 407, 411], ["swIAV", "GENE_OR_GENE_PRODUCT", 413, 418], ["PRCoV", "GENE_OR_GENE_PRODUCT", 420, 425], ["ADV", "ORGANISM", 430, 433], ["A. pleuropneumoniae", "ORGANISM", 459, 478], ["M. hyopneumoniae", "ORGANISM", 480, 496], ["B. bronchiseptica", "ORGANISM", 501, 518], ["pigs", "SPECIES", 10, 14], ["PRRSV", "SPECIES", 16, 21], ["S. suis", "SPECIES", 104, 111], ["M. hyopneumoniae", "SPECIES", 121, 137], ["P. multocida", "SPECIES", 147, 159], ["A. pleuropneumoniae", "SPECIES", 173, 192], ["PRRSV", "SPECIES", 400, 405], ["A. pleuropneumoniae", "SPECIES", 459, 478], ["M. hyopneumoniae", "SPECIES", 480, 496], ["B. bronchiseptica", "SPECIES", 501, 518], ["pigs", "SPECIES", 10, 14], ["PRRSV", "SPECIES", 16, 21], ["PCV2", "SPECIES", 26, 30], ["S. suis", "SPECIES", 104, 111], ["M. hyopneumoniae", "SPECIES", 121, 137], ["P. multocida", "SPECIES", 147, 159], ["A. pleuropneumoniae", "SPECIES", 173, 192], ["PRRSV", "SPECIES", 400, 405], ["PCV2", "SPECIES", 407, 411], ["swIAV", "SPECIES", 413, 418], ["PRCoV", "SPECIES", 420, 425], ["ADV", "SPECIES", 430, 433], ["A. pleuropneumoniae", "SPECIES", 459, 478], ["M. hyopneumoniae", "SPECIES", 480, 496], ["B. bronchiseptica", "SPECIES", 501, 518], ["Korean pigs", "TREATMENT", 3, 14], ["PRRSV", "PROBLEM", 16, 21], ["PCV2", "PROBLEM", 26, 30], ["various bacteria", "PROBLEM", 79, 95], ["S. suis", "TEST", 104, 111], ["M. hyopneumoniae", "PROBLEM", 121, 137], ["P. multocida", "TEST", 147, 159], ["A. pleuropneumoniae", "PROBLEM", 173, 192], ["Bacterium", "TEST", 204, 213], ["bacterium interactions", "PROBLEM", 214, 236], ["coinfection studies", "TEST", 256, 275], ["the main primary pathogens", "PROBLEM", 332, 358], ["common viruses", "PROBLEM", 377, 391], ["PRRSV", "PROBLEM", 400, 405], ["PCV2", "PROBLEM", 407, 411], ["swIAV", "PROBLEM", 413, 418], ["PRCoV", "PROBLEM", 420, 425], ["ADV", "TREATMENT", 430, 433], ["bacteria", "PROBLEM", 445, 453], ["A. pleuropneumoniae", "PROBLEM", 459, 478], ["M. hyopneumoniae", "PROBLEM", 480, 496], ["B. bronchiseptica", "PROBLEM", 501, 518], ["pleuropneumoniae", "OBSERVATION", 462, 478], ["hyopneumoniae", "OBSERVATION", 483, 496], ["bronchiseptica", "OBSERVATION", 504, 518]]], ["Conversely, other pathogens involved in the PRDC are not presented in the following sections while considered in Additional file 1 presenting the different coinfections' situations.Porcine reproductive and respiratory syndrome virusPRRSV is an enveloped single stranded positive RNA virus belonging to the Arteriviridae family.", [["sections", "ANATOMY", 84, 92], ["coinfections", "DISEASE", 156, 168], ["Porcine reproductive and respiratory syndrome virusPRRSV", "DISEASE", 181, 237], ["PRDC", "GENE_OR_GENE_PRODUCT", 44, 48], ["Porcine reproductive and respiratory syndrome virusPRRSV", "ORGANISM", 181, 237], ["Arteriviridae", "GENE_OR_GENE_PRODUCT", 306, 319], ["Arteriviridae family", "PROTEIN", 306, 326], ["Porcine", "SPECIES", 181, 188], ["Porcine reproductive and respiratory syndrome virusPRRSV", "PROBLEM", 181, 237], ["an enveloped single stranded positive RNA virus", "PROBLEM", 241, 288], ["respiratory syndrome", "OBSERVATION", 206, 226], ["positive RNA virus", "OBSERVATION", 270, 288]]], ["Two different species, PRRSV-1 (also known as Betaarterivirus suid 1), from European origin, and PRRSV-2 from American origin, are now distinguished [14] .", [["PRRSV-1", "ORGANISM", 23, 30], ["PRRSV", "SPECIES", 23, 28], ["PRRSV", "SPECIES", 97, 102], ["PRRSV-1", "SPECIES", 23, 30], ["PRRSV-2", "SPECIES", 97, 104], ["Two different species", "PROBLEM", 0, 21], ["PRRSV", "TEST", 23, 28], ["PRRSV", "PROBLEM", 97, 102], ["different", "OBSERVATION_MODIFIER", 4, 13], ["species", "OBSERVATION", 14, 21]]], ["This enveloped virus replicates mainly or exclusively in macrophages such as Alveolar Macrophages (AMs), but also macrophages from the nasal mucosa and Pulmonary Intravascular Macrophages (PIMs) [15, 16] .", [["macrophages", "ANATOMY", 57, 68], ["Alveolar Macrophages", "ANATOMY", 77, 97], ["AMs", "ANATOMY", 99, 102], ["macrophages", "ANATOMY", 114, 125], ["nasal mucosa", "ANATOMY", 135, 147], ["Pulmonary Intravascular Macrophages", "ANATOMY", 152, 187], ["PIMs", "ANATOMY", 189, 193], ["macrophages", "CELL", 57, 68], ["Alveolar Macrophages", "CELL", 77, 97], ["AMs", "CELL", 99, 102], ["macrophages", "CELL", 114, 125], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 135, 147], ["Pulmonary Intravascular Macrophages", "CELL", 152, 187], ["PIMs", "MULTI-TISSUE_STRUCTURE", 189, 193], ["macrophages", "CELL_TYPE", 57, 68], ["Alveolar Macrophages", "CELL_TYPE", 77, 97], ["AMs", "CELL_TYPE", 99, 102], ["macrophages", "CELL_TYPE", 114, 125], ["Pulmonary Intravascular Macrophages", "CELL_TYPE", 152, 187], ["PIMs", "CELL_TYPE", 189, 193], ["This enveloped virus", "PROBLEM", 0, 20], ["Alveolar Macrophages (AMs)", "PROBLEM", 77, 103], ["virus", "OBSERVATION", 15, 20], ["macrophages", "OBSERVATION", 57, 68], ["Alveolar Macrophages", "OBSERVATION", 77, 97], ["macrophages", "OBSERVATION", 114, 125], ["nasal mucosa", "ANATOMY", 135, 147], ["Pulmonary", "ANATOMY", 152, 161], ["Intravascular Macrophages", "OBSERVATION", 162, 187]]], ["In vitro, PRRSV can also replicate in cultured monocytes and monocyte-derived cells including macrophages [17] and in vitro-derived Dendritic Cells (DCs) generated either from Bone Marrow hematopoietic cells (BMDCs) or blood Monocytes (MoDCs), depending on the in vitro culture conditions [18, 19] .", [["monocytes", "ANATOMY", 47, 56], ["monocyte-derived cells", "ANATOMY", 61, 83], ["macrophages", "ANATOMY", 94, 105], ["Dendritic Cells", "ANATOMY", 132, 147], ["DCs", "ANATOMY", 149, 152], ["Bone Marrow hematopoietic cells", "ANATOMY", 176, 207], ["BMDCs", "ANATOMY", 209, 214], ["blood Monocytes", "ANATOMY", 219, 234], ["MoDCs", "ANATOMY", 236, 241], ["PRRSV", "ORGANISM", 10, 15], ["monocytes", "CELL", 47, 56], ["monocyte-derived cells", "CELL", 61, 83], ["macrophages [17]", "CELL", 94, 110], ["Dendritic Cells", "CELL", 132, 147], ["DCs", "CELL", 149, 152], ["Bone Marrow hematopoietic cells", "CELL", 176, 207], ["BMDCs", "CELL", 209, 214], ["blood Monocytes", "CELL", 219, 234], ["MoDCs", "CELL", 236, 241], ["cultured monocytes", "CELL_LINE", 38, 56], ["monocyte-derived cells", "CELL_TYPE", 61, 83], ["macrophages", "CELL_TYPE", 94, 105], ["Dendritic Cells", "CELL_TYPE", 132, 147], ["DCs", "CELL_TYPE", 149, 152], ["Bone Marrow hematopoietic cells", "CELL_TYPE", 176, 207], ["BMDCs", "CELL_TYPE", 209, 214], ["blood Monocytes", "CELL_TYPE", 219, 234], ["MoDCs", "CELL_TYPE", 236, 241], ["PRRSV", "SPECIES", 10, 15], ["monocytes", "TEST", 47, 56], ["monocyte", "TEST", 61, 69], ["macrophages", "TEST", 94, 105], ["vitro", "TEST", 118, 123], ["Dendritic Cells", "PROBLEM", 132, 147], ["Bone Marrow hematopoietic cells", "PROBLEM", 176, 207], ["BMDCs", "TEST", 209, 214], ["blood Monocytes", "TEST", 219, 234], ["the in vitro culture conditions", "TEST", 257, 288], ["Dendritic Cells", "OBSERVATION", 132, 147], ["Bone", "ANATOMY", 176, 180], ["Marrow hematopoietic cells", "OBSERVATION", 181, 207]]], ["However, such in vitro generated DCs are not representative of in vivo primary DCs which do not seem to be permissive to viral replication [20] .", [["DCs", "ANATOMY", 33, 36], ["DCs", "ANATOMY", 79, 82], ["DCs", "CELL", 33, 36], ["DCs", "CELL", 79, 82], ["DCs", "CELL_TYPE", 33, 36], ["primary DCs", "CELL_TYPE", 71, 82]]], ["In fact, MoDC and BMDC (at least when generated using Granulocyte Macrophage Colony-Stimulating Factor, GM-CSF) although possessing functional overlaps with the DC family, do not represent bona fide DCs, which represent an own lineage of hematopoietic cells distinct from the monocytic lineage [21] .", [["BMDC", "ANATOMY", 18, 22], ["DC", "ANATOMY", 161, 163], ["DCs", "ANATOMY", 199, 202], ["hematopoietic cells", "ANATOMY", 238, 257], ["monocytic lineage", "ANATOMY", 276, 293], ["MoDC", "GENE_OR_GENE_PRODUCT", 9, 13], ["BMDC", "CELL", 18, 22], ["Granulocyte Macrophage Colony-Stimulating Factor", "GENE_OR_GENE_PRODUCT", 54, 102], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 104, 110], ["DCs", "CELL", 199, 202], ["hematopoietic cells", "CELL", 238, 257], ["monocytic lineage", "CELL", 276, 293], ["MoDC", "CELL_TYPE", 9, 13], ["BMDC", "CELL_TYPE", 18, 22], ["Granulocyte Macrophage Colony-Stimulating Factor", "PROTEIN", 54, 102], ["GM", "PROTEIN", 104, 106], ["CSF", "PROTEIN", 107, 110], ["DC family", "PROTEIN", 161, 170], ["bona fide DCs", "CELL_TYPE", 189, 202], ["hematopoietic cells", "CELL_TYPE", 238, 257], ["Granulocyte Macrophage Colony", "TEST", 54, 83], ["Stimulating Factor", "TEST", 84, 102], ["hematopoietic cells", "PROBLEM", 238, 257], ["fide DCs", "OBSERVATION", 194, 202], ["hematopoietic cells", "OBSERVATION", 238, 257], ["monocytic lineage", "OBSERVATION", 276, 293]]], ["Different cell surface molecules are involved in PRRSV entry and infection of cells: heparan sulfate, porcine sialoadhesin-also known as sialic acid-binding immunoglobulin-type lectin 1 (Siglec-1), Siglec-10, CD151 and CD163 [22, 23] .", [["cell surface", "ANATOMY", 10, 22], ["cells", "ANATOMY", 78, 83], ["infection", "DISEASE", 65, 74], ["heparan sulfate", "CHEMICAL", 85, 100], ["cell", "CELL", 10, 14], ["PRRSV", "ORGANISM", 49, 54], ["cells", "CELL", 78, 83], ["heparan sulfate", "SIMPLE_CHEMICAL", 85, 100], ["porcine", "ORGANISM", 102, 109], ["sialoadhesin", "GENE_OR_GENE_PRODUCT", 110, 122], ["sialic acid-binding immunoglobulin-type lectin 1", "GENE_OR_GENE_PRODUCT", 137, 185], ["Siglec-1", "GENE_OR_GENE_PRODUCT", 187, 195], ["Siglec-10", "GENE_OR_GENE_PRODUCT", 198, 207], ["CD151", "GENE_OR_GENE_PRODUCT", 209, 214], ["CD163", "GENE_OR_GENE_PRODUCT", 219, 224], ["cell surface molecules", "PROTEIN", 10, 32], ["porcine sialoadhesin", "PROTEIN", 102, 122], ["sialic acid-binding immunoglobulin-type lectin 1", "PROTEIN", 137, 185], ["Siglec-1", "PROTEIN", 187, 195], ["Siglec-10", "PROTEIN", 198, 207], ["CD151", "PROTEIN", 209, 214], ["CD163", "PROTEIN", 219, 224], ["porcine", "SPECIES", 102, 109], ["PRRSV", "SPECIES", 49, 54], ["Different cell surface molecules", "PROBLEM", 0, 32], ["PRRSV entry", "PROBLEM", 49, 60], ["infection of cells", "PROBLEM", 65, 83], ["heparan sulfate", "TREATMENT", 85, 100], ["porcine sialoadhesin", "TREATMENT", 102, 122], ["sialic acid-binding immunoglobulin", "TEST", 137, 171], ["type lectin", "TEST", 172, 183], ["Siglec", "TEST", 187, 193], ["Siglec", "TEST", 198, 204], ["CD151", "TEST", 209, 214], ["CD163", "TEST", 219, 224], ["cell surface molecules", "OBSERVATION", 10, 32], ["PRRSV entry", "OBSERVATION", 49, 60], ["infection", "OBSERVATION", 65, 74]]], ["Heparan sulfate is a GlycosAminoGlycan (GAG) that seems to play a modest or secondary role in PRRSV infection since the blocking of this receptor on AMs induced only a mild decrease in PRRSV infectivity.", [["AMs", "ANATOMY", 149, 152], ["Heparan sulfate", "CHEMICAL", 0, 15], ["GlycosAminoGlycan", "CHEMICAL", 21, 38], ["GAG", "CHEMICAL", 40, 43], ["PRRSV infection", "DISEASE", 94, 109], ["Heparan sulfate", "CHEMICAL", 0, 15], ["GlycosAminoGlycan", "CHEMICAL", 21, 38], ["Heparan sulfate", "SIMPLE_CHEMICAL", 0, 15], ["GlycosAminoGlycan", "SIMPLE_CHEMICAL", 21, 38], ["GAG", "SIMPLE_CHEMICAL", 40, 43], ["PRRSV", "ORGANISM", 94, 99], ["AMs", "CELL", 149, 152], ["PRRSV", "ORGANISM", 185, 190], ["AMs", "CELL_TYPE", 149, 152], ["PRRSV", "SPECIES", 94, 99], ["PRRSV", "SPECIES", 185, 190], ["Heparan sulfate", "TREATMENT", 0, 15], ["a GlycosAminoGlycan (GAG)", "TREATMENT", 19, 44], ["PRRSV infection", "PROBLEM", 94, 109], ["a mild decrease in PRRSV infectivity", "PROBLEM", 166, 202], ["PRRSV infection", "OBSERVATION", 94, 109], ["mild", "OBSERVATION_MODIFIER", 168, 172], ["decrease", "OBSERVATION_MODIFIER", 173, 181], ["PRRSV infectivity", "OBSERVATION", 185, 202]]], ["Moreover, this effect was not observed with all the PRRSV isolates tested, suggesting that the involvement of heparan sulfate depends on the antigenic diversity of PRRSV [22] .", [["heparan sulfate", "CHEMICAL", 110, 125], ["sulfate", "CHEMICAL", 118, 125], ["PRRSV", "ORGANISM", 52, 57], ["heparan sulfate", "SIMPLE_CHEMICAL", 110, 125], ["PRRSV", "ORGANISM", 164, 169], ["PRRSV", "SPECIES", 52, 57], ["PRRSV", "SPECIES", 164, 169], ["the PRRSV isolates", "TEST", 48, 66], ["heparan sulfate", "TREATMENT", 110, 125], ["PRRSV", "PROBLEM", 164, 169]]], ["Siglec-1/CD169 is a member of the sialic acid-binding lectins (Siglecs) family and is expressed on macrophages [22] and Siglec-10 has been identified as an alternative receptor to Siglec-1 [23] .", [["macrophages", "ANATOMY", 99, 110], ["Siglec-1", "GENE_OR_GENE_PRODUCT", 0, 8], ["CD169", "GENE_OR_GENE_PRODUCT", 9, 14], ["sialic acid-binding lectins", "GENE_OR_GENE_PRODUCT", 34, 61], ["Siglecs", "GENE_OR_GENE_PRODUCT", 63, 70], ["macrophages", "CELL", 99, 110], ["Siglec-10", "GENE_OR_GENE_PRODUCT", 120, 129], ["Siglec-1", "GENE_OR_GENE_PRODUCT", 180, 188], ["Siglec-1/CD169", "PROTEIN", 0, 14], ["sialic acid-binding lectins (Siglecs) family", "PROTEIN", 34, 78], ["macrophages", "CELL_TYPE", 99, 110], ["Siglec-10", "PROTEIN", 120, 129], ["Siglec", "PROTEIN", 180, 186], ["Siglec", "TEST", 0, 6]]], ["Binding of PRRSV to Siglecs induces its internalisation by clathrin-mediated endocytosis.", [["PRRSV", "ORGANISM", 11, 16], ["Siglecs", "GENE_OR_GENE_PRODUCT", 20, 27], ["clathrin", "GENE_OR_GENE_PRODUCT", 59, 67], ["Siglecs", "PROTEIN", 20, 27], ["clathrin", "PROTEIN", 59, 67], ["PRRSV", "SPECIES", 11, 16], ["PRRSV", "PROBLEM", 11, 16], ["clathrin-mediated endocytosis", "PROBLEM", 59, 88], ["PRRSV", "OBSERVATION", 11, 16], ["endocytosis", "OBSERVATION", 77, 88]]], ["Expression of recombinant porcine sialoadhesin is sufficient to induce the internalisation of PRRSV by non-permissive cells, but not replication [24] .", [["cells", "ANATOMY", 118, 123], ["porcine", "ORGANISM", 26, 33], ["sialoadhesin", "GENE_OR_GENE_PRODUCT", 34, 46], ["PRRSV", "ORGANISM", 94, 99], ["cells", "CELL", 118, 123], ["recombinant porcine sialoadhesin", "PROTEIN", 14, 46], ["non-permissive cells", "CELL_TYPE", 103, 123], ["porcine", "SPECIES", 26, 33], ["porcine", "SPECIES", 26, 33], ["PRRSV", "SPECIES", 94, 99], ["recombinant porcine sialoadhesin", "TREATMENT", 14, 46]]], ["CD163 is a scavenger receptor involved in PRRSV infection [22] .", [["PRRSV infection", "DISEASE", 42, 57], ["CD163", "GENE_OR_GENE_PRODUCT", 0, 5], ["PRRSV", "ORGANISM", 42, 47], ["CD163", "PROTEIN", 0, 5], ["scavenger receptor", "PROTEIN", 11, 29], ["PRRSV", "SPECIES", 42, 47], ["a scavenger receptor", "TREATMENT", 9, 29], ["PRRSV infection", "PROBLEM", 42, 57], ["PRRSV infection", "OBSERVATION", 42, 57]]], ["Its expression on nonpermissive cells makes them susceptible to infection with PRRSV and allows productive replication of the virus [22] .", [["cells", "ANATOMY", 32, 37], ["infection", "DISEASE", 64, 73], ["cells", "CELL", 32, 37], ["PRRSV", "ORGANISM", 79, 84], ["PRRSV", "SPECIES", 79, 84], ["nonpermissive cells", "PROBLEM", 18, 37], ["infection", "PROBLEM", 64, 73], ["PRRSV", "PROBLEM", 79, 84], ["the virus", "PROBLEM", 122, 131], ["nonpermissive cells", "OBSERVATION", 18, 37], ["infection", "OBSERVATION", 64, 73]]], ["Moreover, CD169-KO animals are still susceptible to PRRSV-2 infection [22] , whereas CD163-KO animals are resistant to PRRSV-1 and PRRSV-2 [25, 26] .", [["infection", "DISEASE", 60, 69], ["CD169", "GENE_OR_GENE_PRODUCT", 10, 15], ["PRRSV-2", "ORGANISM", 52, 59], ["CD163", "GENE_OR_GENE_PRODUCT", 85, 90], ["PRRSV-1", "ORGANISM", 119, 126], ["PRRSV-2", "ORGANISM", 131, 138], ["CD169", "PROTEIN", 10, 15], ["CD163", "PROTEIN", 85, 90], ["PRRSV-2", "SPECIES", 52, 59], ["PRRSV-1", "SPECIES", 119, 126], ["Moreover", "TEST", 0, 8], ["CD169", "TEST", 10, 15], ["PRRSV", "PROBLEM", 52, 57], ["2 infection", "PROBLEM", 58, 69], ["CD163", "TEST", 85, 90], ["PRRSV", "TEST", 119, 124], ["PRRSV", "TEST", 131, 136]]], ["Finally, MYH9 has been recently identified as an indispensable partner of CD163 for PRRSV cell entry for both PRRSV-1 and PRRSV-2 [27] .Porcine reproductive and respiratory syndrome virusPRRS clinical signs can be nearly absent to severe depending on the considered PRRSV species and strains.", [["cell", "ANATOMY", 90, 94], ["Porcine reproductive and respiratory syndrome", "DISEASE", 136, 181], ["MYH9", "GENE_OR_GENE_PRODUCT", 9, 13], ["CD163", "GENE_OR_GENE_PRODUCT", 74, 79], ["PRRSV", "ORGANISM", 84, 89], ["cell", "CELL", 90, 94], ["PRRSV-1", "ORGANISM", 110, 117], ["PRRSV", "ORGANISM", 122, 127], ["Porcine reproductive", "ORGANISM", 136, 156], ["PRRSV", "ORGANISM", 266, 271], ["MYH9", "PROTEIN", 9, 13], ["CD163", "PROTEIN", 74, 79], ["Porcine", "SPECIES", 136, 143], ["PRRSV", "SPECIES", 84, 89], ["PRRSV-1", "SPECIES", 110, 117], ["PRRSV", "SPECIES", 266, 271], ["PRRSV cell entry", "TEST", 84, 100], ["PRRSV", "TEST", 110, 115], ["PRRSV", "TEST", 122, 127], ["Porcine reproductive and respiratory syndrome virusPRRS clinical signs", "PROBLEM", 136, 206], ["PRRSV species", "PROBLEM", 266, 279], ["strains", "PROBLEM", 284, 291], ["respiratory syndrome", "OBSERVATION", 161, 181]]], ["When observed, there are, amongst the most frequent, lethargy, dyspnea, tachypnea, as well as a reproductive disease [16] .", [["lethargy", "DISEASE", 53, 61], ["dyspnea", "DISEASE", 63, 70], ["tachypnea", "DISEASE", 72, 81], ["reproductive disease", "DISEASE", 96, 116], ["lethargy", "PROBLEM", 53, 61], ["dyspnea", "PROBLEM", 63, 70], ["tachypnea", "PROBLEM", 72, 81], ["a reproductive disease", "PROBLEM", 94, 116], ["tachypnea", "OBSERVATION", 72, 81]]], ["PRRSV can persist in infected pigs for several months after the initial infection particularly in lymphoid tissues and has the ability to alter the host's immune system to escape it (for review see [16] ).", [["lymphoid tissues", "ANATOMY", 98, 114], ["infection", "DISEASE", 72, 81], ["PRRSV", "ORGANISM", 0, 5], ["pigs", "ORGANISM", 30, 34], ["lymphoid tissues", "TISSUE", 98, 114], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 30, 34], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 30, 34], ["PRRSV", "PROBLEM", 0, 5], ["the initial infection", "PROBLEM", 60, 81], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["pigs", "OBSERVATION_MODIFIER", 30, 34], ["infection", "OBSERVATION", 72, 81], ["lymphoid tissues", "OBSERVATION", 98, 114]]], ["PRRSV interferes with the porcine innate immune response through downregulation of type I InterFeroNs (IFNs-IFN\u03b1 and IFN\u03b2 mostly), which are cytokines known for their antiviral properties [28] .", [["PRRSV", "ORGANISM", 0, 5], ["porcine", "ORGANISM", 26, 33], ["type I InterFeroNs", "GENE_OR_GENE_PRODUCT", 83, 101], ["IFNs-IFN\u03b1", "GENE_OR_GENE_PRODUCT", 103, 112], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 117, 121], ["type I InterFeroNs", "PROTEIN", 83, 101], ["IFNs", "PROTEIN", 103, 107], ["IFN\u03b1", "PROTEIN", 108, 112], ["IFN\u03b2", "PROTEIN", 117, 121], ["cytokines", "PROTEIN", 141, 150], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["the porcine innate immune response", "TREATMENT", 22, 56], ["type I InterFeroNs (IFNs-IFN\u03b1", "TREATMENT", 83, 112], ["IFN", "TREATMENT", 117, 120]]], ["PRRSV-infected macrophages also had a reduced capacity to produce the pro-inflammatory cytokines TNF\u03b1 and IL1\u03b2 [28] and the production of the anti-inflammatory cytokine IL10 was found enhanced during infection [29] .", [["macrophages", "ANATOMY", 15, 26], ["infection", "DISEASE", 200, 209], ["PRRSV", "ORGANISM", 0, 5], ["macrophages", "CELL", 15, 26], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 106, 110], ["IL10", "GENE_OR_GENE_PRODUCT", 169, 173], ["PRRSV-infected macrophages", "CELL_TYPE", 0, 26], ["pro-inflammatory cytokines", "PROTEIN", 70, 96], ["TNF\u03b1", "PROTEIN", 97, 101], ["IL1\u03b2", "PROTEIN", 106, 110], ["anti-inflammatory cytokine", "PROTEIN", 142, 168], ["IL10", "PROTEIN", 169, 173], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["infected macrophages", "PROBLEM", 6, 26], ["a reduced capacity", "PROBLEM", 36, 54], ["the pro-inflammatory cytokines TNF", "TEST", 66, 100], ["IL1", "TEST", 106, 109], ["the anti-inflammatory cytokine IL10", "TREATMENT", 138, 173], ["enhanced during infection", "PROBLEM", 184, 209], ["infected macrophages", "OBSERVATION", 6, 26], ["reduced", "OBSERVATION_MODIFIER", 38, 45], ["capacity", "OBSERVATION_MODIFIER", 46, 54], ["pro-inflammatory", "OBSERVATION_MODIFIER", 70, 86]]], ["Nevertheless, the role of cytokine modulation during PRRS is unclear considering that the effects appeared to depend on the PRRSV species, as well as on the PRRSV isolates, since opposite results can be found with different PRRSV strains [30, 31] .", [["PRRS", "DISEASE", 53, 57], ["PRRSV", "ORGANISM", 124, 129], ["PRRSV", "ORGANISM", 157, 162], ["PRRSV", "ORGANISM", 224, 229], ["cytokine", "PROTEIN", 26, 34], ["PRRS", "SPECIES", 53, 57], ["PRRSV", "SPECIES", 124, 129], ["PRRSV", "SPECIES", 157, 162], ["PRRSV", "SPECIES", 224, 229], ["cytokine modulation", "PROBLEM", 26, 45], ["the PRRSV species", "PROBLEM", 120, 137], ["the PRRSV isolates", "TEST", 153, 171], ["different PRRSV strains", "PROBLEM", 214, 237], ["PRRSV species", "OBSERVATION", 124, 137]]], ["In fact, some PRRSV-2 isolates were shown to enhance IFN\u03b1 production while other PRRSV-1 isolates suppressed it.", [["PRRSV-2", "ORGANISM", 14, 21], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 53, 57], ["PRRSV-1", "ORGANISM", 81, 88], ["IFN\u03b1", "PROTEIN", 53, 57], ["PRRSV-2", "SPECIES", 14, 21], ["PRRSV-1", "SPECIES", 81, 88], ["IFN\u03b1 production", "PROBLEM", 53, 68], ["other PRRSV", "TEST", 75, 86]]], ["Results seemed also very variable for the immunoregulatory IL10 along different isolates of PRRSV-1 [30, 31] , making general conclusions about how PRRSV alters innate immune responses difficult.", [["IL10", "GENE_OR_GENE_PRODUCT", 59, 63], ["PRRSV-1", "ORGANISM", 92, 99], ["PRRSV", "ORGANISM", 148, 153], ["immunoregulatory IL10", "PROTEIN", 42, 63], ["PRRSV-1", "SPECIES", 92, 99], ["PRRSV", "SPECIES", 148, 153], ["the immunoregulatory IL10", "TREATMENT", 38, 63], ["PRRSV", "TEST", 92, 97]]], ["PRRSV impact on adaptive cellular immunity seems also to be highly variable according to the species and the strain [20] .", [["cellular", "ANATOMY", 25, 33], ["PRRSV", "ORGANISM", 0, 5], ["cellular", "CELL", 25, 33], ["PRRSV", "SPECIES", 0, 5], ["PRRSV impact", "PROBLEM", 0, 12], ["adaptive cellular immunity", "TREATMENT", 16, 42]]], ["Conversely, whereas non-protective antibody response against the viral nucleocapsid is found within a week post-infection, neutralizing antibodies appearance is highly delayed for all PRRSV species and strains, appearing only after 3 or 4 weeks of infection and peaking even later [16] .Porcine circovirus type 2PCV2 is a naked circular single stranded DNA virus belonging to the Circoviridae family and responsible for Porcine CircoVirus Disease (PCVD).", [["infection", "DISEASE", 248, 257], ["Porcine CircoVirus Disease", "DISEASE", 420, 446], ["PCVD", "DISEASE", 448, 452], ["viral nucleocapsid", "ORGANISM", 65, 83], ["PRRSV", "ORGANISM", 184, 189], ["Porcine circovirus type 2PCV2", "ORGANISM", 287, 316], ["DNA", "CELLULAR_COMPONENT", 353, 356], ["Circoviridae", "GENE_OR_GENE_PRODUCT", 380, 392], ["PCVD", "CANCER", 448, 452], ["non-protective antibody", "PROTEIN", 20, 43], ["viral nucleocapsid", "PROTEIN", 65, 83], ["neutralizing antibodies", "PROTEIN", 123, 146], ["Porcine circovirus", "SPECIES", 287, 305], ["Porcine", "SPECIES", 420, 427], ["PRRSV", "SPECIES", 184, 189], ["Porcine circovirus type 2PCV2", "SPECIES", 287, 316], ["non-protective antibody response", "PROBLEM", 20, 52], ["the viral nucleocapsid", "PROBLEM", 61, 83], ["neutralizing antibodies appearance", "PROBLEM", 123, 157], ["all PRRSV species", "PROBLEM", 180, 197], ["strains", "PROBLEM", 202, 209], ["infection", "PROBLEM", 248, 257], ["Porcine circovirus type 2PCV2", "PROBLEM", 287, 316], ["a naked circular single stranded DNA virus", "PROBLEM", 320, 362], ["Porcine CircoVirus Disease (PCVD)", "PROBLEM", 420, 453], ["viral nucleocapsid", "OBSERVATION", 65, 83], ["infection", "OBSERVATION", 248, 257], ["circovirus", "OBSERVATION", 295, 305], ["CircoVirus Disease", "OBSERVATION", 428, 446]]], ["The attachment of PCV2 to target cells occurs through chondroitin sulfate B and probably other receptors [32] .", [["cells", "ANATOMY", 33, 38], ["chondroitin sulfate B", "CHEMICAL", 54, 75], ["chondroitin sulfate B", "CHEMICAL", 54, 75], ["PCV2", "ORGANISM", 18, 22], ["cells", "CELL", 33, 38], ["chondroitin sulfate B", "GENE_OR_GENE_PRODUCT", 54, 75], ["target cells", "CELL_TYPE", 26, 38], ["chondroitin sulfate B", "PROTEIN", 54, 75], ["PCV2", "PROBLEM", 18, 22], ["chondroitin sulfate B", "TREATMENT", 54, 75], ["PCV2", "OBSERVATION", 18, 22]]], ["Internalisation is not fully known but it does not seem to involve a specific receptor and the GAGs could mediate internalisation and binding to the target cells [33] .", [["cells", "ANATOMY", 156, 161], ["GAGs", "GENE_OR_GENE_PRODUCT", 95, 99], ["cells", "CELL", 156, 161], ["target cells", "CELL_TYPE", 149, 161]]], ["Most of the time the infection is subclinical but in some circumstances such as coinfections with other respiratory pathogens it can cause the Post-weaning Multisystemic Wasting Syndrome (PMWS), clinically characterized by wasting respiratory disease, and enteritis [34] .", [["respiratory", "ANATOMY", 231, 242], ["infection", "DISEASE", 21, 30], ["coinfections", "DISEASE", 80, 92], ["respiratory pathogens", "DISEASE", 104, 125], ["Multisystemic Wasting Syndrome", "DISEASE", 156, 186], ["PMWS", "DISEASE", 188, 192], ["wasting respiratory disease", "DISEASE", 223, 250], ["enteritis", "DISEASE", 256, 265], ["the infection", "PROBLEM", 17, 30], ["other respiratory pathogens", "PROBLEM", 98, 125], ["Multisystemic Wasting Syndrome", "PROBLEM", 156, 186], ["PMWS", "PROBLEM", 188, 192], ["wasting respiratory disease", "PROBLEM", 223, 250], ["enteritis", "PROBLEM", 256, 265], ["infection", "OBSERVATION", 21, 30], ["subclinical", "OBSERVATION_MODIFIER", 34, 45], ["Multisystemic", "OBSERVATION_MODIFIER", 156, 169], ["Wasting Syndrome", "OBSERVATION", 170, 186], ["wasting", "OBSERVATION_MODIFIER", 223, 230], ["respiratory disease", "OBSERVATION", 231, 250], ["enteritis", "OBSERVATION", 256, 265]]], ["Infection with PCV2 can occur in utero, resulting in stillborn piglets and mummified fetuses, or death at different ages after birth [34] .", [["fetuses", "ANATOMY", 85, 92], ["death", "DISEASE", 97, 102], ["PCV2", "ORGANISM", 15, 19], ["utero", "ORGAN", 33, 38], ["piglets", "ORGANISM_SUBDIVISION", 63, 70], ["fetuses", "ORGAN", 85, 92], ["piglets", "SPECIES", 63, 70], ["Infection", "PROBLEM", 0, 9], ["PCV2", "PROBLEM", 15, 19], ["mummified fetuses", "PROBLEM", 75, 92], ["death", "PROBLEM", 97, 102], ["PCV2", "OBSERVATION", 15, 19]]], ["In young and older animals, PCV2 was found in cells expressing monocytes (CD14 + ), and T and B cells (CD4 + , CD8 + , IgM + ) markers [35] .", [["cells", "ANATOMY", 46, 51], ["monocytes", "ANATOMY", 63, 72], ["T", "ANATOMY", 88, 89], ["B cells", "ANATOMY", 94, 101], ["CD4 + , CD8 +", "ANATOMY", 103, 116], ["PCV2", "ORGANISM", 28, 32], ["cells", "CELL", 46, 51], ["monocytes", "CELL", 63, 72], ["CD14", "GENE_OR_GENE_PRODUCT", 74, 78], ["T", "CELL", 88, 89], ["B cells", "CELL", 94, 101], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD8", "GENE_OR_GENE_PRODUCT", 111, 114], ["IgM", "GENE_OR_GENE_PRODUCT", 119, 122], ["monocytes", "CELL_TYPE", 63, 72], ["CD14", "PROTEIN", 74, 78], ["T and B cells", "CELL_TYPE", 88, 101], ["CD4", "PROTEIN", 103, 106], ["CD8", "PROTEIN", 111, 114], ["IgM", "PROTEIN", 119, 122], ["PCV2", "SPECIES", 28, 32], ["PCV2", "PROBLEM", 28, 32], ["monocytes", "TEST", 63, 72], ["CD14", "TEST", 74, 78], ["T", "TEST", 88, 89], ["CD4", "TEST", 103, 106], ["CD8", "TEST", 111, 114], ["IgM", "TEST", 119, 122], ["markers", "TEST", 127, 134]]], ["Further results showed that active replication of the virus was supported by T and B cells, with enhanced replication in proliferative cells [36] .", [["T", "ANATOMY", 77, 78], ["B cells", "ANATOMY", 83, 90], ["cells", "ANATOMY", 135, 140], ["T", "CELL", 77, 78], ["B cells", "CELL", 83, 90], ["proliferative cells", "CELL", 121, 140], ["T and B cells", "CELL_TYPE", 77, 90], ["proliferative cells", "CELL_TYPE", 121, 140], ["active replication of the virus", "PROBLEM", 28, 59], ["enhanced replication in proliferative cells", "PROBLEM", 97, 140], ["active", "OBSERVATION_MODIFIER", 28, 34], ["replication", "OBSERVATION", 35, 46], ["proliferative cells", "OBSERVATION", 121, 140]]], ["In vitro, PCV2 can also infect many other cell types including endothelial cells, gut epithelial cells, fibrocytes, and DCs [37] .", [["cell", "ANATOMY", 42, 46], ["endothelial cells", "ANATOMY", 63, 80], ["gut epithelial cells", "ANATOMY", 82, 102], ["fibrocytes", "ANATOMY", 104, 114], ["DCs", "ANATOMY", 120, 123], ["PCV2", "ORGANISM", 10, 14], ["cell", "CELL", 42, 46], ["endothelial cells", "CELL", 63, 80], ["gut epithelial cells", "CELL", 82, 102], ["fibrocytes", "CELL", 104, 114], ["DCs", "CELL", 120, 123], ["endothelial cells", "CELL_TYPE", 63, 80], ["gut epithelial cells", "CELL_TYPE", 82, 102], ["fibrocytes", "CELL_TYPE", 104, 114], ["DCs", "CELL_TYPE", 120, 123], ["PCV2", "SPECIES", 10, 14], ["PCV2", "PROBLEM", 10, 14], ["endothelial cells", "PROBLEM", 63, 80], ["gut epithelial cells", "TEST", 82, 102], ["fibrocytes", "TEST", 104, 114], ["DCs", "TEST", 120, 123], ["PCV2", "OBSERVATION", 10, 14], ["cell types", "OBSERVATION", 42, 52], ["endothelial cells", "OBSERVATION", 63, 80], ["epithelial cells", "OBSERVATION", 86, 102], ["fibrocytes", "OBSERVATION", 104, 114]]], ["In DCs the virus seems to persist and remain infective for a prolonged period without replication indicating that these cells might serve as a vehicle for virus spread in the host [38] .", [["DCs", "ANATOMY", 3, 6], ["cells", "ANATOMY", 120, 125], ["DCs", "CELL", 3, 6], ["cells", "CELL", 120, 125], ["DCs", "CELL_TYPE", 3, 6], ["the virus", "PROBLEM", 7, 16], ["infective", "PROBLEM", 45, 54], ["these cells", "PROBLEM", 114, 125], ["virus spread", "PROBLEM", 155, 167], ["virus", "OBSERVATION", 11, 16], ["infective", "OBSERVATION", 45, 54]]], ["PMWS is characterized by the depletion of lymphoid cells affecting T cells, B cells, and NK cells [39] .", [["lymphoid cells", "ANATOMY", 42, 56], ["T cells", "ANATOMY", 67, 74], ["B cells", "ANATOMY", 76, 83], ["NK cells", "ANATOMY", 89, 97], ["PMWS", "DISEASE", 0, 4], ["lymphoid cells", "CELL", 42, 56], ["T cells", "CELL", 67, 74], ["B cells", "CELL", 76, 83], ["NK cells", "CELL", 89, 97], ["lymphoid cells", "CELL_TYPE", 42, 56], ["T cells", "CELL_TYPE", 67, 74], ["B cells", "CELL_TYPE", 76, 83], ["NK cells", "CELL_TYPE", 89, 97], ["PMWS", "PROBLEM", 0, 4], ["lymphoid cells", "PROBLEM", 42, 56], ["T cells", "PROBLEM", 67, 74], ["B cells", "TEST", 76, 83], ["NK cells", "TEST", 89, 97], ["depletion", "OBSERVATION_MODIFIER", 29, 38], ["lymphoid cells", "OBSERVATION", 42, 56], ["NK cells", "OBSERVATION", 89, 97]]], ["This lymphopenia was also associated with impaired responses of Peripheral Blood Mononuclear Cells (PBMCs) to mitogen stimulation with lower levels of IL2, IFN\u03b3, and IL4 production compared to PBMCs from non-infected pigs [40] .", [["Peripheral Blood Mononuclear Cells", "ANATOMY", 64, 98], ["PBMCs", "ANATOMY", 100, 105], ["PBMCs", "ANATOMY", 193, 198], ["lymphopenia", "DISEASE", 5, 16], ["Peripheral Blood Mononuclear Cells", "CELL", 64, 98], ["PBMCs", "CELL", 100, 105], ["IL2", "GENE_OR_GENE_PRODUCT", 151, 154], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 156, 160], ["IL4", "GENE_OR_GENE_PRODUCT", 166, 169], ["PBMCs", "CELL", 193, 198], ["pigs", "ORGANISM", 217, 221], ["Peripheral Blood Mononuclear Cells", "CELL_TYPE", 64, 98], ["PBMCs", "CELL_TYPE", 100, 105], ["mitogen", "PROTEIN", 110, 117], ["IL2", "PROTEIN", 151, 154], ["IFN\u03b3", "PROTEIN", 156, 160], ["IL4", "PROTEIN", 166, 169], ["PBMCs", "CELL_TYPE", 193, 198], ["pigs", "SPECIES", 217, 221], ["This lymphopenia", "PROBLEM", 0, 16], ["impaired responses", "PROBLEM", 42, 60], ["Peripheral Blood Mononuclear Cells (PBMCs)", "TREATMENT", 64, 106], ["mitogen stimulation", "TEST", 110, 129], ["lower levels of IL2", "PROBLEM", 135, 154], ["IFN\u03b3", "PROBLEM", 156, 160], ["IL4 production", "PROBLEM", 166, 180], ["PBMCs", "TEST", 193, 198], ["lymphopenia", "OBSERVATION", 5, 16], ["Peripheral", "ANATOMY_MODIFIER", 64, 74], ["Blood", "ANATOMY", 75, 80], ["Mononuclear Cells", "OBSERVATION", 81, 98]]], ["Another feature of PMWS is an elevated level of IL10 found in lymphoid organs, especially in the T cells rich areas [41] .", [["lymphoid organs", "ANATOMY", 62, 77], ["T cells", "ANATOMY", 97, 104], ["PMWS", "DISEASE", 19, 23], ["IL10", "GENE_OR_GENE_PRODUCT", 48, 52], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 62, 77], ["T cells", "CELL", 97, 104], ["IL10", "PROTEIN", 48, 52], ["T cells", "CELL_TYPE", 97, 104], ["PMWS", "PROBLEM", 19, 23], ["an elevated level of IL10", "PROBLEM", 27, 52], ["lymphoid organs", "PROBLEM", 62, 77], ["PMWS", "OBSERVATION", 19, 23], ["elevated", "OBSERVATION_MODIFIER", 30, 38], ["lymphoid organs", "OBSERVATION", 62, 77]]], ["IL10-mediated immunosuppression could play an important role in the PCV2 infection and the development of PMWS.", [["PCV2 infection", "DISEASE", 68, 82], ["PMWS", "DISEASE", 106, 110], ["IL10", "GENE_OR_GENE_PRODUCT", 0, 4], ["PCV2", "ORGANISM", 68, 72], ["IL10", "PROTEIN", 0, 4], ["PCV2", "SPECIES", 68, 72], ["IL10-mediated immunosuppression", "TREATMENT", 0, 31], ["the PCV2 infection", "PROBLEM", 64, 82], ["PMWS", "PROBLEM", 106, 110], ["immunosuppression", "OBSERVATION", 14, 31], ["PCV2 infection", "OBSERVATION", 68, 82]]], ["PCV2 has also the ability to alter the innate immune response [42] .", [["PCV2", "ORGANISM", 0, 4], ["PCV2", "SPECIES", 0, 4], ["PCV2", "TREATMENT", 0, 4]]], ["Even though the virus does not productively infect DCs, evidence shows that it can interfere with the normal plasmacytoid DCs (pDCs) response.", [["DCs", "ANATOMY", 51, 54], ["plasmacytoid DCs", "ANATOMY", 109, 125], ["pDCs", "ANATOMY", 127, 131], ["DCs", "CELL", 51, 54], ["plasmacytoid DCs", "CELL", 109, 125], ["pDCs", "CELL", 127, 131], ["DCs", "CELL_TYPE", 51, 54], ["plasmacytoid DCs", "CELL_TYPE", 109, 125], ["pDCs", "CELL_TYPE", 127, 131], ["the virus", "PROBLEM", 12, 21], ["virus", "OBSERVATION", 16, 21], ["plasmacytoid DCs", "OBSERVATION", 109, 125]]], ["Upon stimulation with CpG-ODN, pDCs' ability to produce IFN\u03b1 and TNF\u03b1 was impaired in cells previously infected with PCV2 [43] .", [["pDCs", "ANATOMY", 31, 35], ["cells", "ANATOMY", 86, 91], ["CpG-ODN", "CHEMICAL", 22, 29], ["CpG-ODN", "GENE_OR_GENE_PRODUCT", 22, 29], ["pDCs", "CELL", 31, 35], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 56, 60], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 65, 69], ["cells", "CELL", 86, 91], ["PCV2", "ORGANISM", 117, 121], ["pDCs", "CELL_TYPE", 31, 35], ["IFN\u03b1", "PROTEIN", 56, 60], ["TNF\u03b1", "PROTEIN", 65, 69], ["CpG-ODN", "TREATMENT", 22, 29], ["pDCs", "PROBLEM", 31, 35], ["IFN", "TEST", 56, 59], ["TNF", "PROBLEM", 65, 68], ["impaired in cells", "PROBLEM", 74, 91], ["PCV2", "PROBLEM", 117, 121]]], ["PCV2 DNA isolated from infected cells induced the suppression of pDC IFN\u03b1 production [43] .Swine influenza A virusInfluenza A viruses are enveloped single stranded negative RNA viruses belonging to the Orthomyxoviridae family.", [["cells", "ANATOMY", 32, 37], ["PCV2", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 5, 8], ["cells", "CELL", 32, 37], ["pDC IFN\u03b1", "GENE_OR_GENE_PRODUCT", 65, 73], ["Swine influenza A virusInfluenza A viruses", "ORGANISM", 91, 133], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 202, 218], ["PCV2 DNA", "DNA", 0, 8], ["infected cells", "CELL_TYPE", 23, 37], ["IFN", "PROTEIN", 69, 72], ["Orthomyxoviridae family", "PROTEIN", 202, 225], ["Swine influenza", "SPECIES", 91, 106], ["A virusInfluenza A viruses", "SPECIES", 107, 133], ["PCV2", "SPECIES", 0, 4], ["Swine influenza A virusInfluenza A viruses", "SPECIES", 91, 133], ["PCV2 DNA", "PROBLEM", 0, 8], ["infected cells", "PROBLEM", 23, 37], ["Swine influenza A virusInfluenza A viruses", "PROBLEM", 91, 133], ["infected cells", "OBSERVATION", 23, 37]]], ["These enveloped viruses can infect a broad range of hosts, with pigs being one of their natural hosts (for a review see [44] ).", [["pigs", "ORGANISM", 64, 68], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 64, 68], ["These enveloped viruses", "PROBLEM", 0, 23], ["pigs", "TREATMENT", 64, 68], ["viruses", "OBSERVATION", 16, 23]]], ["The three main IAV subtypes encountered in pigs are H1N1, H1N2, and H3N2 [44] , but many genetic lineages and antigenic variants within these subtypes are co-circulating in the pig population worldwide.", [["IAV", "ORGANISM", 15, 18], ["pigs", "ORGANISM", 43, 47], ["H3N2 [44", "ORGANISM", 68, 76], ["pig", "ORGANISM", 177, 180], ["pigs", "SPECIES", 43, 47], ["pig", "SPECIES", 177, 180], ["pigs", "SPECIES", 43, 47], ["pig", "SPECIES", 177, 180], ["H1N1", "PROBLEM", 52, 56], ["H1N2", "PROBLEM", 58, 62], ["H3N2", "PROBLEM", 68, 72], ["many genetic lineages", "PROBLEM", 84, 105], ["antigenic variants", "PROBLEM", 110, 128], ["main", "OBSERVATION_MODIFIER", 10, 14], ["IAV subtypes", "OBSERVATION", 15, 27], ["H1N1", "OBSERVATION", 52, 56], ["genetic lineages", "OBSERVATION", 89, 105], ["antigenic variants", "OBSERVATION", 110, 128], ["pig population", "OBSERVATION", 177, 191]]], ["Subclinical infections with swIAVs are common in pigs, but they can also induce a disease similar to what is observed in humans, with upper respiratory tract distress associated with fever, cough, rhinitis, high morbidity, and low mortality [44] .", [["respiratory tract", "ANATOMY", 140, 157], ["Subclinical infections", "DISEASE", 0, 22], ["swIAVs", "DISEASE", 28, 34], ["respiratory tract distress", "DISEASE", 140, 166], ["fever", "DISEASE", 183, 188], ["cough", "DISEASE", 190, 195], ["rhinitis", "DISEASE", 197, 205], ["pigs", "ORGANISM", 49, 53], ["humans", "ORGANISM", 121, 127], ["upper", "ORGANISM_SUBDIVISION", 134, 139], ["respiratory tract", "ORGANISM_SUBDIVISION", 140, 157], ["pigs", "SPECIES", 49, 53], ["humans", "SPECIES", 121, 127], ["pigs", "SPECIES", 49, 53], ["humans", "SPECIES", 121, 127], ["Subclinical infections", "PROBLEM", 0, 22], ["swIAVs", "PROBLEM", 28, 34], ["a disease", "PROBLEM", 80, 89], ["upper respiratory tract distress", "PROBLEM", 134, 166], ["fever", "PROBLEM", 183, 188], ["cough", "PROBLEM", 190, 195], ["rhinitis", "PROBLEM", 197, 205], ["high morbidity", "PROBLEM", 207, 221], ["low mortality", "PROBLEM", 227, 240], ["infections", "OBSERVATION", 12, 22], ["disease", "OBSERVATION", 82, 89], ["upper", "ANATOMY_MODIFIER", 134, 139], ["respiratory tract", "ANATOMY", 140, 157], ["rhinitis", "OBSERVATION", 197, 205], ["high", "OBSERVATION_MODIFIER", 207, 211], ["morbidity", "OBSERVATION_MODIFIER", 212, 221]]], ["The main targets of swIAVs are epithelial cells of the respiratory tract but IAVs can also non-productively infect alveolar macrophages [45] .", [["swIAVs", "ANATOMY", 20, 26], ["epithelial cells", "ANATOMY", 31, 47], ["respiratory tract", "ANATOMY", 55, 72], ["IAVs", "ANATOMY", 77, 81], ["alveolar macrophages", "ANATOMY", 115, 135], ["swIAVs", "CELL", 20, 26], ["epithelial cells", "CELL", 31, 47], ["respiratory tract", "ORGAN", 55, 72], ["IAVs", "GENE_OR_GENE_PRODUCT", 77, 81], ["alveolar macrophages", "CELL", 115, 135], ["swIAVs", "PROTEIN", 20, 26], ["epithelial cells", "CELL_TYPE", 31, 47], ["alveolar macrophages", "CELL_TYPE", 115, 135], ["epithelial cells of the respiratory tract", "PROBLEM", 31, 72], ["IAVs", "PROBLEM", 77, 81], ["main", "OBSERVATION_MODIFIER", 4, 8], ["targets", "OBSERVATION_MODIFIER", 9, 16], ["epithelial cells", "OBSERVATION", 31, 47], ["respiratory tract", "ANATOMY", 55, 72], ["infect", "OBSERVATION_MODIFIER", 108, 114], ["alveolar macrophages", "OBSERVATION", 115, 135]]], ["Two major glycoproteins are present at the surface of the virus: HemAgglutinin (HA) and NeurAminidase (NA).", [["surface", "ANATOMY", 43, 50], ["NeurAminidase", "CHEMICAL", 88, 101], ["NA", "CHEMICAL", 103, 105], ["surface", "CELLULAR_COMPONENT", 43, 50], ["HemAgglutinin", "GENE_OR_GENE_PRODUCT", 65, 78], ["HA", "GENE_OR_GENE_PRODUCT", 80, 82], ["NeurAminidase", "SIMPLE_CHEMICAL", 88, 101], ["NA", "SIMPLE_CHEMICAL", 103, 105], ["Two major glycoproteins", "PROBLEM", 0, 23], ["HemAgglutinin (HA)", "TREATMENT", 65, 83], ["NeurAminidase (NA)", "TREATMENT", 88, 106], ["major", "OBSERVATION_MODIFIER", 4, 9], ["glycoproteins", "OBSERVATION", 10, 23], ["virus", "OBSERVATION", 58, 63]]], ["Binding of HA with the sialic acid molecules at the surface of the host cells will induce the endocytosis of the viral particle [44] .", [["surface", "ANATOMY", 52, 59], ["cells", "ANATOMY", 72, 77], ["sialic acid", "CHEMICAL", 23, 34], ["sialic acid", "CHEMICAL", 23, 34], ["HA", "GENE_OR_GENE_PRODUCT", 11, 13], ["sialic acid", "SIMPLE_CHEMICAL", 23, 34], ["surface", "CELLULAR_COMPONENT", 52, 59], ["host cells", "CELL", 67, 77], ["sialic acid molecules", "PROTEIN", 23, 44], ["host cells", "CELL_TYPE", 67, 77], ["HA", "PROBLEM", 11, 13], ["the sialic acid molecules", "PROBLEM", 19, 44], ["host cells", "OBSERVATION", 67, 77]]], ["The NA molecule plays the main role in the budding of the virus by removing the sialic acid, allowing the release of neoformed virus particles from the infected cell [44] .", [["cell", "ANATOMY", 161, 165], ["NA", "CHEMICAL", 4, 6], ["sialic acid", "CHEMICAL", 80, 91], ["sialic acid", "CHEMICAL", 80, 91], ["NA molecule", "GENE_OR_GENE_PRODUCT", 4, 15], ["sialic acid", "SIMPLE_CHEMICAL", 80, 91], ["cell", "CELL", 161, 165], ["NA molecule", "PROTEIN", 4, 15], ["the virus", "PROBLEM", 54, 63], ["the sialic acid", "TREATMENT", 76, 91], ["neoformed virus particles", "TREATMENT", 117, 142], ["NA molecule", "OBSERVATION", 4, 15], ["main", "OBSERVATION_MODIFIER", 26, 30], ["infected cell", "OBSERVATION", 152, 165]]], ["The innate response against the virus includes production of high levels of pro-inflammatory cytokines such as IFN\u03b1, TNF\u03b1, and IL6.", [["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 111, 115], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 117, 121], ["IL6", "GENE_OR_GENE_PRODUCT", 127, 130], ["pro-inflammatory cytokines", "PROTEIN", 76, 102], ["IFN\u03b1", "PROTEIN", 111, 115], ["TNF\u03b1", "PROTEIN", 117, 121], ["IL6", "PROTEIN", 127, 130], ["the virus", "PROBLEM", 28, 37], ["high levels of pro-inflammatory cytokines", "PROBLEM", 61, 102], ["IFN\u03b1", "TEST", 111, 115], ["TNF", "TEST", 117, 120], ["IL6", "PROBLEM", 127, 130], ["high levels", "OBSERVATION_MODIFIER", 61, 72], ["pro-inflammatory cytokines", "OBSERVATION", 76, 102]]], ["DCs, in particular pDCs play an important role in this response [46] .", [["DCs", "ANATOMY", 0, 3], ["pDCs", "ANATOMY", 19, 23], ["DCs", "CELL", 0, 3], ["pDCs", "CELL", 19, 23], ["DCs", "CELL_TYPE", 0, 3], ["pDCs", "CELL_TYPE", 19, 23]]], ["An important observation was that the production of these cytokines correlated to the viral loads and the severity of the disease.", [["cytokines", "PROTEIN", 58, 67], ["these cytokines", "PROBLEM", 52, 67], ["the viral loads", "PROBLEM", 82, 97], ["the disease", "PROBLEM", 118, 129], ["viral loads", "OBSERVATION", 86, 97], ["disease", "OBSERVATION", 122, 129]]], ["Infection with swIAV induces cellular and humoral specific immune responses in pigs recovering from the disease and the serum IgG and the mucosal IgA can protect the animal from re-infection [44] .", [["cellular", "ANATOMY", 29, 37], ["serum", "ANATOMY", 120, 125], ["mucosal", "ANATOMY", 138, 145], ["swIAV", "CHEMICAL", 15, 20], ["cellular", "CELL", 29, 37], ["pigs", "ORGANISM", 79, 83], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["IgG", "GENE_OR_GENE_PRODUCT", 126, 129], ["IgA", "GENE_OR_GENE_PRODUCT", 146, 149], ["serum IgG", "PROTEIN", 120, 129], ["mucosal IgA", "PROTEIN", 138, 149], ["pigs", "SPECIES", 79, 83], ["pigs", "SPECIES", 79, 83], ["Infection", "PROBLEM", 0, 9], ["the disease", "PROBLEM", 100, 111], ["the serum IgG", "TEST", 116, 129], ["the mucosal IgA", "TREATMENT", 134, 149], ["re-infection", "PROBLEM", 178, 190], ["disease", "OBSERVATION", 104, 111], ["mucosal", "ANATOMY", 138, 145], ["IgA", "OBSERVATION", 146, 149]]], ["NS1 and PA-X are the main viral proteins that alter the innate immune response, mainly by blocking the type I IFN response [47] as well as the NLRP3 inflammasome activation [48] in infected-epithelial cells and alveolar macrophages.", [["epithelial cells", "ANATOMY", 190, 206], ["alveolar macrophages", "ANATOMY", 211, 231], ["NS1", "GENE_OR_GENE_PRODUCT", 0, 3], ["PA-X", "GENE_OR_GENE_PRODUCT", 8, 12], ["type I IFN", "GENE_OR_GENE_PRODUCT", 103, 113], ["NLRP3", "GENE_OR_GENE_PRODUCT", 143, 148], ["-epithelial cells", "CELL", 189, 206], ["alveolar macrophages", "CELL", 211, 231], ["NS1", "PROTEIN", 0, 3], ["PA", "PROTEIN", 8, 10], ["X", "PROTEIN", 11, 12], ["viral proteins", "PROTEIN", 26, 40], ["IFN", "PROTEIN", 110, 113], ["NLRP3", "PROTEIN", 143, 148], ["infected-epithelial cells", "CELL_TYPE", 181, 206], ["alveolar macrophages", "CELL_TYPE", 211, 231], ["NS1", "PROBLEM", 0, 3], ["the NLRP3 inflammasome activation", "TEST", 139, 172], ["main", "OBSERVATION_MODIFIER", 21, 25], ["viral proteins", "OBSERVATION", 26, 40], ["epithelial cells", "OBSERVATION", 190, 206], ["alveolar macrophages", "OBSERVATION", 211, 231]]], ["Finally, the main mechanisms through which the swIAV escapes the adaptive host immune system are the antigenic drift and the antigenic shift concerning mainly HA and NA which are also the two major antigenic proteins expressed on the surface of the virus and against which the neutralizing humoral response is directed [44] .Porcine respiratory alphacoronavirusPRCoV is an enveloped single stranded positive RNA virus belonging to the Coronaviridae family.", [["surface", "ANATOMY", 234, 241], ["alphacoronavirusPRCoV", "CHEMICAL", 345, 366], ["swIAV", "GENE_OR_GENE_PRODUCT", 47, 52], ["HA", "GENE_OR_GENE_PRODUCT", 159, 161], ["surface", "CELLULAR_COMPONENT", 234, 241], ["Porcine", "ORGANISM", 325, 332], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 435, 448], ["swIAV", "PROTEIN", 47, 52], ["antigenic proteins", "PROTEIN", 198, 216], ["Coronaviridae family", "PROTEIN", 435, 455], ["Porcine", "SPECIES", 325, 332], ["Porcine respiratory alphacoronavirusPRCoV", "SPECIES", 325, 366], ["the swIAV escapes", "PROBLEM", 43, 60], ["the antigenic drift", "PROBLEM", 97, 116], ["the antigenic shift", "PROBLEM", 121, 140], ["mainly HA and NA", "PROBLEM", 152, 168], ["the two major antigenic proteins", "PROBLEM", 184, 216], ["the virus", "TREATMENT", 245, 254], ["Porcine respiratory alphacoronavirusPRCoV", "PROBLEM", 325, 366], ["an enveloped single stranded positive RNA virus", "PROBLEM", 370, 417], ["main", "OBSERVATION_MODIFIER", 13, 17], ["antigenic drift", "OBSERVATION", 101, 116], ["respiratory alphacoronavirusPRCoV", "OBSERVATION", 333, 366], ["positive RNA virus", "OBSERVATION", 399, 417]]], ["In pigs, four Alphacoronavirus, one Betacoronavirus and one Deltacoronavirus have been described [49, 50] .", [["pigs", "ORGANISM", 3, 7], ["Betacoronavirus", "CANCER", 36, 51], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 60, 76], ["pigs", "SPECIES", 3, 7], ["pigs", "SPECIES", 3, 7]]], ["Thus, most of the porcine coronaviruses are from the genus Alphacoronavirus.", [["porcine coronaviruses", "ORGANISM", 18, 39], ["porcine", "SPECIES", 18, 25], ["porcine coronaviruses", "SPECIES", 18, 39], ["the porcine coronaviruses", "PROBLEM", 14, 39], ["porcine coronaviruses", "OBSERVATION", 18, 39], ["genus Alphacoronavirus", "OBSERVATION", 53, 75]]], ["The only respiratory porcine coronavirus, PRCoV, is a variant of Transmissible Gastroenteritis Virus (TGEV) where a large 5\u2032 region deletion (nucleotides 621-681) in the Spike gene of the virus altered the tropism and the virulence.", [["respiratory porcine coronavirus", "DISEASE", 9, 40], ["Transmissible Gastroenteritis Virus", "DISEASE", 65, 100], ["nucleotides 621-681", "CHEMICAL", 142, 161], ["porcine coronavirus", "ORGANISM", 21, 40], ["PRCoV", "GENE_OR_GENE_PRODUCT", 42, 47], ["Transmissible Gastroenteritis Virus", "ORGANISM", 65, 100], ["TGEV", "ORGANISM", 102, 106], ["Spike", "GENE_OR_GENE_PRODUCT", 170, 175], ["5\u2032 region deletion", "DNA", 122, 140], ["nucleotides 621-681", "DNA", 142, 161], ["Spike gene", "DNA", 170, 180], ["porcine coronavirus", "SPECIES", 21, 40], ["porcine coronavirus", "SPECIES", 21, 40], ["Transmissible Gastroenteritis Virus", "SPECIES", 65, 100], ["TGEV", "SPECIES", 102, 106], ["The only respiratory porcine coronavirus", "PROBLEM", 0, 40], ["Transmissible Gastroenteritis Virus", "PROBLEM", 65, 100], ["a large 5\u2032 region deletion", "PROBLEM", 114, 140], ["nucleotides", "TEST", 142, 153], ["the virus", "PROBLEM", 184, 193], ["the tropism", "PROBLEM", 202, 213], ["the virulence", "PROBLEM", 218, 231], ["respiratory porcine coronavirus", "OBSERVATION", 9, 40], ["Transmissible", "OBSERVATION_MODIFIER", 65, 78], ["Gastroenteritis", "OBSERVATION", 79, 94], ["large", "OBSERVATION_MODIFIER", 116, 121], ["virus", "OBSERVATION", 188, 193]]], ["Even if pigs have been shown to be susceptible to the first SARS-CoV (serological evidence and isolation of the virus in a pig farm in the Xiqing County of Tianjin, China) [51] they have not been successfully experimentally infected, at this stage, by SARS-CoV-2 [52] .", [["SARS", "DISEASE", 60, 64], ["pigs", "ORGANISM", 8, 12], ["SARS-CoV", "ORGANISM", 60, 68], ["pig", "ORGANISM", 123, 126], ["pigs", "SPECIES", 8, 12], ["pig", "SPECIES", 123, 126], ["pigs", "SPECIES", 8, 12], ["SARS-CoV", "SPECIES", 60, 68], ["pig", "SPECIES", 123, 126], ["SARS-CoV", "SPECIES", 252, 260], ["the first SARS", "PROBLEM", 50, 64], ["the virus", "PROBLEM", 108, 117], ["infected", "OBSERVATION", 224, 232]]], ["PRCoV uses aminopeptidase-N (CD13) domain IV to enter cells [53] and replicates to high titers in the lungs (1 \u00d7 10 7 -10 8 Tissue Culture Infectious Dose 50-TCID 50 ) specifically in type 1 and 2 pneumocytes.", [["cells", "ANATOMY", 54, 59], ["lungs", "ANATOMY", 102, 107], ["pneumocytes", "ANATOMY", 197, 208], ["aminopeptidase-N (CD13) domain IV", "GENE_OR_GENE_PRODUCT", 11, 44], ["cells", "CELL", 54, 59], ["lungs", "ORGAN", 102, 107], ["2 pneumocytes", "CELL", 195, 208], ["PRCoV", "PROTEIN", 0, 5], ["aminopeptidase-N (CD13) domain IV", "PROTEIN", 11, 44], ["type 1 and 2 pneumocytes", "CELL_TYPE", 184, 208], ["aminopeptidase-N (CD13) domain IV", "TREATMENT", 11, 44], ["high titers", "OBSERVATION_MODIFIER", 83, 94], ["lungs", "ANATOMY", 102, 107], ["pneumocytes", "OBSERVATION", 197, 208]]], ["Moreover, it can infect epithelial cells of the nares, trachea, bronchi, bronchioles, alveoli, and, occasionally, alveolar macrophages [49] .", [["epithelial cells", "ANATOMY", 24, 40], ["nares", "ANATOMY", 48, 53], ["trachea", "ANATOMY", 55, 62], ["bronchi", "ANATOMY", 64, 71], ["bronchioles", "ANATOMY", 73, 84], ["alveoli", "ANATOMY", 86, 93], ["alveolar macrophages", "ANATOMY", 114, 134], ["epithelial cells", "CELL", 24, 40], ["nares", "ORGAN", 48, 53], ["trachea", "MULTI-TISSUE_STRUCTURE", 55, 62], ["bronchi", "MULTI-TISSUE_STRUCTURE", 64, 71], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 73, 84], ["alveoli", "MULTI-TISSUE_STRUCTURE", 86, 93], ["alveolar macrophages", "CELL", 114, 134], ["epithelial cells", "CELL_TYPE", 24, 40], ["alveolar macrophages", "CELL_TYPE", 114, 134], ["epithelial cells of the nares, trachea, bronchi, bronchioles, alveoli, and, occasionally, alveolar macrophages", "PROBLEM", 24, 134], ["epithelial cells", "OBSERVATION", 24, 40], ["nares", "ANATOMY", 48, 53], ["trachea", "ANATOMY", 55, 62], ["bronchi", "ANATOMY", 64, 71], ["bronchioles", "ANATOMY", 73, 84], ["alveoli", "ANATOMY_MODIFIER", 86, 93], ["alveolar", "ANATOMY_MODIFIER", 114, 122], ["macrophages", "OBSERVATION", 123, 134]]], ["Infections with the PRCoV are usually subclinical, but there is variation between strains and some can induce a more severe disease.", [["Infections", "DISEASE", 0, 10], ["PRCoV", "GENE_OR_GENE_PRODUCT", 20, 25], ["Infections", "PROBLEM", 0, 10], ["variation between strains", "PROBLEM", 64, 89], ["a more severe disease", "PROBLEM", 110, 131], ["variation", "OBSERVATION_MODIFIER", 64, 73], ["more", "OBSERVATION_MODIFIER", 112, 116], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["disease", "OBSERVATION", 124, 131]]], ["PrCoV can infect pigs of all ages by direct contact transmission or aerosol [49] .", [["PrCoV", "CHEMICAL", 0, 5], ["PrCoV", "GENE_OR_GENE_PRODUCT", 0, 5], ["pigs", "ORGANISM", 17, 21], ["PrCoV", "PROTEIN", 0, 5], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 17, 21], ["PrCoV", "TREATMENT", 0, 5]]], ["The clinical signs are associated to the respiratory system and are mild to severebronchointerstitial pneumonia-depending the strain and the context (environmental and management factors as well as the presence of other pathogens).Aujeszky's disease virus or PseudoRabies Virus (PRV)Suid herpesvirus 1, usually known as PRV or ADV is the responsible agent of Aujeszky's disease in pigs.", [["respiratory system", "ANATOMY", 41, 59], ["pneumonia", "DISEASE", 102, 111], ["Aujeszky's disease", "DISEASE", 231, 249], ["PseudoRabies Virus", "DISEASE", 259, 277], ["ADV", "CHEMICAL", 327, 330], ["Aujeszky's disease", "DISEASE", 359, 377], ["Aujeszky's disease virus", "ORGANISM", 231, 255], ["PseudoRabies Virus", "ORGANISM", 259, 277], ["PRV)Suid herpesvirus 1", "ORGANISM", 279, 301], ["PRV", "ORGANISM", 320, 323], ["Aujeszky", "ORGANISM", 359, 367], ["pigs", "ORGANISM", 381, 385], ["Aujeszky", "SPECIES", 231, 239], ["PseudoRabies Virus", "SPECIES", 259, 277], ["Suid herpesvirus", "SPECIES", 283, 299], ["Aujeszky", "SPECIES", 359, 367], ["pigs", "SPECIES", 381, 385], ["Aujeszky's disease virus", "SPECIES", 231, 255], ["PseudoRabies Virus", "SPECIES", 259, 277], ["PRV", "SPECIES", 279, 282], ["Suid herpesvirus 1", "SPECIES", 283, 301], ["PRV", "SPECIES", 320, 323], ["ADV", "SPECIES", 327, 330], ["Aujeszky", "SPECIES", 359, 367], ["pigs", "SPECIES", 381, 385], ["The clinical signs", "PROBLEM", 0, 18], ["the respiratory system", "PROBLEM", 37, 59], ["mild to severebronchointerstitial pneumonia", "PROBLEM", 68, 111], ["the strain", "PROBLEM", 122, 132], ["management factors", "TREATMENT", 168, 186], ["other pathogens", "PROBLEM", 214, 229], ["Aujeszky's disease virus", "PROBLEM", 231, 255], ["PseudoRabies Virus (PRV)Suid herpesvirus 1", "PROBLEM", 259, 301], ["Aujeszky's disease", "PROBLEM", 359, 377], ["respiratory system", "ANATOMY", 41, 59], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["severebronchointerstitial", "OBSERVATION_MODIFIER", 76, 101], ["pneumonia", "OBSERVATION", 102, 111], ["PseudoRabies Virus", "OBSERVATION", 259, 277]]], ["It is a double stranded enveloped DNA virus from the Herpesviridae family and Alphaherpesvirinae subfamily targeting respiratory and/or genital mucosae for its replication [54] .", [["respiratory", "ANATOMY", 117, 128], ["genital mucosae", "ANATOMY", 136, 151], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 53, 66], ["Alphaherpesvirinae", "GENE_OR_GENE_PRODUCT", 78, 96], ["genital mucosae", "ORGAN", 136, 151], ["Alphaherpesvirinae subfamily", "PROTEIN", 78, 106], ["a double stranded enveloped DNA virus", "PROBLEM", 6, 43], ["genital mucosae", "ANATOMY", 136, 151]]], ["ADV has a very broad host range varying from domestic animals like pigs, cattle, goats, sheep, cats and dogs to wild animals such as ferrets, foxes, hares, raccoons, and wild deer, and where it induces different diseases [54] .", [["ADV", "CHEMICAL", 0, 3], ["pigs", "ORGANISM", 67, 71], ["goats", "ORGANISM_SUBDIVISION", 81, 86], ["sheep", "ORGANISM", 88, 93], ["cats", "ORGANISM", 95, 99], ["dogs", "ORGANISM", 104, 108], ["ferrets", "ORGANISM", 133, 140], ["pigs", "SPECIES", 67, 71], ["cattle", "SPECIES", 73, 79], ["goats", "SPECIES", 81, 86], ["sheep", "SPECIES", 88, 93], ["cats", "SPECIES", 95, 99], ["dogs", "SPECIES", 104, 108], ["ferrets", "SPECIES", 133, 140], ["ADV", "SPECIES", 0, 3], ["pigs", "SPECIES", 67, 71], ["cattle", "SPECIES", 73, 79], ["goats", "SPECIES", 81, 86], ["sheep", "SPECIES", 88, 93], ["ferrets", "SPECIES", 133, 140], ["wild deer", "SPECIES", 170, 179], ["different diseases", "PROBLEM", 202, 220]]], ["Infected animals usually show fever, sneezing, coughing and vomiting accompanied occasionally with typical nervous manifestations like convulsions, aggressiveness and lack of coordination.", [["nervous", "ANATOMY", 107, 114], ["fever", "DISEASE", 30, 35], ["sneezing", "DISEASE", 37, 45], ["coughing", "DISEASE", 47, 55], ["vomiting", "DISEASE", 60, 68], ["convulsions", "DISEASE", 135, 146], ["aggressiveness", "DISEASE", 148, 162], ["nervous", "ANATOMICAL_SYSTEM", 107, 114], ["fever", "PROBLEM", 30, 35], ["sneezing", "PROBLEM", 37, 45], ["coughing", "PROBLEM", 47, 55], ["vomiting", "PROBLEM", 60, 68], ["typical nervous manifestations", "PROBLEM", 99, 129], ["convulsions", "PROBLEM", 135, 146], ["aggressiveness", "PROBLEM", 148, 162], ["lack of coordination", "PROBLEM", 167, 187], ["fever", "OBSERVATION", 30, 35], ["sneezing", "OBSERVATION", 37, 45], ["convulsions", "OBSERVATION", 135, 146]]], ["Mortality rate can reach 100% in suckling piglets while in mature pigs the infection is inapparent or mild [54] .Aujeszky's disease virus or PseudoRabies Virus (PRV)ADV possesses eleven types of envelope glycoproteins playing major roles in the interaction with host cells and the induction of immune response [54] .", [["cells", "ANATOMY", 267, 272], ["infection", "DISEASE", 75, 84], ["Aujeszky's disease", "DISEASE", 113, 131], ["ADV", "CHEMICAL", 165, 168], ["piglets", "ORGANISM", 42, 49], ["pigs", "ORGANISM", 66, 70], ["Aujeszky's disease virus", "ORGANISM", 113, 137], ["PseudoRabies Virus", "ORGANISM", 141, 159], ["PRV)ADV", "ORGANISM", 161, 168], ["host cells", "CELL", 262, 272], ["envelope glycoproteins", "PROTEIN", 195, 217], ["host cells", "CELL_TYPE", 262, 272], ["piglets", "SPECIES", 42, 49], ["pigs", "SPECIES", 66, 70], ["Aujeszky", "SPECIES", 113, 121], ["PseudoRabies Virus", "SPECIES", 141, 159], ["pigs", "SPECIES", 66, 70], ["Aujeszky's disease virus", "SPECIES", 113, 137], ["PseudoRabies Virus", "SPECIES", 141, 159], ["PRV", "SPECIES", 161, 164], ["ADV", "SPECIES", 165, 168], ["Mortality rate", "TEST", 0, 14], ["the infection", "PROBLEM", 71, 84], ["Aujeszky's disease virus", "PROBLEM", 113, 137], ["PseudoRabies Virus", "PROBLEM", 141, 159], ["envelope glycoproteins", "TREATMENT", 195, 217], ["host cells", "TREATMENT", 262, 272], ["infection", "OBSERVATION", 75, 84], ["mild", "OBSERVATION_MODIFIER", 102, 106], ["PseudoRabies Virus", "OBSERVATION", 141, 159]]], ["Viral binding and fusion with the plasma membrane of the target cell-epithelial cells, neurons and alveolar macrophages-are controlled by a cascade of events orchestred by glycoproteins C (gC), gB, gD, gH and gL.", [["plasma membrane", "ANATOMY", 34, 49], ["cell-epithelial cells", "ANATOMY", 64, 85], ["neurons", "ANATOMY", 87, 94], ["alveolar macrophages", "ANATOMY", 99, 119], ["plasma membrane", "CELLULAR_COMPONENT", 34, 49], ["cell", "CELL", 64, 68], ["epithelial cells", "CELL", 69, 85], ["neurons", "CELL", 87, 94], ["alveolar macrophages", "CELL", 99, 119], ["glycoproteins C", "GENE_OR_GENE_PRODUCT", 172, 187], ["gC", "GENE_OR_GENE_PRODUCT", 189, 191], ["gB", "GENE_OR_GENE_PRODUCT", 194, 196], ["gD", "GENE_OR_GENE_PRODUCT", 198, 200], ["gH", "GENE_OR_GENE_PRODUCT", 202, 204], ["gL", "GENE_OR_GENE_PRODUCT", 209, 211], ["target cell-epithelial cells", "CELL_TYPE", 57, 85], ["neurons", "CELL_TYPE", 87, 94], ["alveolar macrophages", "CELL_TYPE", 99, 119], ["glycoproteins C", "PROTEIN", 172, 187], ["gC", "PROTEIN", 189, 191], ["gB", "PROTEIN", 194, 196], ["gD", "PROTEIN", 198, 200], ["gH", "PROTEIN", 202, 204], ["gL", "PROTEIN", 209, 211], ["Viral binding and fusion", "PROBLEM", 0, 24], ["the plasma membrane", "TEST", 30, 49], ["epithelial cells", "PROBLEM", 69, 85], ["alveolar macrophages", "PROBLEM", 99, 119], ["gC", "TEST", 189, 191], ["gB", "TEST", 194, 196], ["fusion", "OBSERVATION", 18, 24], ["target cell", "OBSERVATION", 57, 68], ["epithelial cells", "OBSERVATION", 69, 85], ["alveolar macrophages", "OBSERVATION", 99, 119], ["gB", "ANATOMY", 194, 196], ["gL", "ANATOMY", 209, 211]]], ["The binding process starts with an interaction of gC with heparin sulfate proteoglycans [54, 55] .", [["heparin sulfate", "CHEMICAL", 58, 73], ["sulfate", "CHEMICAL", 66, 73], ["gC", "GENE_OR_GENE_PRODUCT", 50, 52], ["heparin sulfate proteoglycans", "SIMPLE_CHEMICAL", 58, 87], ["gC", "PROTEIN", 50, 52], ["The binding process", "PROBLEM", 0, 19], ["gC with heparin sulfate proteoglycans", "TREATMENT", 50, 87]]], ["Stabilization of this interaction is then assured by the binding of gD to specific cellular receptors known as herpesvirus entry mediators such as HveA (TNFRSF14), HveB (PRR2, nectin 2), HveC (PRR1, nectin 1), HveD (PVR, CD55), and 3-O-sulfated heparin sulfate [54, 56] .", [["cellular", "ANATOMY", 83, 91], ["heparin sulfate", "CHEMICAL", 245, 260], ["3-O-sulfated heparin sulfate", "CHEMICAL", 232, 260], ["gD", "GENE_OR_GENE_PRODUCT", 68, 70], ["cellular", "CELL", 83, 91], ["herpesvirus", "ORGANISM", 111, 122], ["HveA", "GENE_OR_GENE_PRODUCT", 147, 151], ["TNFRSF14", "GENE_OR_GENE_PRODUCT", 153, 161], ["HveB", "GENE_OR_GENE_PRODUCT", 164, 168], ["PRR2, nectin 2", "GENE_OR_GENE_PRODUCT", 170, 184], ["HveC", "GENE_OR_GENE_PRODUCT", 187, 191], ["PRR1, nectin 1", "GENE_OR_GENE_PRODUCT", 193, 207], ["HveD", "GENE_OR_GENE_PRODUCT", 210, 214], ["PVR", "GENE_OR_GENE_PRODUCT", 216, 219], ["CD55", "GENE_OR_GENE_PRODUCT", 221, 225], ["3-O-sulfated heparin sulfate", "SIMPLE_CHEMICAL", 232, 260], ["gD", "PROTEIN", 68, 70], ["cellular receptors", "PROTEIN", 83, 101], ["herpesvirus entry mediators", "PROTEIN", 111, 138], ["HveA", "PROTEIN", 147, 151], ["TNFRSF14", "PROTEIN", 153, 161], ["HveB", "PROTEIN", 164, 168], ["PRR2", "PROTEIN", 170, 174], ["nectin 2", "PROTEIN", 176, 184], ["HveC", "PROTEIN", 187, 191], ["PRR1", "PROTEIN", 193, 197], ["nectin 1", "PROTEIN", 199, 207], ["HveD", "PROTEIN", 210, 214], ["PVR", "PROTEIN", 216, 219], ["CD55", "PROTEIN", 221, 225], ["HveA (TNFRSF14)", "TREATMENT", 147, 162], ["HveB (PRR2", "TREATMENT", 164, 174], ["nectin", "TREATMENT", 176, 182], ["HveC (PRR1", "TREATMENT", 187, 197], ["nectin", "TREATMENT", 199, 205], ["3-O-sulfated heparin sulfate", "TREATMENT", 232, 260]]], ["At this stage, Tyrosine-based or dileucine-based endocytosis in parallel with clathrin-mediated endocytosis occur by the mediation of gB, gH and gL, leading to the penetration of the capsid and the tegument into the cellular cytoplasm.", [["tegument", "ANATOMY", 198, 206], ["cellular cytoplasm", "ANATOMY", 216, 234], ["dileucine", "CHEMICAL", 33, 42], ["Tyrosine", "CHEMICAL", 15, 23], ["dileucine", "CHEMICAL", 33, 42], ["Tyrosine", "SIMPLE_CHEMICAL", 15, 23], ["dileucine", "SIMPLE_CHEMICAL", 33, 42], ["clathrin", "GENE_OR_GENE_PRODUCT", 78, 86], ["gB", "GENE_OR_GENE_PRODUCT", 134, 136], ["gH", "GENE_OR_GENE_PRODUCT", 138, 140], ["gL", "GENE_OR_GENE_PRODUCT", 145, 147], ["capsid", "CELLULAR_COMPONENT", 183, 189], ["tegument", "CELLULAR_COMPONENT", 198, 206], ["cellular cytoplasm", "ORGANISM_SUBSTANCE", 216, 234], ["clathrin", "PROTEIN", 78, 86], ["gB", "PROTEIN", 134, 136], ["gH", "PROTEIN", 138, 140], ["gL", "PROTEIN", 145, 147], ["capsid", "PROTEIN", 183, 189], ["Tyrosine-based", "TREATMENT", 15, 29], ["dileucine", "TREATMENT", 33, 42], ["based endocytosis", "PROBLEM", 43, 60], ["clathrin-mediated endocytosis", "TREATMENT", 78, 107], ["the capsid", "TREATMENT", 179, 189], ["gB", "ANATOMY", 134, 136], ["cellular cytoplasm", "OBSERVATION", 216, 234]]], ["Finally, the interaction of the capsid with dynein leads to the release of viral DNA into the cellular nucleus after a transport along microtubules from the periphery to the nuclear pores [55] .Aujeszky's disease virus or PseudoRabies Virus (PRV)Porcine humoral immune response is induced by ADV and neutralizing antibodies are mainly directed against gC [57] .", [["cellular nucleus", "ANATOMY", 94, 110], ["microtubules", "ANATOMY", 135, 147], ["nuclear pores", "ANATOMY", 174, 187], ["Aujeszky's disease", "DISEASE", 194, 212], ["ADV", "CHEMICAL", 292, 295], ["capsid", "CELLULAR_COMPONENT", 32, 38], ["dynein", "GENE_OR_GENE_PRODUCT", 44, 50], ["DNA", "CELLULAR_COMPONENT", 81, 84], ["cellular nucleus", "CELLULAR_COMPONENT", 94, 110], ["microtubules", "CELLULAR_COMPONENT", 135, 147], ["nuclear", "CELLULAR_COMPONENT", 174, 181], ["Aujeszky's disease virus", "ORGANISM", 194, 218], ["PseudoRabies Virus", "ORGANISM", 222, 240], ["PRV", "ORGANISM", 242, 245], ["Porcine", "ORGANISM", 246, 253], ["ADV", "ORGANISM", 292, 295], ["dynein", "PROTEIN", 44, 50], ["viral DNA", "DNA", 75, 84], ["neutralizing antibodies", "PROTEIN", 300, 323], ["gC", "PROTEIN", 352, 354], ["Aujeszky", "SPECIES", 194, 202], ["Porcine", "SPECIES", 246, 253], ["Aujeszky's disease virus", "SPECIES", 194, 218], ["PseudoRabies Virus", "SPECIES", 222, 240], ["PRV", "SPECIES", 242, 245], ["ADV", "SPECIES", 292, 295], ["viral DNA", "PROBLEM", 75, 84], ["Aujeszky's disease virus", "PROBLEM", 194, 218], ["PseudoRabies Virus (PRV", "TREATMENT", 222, 245], ["Porcine humoral immune response", "TREATMENT", 246, 277], ["neutralizing antibodies", "TEST", 300, 323], ["viral DNA", "OBSERVATION", 75, 84], ["cellular nucleus", "ANATOMY", 94, 110], ["periphery", "ANATOMY_MODIFIER", 157, 166], ["PseudoRabies Virus", "OBSERVATION", 222, 240]]], ["Specific cell mediated immune responses are also triggered and MHC class I restricted, gC-specific, cytotoxic cells are induced.", [["cell", "ANATOMY", 9, 13], ["cells", "ANATOMY", 110, 115], ["cell", "CELL", 9, 13], ["gC", "GENE_OR_GENE_PRODUCT", 87, 89], ["cytotoxic cells", "CELL", 100, 115], ["MHC class I", "PROTEIN", 63, 74], ["gC", "PROTEIN", 87, 89], ["cytotoxic cells", "CELL_TYPE", 100, 115], ["gC", "TEST", 87, 89], ["cytotoxic cells", "PROBLEM", 100, 115], ["cytotoxic cells", "OBSERVATION", 100, 115]]], ["ADV also alters the IFN signaling pathway by suppressing STAT1 tyrosine phosphorylation leading to an inhibition of IFN-Stimulated Genes (ISGs) expression [54, 57] .Aujeszky's disease virus or PseudoRabies Virus (PRV)ADV may be involved in the PRDC and can be isolated alone or with other pathogens.", [["PRDC", "ANATOMY", 244, 248], ["ADV", "CHEMICAL", 0, 3], ["tyrosine", "CHEMICAL", 63, 71], ["Aujeszky's disease", "DISEASE", 165, 183], ["ADV", "CHEMICAL", 217, 220], ["tyrosine", "CHEMICAL", 63, 71], ["ADV", "SIMPLE_CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 20, 23], ["STAT1", "GENE_OR_GENE_PRODUCT", 57, 62], ["IFN-Stimulated Genes", "GENE_OR_GENE_PRODUCT", 116, 136], ["Aujeszky's disease virus", "ORGANISM", 165, 189], ["PseudoRabies Virus", "ORGANISM", 193, 211], ["PRV)ADV", "ORGANISM", 213, 220], ["PRDC", "CANCER", 244, 248], ["IFN", "PROTEIN", 20, 23], ["STAT1", "PROTEIN", 57, 62], ["IFN", "PROTEIN", 116, 119], ["ISGs", "DNA", 138, 142], ["Aujeszky", "SPECIES", 165, 173], ["PseudoRabies Virus", "SPECIES", 193, 211], ["ADV", "SPECIES", 0, 3], ["Aujeszky's disease virus", "SPECIES", 165, 189], ["PseudoRabies Virus", "SPECIES", 193, 211], ["PRV", "SPECIES", 213, 216], ["ADV", "SPECIES", 217, 220], ["the IFN signaling pathway", "TREATMENT", 16, 41], ["suppressing STAT1 tyrosine phosphorylation", "TREATMENT", 45, 87], ["Aujeszky's disease virus", "PROBLEM", 165, 189], ["PseudoRabies Virus (PRV)ADV", "PROBLEM", 193, 220], ["other pathogens", "PROBLEM", 283, 298]]], ["Accordingly, a study conducted in Taiwan reported the association of ADV with PCV2 in 10.3% of the evaluated pigs using a multiplex PCR [58] .Actinobacillus pleuropneumoniaeAnimals affected with this Gram negative bacterium develop a pleuropneumonia characterized by fibrinohemorrhagic necrotizing bronchopneumonia and fibrinous pleuritis which can reach a high mortality rate [59, 60] .", [["ADV", "CHEMICAL", 69, 72], ["pleuropneumonia", "DISEASE", 234, 249], ["bronchopneumonia", "DISEASE", 298, 314], ["pleuritis", "DISEASE", 329, 338], ["PCV2", "ORGANISM", 78, 82], ["pigs", "ORGANISM", 109, 113], ["Actinobacillus pleuropneumoniae", "ORGANISM", 142, 173], ["Animals", "ORGANISM", 173, 180], ["pigs", "SPECIES", 109, 113], ["Actinobacillus pleuropneumoniae", "SPECIES", 142, 173], ["ADV", "SPECIES", 69, 72], ["PCV2", "SPECIES", 78, 82], ["pigs", "SPECIES", 109, 113], ["Actinobacillus pleuropneumoniae", "SPECIES", 142, 173], ["a study", "TEST", 13, 20], ["PCV2", "TREATMENT", 78, 82], ["a multiplex PCR", "TEST", 120, 135], ["Actinobacillus pleuropneumoniae", "PROBLEM", 142, 173], ["this Gram negative bacterium", "PROBLEM", 195, 223], ["a pleuropneumonia", "PROBLEM", 232, 249], ["fibrinohemorrhagic necrotizing bronchopneumonia", "PROBLEM", 267, 314], ["fibrinous pleuritis", "PROBLEM", 319, 338], ["pleuropneumoniae", "OBSERVATION", 157, 173], ["pleuropneumonia", "OBSERVATION", 234, 249], ["fibrinohemorrhagic", "OBSERVATION_MODIFIER", 267, 285], ["necrotizing", "OBSERVATION_MODIFIER", 286, 297], ["bronchopneumonia", "OBSERVATION", 298, 314], ["fibrinous", "OBSERVATION_MODIFIER", 319, 328], ["pleuritis", "OBSERVATION", 329, 338]]], ["Although the disease is best known in its acute/peracute forms, subacute and/or chronic presentations with low or no mortality are highly prevalent, especially in the presence of antibiotic treatments.", [["the disease", "PROBLEM", 9, 20], ["its acute/peracute forms", "PROBLEM", 38, 62], ["subacute and/or chronic presentations", "PROBLEM", 64, 101], ["mortality", "PROBLEM", 117, 126], ["antibiotic treatments", "TREATMENT", 179, 200], ["disease", "OBSERVATION", 13, 20], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["subacute", "OBSERVATION_MODIFIER", 64, 72], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["low", "OBSERVATION_MODIFIER", 107, 110]]], ["Many herds are subclinically infected without previous or present episodes of clinical disease and in the absence of suggestive lesions at the slaughter house.", [["lesions", "ANATOMY", 128, 135], ["lesions", "PATHOLOGICAL_FORMATION", 128, 135], ["subclinically infected", "PROBLEM", 15, 37], ["clinical disease", "PROBLEM", 78, 94], ["suggestive lesions", "PROBLEM", 117, 135], ["subclinically", "OBSERVATION_MODIFIER", 15, 28], ["infected", "OBSERVATION", 29, 37], ["lesions", "OBSERVATION", 128, 135]]], ["Animals are, nevertheless, carriers of the pathogen.", [["Animals", "ORGANISM", 0, 7], ["the pathogen", "PROBLEM", 39, 51]]], ["This happens in several conventional herds which may be simultaneously infected not only with several low/intermediate virulent strains, but also, in some cases, with strains highly likely to cause disease.", [["simultaneously infected", "PROBLEM", 56, 79], ["several low/intermediate virulent strains", "PROBLEM", 94, 135], ["strains", "PROBLEM", 167, 174], ["disease", "PROBLEM", 198, 205], ["infected", "OBSERVATION", 71, 79], ["virulent strains", "OBSERVATION_MODIFIER", 119, 135]]], ["In the latter case, outbreaks may suddenly appear in the presence of concomitant diseases or as a consequence of changes in management and/or environment [59, 60] .", [["concomitant diseases", "PROBLEM", 69, 89], ["changes in management", "TREATMENT", 113, 134], ["concomitant", "OBSERVATION_MODIFIER", 69, 80], ["diseases", "OBSERVATION", 81, 89]]], ["Eighteen serotypes of the bacterium have been described, which can all induce disease, although clear differences in virulence have been described [59, 60] .", [["Eighteen serotypes of the bacterium", "PROBLEM", 0, 35], ["disease", "PROBLEM", 78, 85], ["serotypes", "OBSERVATION", 9, 18]]], ["These bacteria can be found mainly in tonsils of carrier animals; virulent strains have a tropism for the lower respiratory tract where they preferentially bind to ciliated cells of the terminal bronchioli and pneumocytes [59, 60] .", [["tonsils", "ANATOMY", 38, 45], ["lower respiratory tract", "ANATOMY", 106, 129], ["ciliated cells", "ANATOMY", 164, 178], ["bronchioli", "ANATOMY", 195, 205], ["pneumocytes", "ANATOMY", 210, 221], ["tonsils", "ORGAN", 38, 45], ["lower", "ORGANISM_SUBDIVISION", 106, 111], ["respiratory tract", "ORGANISM_SUBDIVISION", 112, 129], ["ciliated cells", "CELL", 164, 178], ["terminal bronchioli", "CELLULAR_COMPONENT", 186, 205], ["pneumocytes", "CELL", 210, 221], ["ciliated cells", "CELL_TYPE", 164, 178], ["terminal bronchioli", "CELL_TYPE", 186, 205], ["pneumocytes", "CELL_TYPE", 210, 221], ["These bacteria", "PROBLEM", 0, 14], ["virulent strains", "PROBLEM", 66, 82], ["the lower respiratory tract", "PROBLEM", 102, 129], ["pneumocytes", "TEST", 210, 221], ["lower", "ANATOMY_MODIFIER", 106, 111], ["respiratory tract", "ANATOMY", 112, 129], ["ciliated cells", "OBSERVATION", 164, 178], ["terminal", "ANATOMY_MODIFIER", 186, 194], ["bronchioli", "ANATOMY", 195, 205], ["pneumocytes", "ANATOMY", 210, 221]]], ["Different virulence factors expressed by A. pleuropneumoniae are involved in the colonization and the development of the disease.", [["A. pleuropneumoniae", "ORGANISM", 41, 60], ["virulence factors", "PROTEIN", 10, 27], ["A. pleuropneumoniae", "SPECIES", 41, 60], ["A. pleuropneumoniae", "SPECIES", 41, 60], ["Different virulence factors", "PROBLEM", 0, 27], ["A. pleuropneumoniae", "PROBLEM", 41, 60], ["the colonization", "PROBLEM", 77, 93], ["the disease", "PROBLEM", 117, 128], ["pleuropneumoniae", "OBSERVATION", 44, 60], ["colonization", "OBSERVATION", 81, 93], ["disease", "OBSERVATION", 121, 128]]], ["Adhesion to cells could be mediated by type IV fimbriae that are expressed upon contact with respiratory epithelial cells in vitro and during lung infection [59, 60] .", [["cells", "ANATOMY", 12, 17], ["respiratory epithelial cells", "ANATOMY", 93, 121], ["lung", "ANATOMY", 142, 146], ["lung infection", "DISEASE", 142, 156], ["cells", "CELL", 12, 17], ["type IV fimbriae", "GENE_OR_GENE_PRODUCT", 39, 55], ["respiratory epithelial cells", "CELL", 93, 121], ["lung", "ORGAN", 142, 146], ["type IV fimbriae", "PROTEIN", 39, 55], ["respiratory epithelial cells", "CELL_TYPE", 93, 121], ["Adhesion to cells", "PROBLEM", 0, 17], ["type IV fimbriae", "PROBLEM", 39, 55], ["respiratory epithelial cells", "PROBLEM", 93, 121], ["lung infection", "PROBLEM", 142, 156], ["respiratory epithelial cells", "OBSERVATION", 93, 121], ["lung", "ANATOMY", 142, 146], ["infection", "OBSERVATION", 147, 156]]], ["Adhesion of A. pleuropneumoniae to respiratory epithelial cells also involves the binding of bacterial lipopolysaccharides to glycosphingolipids on the surface of the cells [59, 60] .", [["respiratory epithelial cells", "ANATOMY", 35, 63], ["surface", "ANATOMY", 152, 159], ["cells", "ANATOMY", 167, 172], ["A. pleuropneumoniae", "ORGANISM", 12, 31], ["respiratory epithelial cells", "CELL", 35, 63], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 103, 122], ["glycosphingolipids", "SIMPLE_CHEMICAL", 126, 144], ["surface", "CELLULAR_COMPONENT", 152, 159], ["cells", "CELL", 167, 172], ["respiratory epithelial cells", "CELL_TYPE", 35, 63], ["A. pleuropneumoniae", "SPECIES", 12, 31], ["A. pleuropneumoniae", "SPECIES", 12, 31], ["A. pleuropneumoniae", "PROBLEM", 12, 31], ["respiratory epithelial cells", "PROBLEM", 35, 63], ["bacterial lipopolysaccharides", "TREATMENT", 93, 122], ["pleuropneumoniae", "OBSERVATION", 15, 31], ["respiratory epithelial cells", "OBSERVATION", 35, 63], ["bacterial lipopolysaccharides", "OBSERVATION", 93, 122], ["cells", "ANATOMY", 167, 172]]], ["The formation of biofilm by the bacteria is likely to play an important role in the colonization of the host [61] .", [["biofilm", "ANATOMY", 17, 24], ["biofilm", "PROBLEM", 17, 24], ["the bacteria", "PROBLEM", 28, 40], ["biofilm", "OBSERVATION", 17, 24], ["is likely to", "UNCERTAINTY", 41, 53]]], ["After attachment to the target cells, the bacteria can produce four different pore-forming exotoxins (Apx I, II, III and IV) inducing the lysis of alveolar epithelial cells, thus allowing the acquisition of nutrients by the bacteria, but also participating in the development of the lesions [60, 62] .", [["cells", "ANATOMY", 31, 36], ["pore", "ANATOMY", 78, 82], ["alveolar epithelial cells", "ANATOMY", 147, 172], ["lesions", "ANATOMY", 283, 290], ["cells", "CELL", 31, 36], ["Apx I", "GENE_OR_GENE_PRODUCT", 102, 107], ["II, III", "GENE_OR_GENE_PRODUCT", 109, 116], ["alveolar epithelial cells", "CELL", 147, 172], ["lesions", "PATHOLOGICAL_FORMATION", 283, 290], ["target cells", "CELL_TYPE", 24, 36], ["pore-forming exotoxins", "PROTEIN", 78, 100], ["Apx I, II, III and IV", "PROTEIN", 102, 123], ["alveolar epithelial cells", "CELL_TYPE", 147, 172], ["the bacteria", "PROBLEM", 38, 50], ["exotoxins", "PROBLEM", 91, 100], ["alveolar epithelial cells", "PROBLEM", 147, 172], ["the lesions", "PROBLEM", 279, 290], ["alveolar epithelial cells", "OBSERVATION", 147, 172], ["lesions", "OBSERVATION", 283, 290]]], ["Some of the virulence factors expressed by A. pleuropneumoniae interfere with the host's immune response.", [["A. pleuropneumoniae", "ORGANISM", 43, 62], ["virulence factors", "PROTEIN", 12, 29], ["A. pleuropneumoniae", "SPECIES", 43, 62], ["A. pleuropneumoniae", "SPECIES", 43, 62], ["the virulence factors", "PROBLEM", 8, 29], ["A. pleuropneumoniae", "PROBLEM", 43, 62]]], ["The toxins Apx I, II and III induce the lysis of not only respiratory epithelial cells, but also of cells involved in the innate immune response such as macrophages and neutrophils [60, 63] .", [["respiratory epithelial cells", "ANATOMY", 58, 86], ["cells", "ANATOMY", 100, 105], ["macrophages", "ANATOMY", 153, 164], ["neutrophils", "ANATOMY", 169, 180], ["Apx I", "GENE_OR_GENE_PRODUCT", 11, 16], ["II", "GENE_OR_GENE_PRODUCT", 18, 20], ["respiratory epithelial cells", "CELL", 58, 86], ["cells", "CELL", 100, 105], ["macrophages", "CELL", 153, 164], ["neutrophils", "CELL", 169, 180], ["Apx I, II and III", "PROTEIN", 11, 28], ["respiratory epithelial cells", "CELL_TYPE", 58, 86], ["macrophages", "CELL_TYPE", 153, 164], ["neutrophils", "CELL_TYPE", 169, 180], ["the lysis", "TREATMENT", 36, 45], ["respiratory epithelial cells", "PROBLEM", 58, 86], ["macrophages", "TEST", 153, 164], ["neutrophils", "TEST", 169, 180], ["lysis", "OBSERVATION", 40, 45], ["respiratory epithelial cells", "OBSERVATION", 58, 86]]], ["At lower concentrations, these toxins lose their lytic properties but can still impair macrophages chemotactic activity and their phagocytic abilities [64] .", [["macrophages", "ANATOMY", 87, 98], ["macrophages", "CELL", 87, 98], ["macrophages", "CELL_TYPE", 87, 98], ["these toxins", "PROBLEM", 25, 37]]], ["The capsular polysaccharides of A. pleuropneumoniae interfere with macrophage phagocytosis and enable resistance to complement-mediated killing [60] .", [["macrophage", "ANATOMY", 67, 77], ["A. pleuropneumoniae", "ORGANISM", 32, 51], ["macrophage", "CELL", 67, 77], ["A. pleuropneumoniae", "SPECIES", 32, 51], ["A. pleuropneumoniae", "SPECIES", 32, 51], ["The capsular polysaccharides", "TREATMENT", 0, 28], ["A. pleuropneumoniae", "PROBLEM", 32, 51], ["macrophage phagocytosis", "TREATMENT", 67, 90], ["capsular", "OBSERVATION_MODIFIER", 4, 12]]], ["A. pleuropneumoniae may also interfere with the antibody response by producing proteases that can degrade porcine IgA and IgG [59, 60] .Mycoplasma hyopneumoniaeThis cell wall-free bacterium is considered to play a primary role in PRDC and is the causative agent of porcine Enzootic Pneumonia (EP), a disease with high morbidity but low mortality rates [65] .", [["cell wall", "ANATOMY", 165, 174], ["PRDC", "ANATOMY", 230, 234], ["porcine Enzootic Pneumonia", "DISEASE", 265, 291], ["EP", "DISEASE", 293, 295], ["A. pleuropneumoniae", "ORGANISM", 0, 19], ["porcine", "ORGANISM", 106, 113], ["IgA", "GENE_OR_GENE_PRODUCT", 114, 117], ["IgG", "GENE_OR_GENE_PRODUCT", 122, 125], ["Mycoplasma hyopneumoniae", "ORGANISM", 136, 160], ["cell wall", "CELLULAR_COMPONENT", 165, 174], ["PRDC", "CANCER", 230, 234], ["porcine", "ORGANISM", 265, 272], ["proteases", "PROTEIN", 79, 88], ["porcine IgA", "PROTEIN", 106, 117], ["IgG", "PROTEIN", 122, 125], ["A. pleuropneumoniae", "SPECIES", 0, 19], ["porcine", "SPECIES", 106, 113], ["Mycoplasma hyopneumoniae", "SPECIES", 136, 160], ["porcine", "SPECIES", 265, 272], ["A. pleuropneumoniae", "SPECIES", 0, 19], ["porcine", "SPECIES", 106, 113], ["Mycoplasma hyopneumoniae", "SPECIES", 136, 160], ["A. pleuropneumoniae", "PROBLEM", 0, 19], ["the antibody response", "PROBLEM", 44, 65], ["porcine IgA", "TEST", 106, 117], ["IgG", "TEST", 122, 125], ["Mycoplasma hyopneumoniae", "PROBLEM", 136, 160], ["free bacterium", "PROBLEM", 175, 189], ["PRDC", "TREATMENT", 230, 234], ["porcine Enzootic Pneumonia", "PROBLEM", 265, 291], ["a disease", "PROBLEM", 298, 307], ["high morbidity", "PROBLEM", 313, 327], ["low mortality rates", "PROBLEM", 332, 351], ["pleuropneumoniae", "OBSERVATION", 3, 19], ["hyopneumoniae", "OBSERVATION", 147, 160], ["wall", "ANATOMY_MODIFIER", 170, 174], ["free bacterium", "OBSERVATION", 175, 189], ["Enzootic", "OBSERVATION_MODIFIER", 273, 281], ["Pneumonia", "OBSERVATION", 282, 291]]], ["The main pathological mechanisms involved in M. hyopneumoniae infections are: (i) adhesion to the ciliated cells of the tracheal epithelium inducing ciliostasis, loss of cilia and exfoliation, dysregulation of cellular homeostasis (with increased intracellular calcium concentration) and secretion of cytotoxic factors, (ii) alteration of the mucociliary tract, (iii) inflammatory reactions sometimes exacerbated and prolonged, and (iv) manipulation of the innate and adaptive immune responses [65, 66] .", [["ciliated cells", "ANATOMY", 98, 112], ["tracheal epithelium", "ANATOMY", 120, 139], ["cilia", "ANATOMY", 170, 175], ["cellular", "ANATOMY", 210, 218], ["intracellular", "ANATOMY", 247, 260], ["mucociliary tract", "ANATOMY", 343, 360], ["M. hyopneumoniae infections", "DISEASE", 45, 72], ["exfoliation", "DISEASE", 180, 191], ["calcium", "CHEMICAL", 261, 268], ["calcium", "CHEMICAL", 261, 268], ["M. hyopneumoniae", "ORGANISM", 45, 61], ["ciliated cells", "CELL", 98, 112], ["tracheal epithelium", "TISSUE", 120, 139], ["cilia", "CELLULAR_COMPONENT", 170, 175], ["cellular", "CELL", 210, 218], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 247, 260], ["calcium", "SIMPLE_CHEMICAL", 261, 268], ["mucociliary tract", "ORGANISM_SUBDIVISION", 343, 360], ["ciliated cells", "CELL_TYPE", 98, 112], ["cytotoxic factors", "PROTEIN", 301, 318], ["M. hyopneumoniae", "SPECIES", 45, 61], ["M. hyopneumoniae", "SPECIES", 45, 61], ["M. hyopneumoniae infections", "PROBLEM", 45, 72], ["the tracheal epithelium", "PROBLEM", 116, 139], ["ciliostasis", "PROBLEM", 149, 160], ["loss of cilia and exfoliation", "PROBLEM", 162, 191], ["dysregulation of cellular homeostasis", "PROBLEM", 193, 230], ["increased intracellular calcium concentration", "TREATMENT", 237, 282], ["cytotoxic factors", "PROBLEM", 301, 318], ["alteration of the mucociliary tract", "PROBLEM", 325, 360], ["inflammatory reactions", "PROBLEM", 368, 390], ["main", "OBSERVATION_MODIFIER", 4, 8], ["pathological", "OBSERVATION", 9, 21], ["hyopneumoniae", "OBSERVATION_MODIFIER", 48, 61], ["infections", "OBSERVATION", 62, 72], ["ciliated cells", "OBSERVATION", 98, 112], ["tracheal", "ANATOMY", 120, 128], ["epithelium", "ANATOMY_MODIFIER", 129, 139], ["ciliostasis", "OBSERVATION", 149, 160], ["loss", "OBSERVATION_MODIFIER", 162, 166], ["cilia", "OBSERVATION_MODIFIER", 170, 175], ["exfoliation", "OBSERVATION_MODIFIER", 180, 191], ["cellular homeostasis", "OBSERVATION", 210, 230], ["calcium concentration", "OBSERVATION_MODIFIER", 261, 282], ["cytotoxic factors", "OBSERVATION", 301, 318], ["mucociliary tract", "ANATOMY", 343, 360], ["inflammatory", "OBSERVATION_MODIFIER", 368, 380]]], ["Among the adhesins described in M. hyopneumoniae, P97 is reported to be a major determinant of cell adhesion [65] [66] [67] .", [["cell", "ANATOMY", 95, 99], ["M. hyopneumoniae", "ORGANISM", 32, 48], ["P97", "GENE_OR_GENE_PRODUCT", 50, 53], ["cell", "CELL", 95, 99], ["adhesins", "PROTEIN", 10, 18], ["P97", "PROTEIN", 50, 53], ["M. hyopneumoniae", "SPECIES", 32, 48], ["M. hyopneumoniae", "SPECIES", 32, 48], ["hyopneumoniae", "OBSERVATION", 35, 48]]], ["Several other adhesins were reported: P102 linked to P97, LppS, LppT, MgPa, P65, P76, P110, P146, P159, and P216 [65, 66] .", [["MgPa, P65, P76, P110, P146, P159, and P216", "CHEMICAL", 70, 112], ["P102", "GENE_OR_GENE_PRODUCT", 38, 42], ["P97", "GENE_OR_GENE_PRODUCT", 53, 56], ["LppS", "GENE_OR_GENE_PRODUCT", 58, 62], ["LppT", "GENE_OR_GENE_PRODUCT", 64, 68], ["MgPa", "GENE_OR_GENE_PRODUCT", 70, 74], ["P65", "GENE_OR_GENE_PRODUCT", 76, 79], ["P76", "GENE_OR_GENE_PRODUCT", 81, 84], ["P110", "GENE_OR_GENE_PRODUCT", 86, 90], ["P146", "GENE_OR_GENE_PRODUCT", 92, 96], ["P159", "GENE_OR_GENE_PRODUCT", 98, 102], ["P102", "PROTEIN", 38, 42], ["P97", "PROTEIN", 53, 56], ["LppS", "PROTEIN", 58, 62], ["LppT", "PROTEIN", 64, 68], ["MgPa", "PROTEIN", 70, 74], ["P65", "PROTEIN", 76, 79], ["P76", "PROTEIN", 81, 84], ["P110", "PROTEIN", 86, 90], ["P146", "PROTEIN", 92, 96], ["P159", "PROTEIN", 98, 102], ["P216", "PROTEIN", 108, 112], ["P97", "TEST", 53, 56], ["LppS", "TEST", 58, 62], ["LppT", "TEST", 64, 68], ["MgPa", "TEST", 70, 74], ["P65", "TEST", 76, 79], ["P76", "TEST", 81, 84], ["P110", "TEST", 86, 90], ["P146", "TEST", 92, 96], ["P159", "TEST", 98, 102]]], ["Most adhesins are transcribed and translated during M. hyopneumoniae infection and then undergo posttranslational cleavage to result in diverse products on the membrane surface [65, 67, 68] .", [["membrane surface", "ANATOMY", 160, 176], ["M. hyopneumoniae", "ORGANISM", 52, 68], ["membrane surface", "CELLULAR_COMPONENT", 160, 176], ["adhesins", "PROTEIN", 5, 13], ["M. hyopneumoniae", "SPECIES", 52, 68], ["M. hyopneumoniae", "SPECIES", 52, 68], ["M. hyopneumoniae infection", "PROBLEM", 52, 78], ["posttranslational cleavage", "PROBLEM", 96, 122], ["infection", "OBSERVATION", 69, 78], ["diverse", "OBSERVATION_MODIFIER", 136, 143], ["products", "OBSERVATION", 144, 152]]], ["The diversity of surface proteins can also derive from the variation in the number of repeats in genes encoding adhesins [69] .", [["surface", "ANATOMY", 17, 24], ["surface proteins", "PROTEIN", 17, 33], ["adhesins", "PROTEIN", 112, 120], ["surface proteins", "PROBLEM", 17, 33], ["diversity", "OBSERVATION_MODIFIER", 4, 13]]], ["These mechanisms of antigenic variation enable the bacterium to escape from immune system recognition and to invade the host [66] .", [["immune system", "ANATOMY", 76, 89], ["antigenic variation", "PROBLEM", 20, 39], ["the bacterium", "PROBLEM", 47, 60], ["immune system recognition", "TEST", 76, 101], ["antigenic variation", "OBSERVATION", 20, 39]]], ["Adhesins can also recruit extracellular matrix components (plasminogen, fibronectin and actin amongst others), and therefore can promote invasion and inflammatory response [65, 70] .Mycoplasma hyopneumoniaeThe immune response induced against M. hyopneumoniae, may have a double action: over-activation of the local immune response resulting in a pathologic inflammatory reaction or local immunosuppression explaining the chronic nature of the associated pathologies [65, 66] .", [["extracellular matrix", "ANATOMY", 26, 46], ["Adhesins", "GENE_OR_GENE_PRODUCT", 0, 8], ["extracellular matrix", "CELLULAR_COMPONENT", 26, 46], ["components", "CELLULAR_COMPONENT", 47, 57], ["plasminogen", "GENE_OR_GENE_PRODUCT", 59, 70], ["fibronectin", "GENE_OR_GENE_PRODUCT", 72, 83], ["actin", "GENE_OR_GENE_PRODUCT", 88, 93], ["Mycoplasma hyopneumoniae", "ORGANISM", 182, 206], ["M. hyopneumoniae", "ORGANISM", 242, 258], ["Adhesins", "PROTEIN", 0, 8], ["extracellular matrix components", "PROTEIN", 26, 57], ["plasminogen", "PROTEIN", 59, 70], ["fibronectin", "PROTEIN", 72, 83], ["actin", "PROTEIN", 88, 93], ["Mycoplasma hyopneumoniae", "SPECIES", 182, 206], ["M. hyopneumoniae", "SPECIES", 242, 258], ["Mycoplasma hyopneumoniae", "SPECIES", 182, 206], ["M. hyopneumoniae", "SPECIES", 242, 258], ["Adhesins", "PROBLEM", 0, 8], ["extracellular matrix components", "TREATMENT", 26, 57], ["plasminogen, fibronectin", "TREATMENT", 59, 83], ["Mycoplasma hyopneumoniae", "PROBLEM", 182, 206], ["M. hyopneumoniae", "PROBLEM", 242, 258], ["a pathologic inflammatory reaction", "PROBLEM", 344, 378], ["local immunosuppression", "TREATMENT", 382, 405], ["the associated pathologies", "PROBLEM", 439, 465], ["extracellular matrix", "OBSERVATION", 26, 46], ["invasion", "OBSERVATION", 137, 145], ["inflammatory", "OBSERVATION_MODIFIER", 150, 162], ["hyopneumoniae", "OBSERVATION", 193, 206], ["hyopneumoniae", "OBSERVATION", 245, 258], ["pathologic", "OBSERVATION_MODIFIER", 346, 356], ["inflammatory", "OBSERVATION_MODIFIER", 357, 369], ["local immunosuppression", "OBSERVATION", 382, 405], ["chronic", "OBSERVATION_MODIFIER", 421, 428]]], ["Acute M. hyopneumoniae infection leads to the recruitment and activation of various innate immune cells, essentially through the involvement of a large range of cytokines: IL1, IL6 and TNF\u03b1 in lungs; CXCL8, IL1, IL2, IL4, IL6, TNF\u03b1 and IL10 in Bronchus-Associated Lymphoid Tissue (BALT) or TracheoBronchial Lavage Fluid (TBLF) [65, 71, 72] .", [["immune cells", "ANATOMY", 91, 103], ["lungs", "ANATOMY", 193, 198], ["Lymphoid Tissue", "ANATOMY", 264, 279], ["BALT", "ANATOMY", 281, 285], ["M. hyopneumoniae infection", "DISEASE", 6, 32], ["M. hyopneumoniae", "ORGANISM", 6, 22], ["innate immune cells", "CELL", 84, 103], ["IL1", "GENE_OR_GENE_PRODUCT", 172, 175], ["IL6", "GENE_OR_GENE_PRODUCT", 177, 180], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 185, 189], ["lungs", "ORGAN", 193, 198], ["CXCL8", "GENE_OR_GENE_PRODUCT", 200, 205], ["IL1", "GENE_OR_GENE_PRODUCT", 207, 210], ["IL2", "GENE_OR_GENE_PRODUCT", 212, 215], ["IL4", "GENE_OR_GENE_PRODUCT", 217, 220], ["IL6", "GENE_OR_GENE_PRODUCT", 222, 225], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 227, 231], ["IL10", "GENE_OR_GENE_PRODUCT", 236, 240], ["Lymphoid Tissue", "TISSUE", 264, 279], ["BALT", "MULTI-TISSUE_STRUCTURE", 281, 285], ["innate immune cells", "CELL_TYPE", 84, 103], ["cytokines", "PROTEIN", 161, 170], ["IL1", "PROTEIN", 172, 175], ["IL6", "PROTEIN", 177, 180], ["TNF\u03b1", "PROTEIN", 185, 189], ["CXCL8", "PROTEIN", 200, 205], ["IL1", "PROTEIN", 207, 210], ["IL2", "PROTEIN", 212, 215], ["IL4", "PROTEIN", 217, 220], ["IL6", "PROTEIN", 222, 225], ["TNF\u03b1", "PROTEIN", 227, 231], ["IL10", "PROTEIN", 236, 240], ["M. hyopneumoniae", "SPECIES", 6, 22], ["M. hyopneumoniae", "SPECIES", 6, 22], ["Acute M. hyopneumoniae infection", "PROBLEM", 0, 32], ["various innate immune cells", "PROBLEM", 76, 103], ["IL1", "PROBLEM", 172, 175], ["IL6", "PROBLEM", 177, 180], ["TNF", "TEST", 185, 188], ["CXCL8", "TEST", 200, 205], ["IL1", "TEST", 207, 210], ["IL2", "TEST", 212, 215], ["IL4", "TEST", 217, 220], ["IL6", "TEST", 222, 225], ["TNF", "TEST", 227, 230], ["IL10 in Bronchus", "TREATMENT", 236, 252], ["TracheoBronchial Lavage Fluid (TBLF", "TEST", 290, 325], ["hyopneumoniae", "OBSERVATION_MODIFIER", 9, 22], ["infection", "OBSERVATION", 23, 32], ["recruitment", "OBSERVATION_MODIFIER", 46, 57], ["immune cells", "OBSERVATION", 91, 103], ["large", "OBSERVATION_MODIFIER", 146, 151], ["lungs", "ANATOMY", 193, 198], ["CXCL8", "ANATOMY", 200, 205], ["IL2", "ANATOMY", 212, 215], ["IL4", "ANATOMY", 217, 220], ["IL10", "ANATOMY", 236, 240], ["Bronchus", "ANATOMY", 244, 252], ["Lymphoid Tissue", "OBSERVATION", 264, 279], ["TracheoBronchial", "ANATOMY", 290, 306], ["Lavage Fluid", "OBSERVATION", 307, 319]]], ["Some of these inflammatory cytokines (TNF\u03b1, CXCL8, IL1\u03b2, IL6) are produced chronically in the lungs and play powerful roles in apoptosis (TNF\u03b1), differentiation and chemotaxis of neutrophils (respectively, IL6 and IL8), and macrophage activation (TNF\u03b1, IL1\u03b2).", [["lungs", "ANATOMY", 94, 99], ["neutrophils", "ANATOMY", 179, 190], ["macrophage", "ANATOMY", 224, 234], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 38, 42], ["CXCL8", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL6", "GENE_OR_GENE_PRODUCT", 57, 60], ["lungs", "ORGAN", 94, 99], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 138, 142], ["neutrophils", "CELL", 179, 190], ["IL6", "GENE_OR_GENE_PRODUCT", 206, 209], ["IL8", "GENE_OR_GENE_PRODUCT", 214, 217], ["macrophage", "CELL", 224, 234], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 247, 251], ["IL1\u03b2", "GENE_OR_GENE_PRODUCT", 253, 257], ["inflammatory cytokines", "PROTEIN", 14, 36], ["TNF\u03b1", "PROTEIN", 38, 42], ["CXCL8", "PROTEIN", 44, 49], ["IL1\u03b2", "PROTEIN", 51, 55], ["IL6", "PROTEIN", 57, 60], ["TNF\u03b1", "PROTEIN", 138, 142], ["neutrophils", "CELL_TYPE", 179, 190], ["IL6", "PROTEIN", 206, 209], ["IL8", "PROTEIN", 214, 217], ["TNF\u03b1", "PROTEIN", 247, 251], ["IL1\u03b2", "PROTEIN", 253, 257], ["these inflammatory cytokines", "TEST", 8, 36], ["TNF", "TEST", 38, 41], ["CXCL8", "TEST", 44, 49], ["apoptosis (TNF\u03b1)", "TEST", 127, 143], ["neutrophils", "TEST", 179, 190], ["IL6", "TEST", 206, 209], ["IL8", "TEST", 214, 217], ["macrophage activation", "TEST", 224, 245], ["inflammatory", "OBSERVATION_MODIFIER", 14, 26], ["cytokines", "OBSERVATION", 27, 36], ["lungs", "ANATOMY", 94, 99], ["macrophage", "ANATOMY", 224, 234]]], ["Chronic infections are typically associated with intense lymphoid hyperplasia [71] and are characterized by an accumulation of IgG-and IgA-expressing plasma cells, CD4 + T cells, macrophages and DCs in the BALT of inflamed lung tissue [73] .", [["lymphoid hyperplasia", "ANATOMY", 57, 77], ["plasma cells", "ANATOMY", 150, 162], ["CD4 + T cells", "ANATOMY", 164, 177], ["macrophages", "ANATOMY", 179, 190], ["DCs", "ANATOMY", 195, 198], ["BALT", "ANATOMY", 206, 210], ["lung tissue", "ANATOMY", 223, 234], ["Chronic infections", "DISEASE", 0, 18], ["lymphoid hyperplasia", "DISEASE", 57, 77], ["lymphoid hyperplasia", "PATHOLOGICAL_FORMATION", 57, 77], ["IgG", "GENE_OR_GENE_PRODUCT", 127, 130], ["IgA", "GENE_OR_GENE_PRODUCT", 135, 138], ["plasma cells", "CELL", 150, 162], ["CD4", "GENE_OR_GENE_PRODUCT", 164, 167], ["macrophages", "CELL", 179, 190], ["DCs", "CELL", 195, 198], ["BALT", "TISSUE", 206, 210], ["lung tissue", "TISSUE", 223, 234], ["IgG", "PROTEIN", 127, 130], ["IgA", "PROTEIN", 135, 138], ["plasma cells", "CELL_TYPE", 150, 162], ["CD4 + T cells", "CELL_TYPE", 164, 177], ["macrophages", "CELL_TYPE", 179, 190], ["DCs", "CELL_TYPE", 195, 198], ["Chronic infections", "PROBLEM", 0, 18], ["intense lymphoid hyperplasia", "PROBLEM", 49, 77], ["IgG", "TEST", 127, 130], ["IgA", "TEST", 135, 138], ["plasma cells", "PROBLEM", 150, 162], ["CD4", "TEST", 164, 167], ["T cells", "PROBLEM", 170, 177], ["macrophages", "PROBLEM", 179, 190], ["DCs", "PROBLEM", 195, 198], ["inflamed lung tissue", "PROBLEM", 214, 234], ["infections", "OBSERVATION", 8, 18], ["intense", "OBSERVATION_MODIFIER", 49, 56], ["lymphoid hyperplasia", "OBSERVATION", 57, 77], ["accumulation", "OBSERVATION_MODIFIER", 111, 123], ["IgG", "OBSERVATION", 127, 130], ["plasma cells", "OBSERVATION", 150, 162], ["macrophages", "OBSERVATION_MODIFIER", 179, 190], ["BALT", "ANATOMY_MODIFIER", 206, 210], ["inflamed", "ANATOMY_MODIFIER", 214, 222], ["lung", "ANATOMY", 223, 227], ["tissue", "ANATOMY_MODIFIER", 228, 234]]], ["Involvement of T cell activation in chronic inflammation is also supported by the presence of T-cell cytokines such as IL-2 and IL-4 in bronchoalveolar exudates [72] .Mycoplasma hyopneumoniaeIn vitro studies conducted with macrophages cocultured with M. hyopneumoniae highlighted a strong activation of inflammatory pathways inducing the production of cytokines and chemokines, and expression of receptors or pathways inducing cell apoptosis [65, 66, 74, 75] .", [["T cell", "ANATOMY", 15, 21], ["T-cell", "ANATOMY", 94, 100], ["bronchoalveolar exudates", "ANATOMY", 136, 160], ["macrophages", "ANATOMY", 223, 234], ["cell", "ANATOMY", 427, 431], ["inflammation", "DISEASE", 44, 56], ["T cell", "CELL", 15, 21], ["T-cell", "CELL", 94, 100], ["IL-2", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-4", "GENE_OR_GENE_PRODUCT", 128, 132], ["bronchoalveolar", "ORGANISM_SUBSTANCE", 136, 151], ["Mycoplasma hyopneumoniae", "ORGANISM", 167, 191], ["macrophages", "CELL", 223, 234], ["M. hyopneumoniae", "ORGANISM", 251, 267], ["cell", "CELL", 427, 431], ["T-cell cytokines", "PROTEIN", 94, 110], ["IL-2 and IL-4", "PROTEIN", 119, 132], ["macrophages", "CELL_TYPE", 223, 234], ["cytokines", "PROTEIN", 352, 361], ["chemokines", "PROTEIN", 366, 376], ["Mycoplasma hyopneumoniae", "SPECIES", 167, 191], ["M. hyopneumoniae", "SPECIES", 251, 267], ["Mycoplasma hyopneumoniae", "SPECIES", 167, 191], ["M. hyopneumoniae", "SPECIES", 251, 267], ["T cell activation", "PROBLEM", 15, 32], ["chronic inflammation", "PROBLEM", 36, 56], ["T-cell cytokines", "PROBLEM", 94, 110], ["IL", "TEST", 119, 121], ["IL", "TEST", 128, 130], ["bronchoalveolar exudates", "PROBLEM", 136, 160], ["Mycoplasma hyopneumoniae", "PROBLEM", 167, 191], ["vitro studies", "TEST", 194, 207], ["macrophages", "PROBLEM", 223, 234], ["M. hyopneumoniae", "PROBLEM", 251, 267], ["inflammatory pathways", "PROBLEM", 303, 324], ["cytokines and chemokines", "TREATMENT", 352, 376], ["cell apoptosis", "PROBLEM", 427, 441], ["T cell activation", "OBSERVATION", 15, 32], ["chronic", "OBSERVATION_MODIFIER", 36, 43], ["inflammation", "OBSERVATION", 44, 56], ["cell cytokines", "OBSERVATION", 96, 110], ["bronchoalveolar exudates", "OBSERVATION", 136, 160], ["hyopneumoniae", "OBSERVATION", 178, 191], ["inflammatory", "OBSERVATION_MODIFIER", 303, 315], ["cell apoptosis", "OBSERVATION", 427, 441]]], ["Moreover, M. hyopneumoniae is described as an inhibitor of macrophages phagocytic activity, which may explain the chronicity of M. hyopneumoniae infections and the greater host susceptibility to other pathogens [65, 66, 74] .Mycoplasma hyopneumoniaeMycoplasma hyopneumoniae was found to activate costimulatory molecule expression on bona fide DCs with poor TNF\u03b1 production, contrasting with monocytes.", [["macrophages", "ANATOMY", 59, 70], ["DCs", "ANATOMY", 343, 346], ["monocytes", "ANATOMY", 391, 400], ["M. hyopneumoniae infections", "DISEASE", 128, 155], ["M. hyopneumoniae", "ORGANISM", 10, 26], ["macrophages", "CELL", 59, 70], ["M. hyopneumoniae", "ORGANISM", 128, 144], ["Mycoplasma hyopneumoniae", "ORGANISM", 225, 249], ["Mycoplasma hyopneumoniae", "ORGANISM", 249, 273], ["DCs", "CELL", 343, 346], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 357, 361], ["monocytes", "CELL", 391, 400], ["macrophages", "CELL_TYPE", 59, 70], ["costimulatory molecule", "PROTEIN", 296, 318], ["bona fide DCs", "CELL_TYPE", 333, 346], ["TNF\u03b1", "PROTEIN", 357, 361], ["monocytes", "CELL_TYPE", 391, 400], ["M. hyopneumoniae", "SPECIES", 10, 26], ["M. hyopneumoniae", "SPECIES", 128, 144], ["Mycoplasma hyopneumoniae", "SPECIES", 225, 249], ["Mycoplasma hyopneumoniae", "SPECIES", 249, 273], ["M. hyopneumoniae", "SPECIES", 10, 26], ["M. hyopneumoniae", "SPECIES", 128, 144], ["Mycoplasma hyopneumoniae", "SPECIES", 225, 249], ["Mycoplasma hyopneumoniae", "SPECIES", 249, 273], ["M. hyopneumoniae", "PROBLEM", 10, 26], ["macrophages phagocytic activity", "PROBLEM", 59, 90], ["M. hyopneumoniae infections", "PROBLEM", 128, 155], ["Mycoplasma hyopneumoniae", "PROBLEM", 225, 249], ["Mycoplasma hyopneumoniae", "PROBLEM", 249, 273], ["costimulatory molecule expression", "PROBLEM", 296, 329], ["poor TNF\u03b1 production", "PROBLEM", 352, 372], ["monocytes", "TEST", 391, 400], ["hyopneumoniae", "OBSERVATION", 13, 26], ["macrophages phagocytic activity", "OBSERVATION", 59, 90], ["hyopneumoniae", "OBSERVATION_MODIFIER", 131, 144], ["infections", "OBSERVATION", 145, 155], ["greater host", "OBSERVATION_MODIFIER", 164, 176], ["hyopneumoniae", "OBSERVATION", 236, 249], ["hyopneumoniae", "OBSERVATION", 260, 273], ["costimulatory molecule expression", "OBSERVATION", 296, 329], ["poor", "OBSERVATION_MODIFIER", 352, 356]]], ["Interestingly, a strong mitogenic activity for B cells was observed [76] .", [["B cells", "ANATOMY", 47, 54], ["B cells", "CELL", 47, 54], ["B cells", "CELL_TYPE", 47, 54], ["B cells", "PROBLEM", 47, 54]]], ["Altogether, these data indicate that M. hyopneumoniae is well sensed by the innate immune system, but the presence of immune evasion mechanisms targeting antigen presenting cells remains a possibility that needs further investigations.Mycoplasma hyopneumoniaeAntibody responses after infection develop slowly and do not appear to correlate with protection [65, 66] .", [["immune system", "ANATOMY", 83, 96], ["antigen presenting cells", "ANATOMY", 154, 178], ["infection", "DISEASE", 284, 293], ["M. hyopneumoniae", "ORGANISM", 37, 53], ["immune system", "ANATOMICAL_SYSTEM", 83, 96], ["cells", "CELL", 173, 178], ["Mycoplasma hyopneumoniaeAntibody", "ORGANISM", 235, 267], ["antigen presenting cells", "CELL_TYPE", 154, 178], ["M. hyopneumoniae", "SPECIES", 37, 53], ["Mycoplasma hyopneumoniaeAntibody", "SPECIES", 235, 267], ["M. hyopneumoniae", "SPECIES", 37, 53], ["Mycoplasma hyopneumoniaeAntibody", "SPECIES", 235, 267], ["M. hyopneumoniae", "PROBLEM", 37, 53], ["immune evasion mechanisms targeting antigen presenting cells", "PROBLEM", 118, 178], ["further investigations", "TEST", 212, 234], ["Mycoplasma hyopneumoniaeAntibody responses", "PROBLEM", 235, 277], ["infection", "PROBLEM", 284, 293], ["hyopneumoniae", "OBSERVATION", 40, 53], ["infection", "OBSERVATION", 284, 293]]], ["The literature on M. hyopneumoniae infections coupled with information from mouse models indicates that adaptive immune responses represent a fragile balance between pathogenic and protective Th-cell responses, probably belonging to the Th1 or Th17 types [65, 66] .Bordetella bronchisepticaThis aerobic Gram-negative bacterium can be found in the respiratory tract of several animal species and it presents a worldwide distribution in the porcine rearing [77] .", [["Th-cell", "ANATOMY", 192, 199], ["respiratory tract", "ANATOMY", 347, 364], ["M. hyopneumoniae infections", "DISEASE", 18, 45], ["Bordetella bronchiseptica", "DISEASE", 265, 290], ["M. hyopneumoniae", "ORGANISM", 18, 34], ["mouse", "ORGANISM", 76, 81], ["Th-cell", "CELL", 192, 199], ["Th1", "GENE_OR_GENE_PRODUCT", 237, 240], ["Bordetella bronchiseptica", "ORGANISM", 265, 290], ["respiratory tract", "ORGANISM_SUBDIVISION", 347, 364], ["porcine", "ORGANISM", 439, 446], ["Th1 or Th17 types", "CELL_TYPE", 237, 254], ["M. hyopneumoniae", "SPECIES", 18, 34], ["mouse", "SPECIES", 76, 81], ["Bordetella bronchiseptica", "SPECIES", 265, 290], ["M. hyopneumoniae", "SPECIES", 18, 34], ["mouse", "SPECIES", 76, 81], ["Bordetella bronchiseptica", "SPECIES", 265, 290], ["M. hyopneumoniae infections", "PROBLEM", 18, 45], ["adaptive immune responses", "PROBLEM", 104, 129], ["a fragile balance", "PROBLEM", 140, 157], ["Bordetella bronchiseptica", "PROBLEM", 265, 290], ["This aerobic Gram", "TEST", 290, 307], ["negative bacterium", "PROBLEM", 308, 326], ["the respiratory tract", "PROBLEM", 343, 364], ["several animal species", "PROBLEM", 368, 390], ["hyopneumoniae", "OBSERVATION_MODIFIER", 21, 34], ["infections", "OBSERVATION", 35, 45], ["fragile balance", "OBSERVATION", 142, 157], ["Th1", "ANATOMY", 237, 240], ["bronchiseptica", "OBSERVATION", 276, 290], ["negative bacterium", "OBSERVATION", 308, 326], ["respiratory tract", "ANATOMY", 347, 364], ["several", "OBSERVATION_MODIFIER", 368, 375], ["animal species", "OBSERVATION", 376, 390]]], ["B. bronchiseptica has a strong tropism for ciliated cells from the respiratory tissue and is mostly detected in the apical portion of the ciliated cells of turbinates, trachea and lungs [77, 78] .", [["ciliated cells", "ANATOMY", 43, 57], ["respiratory tissue", "ANATOMY", 67, 85], ["apical portion", "ANATOMY", 116, 130], ["ciliated cells", "ANATOMY", 138, 152], ["turbinates", "ANATOMY", 156, 166], ["trachea", "ANATOMY", 168, 175], ["lungs", "ANATOMY", 180, 185], ["B. bronchiseptica", "ORGANISM", 0, 17], ["ciliated cells", "CELL", 43, 57], ["respiratory tissue", "TISSUE", 67, 85], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 116, 122], ["ciliated cells", "CELL", 138, 152], ["turbinates", "ORGAN", 156, 166], ["trachea", "MULTI-TISSUE_STRUCTURE", 168, 175], ["lungs", "ORGAN", 180, 185], ["ciliated cells", "CELL_TYPE", 43, 57], ["ciliated cells", "CELL_TYPE", 138, 152], ["B. bronchiseptica", "SPECIES", 0, 17], ["B. bronchiseptica", "SPECIES", 0, 17], ["B. bronchiseptica", "PROBLEM", 0, 17], ["ciliated cells from the respiratory tissue", "PROBLEM", 43, 85], ["bronchiseptica", "OBSERVATION", 3, 17], ["strong", "OBSERVATION_MODIFIER", 24, 30], ["tropism", "OBSERVATION", 31, 38], ["ciliated cells", "OBSERVATION", 43, 57], ["respiratory tissue", "OBSERVATION", 67, 85], ["apical", "ANATOMY_MODIFIER", 116, 122], ["portion", "ANATOMY_MODIFIER", 123, 130], ["ciliated cells", "OBSERVATION", 138, 152], ["turbinates", "ANATOMY", 156, 166], ["trachea", "ANATOMY", 168, 175], ["lungs", "ANATOMY", 180, 185]]], ["It can also be found in the cytoplasm of neutrophils and macrophages and rarely in the alveolar lumen associated with small tufts of cilia [77, 78] .", [["cytoplasm", "ANATOMY", 28, 37], ["neutrophils", "ANATOMY", 41, 52], ["macrophages", "ANATOMY", 57, 68], ["alveolar lumen", "ANATOMY", 87, 101], ["tufts", "ANATOMY", 124, 129], ["cilia", "ANATOMY", 133, 138], ["cytoplasm", "ORGANISM_SUBSTANCE", 28, 37], ["neutrophils", "CELL", 41, 52], ["macrophages", "CELL", 57, 68], ["alveolar lumen", "MULTI-TISSUE_STRUCTURE", 87, 101], ["cilia", "CELLULAR_COMPONENT", 133, 138], ["neutrophils", "CELL_TYPE", 41, 52], ["macrophages", "CELL_TYPE", 57, 68], ["small tufts of cilia", "PROBLEM", 118, 138], ["cytoplasm", "OBSERVATION_MODIFIER", 28, 37], ["neutrophils", "OBSERVATION", 41, 52], ["macrophages", "OBSERVATION", 57, 68], ["alveolar", "ANATOMY_MODIFIER", 87, 95], ["lumen", "ANATOMY_MODIFIER", 96, 101], ["small", "OBSERVATION_MODIFIER", 118, 123], ["tufts", "OBSERVATION_MODIFIER", 124, 129], ["cilia", "ANATOMY_MODIFIER", 133, 138]]], ["Hence, infected pigs show cilia loss in the bronchial and bronchiolar epithelium associated with multifocal erosion, fibrosis, and hyperplasia.", [["cilia", "ANATOMY", 26, 31], ["bronchial", "ANATOMY", 44, 53], ["bronchiolar epithelium", "ANATOMY", 58, 80], ["cilia loss", "DISEASE", 26, 36], ["fibrosis", "DISEASE", 117, 125], ["hyperplasia", "DISEASE", 131, 142], ["pigs", "ORGANISM", 16, 20], ["cilia", "MULTI-TISSUE_STRUCTURE", 26, 31], ["bronchial", "MULTI-TISSUE_STRUCTURE", 44, 53], ["bronchiolar epithelium", "TISSUE", 58, 80], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["cilia loss in the bronchial and bronchiolar epithelium", "PROBLEM", 26, 80], ["multifocal erosion", "PROBLEM", 97, 115], ["fibrosis", "PROBLEM", 117, 125], ["hyperplasia", "PROBLEM", 131, 142], ["infected", "OBSERVATION", 7, 15], ["cilia loss", "OBSERVATION", 26, 36], ["bronchial", "ANATOMY", 44, 53], ["bronchiolar epithelium", "ANATOMY", 58, 80], ["multifocal", "OBSERVATION_MODIFIER", 97, 107], ["erosion", "OBSERVATION", 108, 115], ["fibrosis", "OBSERVATION", 117, 125], ["hyperplasia", "OBSERVATION", 131, 142]]], ["Neutrophil infiltrates are noted in the peri-conchal meatus and the submucosa of the bronchioles and alveoli, while lymphocyte and plasma cell infiltrations occur at the level of the lamina propria [77, 78] .Bordetella bronchisepticaCell adhesion of B. bronchiseptica is a multifactorial process involving two main virulence factors; Filamentous HemAgglutinin (FHA) and PeRtactiN (PRN) [77, 79] .", [["Neutrophil infiltrates", "ANATOMY", 0, 22], ["peri-conchal meatus", "ANATOMY", 40, 59], ["submucosa", "ANATOMY", 68, 77], ["bronchioles", "ANATOMY", 85, 96], ["alveoli", "ANATOMY", 101, 108], ["lymphocyte", "ANATOMY", 116, 126], ["plasma cell", "ANATOMY", 131, 142], ["lamina propria", "ANATOMY", 183, 197], ["Neutrophil", "CELL", 0, 10], ["peri-conchal meatus", "ORGAN", 40, 59], ["submucosa", "MULTI-TISSUE_STRUCTURE", 68, 77], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 85, 96], ["alveoli", "MULTI-TISSUE_STRUCTURE", 101, 108], ["lymphocyte", "CELL", 116, 126], ["plasma cell", "CELL", 131, 142], ["lamina propria", "TISSUE", 183, 197], ["Bordetella bronchisepticaCell", "ORGANISM", 208, 237], ["B. bronchiseptica", "ORGANISM", 250, 267], ["Filamentous HemAgglutinin", "GENE_OR_GENE_PRODUCT", 334, 359], ["FHA", "GENE_OR_GENE_PRODUCT", 361, 364], ["PeRtactiN", "GENE_OR_GENE_PRODUCT", 370, 379], ["Neutrophil infiltrates", "CELL_TYPE", 0, 22], ["virulence factors", "PROTEIN", 315, 332], ["Filamentous HemAgglutinin", "PROTEIN", 334, 359], ["FHA", "PROTEIN", 361, 364], ["PeRtactiN", "PROTEIN", 370, 379], ["PRN", "PROTEIN", 381, 384], ["B. bronchiseptica", "SPECIES", 250, 267], ["Bordetella bronchisepticaCell", "SPECIES", 208, 237], ["B. bronchiseptica", "SPECIES", 250, 267], ["Neutrophil infiltrates", "PROBLEM", 0, 22], ["lymphocyte", "TEST", 116, 126], ["plasma cell infiltrations", "PROBLEM", 131, 156], ["Bordetella bronchisepticaCell adhesion of B. bronchiseptica", "PROBLEM", 208, 267], ["a multifactorial process", "PROBLEM", 271, 295], ["Filamentous HemAgglutinin (FHA)", "TREATMENT", 334, 365], ["PeRtactiN (PRN)", "TREATMENT", 370, 385], ["infiltrates", "OBSERVATION", 11, 22], ["peri-conchal meatus", "ANATOMY", 40, 59], ["submucosa", "ANATOMY_MODIFIER", 68, 77], ["bronchioles", "ANATOMY", 85, 96], ["alveoli", "ANATOMY_MODIFIER", 101, 108], ["lymphocyte", "ANATOMY", 116, 126], ["plasma cell infiltrations", "OBSERVATION", 131, 156], ["lamina propria", "ANATOMY", 183, 197], ["adhesion", "OBSERVATION_MODIFIER", 238, 246], ["bronchiseptica", "OBSERVATION", 253, 267], ["multifactorial", "OBSERVATION_MODIFIER", 273, 287], ["process", "OBSERVATION", 288, 295], ["main", "OBSERVATION_MODIFIER", 310, 314], ["virulence", "OBSERVATION_MODIFIER", 315, 324]]], ["The expression of both adhesins is controlled by the Bordetella virulence genes (Bvg)AS signal transduction system.", [["Bordetella virulence", "GENE_OR_GENE_PRODUCT", 53, 73], ["Bvg", "GENE_OR_GENE_PRODUCT", 81, 84], ["adhesins", "PROTEIN", 23, 31], ["Bordetella virulence genes", "DNA", 53, 79], ["Bvg", "DNA", 81, 84], ["both", "OBSERVATION_MODIFIER", 18, 22], ["adhesins", "OBSERVATION", 23, 31]]], ["FHA is an adhesin with several binding domains including a carbohydrate-recognition domain responsible of the adhesion to macrophages and ciliated epithelial cells, a heparin-binding domain that mediates the binding to sulfated polysaccharides, and an Arg-Gly-Asp domain (RGD) regulating the InterCellular Adhesion Molecule 1 (ICAM1) by epithelial cells after interaction with the NF-\u03baB signalling pathways [79] .", [["macrophages", "ANATOMY", 122, 133], ["ciliated epithelial cells", "ANATOMY", 138, 163], ["epithelial cells", "ANATOMY", 337, 353], ["heparin", "CHEMICAL", 167, 174], ["carbohydrate", "CHEMICAL", 59, 71], ["Arg-Gly-Asp", "CHEMICAL", 252, 263], ["FHA", "GENE_OR_GENE_PRODUCT", 0, 3], ["macrophages", "CELL", 122, 133], ["ciliated epithelial cells", "CELL", 138, 163], ["heparin", "SIMPLE_CHEMICAL", 167, 174], ["sulfated polysaccharides", "SIMPLE_CHEMICAL", 219, 243], ["InterCellular Adhesion Molecule 1", "GENE_OR_GENE_PRODUCT", 292, 325], ["ICAM1", "GENE_OR_GENE_PRODUCT", 327, 332], ["epithelial cells", "CELL", 337, 353], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 381, 386], ["FHA", "PROTEIN", 0, 3], ["adhesin", "PROTEIN", 10, 17], ["binding domains", "PROTEIN", 31, 46], ["carbohydrate-recognition domain", "PROTEIN", 59, 90], ["macrophages", "CELL_TYPE", 122, 133], ["ciliated epithelial cells", "CELL_TYPE", 138, 163], ["heparin-binding domain", "PROTEIN", 167, 189], ["Arg-Gly-Asp domain", "PROTEIN", 252, 270], ["RGD", "PROTEIN", 272, 275], ["InterCellular Adhesion Molecule 1", "PROTEIN", 292, 325], ["ICAM1", "PROTEIN", 327, 332], ["epithelial cells", "CELL_TYPE", 337, 353], ["NF-\u03baB", "PROTEIN", 381, 386], ["an adhesin", "PROBLEM", 7, 17], ["several binding domains", "PROBLEM", 23, 46], ["the adhesion to macrophages", "PROBLEM", 106, 133], ["ciliated epithelial cells", "PROBLEM", 138, 163], ["a heparin-binding domain", "TREATMENT", 165, 189], ["sulfated polysaccharides", "TREATMENT", 219, 243], ["an Arg-Gly-Asp domain (RGD)", "TREATMENT", 249, 276], ["the InterCellular Adhesion Molecule", "TREATMENT", 288, 323], ["the NF", "TEST", 377, 383], ["ciliated epithelial cells", "OBSERVATION", 138, 163]]], ["This RGD domain is also present in the structure of PRN and contributes to the binding process [77, 79] .", [["PRN", "GENE_OR_GENE_PRODUCT", 52, 55], ["RGD domain", "PROTEIN", 5, 15], ["PRN", "PROTEIN", 52, 55], ["This RGD domain", "PROBLEM", 0, 15]]], ["On the other hand, non-opsonic adhesion mechanisms play a role in binding to the host cells such as carbohydrate-specific mechanisms and those involving sialic acid-containing compounds [77] .Bordetella bronchisepticaVirulence of the bacteria depends on the strains; therefore, clinical signs can be different going from sneezing and transient nasal discharge for moderate and non-toxic strains to bronchopneumonia and atrophy of the nasal turbinate bones for virulent strains, especially if they are associated to other bacteria such as P. multocida [77] .", [["cells", "ANATOMY", 86, 91], ["nasal", "ANATOMY", 344, 349], ["nasal turbinate bones", "ANATOMY", 434, 455], ["strains", "ANATOMY", 469, 476], ["sneezing", "DISEASE", 321, 329], ["bronchopneumonia", "DISEASE", 398, 414], ["atrophy", "DISEASE", 419, 426], ["carbohydrate", "CHEMICAL", 100, 112], ["sialic acid-containing", "CHEMICAL", 153, 175], ["cells", "CELL", 86, 91], ["sialic acid-containing compounds", "SIMPLE_CHEMICAL", 153, 185], ["Bordetella bronchisepticaVirulence", "ORGANISM", 192, 226], ["nasal", "ORGANISM_SUBDIVISION", 344, 349], ["nasal turbinate bones", "MULTI-TISSUE_STRUCTURE", 434, 455], ["P. multocida", "ORGANISM", 538, 550], ["host cells", "CELL_TYPE", 81, 91], ["P. multocida", "SPECIES", 538, 550], ["Bordetella bronchisepticaVirulence", "SPECIES", 192, 226], ["P. multocida", "SPECIES", 538, 550], ["non-opsonic adhesion mechanisms", "PROBLEM", 19, 50], ["sialic acid-containing compounds", "TREATMENT", 153, 185], ["the bacteria", "PROBLEM", 230, 242], ["the strains", "PROBLEM", 254, 265], ["clinical signs", "PROBLEM", 278, 292], ["sneezing", "PROBLEM", 321, 329], ["transient nasal discharge", "PROBLEM", 334, 359], ["moderate and non-toxic strains", "PROBLEM", 364, 394], ["bronchopneumonia", "PROBLEM", 398, 414], ["atrophy of the nasal turbinate bones", "PROBLEM", 419, 455], ["virulent strains", "PROBLEM", 460, 476], ["other bacteria", "PROBLEM", 515, 529], ["adhesion", "OBSERVATION", 31, 39], ["bacteria", "OBSERVATION", 234, 242], ["nasal", "ANATOMY", 344, 349], ["bronchopneumonia", "OBSERVATION", 398, 414], ["atrophy", "OBSERVATION", 419, 426], ["nasal turbinate", "ANATOMY", 434, 449]]], ["Thus, B. bronchiseptica is usually described as primary lung pathogen in young pigs where it causes necrohemorrhagic bronchopneumonia whereas in older pigs this bacterium is mostly known as an opportunistic pathogen contributing to the PRDC [77] .", [["lung", "ANATOMY", 56, 60], ["primary lung pathogen", "DISEASE", 48, 69], ["bronchopneumonia", "DISEASE", 117, 133], ["PRDC", "DISEASE", 236, 240], ["B. bronchiseptica", "ORGANISM", 6, 23], ["lung", "ORGAN", 56, 60], ["pigs", "ORGANISM", 79, 83], ["pigs", "ORGANISM", 151, 155], ["B. bronchiseptica", "SPECIES", 6, 23], ["pigs", "SPECIES", 79, 83], ["pigs", "SPECIES", 151, 155], ["B. bronchiseptica", "SPECIES", 6, 23], ["pigs", "SPECIES", 79, 83], ["pigs", "SPECIES", 151, 155], ["B. bronchiseptica", "PROBLEM", 6, 23], ["primary lung pathogen", "PROBLEM", 48, 69], ["necrohemorrhagic bronchopneumonia", "PROBLEM", 100, 133], ["an opportunistic pathogen", "PROBLEM", 190, 215], ["bronchiseptica", "OBSERVATION", 9, 23], ["lung", "ANATOMY", 56, 60], ["pathogen", "OBSERVATION", 61, 69], ["necrohemorrhagic", "OBSERVATION_MODIFIER", 100, 116], ["bronchopneumonia", "OBSERVATION", 117, 133]]], ["The immune response against B. bronchiseptica is mainly triggered by the different toxins expressed such as adenylate cyclase, tracheal cytotoxin and DermoNecrotic Toxin (DNT).Selection and exclusion criteria for considered studiesIn the following section and Additional file 1, we have used the published studies evaluating multiple infections including viral-viral, bacterial-viral, viral-bacterial and bacterial-bacterial respiratory coinfections and superinfections in swine.", [["respiratory", "ANATOMY", 425, 436], ["DNT", "CHEMICAL", 171, 174], ["infections", "DISEASE", 334, 344], ["respiratory coinfections", "DISEASE", 425, 449], ["superinfections", "DISEASE", 454, 469], ["adenylate", "CHEMICAL", 108, 117], ["B. bronchiseptica", "ORGANISM", 28, 45], ["adenylate cyclase", "GENE_OR_GENE_PRODUCT", 108, 125], ["tracheal cytotoxin", "GENE_OR_GENE_PRODUCT", 127, 145], ["DermoNecrotic Toxin", "SIMPLE_CHEMICAL", 150, 169], ["DNT", "SIMPLE_CHEMICAL", 171, 174], ["swine", "ORGANISM", 473, 478], ["adenylate cyclase", "PROTEIN", 108, 125], ["tracheal cytotoxin", "PROTEIN", 127, 145], ["DermoNecrotic Toxin", "PROTEIN", 150, 169], ["DNT", "PROTEIN", 171, 174], ["B. bronchiseptica", "SPECIES", 28, 45], ["swine", "SPECIES", 473, 478], ["B. bronchiseptica", "SPECIES", 28, 45], ["swine", "SPECIES", 473, 478], ["B. bronchiseptica", "PROBLEM", 28, 45], ["the different toxins", "PROBLEM", 69, 89], ["adenylate cyclase", "TEST", 108, 125], ["tracheal cytotoxin", "TREATMENT", 127, 145], ["DermoNecrotic Toxin", "TREATMENT", 150, 169], ["studies", "TEST", 224, 231], ["the published studies", "TEST", 292, 313], ["multiple infections", "PROBLEM", 325, 344], ["viral", "TEST", 355, 360], ["bacterial", "PROBLEM", 368, 377], ["viral", "PROBLEM", 378, 383], ["bacterial", "PROBLEM", 391, 400], ["bacterial-bacterial respiratory coinfections", "PROBLEM", 405, 449], ["superinfections", "PROBLEM", 454, 469], ["tracheal", "ANATOMY", 127, 135], ["infections", "OBSERVATION", 334, 344], ["bacterial", "OBSERVATION_MODIFIER", 405, 414], ["bacterial", "OBSERVATION_MODIFIER", 415, 424], ["respiratory coinfections", "OBSERVATION", 425, 449], ["superinfections", "OBSERVATION", 454, 469]]], ["Both in vivo and in vitro studies comparing single to multiple infections were included.", [["infections", "DISEASE", 63, 73], ["vitro studies", "TEST", 20, 33], ["multiple infections", "PROBLEM", 54, 73], ["infections", "OBSERVATION", 63, 73]]], ["Studies evaluating vaccinations and the development of diagnostic techniques such as ELISA or qPCR were excluded as well as trials testing antiviral or antibacterial molecules when there was no clear comparison between single and multiple infections.", [["infections", "DISEASE", 239, 249], ["Studies evaluating vaccinations", "TEST", 0, 31], ["diagnostic techniques", "TEST", 55, 76], ["ELISA", "TEST", 85, 90], ["qPCR", "TEST", 94, 98], ["trials testing antiviral", "TREATMENT", 124, 148], ["antibacterial molecules", "TREATMENT", 152, 175], ["clear comparison between single and multiple infections", "PROBLEM", 194, 249], ["multiple", "OBSERVATION_MODIFIER", 230, 238], ["infections", "OBSERVATION", 239, 249]]], ["An attempt to present a synthetic view of coinfections is depicted in the heat maps (see Figures 1, 2, 3) .", [["coinfections", "DISEASE", 42, 54], ["coinfections", "PROBLEM", 42, 54], ["the heat maps", "TEST", 70, 83], ["coinfections", "OBSERVATION", 42, 54]]], ["In these heat maps, we were interested in the effect of the first pathogen on the multiplication of the second one (named \"assessed pathogen\" in the figures) and on the host immune response and/or clinical signs.", [["these heat maps", "TEST", 3, 18], ["clinical signs", "TEST", 197, 211]]], ["These effects were evaluated and a grade from \u2212 5 to + 5 was given to every pathogen depending on the intensity of its impact on the multiplication of the second agent and on the immune response or on the clinical signs.", [["a grade", "TEST", 33, 40], ["the second agent", "TREATMENT", 151, 167], ["the clinical signs", "TEST", 201, 219]]], ["Negative grades were given to pathogens decreasing the multiplication of other pathogens, while positive grades were given to those inducing an increase.", [["pathogens", "PROBLEM", 30, 39], ["other pathogens", "PROBLEM", 73, 88], ["pathogens", "OBSERVATION", 79, 88], ["increase", "OBSERVATION_MODIFIER", 144, 152]]], ["Similarly, negative grades were attributed to pathogens with a tendency to decrease clinical signs or immune response related to the other pathogen.", [["pathogens", "PROBLEM", 46, 55], ["a tendency to decrease clinical signs", "PROBLEM", 61, 98], ["immune response", "PROBLEM", 102, 117], ["the other pathogen", "PROBLEM", 129, 147]]], ["Positive grades were given in case of an increase.", [["Positive grades", "PROBLEM", 0, 15], ["grades", "OBSERVATION_MODIFIER", 9, 15], ["increase", "OBSERVATION_MODIFIER", 41, 49]]], ["The sum of the grades was calculated if the same pathogen combination was evaluated in several studies except in the case of discordant results.", [["the same pathogen", "PROBLEM", 40, 57], ["several studies", "TEST", 87, 102]]], ["This grading was represented in the following heat maps and the number of the identified studies for the same pathogen combination is shown on the maps.", [["heat maps", "TEST", 46, 55], ["the maps", "TEST", 143, 151]]], ["In the heat maps, other pathogens, that are less associated to PRDC such as G. parasuis, M. hyorhinis, M. floculare, P. multocida, and S. suis or even not considered as respiratory pathogens like Staphylococcus aureus, Classical Swine Fever Virus, Hepatitis E Virus, Porcine RubulaVirus, PPV, and Torque Teno sus Virus 1 have also been included.", [["Staphylococcus aureus", "DISEASE", 196, 217], ["Swine Fever", "DISEASE", 229, 240], ["Hepatitis E Virus", "DISEASE", 248, 265], ["PRDC", "GENE_OR_GENE_PRODUCT", 63, 67], ["G. parasuis", "ORGANISM", 76, 87], ["M. hyorhinis", "ORGANISM", 89, 101], ["M. floculare", "ORGANISM", 103, 115], ["P. multocida", "ORGANISM", 117, 129], ["S. suis", "ORGANISM", 135, 142], ["Staphylococcus aureus", "ORGANISM", 196, 217], ["Classical Swine Fever Virus", "ORGANISM", 219, 246], ["Hepatitis E Virus", "ORGANISM", 248, 265], ["Porcine RubulaVirus", "ORGANISM", 267, 286], ["Torque Teno sus Virus 1", "ORGANISM", 297, 320], ["G. parasuis", "SPECIES", 76, 87], ["M. hyorhinis", "SPECIES", 89, 101], ["M. floculare", "SPECIES", 103, 115], ["P. multocida", "SPECIES", 117, 129], ["S. suis", "SPECIES", 135, 142], ["Staphylococcus aureus", "SPECIES", 196, 217], ["Swine Fever Virus", "SPECIES", 229, 246], ["Hepatitis E Virus", "SPECIES", 248, 265], ["Porcine", "SPECIES", 267, 274], ["G. parasuis", "SPECIES", 76, 87], ["M. hyorhinis", "SPECIES", 89, 101], ["M. floculare", "SPECIES", 103, 115], ["P. multocida", "SPECIES", 117, 129], ["S. suis", "SPECIES", 135, 142], ["Staphylococcus aureus", "SPECIES", 196, 217], ["Swine Fever Virus", "SPECIES", 229, 246], ["Hepatitis E Virus", "SPECIES", 248, 265], ["Torque Teno sus Virus 1", "SPECIES", 297, 320], ["the heat maps", "TEST", 3, 16], ["other pathogens", "PROBLEM", 18, 33], ["PRDC", "TREATMENT", 63, 67], ["G. parasuis", "PROBLEM", 76, 87], ["hyorhinis", "PROBLEM", 92, 101], ["multocida", "PROBLEM", 120, 129], ["S. suis", "PROBLEM", 135, 142], ["respiratory pathogens", "PROBLEM", 169, 190], ["Staphylococcus aureus", "PROBLEM", 196, 217], ["Classical Swine Fever Virus", "PROBLEM", 219, 246], ["Hepatitis E Virus", "PROBLEM", 248, 265], ["Porcine RubulaVirus", "TREATMENT", 267, 286], ["PPV", "TREATMENT", 288, 291], ["Torque Teno sus Virus", "TREATMENT", 297, 318], ["pathogens", "OBSERVATION", 24, 33], ["Staphylococcus aureus", "OBSERVATION", 196, 217]]], ["Indeed, these pathogens can also impact the outcome of respiratory infections and deserve, at least, to be mentioned.The different types of coinfections 3.2.1 Virus-virusViral/viral respiratory coinfections have always had an important role in the porcine respiratory disease complex [1] .", [["respiratory", "ANATOMY", 55, 66], ["respiratory", "ANATOMY", 256, 267], ["respiratory infections", "DISEASE", 55, 77], ["coinfections", "DISEASE", 140, 152], ["respiratory coinfections", "DISEASE", 182, 206], ["porcine respiratory disease", "DISEASE", 248, 275], ["3.2.1", "ORGANISM", 153, 158], ["Virus-virusViral", "ORGANISM", 159, 175], ["porcine", "SPECIES", 248, 255], ["these pathogens", "PROBLEM", 8, 23], ["respiratory infections", "PROBLEM", 55, 77], ["coinfections", "TEST", 140, 152], ["Virus", "TEST", 159, 164], ["virusViral", "TREATMENT", 165, 175], ["viral respiratory coinfections", "PROBLEM", 176, 206], ["the porcine respiratory disease complex", "PROBLEM", 244, 283], ["pathogens", "OBSERVATION", 14, 23], ["respiratory", "ANATOMY", 55, 66], ["infections", "OBSERVATION", 67, 77], ["coinfections", "OBSERVATION_MODIFIER", 140, 152], ["3.2.1 Virus", "OBSERVATION", 153, 164], ["respiratory coinfections", "OBSERVATION", 182, 206], ["respiratory disease", "OBSERVATION", 256, 275]]], ["Several studies assessed the presence of two or more viral pathogens in pigs showing respiratory clinical signs in farms located in endemic regions [7, 8, 13] .", [["respiratory", "ANATOMY", 85, 96], ["pigs", "ORGANISM", 72, 76], ["pigs", "SPECIES", 72, 76], ["pigs", "SPECIES", 72, 76], ["Several studies", "TEST", 0, 15], ["more viral pathogens in pigs", "PROBLEM", 48, 76], ["respiratory clinical signs in farms", "PROBLEM", 85, 120], ["endemic", "OBSERVATION_MODIFIER", 132, 139]]], ["The main viruses contributing to the porcine respiratory disease are swIAV, PRRSV, PCV2, and to a lower extent the PRCoV and the ADV.", [["respiratory", "ANATOMY", 45, 56], ["porcine respiratory disease", "DISEASE", 37, 64], ["ADV", "CHEMICAL", 129, 132], ["porcine", "ORGANISM", 37, 44], ["swIAV", "GENE_OR_GENE_PRODUCT", 69, 74], ["PRRSV", "ORGANISM", 76, 81], ["PCV2", "ORGANISM", 83, 87], ["porcine", "SPECIES", 37, 44], ["PRRSV", "SPECIES", 76, 81], ["PCV2", "SPECIES", 83, 87], ["ADV", "SPECIES", 129, 132], ["The main viruses", "PROBLEM", 0, 16], ["the porcine respiratory disease", "PROBLEM", 33, 64], ["PRRSV", "TREATMENT", 76, 81], ["PCV2", "TREATMENT", 83, 87], ["main", "OBSERVATION_MODIFIER", 4, 8], ["viruses", "OBSERVATION", 9, 16], ["porcine", "OBSERVATION_MODIFIER", 37, 44], ["respiratory disease", "OBSERVATION", 45, 64], ["lower extent", "OBSERVATION_MODIFIER", 98, 110], ["ADV", "OBSERVATION", 129, 132]]], ["Due to their fast-spreading and their economic consequences, some viruses were more studied than others in the last 20 years, especially PCV2, PRRSV, and swIAV as shown in Additional file 1A and B. We will thus put more emphasis on these three viruses as causes of primary infections.The different types of coinfections 3.2.1 Virus-virusMany in vivo studies were carried out to assess the severity of the clinical signs and the development of the microscopic/macroscopic lesions.", [["lesions", "ANATOMY", 471, 478], ["primary infections", "DISEASE", 265, 283], ["PCV2", "ORGANISM", 137, 141], ["PRRSV", "ORGANISM", 143, 148], ["3.2.1", "ORGANISM", 320, 325], ["Virus-virus", "ORGANISM", 326, 337], ["lesions", "PATHOLOGICAL_FORMATION", 471, 478], ["Virus-virus", "SPECIES", 326, 337], ["PRRSV", "SPECIES", 143, 148], ["swIAV", "SPECIES", 154, 159], ["Virus-virus", "SPECIES", 326, 337], ["their fast-spreading", "PROBLEM", 7, 27], ["some viruses", "PROBLEM", 61, 73], ["PCV2", "PROBLEM", 137, 141], ["PRRSV", "PROBLEM", 143, 148], ["primary infections", "PROBLEM", 265, 283], ["coinfections 3.2.1 Virus", "PROBLEM", 307, 331], ["virus", "PROBLEM", 332, 337], ["vivo studies", "TEST", 345, 357], ["the clinical signs", "PROBLEM", 401, 419], ["the microscopic/macroscopic lesions", "PROBLEM", 443, 478], ["viruses", "OBSERVATION", 66, 73], ["primary", "OBSERVATION_MODIFIER", 265, 272], ["infections", "OBSERVATION", 273, 283], ["coinfections", "OBSERVATION_MODIFIER", 307, 319], ["3.2.1 Virus", "OBSERVATION", 320, 331], ["macroscopic", "OBSERVATION_MODIFIER", 459, 470], ["lesions", "OBSERVATION", 471, 478]]], ["This approach enabled a comparison between coinfection/superinfection and single-infection conditions.", [["coinfection", "DISEASE", 43, 54], ["superinfection", "DISEASE", 55, 69], ["infection", "DISEASE", 81, 90], ["coinfection/superinfection", "PROBLEM", 43, 69], ["single-infection conditions", "PROBLEM", 74, 101], ["superinfection", "OBSERVATION", 55, 69], ["infection", "OBSERVATION", 81, 90]]], ["Then, viral interference was progressively more frequently measured as a way to better understand the consequences of coinfections.", [["coinfections", "DISEASE", 118, 130], ["viral interference", "PROBLEM", 6, 24], ["coinfections", "PROBLEM", 118, 130], ["viral interference", "OBSERVATION", 6, 24], ["coinfections", "OBSERVATION", 118, 130]]], ["In the last decades, the strong development of molecular biology and various tools enabled the evaluation of the immune response developed following polyviral infections.The different types of coinfections 3.2.1 Virus-virusIn Additional file 1, the selected studies that were carried out on viral coinfections are presented from the oldest in vivo experiments to the latest in vitro and ex vivo experiments (Additional file 1A and B).", [["polyviral infections", "DISEASE", 149, 169], ["coinfections", "DISEASE", 193, 205], ["viral coinfections", "DISEASE", 291, 309], ["the evaluation", "TEST", 91, 105], ["the immune response", "PROBLEM", 109, 128], ["polyviral infections", "PROBLEM", 149, 169], ["coinfections", "TEST", 193, 205], ["the selected studies", "TEST", 245, 265], ["viral coinfections", "PROBLEM", 291, 309], ["strong", "OBSERVATION_MODIFIER", 25, 31], ["polyviral infections", "OBSERVATION", 149, 169], ["coinfections", "OBSERVATION", 193, 205]]], ["This data synthesis highlights the major impact of PRRSV primary infection, which can both increase the titre of the following virus (PCV2, Hepatitis E Virus-HEV) in vitro [80] and in vivo [81] [82] [83] (Figure 1A ), but can also worsen the clinical score associated to the disease ( Figure 3A ).", [["PRRSV primary infection", "DISEASE", 51, 74], ["PRRSV", "ORGANISM", 51, 56], ["PCV2", "ORGANISM", 134, 138], ["Hepatitis E Virus-HEV", "ORGANISM", 140, 161], ["Hepatitis E Virus", "SPECIES", 140, 157], ["PRRSV", "SPECIES", 51, 56], ["PCV2", "SPECIES", 134, 138], ["Hepatitis E Virus-HEV", "SPECIES", 140, 161], ["PRRSV primary infection", "PROBLEM", 51, 74], ["the following virus", "PROBLEM", 113, 132], ["PCV2", "PROBLEM", 134, 138], ["Hepatitis E Virus", "TREATMENT", 140, 157], ["the disease", "PROBLEM", 271, 282], ["PRRSV", "OBSERVATION_MODIFIER", 51, 56], ["primary", "OBSERVATION_MODIFIER", 57, 64], ["infection", "OBSERVATION", 65, 74], ["disease", "OBSERVATION", 275, 282]]], ["Interestingly, even when the PRRSV does not increase the viral production of the other virus, as observed in coinfections involving swIAV [84] or PRCoV [85] (Figure 1A) , it can also worsen the associated clinical signs.", [["coinfections", "DISEASE", 109, 121], ["PRRSV", "ORGANISM", 29, 34], ["PRRSV", "SPECIES", 29, 34], ["the PRRSV", "PROBLEM", 25, 34], ["the viral production", "PROBLEM", 53, 73], ["the other virus", "PROBLEM", 77, 92], ["PRCoV", "TEST", 146, 151], ["viral", "OBSERVATION", 57, 62]]], ["SwIAV and PCV2 as primary infectious agents have been less studied.", [["SwIAV", "CHEMICAL", 0, 5], ["PCV2", "ORGANISM", 10, 14], ["SwIAV", "SPECIES", 0, 5], ["PCV2", "SPECIES", 10, 14], ["SwIAV", "TREATMENT", 0, 5], ["PCV2", "TREATMENT", 10, 14], ["primary infectious agents", "TREATMENT", 18, 43]]], ["However, it can be observed that swIAV can interfere with other virus productions (PRRSV and PRCoV) [85, 86] whereas PCV2 has some detrimental impact on the clinical outcome of secondary viral infections (PRRSV, swIAV, and PPV) [87] [88] [89] (see Additional file 1 and Figure 1A) .", [["swIAV", "CHEMICAL", 33, 38], ["viral infections", "DISEASE", 187, 203], ["swIAV", "GENE_OR_GENE_PRODUCT", 33, 38], ["PRRSV", "ORGANISM", 83, 88], ["PRCoV", "GENE_OR_GENE_PRODUCT", 93, 98], ["PCV2", "ORGANISM", 117, 121], ["swIAV", "PROTEIN", 33, 38], ["PRRSV", "SPECIES", 83, 88], ["PRCoV", "SPECIES", 93, 98], ["PCV2", "SPECIES", 117, 121], ["PRRSV", "SPECIES", 205, 210], ["other virus productions", "PROBLEM", 58, 81], ["PCV2", "PROBLEM", 117, 121], ["secondary viral infections", "PROBLEM", 177, 203], ["PPV", "TEST", 223, 226], ["viral infections", "OBSERVATION", 187, 203]]], ["Then, regarding the inflammation induced in coinfection conditions, various outcomes were observed depending which viruses were considered (Figure 2A) .Bacterium-virus and virus-bacteriumMany in vitro and in vivo experiments, with different bacterium-virus and virus-bacterium combinations, have been performed to identify the underlying mechanisms of the PRDC (see Figures 1B, C, 2B , C, and 3B).", [["inflammation", "DISEASE", 20, 32], ["Bacterium-virus", "ORGANISM", 152, 167], ["bacterium-virus", "ORGANISM", 241, 256], ["C", "GENE_OR_GENE_PRODUCT", 386, 387], ["Bacterium-virus", "SPECIES", 152, 167], ["Bacterium-virus", "SPECIES", 152, 167], ["the inflammation", "PROBLEM", 16, 32], ["coinfection conditions", "PROBLEM", 44, 66], ["Bacterium", "TEST", 152, 161], ["virus", "PROBLEM", 162, 167], ["virus", "PROBLEM", 172, 177], ["bacteriumMany", "TREATMENT", 178, 191], ["vitro", "TREATMENT", 195, 200], ["different bacterium", "PROBLEM", 231, 250], ["virus", "PROBLEM", 251, 256], ["virus", "PROBLEM", 261, 266], ["bacterium", "PROBLEM", 267, 276], ["the PRDC", "TEST", 352, 360], ["C", "TEST", 378, 379], ["inflammation", "OBSERVATION", 20, 32], ["coinfection", "OBSERVATION", 44, 55]]], ["The main studies are presented in Additional file 1C and D.Bacterium-virus and virus-bacteriumBacterium-viral coinfections can also involve various primary respiratory pathogens.", [["coinfections", "DISEASE", 110, 122], ["primary respiratory pathogens", "DISEASE", 148, 177], ["D.Bacterium-virus", "ORGANISM", 57, 74], ["virus-", "ORGANISM", 79, 85], ["bacteriumBacterium-viral", "ORGANISM", 85, 109], ["D.Bacterium-virus", "SPECIES", 57, 74], ["The main studies", "TEST", 0, 16], ["Additional file 1C", "TEST", 34, 52], ["D.Bacterium", "TEST", 57, 68], ["virus", "PROBLEM", 69, 74], ["virus", "PROBLEM", 79, 84], ["bacteriumBacterium", "PROBLEM", 85, 103], ["viral coinfections", "PROBLEM", 104, 122], ["various primary respiratory pathogens", "PROBLEM", 140, 177], ["viral coinfections", "OBSERVATION", 104, 122], ["primary", "OBSERVATION_MODIFIER", 148, 155], ["respiratory pathogens", "OBSERVATION", 156, 177]]], ["Among them, the most frequently studied bacterium is M. hyopneumoniae, a pathogen that induces a chronic respiratory disease and can influence the outcome of a subsequent viral infection.", [["respiratory", "ANATOMY", 105, 116], ["chronic respiratory disease", "DISEASE", 97, 124], ["viral infection", "DISEASE", 171, 186], ["M. hyopneumoniae", "ORGANISM", 53, 69], ["M. hyopneumoniae", "SPECIES", 53, 69], ["M. hyopneumoniae", "SPECIES", 53, 69], ["M. hyopneumoniae", "PROBLEM", 53, 69], ["a pathogen", "PROBLEM", 71, 81], ["a chronic respiratory disease", "PROBLEM", 95, 124], ["a subsequent viral infection", "PROBLEM", 158, 186], ["hyopneumoniae", "OBSERVATION", 56, 69], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["respiratory disease", "OBSERVATION", 105, 124], ["viral", "OBSERVATION_MODIFIER", 171, 176], ["infection", "OBSERVATION", 177, 186]]], ["However, mycoplasma infection needs to be already well established in the respiratory tract at the time of the viral infection to potentiate it.", [["respiratory tract", "ANATOMY", 74, 91], ["mycoplasma infection", "DISEASE", 9, 29], ["viral infection", "DISEASE", 111, 126], ["respiratory tract", "ORGANISM_SUBDIVISION", 74, 91], ["mycoplasma infection", "PROBLEM", 9, 29], ["the viral infection", "PROBLEM", 107, 126], ["mycoplasma", "OBSERVATION_MODIFIER", 9, 19], ["infection", "OBSERVATION", 20, 29], ["respiratory tract", "ANATOMY", 74, 91], ["viral", "OBSERVATION_MODIFIER", 111, 116], ["infection", "OBSERVATION", 117, 126]]], ["Indeed, M. hyopneumoniae inoculated to pigs simultaneously or shortly before the virus did not strongly impact the severity of the viral infections (PCV2, swIAV, PRRSV) [90] [91] [92] , while its impact was clearly evidenced when inoculated 3 weeks before viral infections [93] .Bacterium-virus and virus-bacteriumIt is well-known that viral infections can induce an ideal environment for a bacterial superinfection through different mechanisms such as the destruction of the epithelial barrier, the over-expression of the receptors involved in the bacterial adhesion to the cells, and the alteration of the host immune response [1, 2, 94, 95] .", [["epithelial barrier", "ANATOMY", 476, 494], ["cells", "ANATOMY", 575, 580], ["viral infections", "DISEASE", 131, 147], ["viral infections", "DISEASE", 256, 272], ["viral infections", "DISEASE", 336, 352], ["superinfection", "DISEASE", 401, 415], ["M. hyopneumoniae", "ORGANISM", 8, 24], ["pigs", "ORGANISM", 39, 43], ["PCV2", "ORGANISM", 149, 153], ["Bacterium-virus", "ORGANISM", 279, 294], ["virus-bacteriumIt", "ORGANISM", 299, 316], ["epithelial barrier", "TISSUE", 476, 494], ["cells", "CELL", 575, 580], ["M. hyopneumoniae", "SPECIES", 8, 24], ["pigs", "SPECIES", 39, 43], ["Bacterium-virus", "SPECIES", 279, 294], ["virus-bacteriumIt", "SPECIES", 299, 316], ["M. hyopneumoniae", "SPECIES", 8, 24], ["pigs", "SPECIES", 39, 43], ["PRRSV", "SPECIES", 162, 167], ["Bacterium-virus", "SPECIES", 279, 294], ["M. hyopneumoniae", "PROBLEM", 8, 24], ["the virus", "PROBLEM", 77, 86], ["the viral infections", "PROBLEM", 127, 147], ["viral infections", "PROBLEM", 256, 272], ["Bacterium", "TEST", 279, 288], ["virus", "PROBLEM", 289, 294], ["virus", "PROBLEM", 299, 304], ["bacteriumIt", "PROBLEM", 305, 316], ["viral infections", "PROBLEM", 336, 352], ["a bacterial superinfection", "PROBLEM", 389, 415], ["the epithelial barrier", "TREATMENT", 472, 494], ["the bacterial adhesion", "PROBLEM", 545, 567], ["hyopneumoniae", "OBSERVATION", 11, 24], ["viral infections", "OBSERVATION", 131, 147], ["virus", "OBSERVATION", 289, 294], ["bacterial", "OBSERVATION_MODIFIER", 391, 400], ["superinfection", "OBSERVATION", 401, 415], ["epithelial", "ANATOMY_MODIFIER", 476, 486], ["bacterial adhesion", "OBSERVATION", 549, 567]]], ["The swIAV infection has been shown, for instance, as a way to facilitate the colonization of epithelial cells by S. suis, but only for the serotypes containing sialic-acid in their capsule [96] .", [["epithelial cells", "ANATOMY", 93, 109], ["infection", "DISEASE", 10, 19], ["sialic-acid", "CHEMICAL", 160, 171], ["sialic-acid", "CHEMICAL", 160, 171], ["epithelial cells", "CELL", 93, 109], ["S. suis", "ORGANISM", 113, 120], ["sialic-acid", "SIMPLE_CHEMICAL", 160, 171], ["epithelial cells", "CELL_TYPE", 93, 109], ["S. suis", "SPECIES", 113, 120], ["S. suis", "SPECIES", 113, 120], ["The swIAV infection", "PROBLEM", 0, 19], ["epithelial cells", "PROBLEM", 93, 109], ["the serotypes", "TREATMENT", 135, 148], ["infection", "OBSERVATION", 10, 19], ["epithelial cells", "OBSERVATION", 93, 109]]], ["The swIAV infection induces a loss of ciliated cells leading to the impairment of the mucociliary clearance function, but induces also the presence of the viral HA on the surface of infected cells that interacts with the sialic acid of the bacterial capsule, leading to increased adherence of S. suis [96, 97] .", [["ciliated cells", "ANATOMY", 38, 52], ["mucociliary", "ANATOMY", 86, 97], ["surface", "ANATOMY", 171, 178], ["cells", "ANATOMY", 191, 196], ["capsule", "ANATOMY", 250, 257], ["infection", "DISEASE", 10, 19], ["sialic acid", "CHEMICAL", 221, 232], ["sialic acid", "CHEMICAL", 221, 232], ["ciliated cells", "CELL", 38, 52], ["mucociliary", "ORGAN", 86, 97], ["surface", "CELLULAR_COMPONENT", 171, 178], ["cells", "CELL", 191, 196], ["sialic acid", "SIMPLE_CHEMICAL", 221, 232], ["S. suis", "ORGANISM", 293, 300], ["ciliated cells", "CELL_TYPE", 38, 52], ["infected cells", "CELL_TYPE", 182, 196], ["S. suis", "SPECIES", 293, 300], ["S. suis", "SPECIES", 293, 300], ["The swIAV infection", "PROBLEM", 0, 19], ["a loss of ciliated cells", "PROBLEM", 28, 52], ["the mucociliary clearance function", "PROBLEM", 82, 116], ["the viral HA", "PROBLEM", 151, 163], ["infected cells", "PROBLEM", 182, 196], ["the sialic acid of the bacterial capsule", "PROBLEM", 217, 257], ["S. suis", "TEST", 293, 300], ["infection", "OBSERVATION", 10, 19], ["loss", "OBSERVATION_MODIFIER", 30, 34], ["ciliated cells", "OBSERVATION", 38, 52], ["mucociliary clearance", "OBSERVATION", 86, 107], ["viral", "OBSERVATION", 155, 160], ["infected cells", "OBSERVATION", 182, 196], ["sialic acid", "OBSERVATION", 221, 232], ["bacterial capsule", "OBSERVATION", 240, 257], ["increased", "OBSERVATION_MODIFIER", 270, 279], ["adherence", "OBSERVATION_MODIFIER", 280, 289]]], ["Although these swIAV effects on S. suis have been clearly shown in vitro, no clear in vivo impact of swIAV infection on S. suis pulmonary load has been described [98] .", [["pulmonary", "ANATOMY", 128, 137], ["swIAV", "CHEMICAL", 101, 106], ["infection", "DISEASE", 107, 116], ["swIAV", "CANCER", 15, 20], ["S. suis", "ORGANISM", 32, 39], ["swIAV", "ORGANISM", 101, 106], ["S. suis", "ORGANISM", 120, 127], ["pulmonary", "ORGAN", 128, 137], ["S. suis", "SPECIES", 32, 39], ["S. suis", "SPECIES", 120, 127], ["S. suis", "SPECIES", 32, 39], ["swIAV", "SPECIES", 101, 106], ["S. suis", "SPECIES", 120, 127], ["S. suis", "PROBLEM", 32, 39], ["swIAV infection", "PROBLEM", 101, 116], ["S. suis pulmonary load", "PROBLEM", 120, 142], ["swIAV", "OBSERVATION_MODIFIER", 101, 106], ["infection", "OBSERVATION", 107, 116], ["pulmonary", "ANATOMY", 128, 137]]], ["It was clearly shown that the presence of both pathogens significantly induces more inflammation than single infections [98, 99] .Bacterium-virus and virus-bacteriumOverall, studies carried out in pigs showed that a bacterium-virus or a virus-bacterium coinfection frequently induces an aggravation of pulmonary lesions ( Figure 3B ) and a higher inflammation ( Figure 2B ) and immune response, with increased production of pro-inflammatory cytokines.", [["pulmonary lesions", "ANATOMY", 302, 319], ["inflammation", "DISEASE", 84, 96], ["infections", "DISEASE", 109, 119], ["coinfection", "DISEASE", 253, 264], ["aggravation of pulmonary lesions", "DISEASE", 287, 319], ["inflammation", "DISEASE", 347, 359], ["Bacterium-virus", "ORGANISM", 130, 145], ["pigs", "ORGANISM", 197, 201], ["bacterium-virus", "ORGANISM", 216, 231], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 302, 319], ["pro-inflammatory cytokines", "PROTEIN", 424, 450], ["Bacterium-virus", "SPECIES", 130, 145], ["pigs", "SPECIES", 197, 201], ["bacterium-virus", "SPECIES", 216, 231], ["Bacterium-virus", "SPECIES", 130, 145], ["pigs", "SPECIES", 197, 201], ["both pathogens", "PROBLEM", 42, 56], ["single infections", "PROBLEM", 102, 119], ["Bacterium", "TEST", 130, 139], ["virus", "PROBLEM", 140, 145], ["virus", "PROBLEM", 150, 155], ["bacteriumOverall", "PROBLEM", 156, 172], ["studies", "TEST", 174, 181], ["a bacterium-virus", "PROBLEM", 214, 231], ["a virus-bacterium coinfection", "PROBLEM", 235, 264], ["pulmonary lesions", "PROBLEM", 302, 319], ["a higher inflammation", "PROBLEM", 338, 359], ["immune response", "PROBLEM", 378, 393], ["increased production of pro-inflammatory cytokines", "PROBLEM", 400, 450], ["both", "OBSERVATION_MODIFIER", 42, 46], ["pathogens", "OBSERVATION", 47, 56], ["inflammation", "OBSERVATION_MODIFIER", 84, 96], ["pulmonary", "ANATOMY", 302, 311], ["lesions", "OBSERVATION", 312, 319], ["higher", "OBSERVATION_MODIFIER", 340, 346], ["inflammation", "OBSERVATION", 347, 359], ["increased", "OBSERVATION_MODIFIER", 400, 409], ["production", "OBSERVATION_MODIFIER", 410, 420], ["pro-inflammatory cytokines", "OBSERVATION", 424, 450]]], ["In many bacterium-virus and virus-bacterium associations, this worsened outcome seems to be the result of additive effects from both pathogens rather than a real synergy [100, 101] .", [["bacterium-virus", "ORGANISM", 8, 23], ["many bacterium", "PROBLEM", 3, 17], ["virus", "PROBLEM", 18, 23], ["virus", "PROBLEM", 28, 33], ["both pathogens", "PROBLEM", 128, 142]]], ["However, a potentiation of the viral infection by bacteria can also be observed in other cases, such as in the M. hyopneumoniae-PRRSV coinfection [102] .", [["infection", "DISEASE", 37, 46], ["coinfection", "DISEASE", 134, 145], ["M. hyopneumoniae-PRRSV", "ORGANISM", 111, 133], ["M. hyopneumoniae", "SPECIES", 111, 127], ["-PRRSV", "SPECIES", 127, 133], ["M. hyopneumoniae", "SPECIES", 111, 127], ["the viral infection", "PROBLEM", 27, 46], ["bacteria", "PROBLEM", 50, 58], ["the M. hyopneumoniae", "PROBLEM", 107, 127], ["PRRSV coinfection", "PROBLEM", 128, 145], ["viral", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46], ["hyopneumoniae", "OBSERVATION", 114, 127], ["PRRSV coinfection", "OBSERVATION", 128, 145]]], ["In that case, higher amounts of PRRSV genomes were detected in lymphoid tissue and blood [102] and a slower viral clearance was observed [75] (Figure 1B) , suggesting that the recruitment of immune cells in the lung parenchyma upon established M. hyopneumoniae infection may provide a steady supply of susceptible cells for PRRSV [1] .", [["lymphoid tissue", "ANATOMY", 63, 78], ["blood", "ANATOMY", 83, 88], ["immune cells", "ANATOMY", 191, 203], ["lung parenchyma", "ANATOMY", 211, 226], ["cells", "ANATOMY", 314, 319], ["infection", "DISEASE", 261, 270], ["PRRSV", "ORGANISM", 32, 37], ["lymphoid tissue", "TISSUE", 63, 78], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["immune cells", "CELL", 191, 203], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 211, 226], ["M. hyopneumoniae", "ORGANISM", 244, 260], ["cells", "CELL", 314, 319], ["PRRSV", "ORGANISM", 324, 329], ["PRRSV genomes", "DNA", 32, 45], ["immune cells", "CELL_TYPE", 191, 203], ["susceptible cells", "CELL_TYPE", 302, 319], ["M. hyopneumoniae", "SPECIES", 244, 260], ["PRRSV", "SPECIES", 32, 37], ["M. hyopneumoniae", "SPECIES", 244, 260], ["PRRSV", "SPECIES", 324, 329], ["PRRSV genomes", "PROBLEM", 32, 45], ["blood", "TEST", 83, 88], ["a slower viral clearance", "PROBLEM", 99, 123], ["immune cells in the lung parenchyma", "PROBLEM", 191, 226], ["M. hyopneumoniae infection", "PROBLEM", 244, 270], ["susceptible cells", "PROBLEM", 302, 319], ["PRRSV", "PROBLEM", 324, 329], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["amounts", "OBSERVATION_MODIFIER", 21, 28], ["PRRSV genomes", "OBSERVATION", 32, 45], ["lymphoid tissue", "OBSERVATION", 63, 78], ["immune cells", "OBSERVATION", 191, 203], ["lung", "ANATOMY", 211, 215], ["parenchyma", "ANATOMY_MODIFIER", 216, 226]]], ["Then, in porcine AMs and in the \"African green monkey\" (originally described as porcine origin) St-Jude Porcine Lung (SJPL) cell line, PRRSV infection has been shown to be blocked by a pre-infection with A. pleuropneupmoniae, this antiviral activity being due to the A. pleuropneumoniae metabolites [103] ( Figure 1B) .", [["AMs", "ANATOMY", 17, 20], ["Lung (SJPL) cell line", "ANATOMY", 112, 133], ["PRRSV infection", "DISEASE", 135, 150], ["porcine", "ORGANISM", 9, 16], ["AMs", "CELL", 17, 20], ["monkey", "ORGANISM", 47, 53], ["porcine", "ORGANISM", 80, 87], ["St-Jude Porcine Lung (SJPL) cell line", "CELL", 96, 133], ["PRRSV", "ORGANISM", 135, 140], ["A. pleuropneupmoniae", "ORGANISM", 204, 224], ["A. pleuropneumoniae", "ORGANISM", 267, 286], ["porcine AMs", "CELL_TYPE", 9, 20], ["St-Jude Porcine Lung (SJPL) cell line", "CELL_LINE", 96, 133], ["porcine", "SPECIES", 9, 16], ["Porcine", "SPECIES", 104, 111], ["A. pleuropneupmoniae", "SPECIES", 204, 224], ["A. pleuropneumoniae", "SPECIES", 267, 286], ["African green monkey", "SPECIES", 33, 53], ["PRRSV", "SPECIES", 135, 140], ["A. pleuropneupmoniae", "SPECIES", 204, 224], ["A. pleuropneumoniae", "SPECIES", 267, 286], ["St-Jude Porcine Lung (SJPL) cell line", "TREATMENT", 96, 133], ["PRRSV infection", "PROBLEM", 135, 150], ["A. pleuropneupmoniae", "PROBLEM", 204, 224], ["this antiviral activity", "TREATMENT", 226, 249], ["the A. pleuropneumoniae metabolites", "TEST", 263, 298], ["Lung", "ANATOMY", 112, 116], ["cell line", "OBSERVATION", 124, 133], ["PRRSV infection", "OBSERVATION", 135, 150]]], ["Given the fact that in vivo studies involving PRRSV and A. pleuropneumoniae did not always investigate the impact of an A. pleuropneumoniae pre-infection on the subsequent PRRSV infection [104, 105] , as done in experiments performed in vitro [103] , it cannot be easily concluded if this interference would be observed in the target species.", [["PRRSV infection", "DISEASE", 172, 187], ["PRRSV", "ORGANISM", 46, 51], ["A. pleuropneumoniae", "ORGANISM", 56, 75], ["A. pleuropneumoniae", "ORGANISM", 120, 139], ["PRRSV", "SPECIES", 46, 51], ["A. pleuropneumoniae", "SPECIES", 56, 75], ["A. pleuropneumoniae", "SPECIES", 120, 139], ["PRRSV", "SPECIES", 46, 51], ["A. pleuropneumoniae", "SPECIES", 56, 75], ["A. pleuropneumoniae", "SPECIES", 120, 139], ["PRRSV", "SPECIES", 172, 177], ["vivo studies", "TEST", 23, 35], ["PRRSV", "PROBLEM", 46, 51], ["A. pleuropneumoniae", "PROBLEM", 56, 75], ["an A. pleuropneumoniae pre-infection", "PROBLEM", 117, 153], ["the subsequent PRRSV infection", "PROBLEM", 157, 187], ["pleuropneumoniae", "OBSERVATION", 123, 139], ["infection", "OBSERVATION", 178, 187]]], ["However, in vivo, PRRSV-A. pleuropneumoniae interactions were reported as absent or mild [104, 105] (Figure 3B ).Bacterium-bacteriumIn virus-bacterium coinfections, the dogma usually encountered is that viruses play an immunomodulatory role, which favors bacterial superinfections.", [["Bacterium", "CHEMICAL", 113, 122], ["coinfections", "DISEASE", 151, 163], ["PRRSV-A. pleuropneumoniae", "ORGANISM", 18, 43], ["Bacterium-bacteriumIn virus-bacterium", "ORGANISM", 113, 150], ["A. pleuropneumoniae", "SPECIES", 24, 43], ["PRRSV-A. pleuropneumoniae", "SPECIES", 18, 43], ["Bacterium", "TEST", 113, 122], ["bacteriumIn virus", "PROBLEM", 123, 140], ["bacterium coinfections", "PROBLEM", 141, 163], ["bacterial superinfections", "PROBLEM", 255, 280], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["bacteriumIn virus", "OBSERVATION", 123, 140], ["bacterium coinfections", "OBSERVATION", 141, 163], ["immunomodulatory", "OBSERVATION_MODIFIER", 219, 235], ["favors", "UNCERTAINTY", 248, 254], ["bacterial", "OBSERVATION_MODIFIER", 255, 264], ["superinfections", "OBSERVATION", 265, 280]]], ["Nevertheless, a pre-disposing effect is also described for M. hyopneumoniae, which promotes viral but also bacterial superinfections [65] (Figure 1D ).", [["M. hyopneumoniae", "ORGANISM", 59, 75], ["M. hyopneumoniae", "SPECIES", 59, 75], ["M. hyopneumoniae", "SPECIES", 59, 75], ["M. hyopneumoniae", "PROBLEM", 59, 75], ["bacterial superinfections", "PROBLEM", 107, 132], ["hyopneumoniae", "OBSERVATION", 62, 75], ["bacterial", "OBSERVATION_MODIFIER", 107, 116], ["superinfections", "OBSERVATION", 117, 132]]], ["Few studies of experimental coinfections or superinfections with M. hyopneumoniae and/or other bacteria involved in PRDC were performed compared to coinfections involving viruses.", [["coinfections", "DISEASE", 28, 40], ["superinfections", "DISEASE", 44, 59], ["coinfections", "DISEASE", 148, 160], ["M. hyopneumoniae", "ORGANISM", 65, 81], ["PRDC", "CANCER", 116, 120], ["M. hyopneumoniae", "SPECIES", 65, 81], ["M. hyopneumoniae", "SPECIES", 65, 81], ["Few studies", "TEST", 0, 11], ["experimental coinfections", "PROBLEM", 15, 40], ["superinfections", "PROBLEM", 44, 59], ["M. hyopneumoniae", "PROBLEM", 65, 81], ["other bacteria", "PROBLEM", 89, 103], ["PRDC", "TEST", 116, 120], ["viruses", "PROBLEM", 171, 178], ["experimental", "OBSERVATION_MODIFIER", 15, 27], ["coinfections", "OBSERVATION", 28, 40], ["superinfections", "OBSERVATION", 44, 59], ["hyopneumoniae", "OBSERVATION", 68, 81]]], ["These studies are reported in Additional file 1E.", [["These studies", "TEST", 0, 13]]], ["Overall, these coinfections or superinfections induce more clinical signs and lung lesions and poorer technical performances when compared to single infections with the same infectious pathogens ( Figure 3C ).", [["lung lesions", "ANATOMY", 78, 90], ["coinfections", "DISEASE", 15, 27], ["superinfections", "DISEASE", 31, 46], ["infections", "DISEASE", 149, 159], ["lung lesions", "PATHOLOGICAL_FORMATION", 78, 90], ["these coinfections", "PROBLEM", 9, 27], ["superinfections", "PROBLEM", 31, 46], ["lung lesions", "PROBLEM", 78, 90], ["single infections", "PROBLEM", 142, 159], ["the same infectious pathogens", "PROBLEM", 165, 194], ["coinfections", "OBSERVATION", 15, 27], ["superinfections", "OBSERVATION", 31, 46], ["lung", "ANATOMY", 78, 82], ["lesions", "OBSERVATION", 83, 90], ["infectious", "OBSERVATION_MODIFIER", 174, 184]]], ["The bacterialbacterial coinfections are also responsible for immune response alterations (for reviews see [106, 107] ).", [["The bacterialbacterial coinfections", "PROBLEM", 0, 35], ["immune response alterations", "PROBLEM", 61, 88], ["bacterialbacterial", "ANATOMY", 4, 22], ["coinfections", "OBSERVATION", 23, 35]]], ["For example, macrophages from pigs infected by M. hyopneumoniae decrease their phagocytosis capacity against A. pleuropneumoniae [60, 65] .", [["macrophages", "ANATOMY", 13, 24], ["macrophages", "CELL", 13, 24], ["pigs", "ORGANISM", 30, 34], ["M. hyopneumoniae", "ORGANISM", 47, 63], ["A. pleuropneumoniae", "ORGANISM", 109, 128], ["macrophages", "CELL_TYPE", 13, 24], ["pigs", "SPECIES", 30, 34], ["M. hyopneumoniae", "SPECIES", 47, 63], ["A. pleuropneumoniae", "SPECIES", 109, 128], ["pigs", "SPECIES", 30, 34], ["M. hyopneumoniae", "SPECIES", 47, 63], ["A. pleuropneumoniae", "SPECIES", 109, 128], ["macrophages", "PROBLEM", 13, 24], ["hyopneumoniae", "PROBLEM", 50, 63], ["their phagocytosis capacity", "PROBLEM", 73, 100], ["A. pleuropneumoniae", "PROBLEM", 109, 128], ["macrophages", "OBSERVATION", 13, 24]]], ["M. hyorhinis and M. flocculare, two mycoplasmas commonly co-isolated with M. hyopneumoniae in gross pneumonia-like lesions, may also impact the immune response by inducing the cytotoxicity of immune cells and/or the secretion of cytokines affecting its outcome [108] .", [["lesions", "ANATOMY", 115, 122], ["immune cells", "ANATOMY", 192, 204], ["pneumonia", "DISEASE", 100, 109], ["M. hyorhinis", "ORGANISM", 0, 12], ["M. flocculare", "ORGANISM", 17, 30], ["M. hyopneumoniae", "ORGANISM", 74, 90], ["gross pneumonia-like lesions", "PATHOLOGICAL_FORMATION", 94, 122], ["immune cells", "CELL", 192, 204], ["immune cells", "CELL_TYPE", 192, 204], ["cytokines", "PROTEIN", 229, 238], ["M. hyorhinis", "SPECIES", 0, 12], ["M. flocculare", "SPECIES", 17, 30], ["M. hyopneumoniae", "SPECIES", 74, 90], ["M. hyorhinis", "SPECIES", 0, 12], ["M. flocculare", "SPECIES", 17, 30], ["M. hyopneumoniae", "SPECIES", 74, 90], ["M. hyorhinis", "PROBLEM", 0, 12], ["M. flocculare", "PROBLEM", 17, 30], ["two mycoplasmas", "PROBLEM", 32, 47], ["M. hyopneumoniae", "PROBLEM", 74, 90], ["gross pneumonia", "PROBLEM", 94, 109], ["like lesions", "PROBLEM", 110, 122], ["the cytotoxicity", "TEST", 172, 188], ["immune cells", "PROBLEM", 192, 204], ["the secretion of cytokines", "PROBLEM", 212, 238], ["hyorhinis", "OBSERVATION", 3, 12], ["M. flocculare", "OBSERVATION", 17, 30], ["gross", "OBSERVATION_MODIFIER", 94, 99], ["pneumonia", "OBSERVATION", 100, 109], ["lesions", "OBSERVATION", 115, 122], ["immune cells", "OBSERVATION", 192, 204]]], ["Co-stimulation of porcine BMDCs with M. hyopneumoniae and M. hyorhinis induces a strong IL12 production.", [["BMDCs", "ANATOMY", 26, 31], ["porcine", "ORGANISM", 18, 25], ["BMDCs", "CELL", 26, 31], ["M. hyopneumoniae", "ORGANISM", 37, 53], ["M. hyorhinis", "ORGANISM", 58, 70], ["IL12", "GENE_OR_GENE_PRODUCT", 88, 92], ["porcine BMDCs", "CELL_TYPE", 18, 31], ["IL12", "PROTEIN", 88, 92], ["porcine", "SPECIES", 18, 25], ["M. hyopneumoniae", "SPECIES", 37, 53], ["M. hyorhinis", "SPECIES", 58, 70], ["porcine", "SPECIES", 18, 25], ["M. hyopneumoniae", "SPECIES", 37, 53], ["M. hyorhinis", "SPECIES", 58, 70], ["Co-stimulation of porcine BMDCs", "TREATMENT", 0, 31], ["M. hyopneumoniae", "PROBLEM", 37, 53], ["M. hyorhinis", "PROBLEM", 58, 70], ["porcine BMDCs", "OBSERVATION", 18, 31], ["M. hyopneumoniae", "OBSERVATION", 37, 53], ["M. hyorhinis", "OBSERVATION", 58, 70], ["strong", "OBSERVATION_MODIFIER", 81, 87], ["IL12 production", "OBSERVATION", 88, 103]]], ["In this last in vitro model, M. hyopneumoniae associated with M. flocculare reduces TNF\u03b1 production compared to BMDCs stimulation by M. flocculare alone producing a TNF\u03b1 concentration greater than that observed after stimulation with M. hyopneumoniae alone and M. hyorhinis alone [108] .", [["BMDCs", "ANATOMY", 112, 117], ["M. hyopneumoniae", "ORGANISM", 29, 45], ["M. flocculare", "ORGANISM", 62, 75], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 84, 88], ["BMDCs", "CELL", 112, 117], ["M. flocculare", "ORGANISM", 133, 146], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 165, 169], ["M. hyopneumoniae", "ORGANISM", 234, 250], ["M. hyorhinis", "ORGANISM", 261, 273], ["TNF\u03b1", "PROTEIN", 84, 88], ["BMDCs", "CELL_TYPE", 112, 117], ["TNF\u03b1", "PROTEIN", 165, 169], ["M. hyopneumoniae", "SPECIES", 29, 45], ["M. flocculare", "SPECIES", 62, 75], ["M. flocculare", "SPECIES", 133, 146], ["M. hyopneumoniae", "SPECIES", 234, 250], ["M. hyorhinis", "SPECIES", 261, 273], ["M. hyopneumoniae", "SPECIES", 29, 45], ["M. flocculare", "SPECIES", 62, 75], ["M. flocculare", "SPECIES", 133, 146], ["M. hyopneumoniae", "SPECIES", 234, 250], ["M. hyorhinis", "SPECIES", 261, 273], ["M. hyopneumoniae", "PROBLEM", 29, 45], ["M. flocculare", "PROBLEM", 62, 75], ["TNF\u03b1 production", "TREATMENT", 84, 99], ["BMDCs stimulation", "TREATMENT", 112, 129], ["a TNF\u03b1 concentration", "TREATMENT", 163, 183], ["M. hyopneumoniae", "PROBLEM", 234, 250], ["hyopneumoniae", "OBSERVATION", 32, 45]]], ["Therefore, M. flocculare might play an initial role in pulmonary inflammation by inducing the production of TNF\u03b1 by resident myeloid cells.", [["pulmonary", "ANATOMY", 55, 64], ["myeloid cells", "ANATOMY", 125, 138], ["inflammation", "DISEASE", 65, 77], ["M. flocculare", "ORGANISM", 11, 24], ["pulmonary", "ORGAN", 55, 64], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 108, 112], ["myeloid cells", "CELL", 125, 138], ["TNF\u03b1", "PROTEIN", 108, 112], ["resident myeloid cells", "CELL_TYPE", 116, 138], ["M. flocculare", "SPECIES", 11, 24], ["M. flocculare", "SPECIES", 11, 24], ["pulmonary inflammation", "PROBLEM", 55, 77], ["pulmonary", "ANATOMY", 55, 64], ["inflammation", "OBSERVATION", 65, 77], ["myeloid cells", "OBSERVATION", 125, 138]]], ["Supplementary investigations will be needed to elucidate the role of this cytokine in the pathogenesis of the disease [108] .", [["cytokine", "PROTEIN", 74, 82], ["Supplementary investigations", "TEST", 0, 28], ["the disease", "PROBLEM", 106, 117]]], ["Other examples of bacterium-bacterium in vivo coinfections are presented in Additional file 1E.Mechanisms of coinfections interferencesRegarding coinfections and superinfections, most studies assessed the clinical outcome of the process but less is known about the mechanisms of interactions between pathogens and the consequences for the pathogens themselves, the infected cells and more generally for the host.Mechanisms of coinfections interferencesThe outcome of dual infection is variable depending on the antagonism, neutrality or synergy between the infectious agents.", [["cells", "ANATOMY", 374, 379], ["coinfections", "DISEASE", 46, 58], ["coinfections", "DISEASE", 109, 121], ["coinfections", "DISEASE", 145, 157], ["superinfections", "DISEASE", 162, 177], ["coinfections", "DISEASE", 426, 438], ["infection", "DISEASE", 472, 481], ["cells", "CELL", 374, 379], ["infected cells", "CELL_TYPE", 365, 379], ["bacterium", "PROBLEM", 18, 27], ["bacterium", "PROBLEM", 28, 37], ["vivo coinfections", "PROBLEM", 41, 58], ["coinfections interferences", "PROBLEM", 109, 135], ["coinfections", "PROBLEM", 145, 157], ["superinfections", "PROBLEM", 162, 177], ["most studies", "TEST", 179, 191], ["interactions between pathogens", "PROBLEM", 279, 309], ["the pathogens themselves", "PROBLEM", 335, 359], ["the infected cells", "PROBLEM", 361, 379], ["coinfections interferences", "PROBLEM", 426, 452], ["dual infection", "PROBLEM", 467, 481], ["the antagonism", "PROBLEM", 507, 521], ["the infectious agents", "TREATMENT", 553, 574], ["bacterium", "OBSERVATION", 18, 27], ["bacterium", "OBSERVATION_MODIFIER", 28, 37], ["vivo coinfections", "OBSERVATION", 41, 58], ["coinfections", "OBSERVATION", 109, 121], ["coinfections", "OBSERVATION", 145, 157], ["superinfections", "OBSERVATION", 162, 177], ["infected cells", "OBSERVATION", 365, 379], ["coinfections", "OBSERVATION", 426, 438], ["dual", "OBSERVATION_MODIFIER", 467, 471], ["infection", "OBSERVATION", 472, 481], ["infectious", "OBSERVATION", 557, 567]]], ["On the host side, coinfection can make the host response ineffective, and vice versa.", [["coinfection", "DISEASE", 18, 29], ["coinfection", "PROBLEM", 18, 29], ["coinfection", "OBSERVATION", 18, 29]]], ["If we look now at the possible interactions that can occur between pathogens we have to consider the nature of the infectious agents (summary provided in Figure 4) .", [["infectious", "OBSERVATION", 115, 125]]], ["Different situations can be observed and coinfections can involve virus with virus, bacterium with virus and vice versa, and bacterium with bacterium.Virus-virus interactionsRegarding virus-virus interactions, consequences are diversified and many studies looking at virus replication in coinfection situations have been carried out [2].", [["coinfections", "DISEASE", 41, 53], ["Virus-virus", "ORGANISM", 150, 161], ["virus-virus", "ORGANISM", 184, 195], ["Virus-virus", "SPECIES", 150, 161], ["virus-virus", "SPECIES", 184, 195], ["Virus-virus", "SPECIES", 150, 161], ["Different situations", "PROBLEM", 0, 20], ["coinfections", "PROBLEM", 41, 53], ["virus", "PROBLEM", 66, 71], ["virus", "PROBLEM", 77, 82], ["bacterium", "PROBLEM", 84, 93], ["virus", "PROBLEM", 99, 104], ["bacterium", "PROBLEM", 125, 134], ["bacterium", "PROBLEM", 140, 149], ["Virus", "PROBLEM", 150, 155], ["virus", "PROBLEM", 184, 189], ["virus interactions", "PROBLEM", 190, 208], ["many studies", "TEST", 243, 255], ["virus replication", "TREATMENT", 267, 284], ["virus", "OBSERVATION", 156, 161]]], ["The first consequence of coinfection could be the so-called viral interference, a situation whereby one virus interferes with the replication of the other one making the cells resistant to the superinfecting virus [109] .Virus-virus interactionsThe most common way for viral interference is indirect and based on the production of type 1 and 3 IFNs which induce the expression of ISGs after interacting with their cognate receptors [110, 111] .", [["cells", "ANATOMY", 170, 175], ["coinfection", "DISEASE", 25, 36], ["cells", "CELL", 170, 175], ["Virus-virus", "ORGANISM", 221, 232], ["IFNs", "GENE_OR_GENE_PRODUCT", 344, 348], ["ISGs", "GENE_OR_GENE_PRODUCT", 380, 384], ["IFNs", "PROTEIN", 344, 348], ["ISGs", "PROTEIN", 380, 384], ["cognate receptors", "PROTEIN", 414, 431], ["Virus-virus", "SPECIES", 221, 232], ["Virus-virus", "SPECIES", 221, 232], ["coinfection", "PROBLEM", 25, 36], ["the so-called viral interference", "PROBLEM", 46, 78], ["one virus", "PROBLEM", 100, 109], ["the cells", "PROBLEM", 166, 175], ["the superinfecting virus", "PROBLEM", 189, 213], ["Virus", "PROBLEM", 221, 226], ["viral interference", "PROBLEM", 269, 287], ["coinfection", "OBSERVATION", 25, 36], ["virus", "OBSERVATION", 227, 232]]], ["These proteins then activate numerous mediators of the cellular antiviral system that may non-specifically block the replication of viruses.", [["cellular", "ANATOMY", 55, 63], ["cellular", "CELL", 55, 63], ["numerous mediators of the cellular antiviral system", "PROBLEM", 29, 80], ["numerous", "OBSERVATION_MODIFIER", 29, 37], ["cellular antiviral system", "OBSERVATION", 55, 80], ["replication", "OBSERVATION_MODIFIER", 117, 128], ["viruses", "OBSERVATION", 132, 139]]], ["They may also interfere, to a certain extent, with bacterial multiplication since IFN can also be induced by Intracellular Bacterial Pathogens (IBPs) or some extracellular bacteria [107, 112] .", [["extracellular", "ANATOMY", 158, 171], ["IFN", "CHEMICAL", 82, 85], ["IFN", "GENE_OR_GENE_PRODUCT", 82, 85], ["IBPs", "GENE_OR_GENE_PRODUCT", 144, 148], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 158, 171], ["IFN", "PROTEIN", 82, 85], ["bacterial multiplication", "PROBLEM", 51, 75], ["IFN", "PROBLEM", 82, 85], ["Intracellular Bacterial Pathogens", "PROBLEM", 109, 142], ["IBPs", "TEST", 144, 148], ["some extracellular bacteria", "PROBLEM", 153, 180], ["Bacterial", "OBSERVATION_MODIFIER", 123, 132], ["Pathogens", "OBSERVATION", 133, 142], ["extracellular", "OBSERVATION_MODIFIER", 158, 171], ["bacteria", "OBSERVATION", 172, 180]]], ["Nevertheless, in some situations type 1 IFNs can also increase the host susceptibility to subsequent bacterial infection [113] through impaired macrophage recruitment with a reduced CXCL1 and CXCL2 transcription [114] and a reduced IL17 [115] production.", [["macrophage", "ANATOMY", 144, 154], ["infection", "DISEASE", 111, 120], ["type 1 IFNs", "GENE_OR_GENE_PRODUCT", 33, 44], ["macrophage", "CELL", 144, 154], ["CXCL1", "GENE_OR_GENE_PRODUCT", 182, 187], ["CXCL2", "GENE_OR_GENE_PRODUCT", 192, 197], ["IL17", "GENE_OR_GENE_PRODUCT", 232, 236], ["IFNs", "PROTEIN", 40, 44], ["CXCL1", "PROTEIN", 182, 187], ["CXCL2", "PROTEIN", 192, 197], ["subsequent bacterial infection", "PROBLEM", 90, 120], ["impaired macrophage recruitment", "PROBLEM", 135, 166], ["a reduced CXCL1", "TREATMENT", 172, 187], ["CXCL2 transcription", "TEST", 192, 211], ["a reduced IL17", "PROBLEM", 222, 236], ["bacterial", "OBSERVATION_MODIFIER", 101, 110], ["infection", "OBSERVATION", 111, 120], ["macrophage recruitment", "OBSERVATION", 144, 166]]], ["Then, there is also the non-interferon-mediated viral interference (or intrinsic interference) which is a cellular state of resistance induced by the virus to new viral infection by closely related or unrelated viruses [116] .", [["cellular", "ANATOMY", 106, 114], ["viral infection", "DISEASE", 163, 178], ["non-interferon", "GENE_OR_GENE_PRODUCT", 24, 38], ["cellular", "CELL", 106, 114], ["the non-interferon-mediated viral interference", "PROBLEM", 20, 66], ["the virus", "PROBLEM", 146, 155], ["new viral infection", "PROBLEM", 159, 178], ["unrelated viruses", "PROBLEM", 201, 218], ["viral interference", "OBSERVATION", 48, 66], ["new", "OBSERVATION_MODIFIER", 159, 162], ["viral", "OBSERVATION_MODIFIER", 163, 168], ["infection", "OBSERVATION", 169, 178]]], ["Various mechanisms are described to explain this cellular state of direct or indirect resistance (for examples see [2]).", [["cellular", "ANATOMY", 49, 57], ["cellular", "CELL", 49, 57]]], ["In this type of interference, which can occur between viruses but also between viruses and bacteria [107, 117] , there is a competition between pathogens for the metabolites and all the host factors that allow their multiplication.", [["viruses", "PROBLEM", 54, 61], ["viruses", "PROBLEM", 79, 86], ["bacteria", "PROBLEM", 91, 99], ["a competition between pathogens", "PROBLEM", 122, 153], ["interference", "OBSERVATION", 16, 28]]], ["Besides the mechanisms involving a competition for common cellular factors, there are also several other mechanisms of interference described.", [["cellular", "ANATOMY", 58, 66], ["cellular", "CELL", 58, 66], ["cellular factors", "PROTEIN", 58, 74], ["common cellular factors", "PROBLEM", 51, 74], ["interference", "OBSERVATION", 119, 131]]], ["These relies on viral Defective Interfering (DI) particles [118] , RNA interference (RNAi) [119] , non-specific double stranded RNA (dsRNA) [120] as well as trans-acting proteins [121] .", [["trans-acting proteins", "PROTEIN", 157, 178], ["viral Defective Interfering (DI) particles", "PROBLEM", 16, 58], ["non-specific double stranded RNA (dsRNA)", "PROBLEM", 99, 139], ["stranded RNA", "OBSERVATION_MODIFIER", 119, 131]]], ["Interference can occur at specific steps or multiple steps of the viral replication cycle (attachment, penetration, genome replication and/or budding) and can be direct or indirect.", [["the viral replication cycle", "TREATMENT", 62, 89], ["genome replication", "TREATMENT", 116, 134]]], ["Inhibition of superinfection (superinfection exclusion and superinfection suppression) is one of several consequences that can be observed in the interference between related and unrelated microorganisms.", [["superinfection", "DISEASE", 14, 28], ["superinfection", "DISEASE", 30, 44], ["superinfection", "DISEASE", 59, 73], ["superinfection (superinfection exclusion", "PROBLEM", 14, 54], ["superinfection suppression", "PROBLEM", 59, 85], ["unrelated microorganisms", "PROBLEM", 179, 203], ["superinfection", "OBSERVATION", 14, 28], ["superinfection", "OBSERVATION", 30, 44]]], ["In superinfection exclusion, an established infection interferes with a subsequent, closely related infection [2, 122] .", [["superinfection", "DISEASE", 3, 17], ["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 100, 109], ["superinfection exclusion", "TREATMENT", 3, 27], ["an established infection", "PROBLEM", 29, 53], ["closely related infection", "PROBLEM", 84, 109], ["superinfection", "OBSERVATION", 3, 17], ["infection", "OBSERVATION", 44, 53], ["infection", "OBSERVATION", 100, 109]]], ["An example of this phenomenon in pigs is the exclusion of highly virulent classical swine fever virus strain Margarita in wild boars persistently infected with this virus upon a challenge infection with the same Margarita strain [123] .", [["swine fever", "DISEASE", 84, 95], ["infection", "DISEASE", 188, 197], ["pigs", "ORGANISM", 33, 37], ["classical", "ORGANISM", 74, 83], ["swine fever virus", "ORGANISM", 84, 101], ["boars", "ORGANISM", 127, 132], ["pigs", "SPECIES", 33, 37], ["swine fever virus", "SPECIES", 84, 101], ["boars", "SPECIES", 127, 132], ["pigs", "SPECIES", 33, 37], ["swine fever virus", "SPECIES", 84, 101], ["this phenomenon", "PROBLEM", 14, 29], ["highly virulent classical swine fever virus strain Margarita", "PROBLEM", 58, 118], ["this virus", "PROBLEM", 160, 170], ["a challenge infection", "PROBLEM", 176, 197], ["highly", "OBSERVATION_MODIFIER", 58, 64], ["virulent", "OBSERVATION_MODIFIER", 65, 73]]], ["Superinfection suppression is a quite close concept where this time persistently infected cells resist to a challenge with a heterologous virus [2] .", [["cells", "ANATOMY", 90, 95], ["Superinfection", "DISEASE", 0, 14], ["cells", "CELL", 90, 95], ["Superinfection suppression", "PROBLEM", 0, 26], ["persistently infected cells", "PROBLEM", 68, 95], ["a heterologous virus", "TREATMENT", 123, 143]]], ["Furthermore, when the host immune response-innate or adaptive-is considered in the study of the complex interactions taking place in viral coinfections, additional mechanisms of indirect interference linked to cellular and humoral cross-protection-resulting from a first viral contact with a wild-type or a vaccine strain-can be described.Virus-virus interactionsConversely, in some situations, viral coinfections can directly or indirectly result in enhanced replication and virulence for one or both pathogens as observed in several studies involving porcine viruses [80, 83, [124] [125] [126] .", [["cellular", "ANATOMY", 210, 218], ["viral coinfections", "DISEASE", 133, 151], ["viral coinfections", "DISEASE", 395, 413], ["cellular", "CELL", 210, 218], ["Virus-virus", "ORGANISM", 339, 350], ["porcine", "ORGANISM", 553, 560], ["Virus-virus", "SPECIES", 339, 350], ["Virus-virus", "SPECIES", 339, 350], ["viral coinfections", "PROBLEM", 133, 151], ["indirect interference", "PROBLEM", 178, 199], ["humoral cross-protection", "TREATMENT", 223, 247], ["a vaccine strain", "TREATMENT", 305, 321], ["Virus", "PROBLEM", 339, 344], ["viral coinfections", "PROBLEM", 395, 413], ["enhanced replication", "PROBLEM", 451, 471], ["virulence", "PROBLEM", 476, 485], ["both pathogens", "PROBLEM", 497, 511], ["porcine viruses", "TEST", 553, 568], ["viral coinfections", "OBSERVATION", 133, 151], ["virus", "OBSERVATION", 345, 350], ["pathogens", "OBSERVATION", 502, 511]]], ["In other cases, coinfection/superinfection has no effects on virus replications and the viruses can coexist in a relation called accommodation [2] .", [["coinfection", "DISEASE", 16, 27], ["superinfection", "DISEASE", 28, 42], ["coinfection/superinfection", "PROBLEM", 16, 42], ["virus replications", "TREATMENT", 61, 79], ["the viruses", "PROBLEM", 84, 95], ["coinfection", "OBSERVATION", 16, 27], ["superinfection", "OBSERVATION", 28, 42]]], ["Besides consequences in terms of viral replication, there are also consequences for the genetic of the viruses and their evolution through events of recombination between closely related viral genomes.", [["viral genomes", "DNA", 187, 200], ["viral replication", "TREATMENT", 33, 50], ["the viruses", "PROBLEM", 99, 110], ["viral genomes", "PROBLEM", 187, 200], ["viral replication", "OBSERVATION", 33, 50], ["viruses", "OBSERVATION", 103, 110], ["viral genomes", "OBSERVATION", 187, 200]]], ["Recombination, the parameters influencing it and its consequences were reviewed in RNA and DNA viruses [127, 128] .", [["DNA", "CELLULAR_COMPONENT", 91, 94], ["DNA viruses", "TEST", 91, 102]]], ["Then, as a result of all these possible interactions between viruses, the severity of the resulting disease and its epidemiology can be altered as exemplified in Additional file 1.", [["viruses", "PROBLEM", 61, 68], ["the resulting disease", "PROBLEM", 86, 107], ["disease", "OBSERVATION", 100, 107]]], ["In the pig studies, most often, however, the exact mechanisms controlling interactions between viruses were not elucidated.Bacterium-virus and virus-bacterium interactionsSeveral mechanisms explaining bacterium-virus and virus-bacterium interactions have been identified (for reviews see [1, 94, 117] ).", [["pig", "ORGANISM", 7, 10], ["Bacterium-virus", "ORGANISM", 123, 138], ["bacterium-virus", "ORGANISM", 201, 216], ["Bacterium-virus", "SPECIES", 123, 138], ["pig", "SPECIES", 7, 10], ["Bacterium-virus", "SPECIES", 123, 138], ["the pig studies", "TEST", 3, 18], ["Bacterium", "TEST", 123, 132], ["virus", "PROBLEM", 133, 138], ["virus", "PROBLEM", 143, 148], ["bacterium interactions", "PROBLEM", 149, 171], ["bacterium", "PROBLEM", 201, 210], ["virus", "PROBLEM", 211, 216], ["virus", "PROBLEM", 221, 226], ["bacterium interactions", "PROBLEM", 227, 249]]], ["The interactions can have either a positive or a negative impact on both pathogens depending on the bacterial and viral species involved.", [["a positive", "PROBLEM", 33, 43], ["both pathogens", "PROBLEM", 68, 82], ["the bacterial and viral species", "PROBLEM", 96, 127], ["viral species", "OBSERVATION", 114, 127]]], ["Usually, when the interactions are direct they promote viral infection without affecting the bacterial species [1, 94, 117] .", [["infection", "DISEASE", 61, 70], ["viral infection", "PROBLEM", 55, 70], ["the bacterial species", "PROBLEM", 89, 110], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 61, 70]]], ["Examples of these direct interactions are (i) direct binding of the virus to a bacterium or (ii) the utilization of a bacterial product by the virus.", [["the virus", "PROBLEM", 64, 73], ["a bacterium", "PROBLEM", 77, 88], ["a bacterial product", "TREATMENT", 116, 135], ["the virus", "PROBLEM", 139, 148]]], ["An example of direct interactions in the respiratory tract is the cleavage of the IAV HA into HA1 and HA2 by a Staphylococcus aureus protease helping the viral particle to become infectious [129] .", [["respiratory tract", "ANATOMY", 41, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 41, 58], ["HA1", "GENE_OR_GENE_PRODUCT", 94, 97], ["HA2", "GENE_OR_GENE_PRODUCT", 102, 105], ["Staphylococcus aureus", "ORGANISM", 111, 132], ["HA1", "PROTEIN", 94, 97], ["HA2", "PROTEIN", 102, 105], ["Staphylococcus aureus protease", "PROTEIN", 111, 141], ["Staphylococcus aureus", "SPECIES", 111, 132], ["Staphylococcus aureus", "SPECIES", 111, 132], ["direct interactions in the respiratory tract", "PROBLEM", 14, 58], ["the IAV HA into HA1", "PROBLEM", 78, 97], ["HA2", "PROBLEM", 102, 105], ["a Staphylococcus aureus protease", "PROBLEM", 109, 141], ["the viral particle", "PROBLEM", 150, 168], ["infectious", "PROBLEM", 179, 189], ["respiratory tract", "ANATOMY", 41, 58], ["Staphylococcus aureus", "OBSERVATION", 111, 132], ["viral particle", "OBSERVATION_MODIFIER", 154, 168], ["infectious", "OBSERVATION", 179, 189]]], ["On the contrary, when interactions are indirect they often provide an advantage to bacterial infections.", [["bacterial infections", "DISEASE", 83, 103], ["bacterial infections", "PROBLEM", 83, 103], ["infections", "OBSERVATION", 93, 103]]], ["Four mechanisms dealing with indirect interactions have been described: (i) viral alteration of the epithelial barrier, (ii) reduction or suppression of the host immune response, (iii) viral alteration/displacement of the microbiota, and (iv) virus-induced alteration of bacterial cellular receptor expression [94] .", [["epithelial barrier", "ANATOMY", 100, 118], ["cellular", "ANATOMY", 281, 289], ["epithelial barrier", "TISSUE", 100, 118], ["bacterial cellular receptor", "GENE_OR_GENE_PRODUCT", 271, 298], ["bacterial cellular receptor", "PROTEIN", 271, 298], ["viral alteration", "PROBLEM", 76, 92], ["the epithelial barrier, (ii) reduction", "TREATMENT", 96, 134], ["viral alteration/displacement of the microbiota", "PROBLEM", 185, 232], ["(iv) virus", "TREATMENT", 238, 248], ["bacterial cellular receptor expression", "PROBLEM", 271, 309], ["epithelial barrier", "OBSERVATION", 100, 118], ["bacterial cellular receptor expression", "OBSERVATION", 271, 309]]], ["All these mechanisms can operate together for the benefit of the superinfecting bacteria.", [["the superinfecting bacteria", "PROBLEM", 61, 88], ["bacteria", "OBSERVATION", 80, 88]]], ["A typical example of these indirect interactions is provided by PCV2 and swIAV and porcine pathogenic bacteria such as A. pleuropneumoniae [130] and S. suis [96, 97, 131] where the bacteria benefit from the prior viral infections.", [["viral infections", "DISEASE", 213, 229], ["PCV2", "ORGANISM", 64, 68], ["swIAV", "GENE_OR_GENE_PRODUCT", 73, 78], ["porcine pathogenic bacteria", "ORGANISM", 83, 110], ["A. pleuropneumoniae", "ORGANISM", 119, 138], ["S. suis", "ORGANISM", 149, 156], ["porcine", "SPECIES", 83, 90], ["A. pleuropneumoniae", "SPECIES", 119, 138], ["S. suis", "SPECIES", 149, 156], ["swIAV", "SPECIES", 73, 78], ["A. pleuropneumoniae", "SPECIES", 119, 138], ["S. suis", "SPECIES", 149, 156], ["PCV2", "PROBLEM", 64, 68], ["porcine pathogenic bacteria", "PROBLEM", 83, 110], ["A. pleuropneumoniae", "TEST", 119, 138], ["S. suis", "TEST", 149, 156], ["the bacteria", "PROBLEM", 177, 189], ["the prior viral infections", "PROBLEM", 203, 229], ["viral infections", "OBSERVATION", 213, 229]]], ["However, bacteria can also directly benefit from a previous viral infection as observed in a study demonstrating that Staphylococcus aureus was able to bind viral HA [132] .", [["viral infection", "DISEASE", 60, 75], ["Staphylococcus aureus", "ORGANISM", 118, 139], ["Staphylococcus aureus", "SPECIES", 118, 139], ["Staphylococcus aureus", "SPECIES", 118, 139], ["bacteria", "PROBLEM", 9, 17], ["a previous viral infection", "PROBLEM", 49, 75], ["a study", "TEST", 91, 98], ["Staphylococcus aureus", "PROBLEM", 118, 139], ["bind viral HA", "PROBLEM", 152, 165], ["bacteria", "OBSERVATION", 9, 17], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infection", "OBSERVATION", 66, 75], ["Staphylococcus aureus", "OBSERVATION", 118, 139]]], ["The consequence of that binding was an enhanced bacterial internalisation by two mechanisms: (i) binding to HA exposed at the surface of infected cells, and (ii) binding to free extracellular virions.Bacterium-virus and virus-bacterium interactionsIn some other situations, non-pathogenic bacteria can also directly or indirectly protect the host from viral infection as typically observed with probiotic bacteria which can show antiviral activity through the binding/ capture of the viruses and/or the competition for cell adhesion (for a review see [117] ).", [["surface", "ANATOMY", 126, 133], ["cells", "ANATOMY", 146, 151], ["extracellular virions", "ANATOMY", 178, 199], ["cell", "ANATOMY", 519, 523], ["HA", "CHEMICAL", 108, 110], ["viral infection", "DISEASE", 352, 367], ["surface", "CELLULAR_COMPONENT", 126, 133], ["cells", "CELL", 146, 151], ["extracellular virions", "CELLULAR_COMPONENT", 178, 199], ["Bacterium-virus", "ORGANISM", 200, 215], ["cell", "CELL", 519, 523], ["infected cells", "CELL_TYPE", 137, 151], ["Bacterium-virus", "SPECIES", 200, 215], ["Bacterium-virus", "SPECIES", 200, 215], ["an enhanced bacterial internalisation", "PROBLEM", 36, 73], ["HA", "PROBLEM", 108, 110], ["infected cells", "PROBLEM", 137, 151], ["Bacterium", "TEST", 200, 209], ["virus", "PROBLEM", 210, 215], ["virus", "PROBLEM", 220, 225], ["bacterium interactions", "PROBLEM", 226, 248], ["non-pathogenic bacteria", "PROBLEM", 274, 297], ["viral infection", "PROBLEM", 352, 367], ["probiotic bacteria", "PROBLEM", 395, 413], ["antiviral activity", "PROBLEM", 429, 447], ["the viruses", "PROBLEM", 480, 491], ["cell adhesion", "PROBLEM", 519, 532], ["bacterial internalisation", "OBSERVATION", 48, 73], ["infected cells", "OBSERVATION", 137, 151], ["free", "OBSERVATION_MODIFIER", 173, 177], ["extracellular virions", "OBSERVATION", 178, 199], ["non-pathogenic", "OBSERVATION_MODIFIER", 274, 288], ["bacteria", "OBSERVATION", 289, 297], ["viral", "OBSERVATION_MODIFIER", 352, 357], ["infection", "OBSERVATION", 358, 367], ["antiviral activity", "OBSERVATION", 429, 447], ["viruses", "OBSERVATION", 484, 491]]], ["This type of interaction has been frequently observed with enteric bacteria [117] and an example in pigs is the reduced infection of IPEC-J2 cells by vesicular stomatitis virus after pre-incubation of the cells with multiple probiotic bacteria [133] .", [["IPEC-J2 cells", "ANATOMY", 133, 146], ["cells", "ANATOMY", 205, 210], ["infection", "DISEASE", 120, 129], ["IPEC-J2", "CHEMICAL", 133, 140], ["vesicular stomatitis", "DISEASE", 150, 170], ["pigs", "ORGANISM", 100, 104], ["IPEC-J2 cells", "CELL", 133, 146], ["vesicular stomatitis virus", "ORGANISM", 150, 176], ["cells", "CELL", 205, 210], ["IPEC-J2 cells", "CELL_LINE", 133, 146], ["pigs", "SPECIES", 100, 104], ["pigs", "SPECIES", 100, 104], ["stomatitis virus", "SPECIES", 160, 176], ["enteric bacteria", "PROBLEM", 59, 75], ["the reduced infection of IPEC", "PROBLEM", 108, 137], ["J2 cells", "PROBLEM", 138, 146], ["vesicular stomatitis virus", "PROBLEM", 150, 176], ["the cells", "PROBLEM", 201, 210], ["multiple probiotic bacteria", "PROBLEM", 216, 243], ["reduced", "OBSERVATION_MODIFIER", 112, 119], ["infection", "OBSERVATION", 120, 129], ["J2 cells", "OBSERVATION", 138, 146], ["vesicular stomatitis virus", "OBSERVATION", 150, 176], ["multiple", "OBSERVATION_MODIFIER", 216, 224]]], ["An intriguing relationship is occurring between IBP and viruses where metabolic reprogramming in host cells triggered by viruses might support or conversely limit coinfection by an intracellular bacterial partner (for a review see [107] ).", [["cells", "ANATOMY", 102, 107], ["intracellular", "ANATOMY", 181, 194], ["coinfection", "DISEASE", 163, 174], ["IBP", "GENE_OR_GENE_PRODUCT", 48, 51], ["host cells", "CELL", 97, 107], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 194], ["host cells", "CELL_TYPE", 97, 107], ["IBP and viruses", "PROBLEM", 48, 63], ["host cells", "PROBLEM", 97, 107], ["viruses", "PROBLEM", 121, 128], ["viruses", "OBSERVATION", 56, 63], ["metabolic reprogramming", "OBSERVATION", 70, 93], ["host cells", "OBSERVATION", 97, 107]]], ["Different possibilities can be identified in that type of interaction [107] : (i) the first pathogen can reprogram cellular metabolism related to cellular immunity and decrease the defense against the other pathogen, (ii) the metabolic changes triggered by the first pathogen can facilitate the adhesion, the penetration, and the replication of the other, and (iii) the coinfection transform the active replicative state of the first pathogen into a stable persistent state.", [["cellular", "ANATOMY", 115, 123], ["cellular", "ANATOMY", 146, 154], ["cellular", "CELL", 115, 123], ["cellular", "CELL", 146, 154], ["the first pathogen", "PROBLEM", 82, 100], ["cellular metabolism", "PROBLEM", 115, 134], ["cellular immunity", "TREATMENT", 146, 163], ["the other pathogen", "PROBLEM", 197, 215], ["the metabolic changes", "PROBLEM", 222, 243], ["the first pathogen", "PROBLEM", 257, 275], ["the adhesion", "PROBLEM", 291, 303], ["the penetration", "PROBLEM", 305, 320], ["the coinfection", "PROBLEM", 366, 381], ["active", "OBSERVATION_MODIFIER", 396, 402], ["stable", "OBSERVATION_MODIFIER", 450, 456], ["persistent", "OBSERVATION_MODIFIER", 457, 467]]], ["The first possibility associated to a decrease of the cellular defense is a commonly accepted mechanism [134] while the second and the third possibilities are less experimentally demonstrated [107] .Bacterium-bacterium interactionsLooking at bacterium-bacterium interactions, they are extremely complex to assess because of the large diversity of the bacterial world and because little is known about the mechanisms underpinning these interactions during infections.", [["cellular", "ANATOMY", 54, 62], ["Bacterium", "CHEMICAL", 199, 208], ["infections", "DISEASE", 455, 465], ["cellular", "CELL", 54, 62], ["a decrease of the cellular defense", "PROBLEM", 36, 70], ["Bacterium", "PROBLEM", 199, 208], ["bacterium interactions", "PROBLEM", 209, 231], ["bacterium interactions", "PROBLEM", 252, 274], ["decrease", "OBSERVATION_MODIFIER", 38, 46], ["cellular defense", "OBSERVATION", 54, 70], ["less experimentally", "OBSERVATION_MODIFIER", 159, 178], ["large", "OBSERVATION_MODIFIER", 328, 333], ["diversity", "OBSERVATION", 334, 343]]], ["Moreover, it is now also clear that intestinal and respiratory microbiomes affect the interactions between pathogenic bacteria and the porcine host [135] .", [["intestinal", "ANATOMY", 36, 46], ["intestinal", "ORGAN", 36, 46], ["porcine", "SPECIES", 135, 142], ["intestinal and respiratory microbiomes", "PROBLEM", 36, 74], ["pathogenic bacteria", "PROBLEM", 107, 126], ["clear", "OBSERVATION", 25, 30], ["intestinal", "ANATOMY", 36, 46], ["respiratory microbiomes", "OBSERVATION", 51, 74]]], ["Some examples of the complex interactions occurring in bacteria-bacteria coinfections are presented in Additional file 1E, but little is known about the mechanisms controlling these interactions.", [["coinfections", "DISEASE", 73, 85], ["the complex interactions", "PROBLEM", 17, 41], ["bacteria", "PROBLEM", 55, 63], ["bacteria coinfections", "PROBLEM", 64, 85], ["complex", "OBSERVATION_MODIFIER", 21, 28], ["bacteria", "OBSERVATION_MODIFIER", 64, 72], ["coinfections", "OBSERVATION", 73, 85]]], ["However, some mechanisms were provided above and interesting reviews dealing with that subject were published recently [106, 107] discussing the possible direct interactions between bacteria-mainly chemical and physical.", [["direct interactions between bacteria", "PROBLEM", 154, 190]]], ["Indirect interactions between bacteria were not reviewed in these articles but were discussed to some extent in other review papers focusing on polymicrobial infections [1, 136].Limitations of coinfection studiesThe first observation coming from this review must be, even if several studies have been carried out on the subject, a lack of data about some specific coinfections and many discrepancies between studies.", [["infections", "DISEASE", 158, 168], ["coinfection", "DISEASE", 193, 204], ["coinfections", "DISEASE", 364, 376], ["Indirect interactions between bacteria", "PROBLEM", 0, 38], ["polymicrobial infections", "PROBLEM", 144, 168], ["coinfection studies", "TEST", 193, 212], ["several studies", "TEST", 275, 290], ["some specific coinfections", "PROBLEM", 350, 376], ["many discrepancies between studies", "PROBLEM", 381, 415], ["coinfection", "OBSERVATION", 193, 204], ["coinfections", "OBSERVATION", 364, 376]]], ["For instance, there are only a few in vivo studies about PCV2 in virus/virus coinfections and about PCV2 and PRRSV in virus/bacterium coinfections (Additional file 1 and heat maps in Figures 1, 2, 3) .", [["PCV2 in virus/virus coinfections", "DISEASE", 57, 89], ["coinfections", "DISEASE", 134, 146], ["PCV2", "ORGANISM", 57, 61], ["virus/virus", "ORGANISM", 65, 76], ["PCV2", "ORGANISM", 100, 104], ["PRRSV", "ORGANISM", 109, 114], ["PRRSV", "SPECIES", 109, 114], ["PCV2", "SPECIES", 100, 104], ["PRRSV", "SPECIES", 109, 114], ["vivo studies", "TEST", 38, 50], ["PCV2 in virus/virus coinfections", "PROBLEM", 57, 89], ["PCV2", "PROBLEM", 100, 104], ["PRRSV in virus/bacterium coinfections", "PROBLEM", 109, 146], ["heat maps", "TEST", 170, 179], ["Figures", "TEST", 183, 190], ["few", "OBSERVATION_MODIFIER", 31, 34], ["virus coinfections", "OBSERVATION", 71, 89]]], ["Discrepancies are not surprising because of the definition of coinfection is not always the same between studies in addition to huge variations in the coinfection parameters amongst studies.Limitations of coinfection studiesIn this review we focused on experimental (in vivo and in vitro) coinfections, it is worth to underline that these studies are inspired by field veterinarians and epidemiologists observations.", [["coinfection", "DISEASE", 62, 73], ["coinfection", "DISEASE", 151, 162], ["coinfection", "DISEASE", 205, 216], ["coinfections", "DISEASE", 289, 301], ["coinfection", "PROBLEM", 62, 73], ["huge variations in the coinfection parameters", "PROBLEM", 128, 173], ["coinfection studies", "TEST", 205, 224], ["these studies", "TEST", 333, 346], ["coinfection", "OBSERVATION", 62, 73], ["huge", "OBSERVATION_MODIFIER", 128, 132], ["variations", "OBSERVATION", 133, 143], ["coinfection", "OBSERVATION", 151, 162], ["coinfection", "OBSERVATION", 205, 216]]], ["However, the definition of epidemiologist coinfection can also vary between studies.", [["coinfection", "DISEASE", 42, 53], ["epidemiologist coinfection", "PROBLEM", 27, 53]]], ["Indeed, in some cases there is concomitant direct identification of two microorganisms in the same animals, sometimes in the same farms, while in other cases it is just an indirect identification of the microorganisms' presence at some points through indirect serological assays.", [["two microorganisms", "PROBLEM", 68, 86], ["the microorganisms'", "PROBLEM", 199, 218], ["indirect serological assays", "TEST", 251, 278], ["microorganisms", "OBSERVATION", 203, 217]]], ["Moreover, as stated before, the term coinfection is sometimes used to describe some situations of superinfections where the delay can be significant.Limitations of coinfection studiesRegarding the experimental parameters, the Multiplicities Of Infection (MOI), the strains, the potential delays between successive infections, the routes of inoculations, the types of cellular hosts considered (more or less susceptible to one of the microorganism), the genetic background (breeds) and the sanitary status (specific pathogen free or conventional breeding) of the pigs, and the readout to assess coinfection outcome varied a lot between studies.", [["cellular", "ANATOMY", 367, 375], ["coinfection", "DISEASE", 37, 48], ["superinfections", "DISEASE", 98, 113], ["Infection", "DISEASE", 244, 253], ["infections", "DISEASE", 314, 324], ["coinfection", "DISEASE", 594, 605], ["cellular", "CELL", 367, 375], ["pigs", "ORGANISM", 562, 566], ["pigs", "SPECIES", 562, 566], ["pigs", "SPECIES", 562, 566], ["the term coinfection", "PROBLEM", 28, 48], ["superinfections", "PROBLEM", 98, 113], ["coinfection studies", "TEST", 164, 183], ["the experimental parameters", "TEST", 193, 220], ["Infection (MOI", "PROBLEM", 244, 258], ["the strains", "PROBLEM", 261, 272], ["successive infections", "PROBLEM", 303, 324], ["inoculations", "PROBLEM", 340, 352], ["cellular hosts", "PROBLEM", 367, 381], ["the microorganism", "PROBLEM", 429, 446], ["the pigs", "TREATMENT", 558, 566], ["coinfection outcome", "PROBLEM", 594, 613], ["coinfection", "OBSERVATION", 37, 48], ["superinfections", "OBSERVATION", 98, 113], ["Infection", "OBSERVATION", 244, 253], ["infections", "OBSERVATION", 314, 324], ["cellular hosts", "OBSERVATION", 367, 381]]], ["To fully compare studies, a standardization of the assays would be needed.", [["the assays", "TEST", 47, 57]]], ["For instance, whereas M. hyopneumoniae decreases the PRRSV titre in vitro [75] , it increases PRRSV shedding in vivo and indeed worsens the clinical signs upon coinfection [102] .", [["coinfection", "DISEASE", 160, 171], ["M. hyopneumoniae", "ORGANISM", 22, 38], ["PRRSV", "ORGANISM", 53, 58], ["PRRSV", "ORGANISM", 94, 99], ["M. hyopneumoniae", "SPECIES", 22, 38], ["M. hyopneumoniae", "SPECIES", 22, 38], ["PRRSV", "SPECIES", 53, 58], ["PRRSV", "SPECIES", 94, 99], ["M. hyopneumoniae", "PROBLEM", 22, 38], ["coinfection", "PROBLEM", 160, 171], ["hyopneumoniae", "OBSERVATION", 25, 38], ["PRRSV titre", "OBSERVATION", 53, 64]]], ["Consequently, the use of intermediary settings, such as co-culture of different cell types (see [2] for examples), Precision Cut Lung Slices (PCLS) [137] or organoids [138] , could help to understand the complexity of coinfections in the respiratory tissue.", [["cell", "ANATOMY", 80, 84], ["organoids", "ANATOMY", 157, 166], ["respiratory tissue", "ANATOMY", 238, 256], ["coinfections", "DISEASE", 218, 230], ["cell", "CELL", 80, 84], ["respiratory tissue", "TISSUE", 238, 256], ["Precision Cut Lung Slices", "TEST", 115, 140], ["coinfections in the respiratory tissue", "PROBLEM", 218, 256], ["Lung", "ANATOMY", 129, 133], ["coinfections", "OBSERVATION", 218, 230], ["respiratory tissue", "ANATOMY", 238, 256]]], ["In vitro approaches usually consider one or a few cell types with some limitations during the evaluation process of the coinfection consequences.", [["cell", "ANATOMY", 50, 54], ["coinfection", "DISEASE", 120, 131], ["cell", "CELL", 50, 54], ["a few cell types", "TREATMENT", 44, 60], ["the evaluation", "TEST", 90, 104], ["the coinfection consequences", "PROBLEM", 116, 144], ["coinfection", "OBSERVATION", 120, 131]]], ["Some viruses can contribute to the elimination of other viruses just because of their ability to replicate faster on a particular cell type [139] .", [["cell", "ANATOMY", 130, 134], ["cell", "CELL", 130, 134], ["Some viruses", "PROBLEM", 0, 12], ["other viruses", "PROBLEM", 50, 63], ["viruses", "OBSERVATION", 5, 12], ["viruses", "OBSERVATION", 56, 63]]], ["Thus, results obtained in vitro cannot mimic the field situation when both agents coinfect the same pig, providing inaccurate conclusions about the coinfection dynamics.", [["coinfection", "DISEASE", 148, 159], ["pig", "ORGANISM", 100, 103], ["pig", "SPECIES", 100, 103], ["the coinfection dynamics", "PROBLEM", 144, 168]]], ["Under such circumstances, pathogens may simply have different host cells and no longer be under direct competition for resources [140] .", [["cells", "ANATOMY", 67, 72], ["host cells", "CELL", 62, 72], ["host cells", "CELL_TYPE", 62, 72], ["pathogens", "PROBLEM", 26, 35], ["different host cells", "PROBLEM", 52, 72], ["host cells", "OBSERVATION", 62, 72]]], ["Besides the different interactions that infecting agents can have between them through a competition to resources, studies showed clearly that the immune system and the immunological responses can highly affect these interactions by inducing the competitive power of a pathogen or abolishing it and making it less competitive on the resource [141, 142] .", [["immune system", "ANATOMY", 147, 160], ["studies", "TEST", 115, 122], ["the immune system", "PROBLEM", 143, 160], ["a pathogen", "PROBLEM", 267, 277]]], ["The effects of the immune system (especially humoral parameters) are often not taken into consideration in selected in vitro models [140] .", [["immune system", "ANATOMY", 19, 32], ["the immune system", "TEST", 15, 32]]], ["On the other hand, in vivo coinfection experiments have to deal with numerous constraints (health status of the animals used, cost, husbandry, and ethics amongst others) and therefore are not always easy to perform.", [["coinfection", "OBSERVATION", 27, 38]]], ["Hence, although in vivo experiments are required in this very complex field, they surely need to be combined to in silico/in vitro/ex vivo analyses of potential interactions between pathogens.", [["pathogens", "PROBLEM", 182, 191]]], ["Moreover, multiple parameters of the coinfection protocols appeared difficult to set without any a priori such as the choice of the pathogen that will be inoculated first and the delay between infections.", [["coinfection", "DISEASE", 37, 48], ["infections", "DISEASE", 193, 203], ["the coinfection protocols", "TREATMENT", 33, 58], ["the pathogen", "PROBLEM", 128, 140], ["the delay between infections", "PROBLEM", 175, 203], ["multiple", "OBSERVATION_MODIFIER", 10, 18], ["coinfection", "OBSERVATION", 37, 48], ["infections", "OBSERVATION", 193, 203]]], ["One possibility to deal with multiple parameters is to use intra-host infection mathematical modelling [143] allowing to play, at limited cost, with the different parameters of the coinfections.", [["infection", "DISEASE", 70, 79], ["coinfections", "DISEASE", 181, 193], ["intra-host infection", "PROBLEM", 59, 79], ["the coinfections", "PROBLEM", 177, 193], ["coinfections", "OBSERVATION", 181, 193]]], ["The other possibility is to rely on field prevalence studies monitoring the very presence of the pathogens (isolation, PCR) instead of the sero-conversion, in order to have a clear epidemiological picture of when and where coinfections occur.Limitations of coinfection studiesConsequently, ex vivo models such as PCLS generated from freshly sacrificed pigs [137] or organoids [138] are developing.", [["organoids", "ANATOMY", 366, 375], ["coinfections", "DISEASE", 223, 235], ["pigs", "ORGANISM", 352, 356], ["organoids", "CELL", 366, 375], ["pigs", "SPECIES", 352, 356], ["field prevalence studies", "TEST", 36, 60], ["the pathogens", "PROBLEM", 93, 106], ["PCR", "TEST", 119, 122], ["the sero-conversion", "TREATMENT", 135, 154], ["coinfections", "PROBLEM", 223, 235], ["coinfection studies", "TEST", 257, 276], ["ex vivo models", "TEST", 290, 304], ["PCLS", "TEST", 313, 317], ["coinfection", "OBSERVATION", 257, 268]]], ["These models are closer to mimic the in vivo situation than usual in vitro approaches, combining different types of cells and providing the pathogens with a wider range of cell hosts.", [["cells", "ANATOMY", 116, 121], ["cell", "ANATOMY", 172, 176], ["cells", "CELL", 116, 121], ["cell hosts", "CELL", 172, 182], ["vitro approaches", "TREATMENT", 69, 85], ["combining different types of cells", "PROBLEM", 87, 121], ["the pathogens", "PROBLEM", 136, 149], ["cell hosts", "OBSERVATION", 172, 182]]], ["However, the contribution of the immune response to the interaction between different pathogens is rarely considered [97] .", [["different pathogens", "PROBLEM", 76, 95], ["immune response", "OBSERVATION", 33, 48]]], ["Furthermore, the MOI cannot be controlled because the number of infected cells in the slice or the organoid cannot be monitored easily either.Limitations of coinfection studiesAnother limiting factor in coinfection studies is the cell regeneration, which can vary between in vivo and in vitro models.", [["cells", "ANATOMY", 73, 78], ["slice", "ANATOMY", 86, 91], ["organoid", "ANATOMY", 99, 107], ["cell", "ANATOMY", 230, 234], ["coinfection", "DISEASE", 157, 168], ["cells", "CELL", 73, 78], ["slice", "MULTI-TISSUE_STRUCTURE", 86, 91], ["cell", "CELL", 230, 234], ["infected cells", "CELL_TYPE", 64, 78], ["the MOI", "TREATMENT", 13, 20], ["infected cells", "PROBLEM", 64, 78], ["coinfection studies", "TEST", 157, 176], ["coinfection studies", "TEST", 203, 222], ["the cell regeneration", "PROBLEM", 226, 247], ["infected cells", "OBSERVATION", 64, 78], ["coinfection", "OBSERVATION", 157, 168], ["cell regeneration", "OBSERVATION", 230, 247]]], ["Cell regeneration can highly affect the dynamics of a coinfection, giving some pathogens extra target cells guarantying their longer existence while contributing to the clearance of others [140] .", [["Cell", "ANATOMY", 0, 4], ["cells", "ANATOMY", 102, 107], ["coinfection", "DISEASE", 54, 65], ["Cell", "CELL", 0, 4], ["cells", "CELL", 102, 107], ["target cells", "CELL_TYPE", 95, 107], ["Cell regeneration", "PROBLEM", 0, 17], ["a coinfection", "PROBLEM", 52, 65], ["some pathogens extra target cells", "PROBLEM", 74, 107], ["coinfection", "OBSERVATION", 54, 65]]], ["Finally, other potential technical limitations could always be discussed such as the lack of precision or sensitivity in the different diagnostic techniques especially in the presence of multiple agents.", [["multiple agents", "TREATMENT", 187, 202]]], ["Hence, the detection of coinfecting pathogens could be compromised or reduced as compared to their detection level in the context of single infections.Conclusion and perspectivesAs shown in this review many works have been dedicated to the study of coinfections and superinfections in pigs.", [["infections", "DISEASE", 140, 150], ["coinfections", "DISEASE", 249, 261], ["superinfections", "DISEASE", 266, 281], ["pigs", "ORGANISM", 285, 289], ["pigs", "SPECIES", 285, 289], ["pigs", "SPECIES", 285, 289], ["coinfecting pathogens", "PROBLEM", 24, 45], ["their detection level", "TEST", 93, 114], ["single infections", "PROBLEM", 133, 150], ["the study", "TEST", 236, 245], ["coinfections", "PROBLEM", 249, 261], ["superinfections", "PROBLEM", 266, 281], ["pathogens", "OBSERVATION", 36, 45], ["reduced", "OBSERVATION_MODIFIER", 70, 77], ["infections", "OBSERVATION", 140, 150], ["coinfections", "OBSERVATION", 249, 261], ["superinfections", "OBSERVATION", 266, 281]]], ["Usually, when the experiments were carried out in vivo, the researchers were more interested in the clinical outcome than in the interactions occurring between pathogens.", [["pathogens", "PROBLEM", 160, 169]]], ["Indeed, in most of the cases the fine interactions between pathogens and especially the mechanisms behind these interactions and its potential consequences, at the molecular level, on the immune response were not studied for several reasons including technical limitations.", [["pathogens", "PROBLEM", 59, 68]]], ["Also, in the studies assessing the occurrence of coinfections/superinfections in the fields, coinfection identification based on molecular tools such as PCR would be more accurate than sero-prevalence approaches which are less prone to identify currently present pathogens and thus coinfective pathogens.", [["coinfections", "DISEASE", 49, 61], ["superinfections", "DISEASE", 62, 77], ["coinfection", "DISEASE", 93, 104], ["the studies", "TEST", 9, 20], ["coinfections", "PROBLEM", 49, 61], ["superinfections in the fields", "PROBLEM", 62, 91], ["coinfection identification", "PROBLEM", 93, 119], ["molecular tools", "TEST", 129, 144], ["PCR", "TEST", 153, 156], ["pathogens", "PROBLEM", 263, 272], ["coinfective pathogens", "PROBLEM", 282, 303], ["coinfections", "OBSERVATION", 49, 61], ["superinfections", "OBSERVATION", 62, 77]]], ["We thus would like to make recommendations for future studies dealing with respiratory coinfections in pigs: (i) Authors should clearly summarize their coinfection or superinfection experimental setup-doses of pathogens, delays between infections-in their Materials and methods section; (ii) in this summary they would need to clearly present the pathogens they use and they should, as often as possible, select well-characterized strains; (iii) environmental and management conditions would need a strict control and monitoring; (iv) animal genetic and sanitary status would need to be carefully described and monitored during the study; and (v) the multiplications of all the pathogens shall be followed during the experiment using highly sensitive and specific assays.", [["respiratory", "ANATOMY", 75, 86], ["respiratory coinfections", "DISEASE", 75, 99], ["coinfection", "DISEASE", 152, 163], ["superinfection", "DISEASE", 167, 181], ["infections", "DISEASE", 236, 246], ["pigs", "ORGANISM", 103, 107], ["pigs", "SPECIES", 103, 107], ["pigs", "SPECIES", 103, 107], ["future studies", "TEST", 47, 61], ["their coinfection", "PROBLEM", 146, 163], ["superinfection experimental setup", "TREATMENT", 167, 200], ["pathogens", "PROBLEM", 210, 219], ["delays between infections", "PROBLEM", 221, 246], ["management conditions", "TREATMENT", 464, 485], ["a strict control", "TREATMENT", 497, 513], ["the study", "TEST", 628, 637], ["all the pathogens", "PROBLEM", 670, 687], ["coinfection", "OBSERVATION", 152, 163]]], ["A clear description of all these parameters would help the scientific community to compare studies and progress in the understanding of the complex interactions between microorganisms.Conclusion and perspectivesIn the last years, the concept of innate immune memory or trained immunity has gained a lot of interest.", [["the complex interactions between microorganisms", "PROBLEM", 136, 183], ["clear", "OBSERVATION", 2, 7]]], ["This concept is coming from old observation, in 1946 [144] , recognizing that the bacterial vaccine strain \"Bacille de Calmette et Gu\u00e9rin\" (BCG) was protecting not only against Mycobacterium tuberculosis but also against antigenically different microorganism causing childhood mortality, suggesting an \"adaptation\" of the cellular innate immune system.", [["cellular", "ANATOMY", 322, 330], ["Bacille de Calmette et Gu\u00e9rin", "CHEMICAL", 108, 137], ["Mycobacterium tuberculosis", "DISEASE", 177, 203], ["Mycobacterium tuberculosis", "ORGANISM", 177, 203], ["cellular", "CELL", 322, 330], ["Mycobacterium tuberculosis", "SPECIES", 177, 203], ["Mycobacterium tuberculosis", "SPECIES", 177, 203], ["the bacterial vaccine strain", "TREATMENT", 78, 106], ["Bacille de Calmette et Gu\u00e9rin", "TREATMENT", 108, 137], ["Mycobacterium tuberculosis", "PROBLEM", 177, 203], ["antigenically different microorganism", "PROBLEM", 221, 258], ["childhood mortality", "PROBLEM", 267, 286], ["cellular innate immune system", "OBSERVATION", 322, 351]]], ["Since then, many interesting studies about innate immune memory or trained immunity have been published (for a review see [145] ) and it is recognized that cells such as myeloid cells, NK cells, and even epithelial cells [146] can have a higher and quicker response upon re-exposure to a pathogen.", [["cells", "ANATOMY", 156, 161], ["myeloid cells", "ANATOMY", 170, 183], ["NK cells", "ANATOMY", 185, 193], ["epithelial cells", "ANATOMY", 204, 220], ["cells", "CELL", 156, 161], ["myeloid cells", "CELL", 170, 183], ["NK cells", "CELL", 185, 193], ["epithelial cells", "CELL", 204, 220], ["myeloid cells", "CELL_TYPE", 170, 183], ["NK cells", "CELL_TYPE", 185, 193], ["epithelial cells", "CELL_TYPE", 204, 220], ["myeloid cells", "PROBLEM", 170, 183], ["NK cells", "TEST", 185, 193], ["epithelial cells", "PROBLEM", 204, 220], ["a pathogen", "PROBLEM", 286, 296], ["myeloid cells", "OBSERVATION", 170, 183], ["NK cells", "OBSERVATION", 185, 193], ["epithelial cells", "OBSERVATION", 204, 220]]], ["Trained immunity is accompanied by epigenetic changes and most often associated with modifications in cellular metabolism.", [["cellular", "ANATOMY", 102, 110], ["cellular", "CELL", 102, 110], ["epigenetic changes", "PROBLEM", 35, 53], ["modifications in cellular metabolism", "PROBLEM", 85, 121], ["cellular metabolism", "OBSERVATION", 102, 121]]], ["A close look at potential epigenetic changes and cellular metabolism modifications would be of high interest in respiratory coinfection studies in the porcine species.", [["cellular", "ANATOMY", 49, 57], ["respiratory", "ANATOMY", 112, 123], ["respiratory coinfection", "DISEASE", 112, 135], ["cellular", "CELL", 49, 57], ["porcine", "ORGANISM", 151, 158], ["potential epigenetic changes", "PROBLEM", 16, 44], ["cellular metabolism modifications", "TREATMENT", 49, 82], ["high interest in respiratory coinfection studies", "PROBLEM", 95, 143], ["cellular metabolism", "OBSERVATION", 49, 68], ["respiratory coinfection", "OBSERVATION", 112, 135]]], ["Recently an alternative to the mechanism of trained immunity in resident lung innate immune cells named \"epigenetic legacy\" has been described [147] .", [["lung", "ANATOMY", 73, 77], ["immune cells", "ANATOMY", 85, 97], ["lung innate immune cells", "CELL", 73, 97], ["resident lung innate immune cells", "CELL_TYPE", 64, 97], ["lung", "ANATOMY", 73, 77]]], ["In that study, the authors demonstrated that following IAV clearance and clinical recovery (1-month post-infection), mice were better protected from Streptococcus pneumoniae infection by adult bone-marrow-derived AMs displaying transient transcriptional and epigenetic distinct profiles.", [["bone-marrow", "ANATOMY", 193, 204], ["AMs", "ANATOMY", 213, 216], ["infection", "DISEASE", 105, 114], ["Streptococcus pneumoniae infection", "DISEASE", 149, 183], ["IAV", "ORGANISM", 55, 58], ["mice", "ORGANISM", 117, 121], ["Streptococcus pneumoniae", "ORGANISM", 149, 173], ["bone-marrow", "MULTI-TISSUE_STRUCTURE", 193, 204], ["AMs", "CELL", 213, 216], ["adult bone-marrow-derived AMs", "CELL_TYPE", 187, 216], ["mice", "SPECIES", 117, 121], ["Streptococcus pneumoniae", "SPECIES", 149, 173], ["IAV", "SPECIES", 55, 58], ["mice", "SPECIES", 117, 121], ["Streptococcus pneumoniae", "SPECIES", 149, 173], ["that study", "TEST", 3, 13], ["IAV clearance", "TREATMENT", 55, 68], ["infection", "PROBLEM", 105, 114], ["Streptococcus pneumoniae infection", "PROBLEM", 149, 183], ["AMs", "PROBLEM", 213, 216], ["transient transcriptional and epigenetic distinct profiles", "PROBLEM", 228, 286], ["Streptococcus pneumoniae", "OBSERVATION", 149, 173], ["bone", "ANATOMY", 193, 197], ["marrow", "ANATOMY", 198, 204], ["epigenetic distinct", "OBSERVATION", 258, 277]]], ["This newly described consequence of a first viral infection also needs additional studies about PRDC with an identification of the mechanisms shaping the complex interactions between pathogens.Supplementary informationSupplementary information accompanies this paper at https ://doi. org/10.1186/s1356 7-020-00807 -8.Supplementary informationAdditional file 1.", [["viral infection", "DISEASE", 44, 59], ["PRDC", "CANCER", 96, 100], ["a first viral infection", "PROBLEM", 36, 59], ["additional studies", "TEST", 71, 89], ["PRDC", "TREATMENT", 96, 100], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["infection", "OBSERVATION", 50, 59]]], ["Studies about coinfections in the pig respiratory tract and their consequences.", [["respiratory tract", "ANATOMY", 38, 55], ["coinfections in the pig respiratory tract", "DISEASE", 14, 55], ["pig", "ORGANISM", 34, 37], ["respiratory tract", "ORGANISM_SUBDIVISION", 38, 55], ["pig", "SPECIES", 34, 37], ["pig", "SPECIES", 34, 37], ["coinfections in the pig respiratory tract", "PROBLEM", 14, 55], ["respiratory tract", "ANATOMY", 38, 55]]]], "08ecf83a52557998484a4af1d660d62c77482568": [], "44603146f1962a91da062ec4f305ec7dc1bb0307": [["cell factory has some limitations such as intracellular aggregation and misfolding of heterologous proteins, production of lipopolysaccharide, lack of posttranslational modification, and protein degradation due to proteases (Rosano & Ceccarelli, 2014) (Khan, 2013) .", [["cell", "ANATOMY", 0, 4], ["intracellular", "ANATOMY", 42, 55], ["lipopolysaccharide", "CHEMICAL", 123, 141], ["cell", "CELL", 0, 4], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 55], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 123, 141], ["heterologous proteins", "PROTEIN", 86, 107], ["proteases", "PROTEIN", 214, 223], ["some limitations", "PROBLEM", 17, 33], ["intracellular aggregation", "PROBLEM", 42, 67], ["heterologous proteins", "PROBLEM", 86, 107], ["lipopolysaccharide", "PROBLEM", 123, 141], ["posttranslational modification", "PROBLEM", 151, 181], ["protein degradation", "PROBLEM", 187, 206], ["intracellular aggregation", "OBSERVATION", 42, 67], ["posttranslational modification", "OBSERVATION", 151, 181]]]], "46e10fc6c85dc07bb41674915a38924e2570ae19": [["BackgroundThe COVID-19 outbreak has indiscriminately spread across the world, including in countries facing ongoing conflict, protracted humanitarian crises, and large numbers of forcibly displaced individuals.", [["protracted humanitarian crises", "PROBLEM", 126, 156], ["forcibly displaced individuals", "PROBLEM", 179, 209], ["protracted", "OBSERVATION_MODIFIER", 126, 136], ["humanitarian crises", "OBSERVATION", 137, 156], ["large", "OBSERVATION_MODIFIER", 162, 167], ["numbers", "OBSERVATION_MODIFIER", 168, 175], ["forcibly", "OBSERVATION_MODIFIER", 179, 187], ["displaced", "OBSERVATION_MODIFIER", 188, 197]]], ["Countries experiencing humanitarian emergencies are particularly vulnerable to the spread of infectious diseases and have limited capacity to confront the challenges associated with containing the spread of COVID-19 and treating existing cases.", [["infectious diseases", "DISEASE", 93, 112], ["COVID-19", "CHEMICAL", 207, 215], ["humanitarian emergencies", "TREATMENT", 23, 47], ["infectious diseases", "PROBLEM", 93, 112], ["limited capacity", "PROBLEM", 122, 138], ["COVID", "TEST", 207, 212], ["infectious", "OBSERVATION", 93, 103]]], ["Despite this reality, aid agencies, international actors, and donor governments have been slow to coordinate a multifaceted response, and few policies have been put forth to develop sufficient test-treatisolate capacity and to equip medical facilities and health personnel with the resources necessary to care for patients with COVID-19.", [["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 314, 322], ["donor governments", "TREATMENT", 62, 79], ["COVID", "TEST", 328, 333]]], ["Although the Global Humanitarian Response Plan for COVID-19 sets forth an important strategic framework to address the virus, countries in humanitarian settings still face immense gaps in their capacity to implement proposed solutions [1] .", [["COVID", "TEST", 51, 56], ["the virus", "PROBLEM", 115, 124], ["humanitarian settings", "TREATMENT", 139, 160]]], ["Without further coordinated global assistance to support context-specific solutions in countries affected by humanitarian crises, there is considerable risk that COVID-19 will devastate vulnerable populations of displaced individuals, continue to spread across borders, and threaten global health security.", [["COVID", "TEST", 162, 167], ["displaced individuals", "PROBLEM", 212, 233], ["displaced", "OBSERVATION_MODIFIER", 212, 221]]], ["This call-to-action highlights the challenges of addressing COVID-19 in humanitarian settings and presents key recommendations for national governments, international agencies, and humanitarian responders to control the spread of COVID-19 and treat severely infected patients given limited resources.Heightened risks of the impact of COVID-19 in crisis settingsDespite global calls to support low-to-middle income countries in addressing COVID-19, little attention has been given to refugees and internally displaced persons (IDPs) in humanitarian contexts, particularly those living in camps or informal settings.", [["COVID-19", "CHEMICAL", 230, 238], ["COVID-19", "CHEMICAL", 334, 342], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 267, 275], ["persons", "SPECIES", 517, 524], ["COVID-19", "SPECIES", 230, 238], ["addressing COVID", "TREATMENT", 49, 65], ["humanitarian", "TREATMENT", 181, 193], ["COVID", "TREATMENT", 230, 235], ["severely infected patients", "PROBLEM", 249, 275], ["COVID", "TEST", 334, 339], ["crisis settings", "TREATMENT", 346, 361]]], ["Refugees and IDPs are often forced into settlements with high population densities, and these overcrowded areas tend to have limited public health services, poor sanitation and waste disposal facilities, and inadequate access to clean watermaking them particularly susceptible to a COVID-19 outbreak.", [["IDPs", "TREATMENT", 13, 17], ["high population densities", "PROBLEM", 57, 82], ["waste disposal facilities", "TREATMENT", 177, 202], ["a COVID", "TEST", 280, 287]]], ["According to the United Nations High Commissioner for Refugees, approximately 84% of the 70 million individuals who have been forced to flee their homes are hosted by low-to-middle income countries with weak health systems and water, sanitation, and hygiene (WASH) tools [2] .", [["individuals", "ORGANISM", 100, 111]]], ["Of the countries with reported cases of COVID-19, over thirty play host to registered refugee populations of over 20,000 people, in addition to a considerable number of unregistered refugees [3] .", [["people", "ORGANISM", 121, 127], ["people", "SPECIES", 121, 127], ["COVID", "TEST", 40, 45]]], ["The United Nations has already ordered the evacuation of Moria refugee camp in Lesbos, Greece, which was designed to host 3000 people but now hosts over 20,000 and has been reported to have widespread malnutrition and poor hygiene [5] .", [["malnutrition", "DISEASE", 201, 213], ["people", "ORGANISM", 127, 133], ["people", "SPECIES", 127, 133], ["the evacuation", "TREATMENT", 39, 53], ["widespread malnutrition", "PROBLEM", 190, 213], ["widespread", "OBSERVATION_MODIFIER", 190, 200], ["malnutrition", "OBSERVATION", 201, 213]]], ["In more established camps such as that of Cox's Bazar in Bangladesh, which hosts half a million Rohingya refugees, it is likely that the spread of COVID-19 will still pose challenges as the management of cases requires referrals to health facilities that are already overstretched.Heightened risks of the impact of COVID-19 in crisis settingsThe scientific community has continued to make advances in understanding the most effective ways to manage severe cases of COVD-19, most recently with the publication of a clinical trial on the use of dexamethasone [6] .", [["COVID-19", "CHEMICAL", 315, 323], ["COVD", "DISEASE", 465, 469], ["dexamethasone", "CHEMICAL", 543, 556], ["dexamethasone", "CHEMICAL", 543, 556], ["dexamethasone", "SIMPLE_CHEMICAL", 543, 556], ["COVID", "TEST", 315, 320], ["crisis settings", "TREATMENT", 327, 342], ["severe cases of COVD", "PROBLEM", 449, 469], ["dexamethasone", "TREATMENT", 543, 556], ["is likely", "UNCERTAINTY", 118, 127]]], ["It is known that COVID-19 is transmitted via aerosolized particles, larger droplets, and sustained contact with contaminated surfaces and that severe cases often result in an overwhelming inflammatory response affecting the lungs.", [["lungs", "ANATOMY", 224, 229], ["COVID-19", "GENE_OR_GENE_PRODUCT", 17, 25], ["lungs", "ORGAN", 224, 229], ["COVID", "TEST", 17, 22], ["severe cases", "PROBLEM", 143, 155], ["an overwhelming inflammatory response affecting the lungs", "PROBLEM", 172, 229], ["larger", "OBSERVATION_MODIFIER", 68, 74], ["droplets", "OBSERVATION_MODIFIER", 75, 83], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["overwhelming", "OBSERVATION_MODIFIER", 175, 187], ["inflammatory", "OBSERVATION", 188, 200], ["lungs", "ANATOMY", 224, 229]]], ["Data from affected countries suggest that age (> 65), one or more serious comorbidities, particularly cardiovascular disease or uncontrolled diabetes, and smoking are correlated with increased rates of mortality [7, 8] .", [["cardiovascular", "ANATOMY", 102, 116], ["cardiovascular disease", "DISEASE", 102, 124], ["diabetes", "DISEASE", 141, 149], ["smoking", "CHEMICAL", 155, 162], ["more serious comorbidities", "PROBLEM", 61, 87], ["cardiovascular disease", "PROBLEM", 102, 124], ["uncontrolled diabetes", "PROBLEM", 128, 149], ["increased rates of mortality", "PROBLEM", 183, 211], ["uncontrolled", "OBSERVATION_MODIFIER", 128, 140], ["diabetes", "OBSERVATION", 141, 149]]], ["Data from the Centers for Disease Control and Prevention also show that approximately 55% of patients aged 20-64 are at risk for moderate to severe infection and require respiratory support in the form of oxygen via nasal cannula, positive pressure ventilation, or in the worst cases, mechanical ventilation [9] .", [["respiratory", "ANATOMY", 170, 181], ["nasal", "ANATOMY", 216, 221], ["infection", "DISEASE", 148, 157], ["oxygen", "CHEMICAL", 205, 211], ["oxygen", "CHEMICAL", 205, 211], ["patients", "ORGANISM", 93, 101], ["oxygen", "SIMPLE_CHEMICAL", 205, 211], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 216, 229], ["patients", "SPECIES", 93, 101], ["Disease Control", "TREATMENT", 26, 41], ["moderate to severe infection", "PROBLEM", 129, 157], ["respiratory support", "TREATMENT", 170, 189], ["oxygen via nasal cannula", "TREATMENT", 205, 229], ["positive pressure ventilation", "TREATMENT", 231, 260], ["mechanical ventilation", "TREATMENT", 285, 307], ["moderate", "OBSERVATION_MODIFIER", 129, 137], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["infection", "OBSERVATION", 148, 157], ["respiratory support", "OBSERVATION", 170, 189], ["pressure ventilation", "OBSERVATION", 240, 260]]], ["Despite these daunting statistics, the majority of COVID-19 cases are asymptomatic or present with mild symptoms, such as a cough and congestion.", [["cough", "DISEASE", 124, 129], ["congestion", "DISEASE", 134, 144], ["COVID", "TEST", 51, 56], ["asymptomatic", "PROBLEM", 70, 82], ["mild symptoms", "PROBLEM", 99, 112], ["a cough", "PROBLEM", 122, 129], ["congestion", "PROBLEM", 134, 144], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["symptoms", "OBSERVATION", 104, 112], ["cough", "OBSERVATION", 124, 129], ["congestion", "OBSERVATION", 134, 144]]], ["This trend is expected to hold true among refugees and IDPs as well.", [["IDPs", "TREATMENT", 55, 59]]], ["The actual burden of COVID-19 in areas hosting refugees and IDPs is still unknown given a serious lack of testing capabilities.", [["COVID-19", "CHEMICAL", 21, 29], ["COVID", "TEST", 21, 26], ["burden", "OBSERVATION_MODIFIER", 11, 17]]], ["Due to overcrowding, poor WASH tools, and limited availability of advanced health services, it is expected that rates of transmission and mortality will be higher in humanitarian settings.", [["overcrowding", "PROBLEM", 7, 19], ["poor WASH tools", "PROBLEM", 21, 36], ["overcrowding", "OBSERVATION_MODIFIER", 7, 19], ["poor", "OBSERVATION_MODIFIER", 21, 25], ["WASH", "OBSERVATION", 26, 30]]], ["In Somalia, documentary sources claim that nearly 70% of daily tests are returning positive as the country surpasses 3000 reported cases [10] .Heightened risks of the impact of COVID-19 in crisis settingsFor severely infected patients, hospitalization, respiratory support, and even cardiac resuscitation may be necessary, in addition to continued management of chronic comorbid conditions such as cancer and cardiovascular disease that are increasingly prevalent in humanitarian settings [11, 12] .", [["respiratory", "ANATOMY", 253, 264], ["cardiac", "ANATOMY", 283, 290], ["cancer", "ANATOMY", 398, 404], ["cardiovascular", "ANATOMY", 409, 423], ["COVID-19", "CHEMICAL", 177, 185], ["severely infected", "DISEASE", 208, 225], ["cancer", "DISEASE", 398, 404], ["cardiovascular disease", "DISEASE", 409, 431], ["patients", "ORGANISM", 226, 234], ["cardiac", "ORGAN", 283, 290], ["cancer", "CANCER", 398, 404], ["cardiovascular", "ANATOMICAL_SYSTEM", 409, 423], ["patients", "SPECIES", 226, 234], ["daily tests", "TEST", 57, 68], ["COVID", "TEST", 177, 182], ["crisis settings", "TREATMENT", 189, 204], ["severely infected patients", "PROBLEM", 208, 234], ["respiratory support", "TREATMENT", 253, 272], ["cardiac resuscitation", "TREATMENT", 283, 304], ["chronic comorbid conditions", "PROBLEM", 362, 389], ["cancer", "PROBLEM", 398, 404], ["cardiovascular disease", "PROBLEM", 409, 431], ["severely", "OBSERVATION_MODIFIER", 208, 216], ["infected", "OBSERVATION", 217, 225], ["chronic", "OBSERVATION_MODIFIER", 362, 369], ["comorbid", "OBSERVATION", 370, 378], ["cancer", "OBSERVATION", 398, 404], ["cardiovascular disease", "OBSERVATION", 409, 431]]], ["These patients will likely struggle immensely to receive care in such contexts given that the majority of conflict-affected nations with large populations of IDPs and refugees do not have the health infrastructure nor the medical personnel to provide these services.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["care", "TREATMENT", 57, 61]]], ["In humanitarian contexts, hospitals have been destroyed; medical personnel have been killed or displaced; and, the provision of medical supplies, including personal protective equipment (PPE) required to prevent COVID-19 transmission, is inadequate [13] .", [["medical supplies", "TREATMENT", 128, 144], ["personal protective equipment (PPE)", "TREATMENT", 156, 191]]], ["It must also be noted that most available research and interventions using anti-viral medications, such as Remdesivir and steroids for cytokine storm, have been developed against a backbone of high-income and highdependency intensive care, which are rarely available in humanitarian settings.Upholding international frameworks and protecting global health securityMany of the nations that host the majority of the world's refugees are signatories to the 1951 UN Refugee Convention and its 1967 Protocol or similar regional frameworks that state that refugees should receive the same health services as nationals [15] .", [["Remdesivir", "CHEMICAL", 107, 117], ["steroids", "CHEMICAL", 122, 130], ["Remdesivir", "CHEMICAL", 107, 117], ["steroids", "CHEMICAL", 122, 130], ["Remdesivir", "SIMPLE_CHEMICAL", 107, 117], ["steroids", "SIMPLE_CHEMICAL", 122, 130], ["cytokine", "PROTEIN", 135, 143], ["interventions", "TREATMENT", 55, 68], ["anti-viral medications", "TREATMENT", 75, 97], ["Remdesivir", "TREATMENT", 107, 117], ["steroids", "TREATMENT", 122, 130], ["cytokine storm", "TREATMENT", 135, 149], ["highdependency intensive care", "TREATMENT", 209, 238]]], ["Given these international commitments and the necessity of treating all affected populations to contain the spread of COVID-19, refugees and IDPs must be included in national response plans.", [["all affected populations", "PROBLEM", 68, 92]]], ["Furthermore, the COVID-19 pandemic can affect anyone, regardless of race, gender, age, or political affiliation.", [["the COVID", "TEST", 13, 22]]], ["Like all infectious pathogens, COVID-19 has no regard for national borders.", [["all infectious pathogens", "PROBLEM", 5, 29], ["COVID", "TEST", 31, 36], ["all", "OBSERVATION_MODIFIER", 5, 8], ["infectious", "OBSERVATION", 9, 19]]], ["Given the transient nature of populations in crisis settings, an inadequate response to COVID-19 in such settings is likely to prolong the spread of the virus and threaten global health security.", [["COVID-19", "CHEMICAL", 88, 96], ["crisis settings", "TREATMENT", 45, 60], ["COVID", "TEST", 88, 93], ["the virus", "PROBLEM", 149, 158], ["populations", "OBSERVATION_MODIFIER", 30, 41]]], ["As such, it is the collective responsibility of global leaders and international organizations to coordinate a robust response to prevent the spread of COVID-19 and treat affected patients in humanitarian settings.COVID-19 response priorities in humanitarian settingsThere is much that should be done to address COVID-19 in humanitarian settings.", [["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["COVID", "TEST", 152, 157], ["humanitarian settings", "TREATMENT", 192, 213], ["COVID", "TEST", 214, 219], ["humanitarian settings", "TREATMENT", 246, 267], ["COVID", "TEST", 312, 317]]], ["First, governments, aid agencies, and international actors must put forth clear prevention and treatment options that are consistent with available resources.", [["treatment options", "TREATMENT", 95, 112]]], ["To reduce transmission of this highly contagious pathogen, there needs to be effective communication of risks to both affected populations and front-line responders, explaining how the virus is transmitted, the importance of handwashing, sanitation, and hygiene in reducing transmission, and the necessary steps to take if there is concern for infection.", [["infection", "DISEASE", 344, 353], ["front-line", "CELL", 143, 153], ["this highly contagious pathogen", "PROBLEM", 26, 57], ["both affected populations", "PROBLEM", 113, 138], ["front-line responders", "TREATMENT", 143, 164], ["the virus", "PROBLEM", 181, 190], ["sanitation", "TREATMENT", 238, 248], ["infection", "PROBLEM", 344, 353], ["concern for", "UNCERTAINTY", 332, 343], ["infection", "OBSERVATION", 344, 353]]], ["Only then can stakeholders work together to further prevent transmission by implementing physical distancing measures, restructuring settlements, and improving the availability of WASH, as dictated by the World Health Organizations response guidelines [16] .", [["physical distancing measures", "TREATMENT", 89, 117]]], ["Second, given the reality of inadequate laboratory access in crisis settings, resource-stratified guidelines for the use of limited testing must be put forth to identify cases and prevent further transmission.", [["crisis settings", "TREATMENT", 61, 76], ["limited testing", "TEST", 124, 139]]], ["The mistakes of severely affected countries and the successes of countries who have been able to avoid and reduce transmission have taught us that early and broad testing is imperative to controlling the spread of this virus.", [["broad testing", "TEST", 157, 170], ["this virus", "PROBLEM", 214, 224], ["severely", "OBSERVATION_MODIFIER", 16, 24], ["affected", "OBSERVATION_MODIFIER", 25, 33]]], ["Until widespread testing is available, governments and humanitarian agencies must provide explicit guidance for the use of limited tests, perhaps prioritizing at-risk populations and healthcare workers.", [["widespread testing", "TEST", 6, 24], ["limited tests", "TEST", 123, 136]]], ["Third, because it is expected that transmission will not be well-controlled in some settings, there must be a context-specific preparedness plan for case management.", [["case management", "TREATMENT", 149, 164]]], ["In addition to ensuring the availability of resources that could be potentially life-saving, such as PPE for healthcare workers, oxygen tanks, nasal cannulas, and ventilators when possible, this is a setting where mobilizing additional healthcare professionals, creating mobile screening sites, and establishing temporary healthcare facilities would be effective in treating a potential surge of acutely ill patients.", [["nasal", "ANATOMY", 143, 148], ["oxygen", "CHEMICAL", 129, 135], ["acutely ill", "DISEASE", 396, 407], ["oxygen", "CHEMICAL", 129, 135], ["oxygen", "SIMPLE_CHEMICAL", 129, 135], ["nasal cannulas", "MULTI-TISSUE_STRUCTURE", 143, 157], ["patients", "ORGANISM", 408, 416], ["patients", "SPECIES", 408, 416], ["healthcare workers", "TREATMENT", 109, 127], ["oxygen tanks", "TREATMENT", 129, 141], ["nasal cannulas", "TREATMENT", 143, 157], ["ventilators", "TREATMENT", 163, 174], ["temporary healthcare facilities", "TREATMENT", 312, 343]]], ["It may be more practical to have safe wards supporting non-invasive respiratory needs as opposed to sophisticated intensive care technologies that are not likely to be the best use of limited resources.", [["respiratory", "ANATOMY", 68, 79], ["non-invasive respiratory needs", "TREATMENT", 55, 85], ["sophisticated intensive care technologies", "TREATMENT", 100, 141], ["not likely", "UNCERTAINTY", 151, 161]]], ["If resources are limited and patients are expectant, frank conversations must be had to determine the patient's goals of care along the spectrum of illness.", [["illness", "DISEASE", 148, 155], ["patients", "ORGANISM", 29, 37], ["patient", "ORGANISM", 102, 109], ["patients", "SPECIES", 29, 37], ["patient", "SPECIES", 102, 109], ["illness", "PROBLEM", 148, 155]]], ["In spite of the limited availability of treatment resources for COVID-19, however, frontline responders should not divert resources away from already necessary life-saving health services, such as emergency obstetrics and vaccination.", [["treatment resources", "TREATMENT", 40, 59], ["COVID", "TEST", 64, 69], ["vaccination", "TREATMENT", 222, 233]]], ["Lastly, given the immense demand for health practitioners, the COVID-19 pandemic provides an opportunity to review national healthcare policies and integrate refugees into national health systems, allowing displaced healthcare workers to practice and fill human resource gaps.A call to actionIt is well known by now that COVID-19 is highly contagious and will spread quickly in humanitarian settings, particularly in confined and crowded camp settings.", [["human", "ORGANISM", 256, 261], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 256, 261], ["COVID", "TEST", 321, 326], ["humanitarian settings", "TREATMENT", 378, 399]]], ["In fact, this may be occurring already, but due to limited testing capacity for COVID-19 infection in such settings, there is no way to assess the current burden.", [["infection", "DISEASE", 89, 98], ["COVID-19", "ORGANISM", 80, 88], ["COVID-19", "SPECIES", 80, 88], ["limited testing capacity", "TEST", 51, 75], ["COVID", "TEST", 80, 85], ["19 infection", "PROBLEM", 86, 98], ["may be", "UNCERTAINTY", 14, 20], ["infection", "OBSERVATION", 89, 98]]], ["Without a strategy to identify cases of COVID-19, to mitigate the spread of infection, and to treat affected patients, the rapid transmission and ultimate death of thousands of people in humanitarian settings becomes an inevitable and unspoken truth of this pandemic [18] .", [["infection", "DISEASE", 76, 85], ["death", "DISEASE", 155, 160], ["patients", "ORGANISM", 109, 117], ["people", "ORGANISM", 177, 183], ["patients", "SPECIES", 109, 117], ["people", "SPECIES", 177, 183], ["COVID", "TEST", 40, 45], ["infection", "PROBLEM", 76, 85], ["infection", "OBSERVATION", 76, 85]]], ["If this was not enough motivation, the spread of infection, particularly in urban areas, is linked to cases among the most vulnerable.", [["infection", "DISEASE", 49, 58], ["infection", "PROBLEM", 49, 58], ["spread", "OBSERVATION_MODIFIER", 39, 45], ["infection", "OBSERVATION", 49, 58], ["most vulnerable", "OBSERVATION_MODIFIER", 118, 133]]], ["Our connectedness is undeniable, and inaction in addressing COVID-19 in humanitarian settings may threaten global health security moving forward.", [["COVID", "TEST", 60, 65], ["humanitarian settings", "TREATMENT", 72, 93]]], ["In order to achieve the response priorities highlighted, national governments, international agencies, and humanitarian organizations must promptly collaborate to develop context-specific strategies to promote risk communication, prioritize the use of existing testing kits and increase their overall availability, provide resources to treat affected patients, and engage displaced populations.", [["patients", "ORGANISM", 351, 359], ["patients", "SPECIES", 351, 359], ["existing testing kits", "TEST", 252, 273], ["displaced populations", "PROBLEM", 372, 393]]], ["While addressing COVID-19 in humanitarian settings may appear to be an acute challenge, stakeholders, especially national governments and international donors, can consider commitments to combatting COVID-19 as long-term investments in the success of a given country's health system and the livelihood of its inhabitants.", [["COVID-19", "DNA", 17, 25], ["COVID", "TEST", 17, 22], ["an acute challenge", "PROBLEM", 68, 86], ["long-term investments", "TREATMENT", 211, 232], ["acute", "OBSERVATION_MODIFIER", 71, 76]]]], "f22b3b066e324fb5292d68c230c84678d44dd6be": [["IntroductionAs of Mar 9, 2020, more than 100,000 COVID-19 cases and 3,800 deaths have been reported globally, including over 28,000 cases and 600 deaths in 100 countries or regions outside China.", [["deaths", "DISEASE", 74, 80], ["deaths", "DISEASE", 146, 152]]], ["China, which had initiated the largest community containment effort in history, has been successful at containing the outbreak, and since mid-February the daily number of new COVID-19 cases has been declining in China.", [["new COVID", "TEST", 171, 180], ["largest", "OBSERVATION_MODIFIER", 31, 38]]], ["2 In the Republic of Korea (ROK) with one of the highest number of infections outside China, the outbreak also appears to have stabilized after application of rigorous measures such as strict contact tracing and large-scale quarantine.IntroductionSingapore, a city-state and global travel hub in Southeast Asia, was one of the first countries to be affected by COVID-19, and for a while was the country with the highest COVID-19 numbers outside of China from Feb 5, 2020 to Feb 18, 2020.", [["infections", "DISEASE", 67, 77], ["rigorous measures", "TREATMENT", 159, 176], ["strict contact tracing", "TEST", 185, 207], ["large-scale quarantine", "TREATMENT", 212, 234], ["infections", "OBSERVATION", 67, 77]]], ["This was in part due to Singapore's strategy of using a comprehensive surveillance system to detect as many cases as possible, and to contain them at the individual level.", [["Singapore's strategy", "TREATMENT", 24, 44], ["a comprehensive surveillance system", "TEST", 54, 89]]], ["Despite early importations resulting in local chains of transmission, the rise in the number of cases has been steady without the exponential growth observed elsewhere.", [["the exponential growth", "PROBLEM", 126, 148], ["rise", "OBSERVATION_MODIFIER", 74, 78]]], ["This suggests that this strategy, coupled with community-based measures proportionate to the transmission risk, has been effective in containing spread, and could be considered in countries in the early stages of the outbreak where it is not possible to mount massive community-wide containment efforts.Singapore's approachSingapore was one of the worst affected areas in the 2003 SARS outbreak, and since then Singapore has steadily built up its outbreak preparedness, including developing a national pandemic preparedness plan based on risk assessment and calibration of response measures that are proportionate to the risk.", [["SARS", "DISEASE", 381, 385], ["Singapore's approachSingapore", "TREATMENT", 303, 332], ["risk assessment", "TEST", 538, 553], ["calibration of response measures", "TREATMENT", 558, 590], ["not possible", "UNCERTAINTY", 238, 250]]], ["This includes holding regular exercises, and building the National Centre for Infectious Diseases (NCID), a 330-bed purpose built infectious diseases management facility with integrated clinical, laboratory and epidemiologic functions.Singapore's approachOne of the lessons learnt from SARS is that clear leadership and direction is critical to ensure coordinated response across all sectors.", [["Infectious Diseases", "DISEASE", 78, 97], ["infectious diseases", "DISEASE", 130, 149], ["SARS", "DISEASE", 286, 290], ["SARS", "PROBLEM", 286, 290]]], ["Therefore, a Multi-Ministry Task Force was set up before Singapore had its first COVID-19 case to provide central coordination for a Whole-of-Government handling of the crisis.Surveillance and containment measuresSingapore's surveillance for COVID-19 aimed to identify as many cases as possible using complementary detection methods.", [["the crisis", "PROBLEM", 165, 175], ["Surveillance", "TEST", 176, 188], ["COVID", "TEST", 242, 247], ["complementary detection methods", "TREATMENT", 301, 332]]], ["First, a case definition to identify suspect cases, at healthcare facilities or through contact tracing, was established based on clinical and epidemiological criteria, and evolved over time as more information became available.", [["contact tracing", "TEST", 88, 103]]], ["To identify cases in the community that do not fulfill the case definition, an enhanced surveillance system was set up to detect COVID-19 among all cases of pneumonia in hospital and primary care, severely-ill patients in hospital intensive care units and deaths with possible infectious cause, and influenza-like illness (ILI) in sentinel primary care clinics.", [["pneumonia", "DISEASE", 157, 166], ["deaths", "DISEASE", 256, 262], ["influenza-like illness", "DISEASE", 299, 321], ["ILI", "DISEASE", 323, 326], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["an enhanced surveillance system", "TEST", 76, 107], ["COVID", "TEST", 129, 134], ["pneumonia", "PROBLEM", 157, 166], ["infectious cause", "PROBLEM", 277, 293], ["influenza", "PROBLEM", 299, 308], ["pneumonia", "OBSERVATION", 157, 166], ["possible", "UNCERTAINTY", 268, 276], ["infectious", "OBSERVATION_MODIFIER", 277, 287]]], ["Finally, doctors were also allowed to test patients whom they viewed with suspicion for clinical or epidemiological reasons.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51]]], ["To support the surveillance system, SARS-CoV-2 RT-PCR laboratory testing capacity was scaled up rapidly to all public hospitals in Singapore, and is able to handle 2,200 tests a day for a population of 5.7m.", [["SARS-CoV", "SPECIES", 36, 44], ["the surveillance system", "TEST", 11, 34], ["SARS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["PCR laboratory testing capacity", "TEST", 50, 81]]], ["Similarly, ROK has also quickly expanded testing capacities, including setting up drive-through testing stations, and has conducted over 200,000 tests to date.", [["ROK", "GENE_OR_GENE_PRODUCT", 11, 14], ["ROK", "PROTEIN", 11, 14], ["quickly expanded testing capacities", "PROBLEM", 24, 59]]], ["Contact tracing was also initiated to determine their movement history 14 days prior to symptom onset to isolation to determine possible sources of infection and also to prevent onward transmission among close contacts.", [["infection", "DISEASE", 148, 157], ["Contact tracing", "TEST", 0, 15], ["symptom", "PROBLEM", 88, 95], ["infection", "PROBLEM", 148, 157], ["infection", "OBSERVATION", 148, 157]]], ["Any contact with current or recent symptoms after exposure to the case was referred to hospitals for isolation and testing as part of active case finding.", [["recent symptoms", "PROBLEM", 28, 43], ["isolation and testing", "TEST", 101, 122]]], ["Close contacts who were well were placed under mandatory quarantine for 14 days from their last date of exposure, while other lower-risk contacts were put on phone surveillance.Surveillance and containment measuresAs of Mar 10, 2020, over 4000 close contacts had been placed under quarantine, and 8 cases developed symptoms while under quarantine and tested positive.", [["Surveillance", "TEST", 177, 189], ["symptoms", "PROBLEM", 315, 323], ["containment", "OBSERVATION_MODIFIER", 194, 205]]], ["To facilitate compliance and reduce hardship, the Quarantine Order Allowance Scheme provides economic assistance.", [["economic assistance", "TREATMENT", 93, 112]]], ["At the same time, the Infectious Diseases Act provides legal power to enforce contact tracing and quarantine, and to prosecute those who do not comply.Healthcare measuresA network of more than 800 Public Health Preparedness Clinics (PHPCs) was activated to enhance management of respiratory infections in the primary care setting, with subsidies extended to Singapore residents to incentivize them to seek care at these PHPCs.", [["respiratory", "ANATOMY", 279, 290], ["respiratory infections", "DISEASE", 279, 301], ["PHPCs", "CANCER", 420, 425], ["respiratory infections", "PROBLEM", 279, 301], ["Infectious", "OBSERVATION", 22, 32], ["respiratory", "ANATOMY", 279, 290], ["infections", "OBSERVATION", 291, 301]]], ["As early COVID-19 disease is mild and undifferentiated, medical practitioners were instructed to provide extended medical leave of up to five days for patients with respiratory symptoms.", [["respiratory", "ANATOMY", 165, 176], ["respiratory symptoms", "DISEASE", 165, 185], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 151, 159], ["early COVID-19 disease", "PROBLEM", 3, 25], ["respiratory symptoms", "PROBLEM", 165, 185], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["undifferentiated", "OBSERVATION_MODIFIER", 38, 54]]], ["This allowed possible COVID-19 cases to self-isolate at home to reduce the number of undetected cases seeding community transmission.", [["COVID", "TEST", 22, 27]]], ["Those with persistent or worsening symptoms are advised to return to the same doctor for evaluation and referral for testing.Healthcare measuresAt the hospitals, infection control measures were strengthened, including strict visitor controls, cohorting of patients with pneumonia or respiratory infection, and maintenance of strict infection control practices across all settings with personal protective equipment levels appropriate for the patient care setting.", [["respiratory", "ANATOMY", 283, 294], ["infection", "DISEASE", 162, 171], ["pneumonia", "DISEASE", 270, 279], ["respiratory infection", "DISEASE", 283, 304], ["infection", "DISEASE", 332, 341], ["patients", "ORGANISM", 256, 264], ["patient", "ORGANISM", 442, 449], ["patients", "SPECIES", 256, 264], ["patient", "SPECIES", 442, 449], ["persistent or worsening symptoms", "PROBLEM", 11, 43], ["evaluation", "TEST", 89, 99], ["testing", "TEST", 117, 124], ["Healthcare measures", "TREATMENT", 125, 144], ["infection control measures", "TREATMENT", 162, 188], ["pneumonia", "PROBLEM", 270, 279], ["respiratory infection", "PROBLEM", 283, 304], ["strict infection control practices", "TREATMENT", 325, 359], ["personal protective equipment levels", "TREATMENT", 385, 421], ["persistent", "OBSERVATION_MODIFIER", 11, 21], ["worsening", "OBSERVATION_MODIFIER", 25, 34], ["infection", "OBSERVATION", 162, 171], ["pneumonia", "OBSERVATION", 270, 279], ["respiratory", "ANATOMY", 283, 294], ["infection", "OBSERVATION", 295, 304], ["infection", "OBSERVATION", 332, 341]]], ["Movement of patients and doctors between healthcare institutions was also limited to prevent multiple institutions from being affected at the same time.Border control measuresApart from detecting cases and containing spread, prevention of imported cases is important to reduce the force of infection from external sources.", [["infection", "DISEASE", 290, 299], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["Border control measures", "TREATMENT", 152, 175], ["infection", "PROBLEM", 290, 299], ["spread", "OBSERVATION_MODIFIER", 217, 223], ["infection", "OBSERVATION", 290, 299]]], ["In Singapore, temperature and health screening of incoming travelers from Wuhan since Jan 3, 2020, and extended to all travellers since Jan 29, 2020, is in place at all ports of entry.", [["health screening", "TEST", 30, 46]]], ["Public education is a key strategy to empower the public, and is done through traditional print and broadcast media, as well as social media.", [["broadcast media", "TREATMENT", 100, 115]]], ["This includes messages on regular handwashing and seeking medical treatment early and staying at home when unwell.", [["medical treatment", "TREATMENT", 58, 75], ["unwell", "PROBLEM", 107, 113]]], ["The use of masks was only encouraged for ill persons to prevent them from infecting others, and the government distributed four masks to every household.", [["persons", "ORGANISM", 45, 52], ["persons", "SPECIES", 45, 52], ["masks", "TREATMENT", 11, 16]]], ["Detailed anonymised information on COVID-19 cases is shared publicly to prevent speculation, while misinformation is quickly debunked and clarified on a government website.Community and social measuresIn the workplace, employees are encouraged to monitor their temperature and health regularly, and institutions to step up their business continuity plans, including allowing employees to telecommute where possible and having segregated teams.", [["COVID", "TEST", 35, 40]]], ["Advisories to avoid large-scale events of more than 1,000 people are in place, while ongoing events are advised to take precautions such as health screening and turning away ill individuals.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["health screening", "TEST", 140, 156]]], ["Schools have remained open, and have implemented precautionary measures such as reduction of mass assemblies, inter-class and inter-school activities, and staggered meal times.", [["precautionary measures", "TREATMENT", 49, 71], ["mass assemblies", "PROBLEM", 93, 108], ["mass", "OBSERVATION", 93, 97]]], ["Mass fever screening through thermal temperature scanners is widely instituted at entry to public buildings, such as offices, hotels, community centres and places of worship.Community and social measuresAlthough these precautions are implemented, relative normalcy of day-to-day life has been maintained in Singapore.", [["fever", "DISEASE", 5, 10], ["Mass fever screening", "PROBLEM", 0, 20], ["thermal temperature scanners", "TREATMENT", 29, 57], ["these precautions", "TREATMENT", 212, 229]]], ["Notably, Singapore has not implemented school closures or other major social distancing measures, as there is no evidence of widespread community transmission, and rates of COVID-19 infection among children remain low.", [["infection", "DISEASE", 182, 191], ["COVID-19", "ORGANISM", 173, 181], ["children", "ORGANISM", 198, 206], ["children", "SPECIES", 198, 206], ["COVID-19", "SPECIES", 173, 181], ["COVID", "TEST", 173, 178], ["infection", "PROBLEM", 182, 191], ["no evidence of", "UNCERTAINTY", 110, 124], ["widespread", "OBSERVATION_MODIFIER", 125, 135]]], ["However, Singapore's experience suggests it is possible to avoid major social disruptions and contain the spread of COVID-19, as a sustainable approach over the long term.Success and ChallengesWith the combination of measures, Singapore has been able to interrupt transmission to contain the outbreak.", [["major social disruptions", "PROBLEM", 65, 89]]], ["The majority of cases were detected through application of the case definition at the point of medical consult or through contact tracing.", [["contact tracing", "TEST", 122, 137]]], ["5 Statistical modeling of the effective reproduction number has shown it to be consistently below 1, suggesting that containment efforts are successful (Pung et al, unpublished data).Success and ChallengesHowever, several challenges lie ahead.", [["effective", "OBSERVATION_MODIFIER", 30, 39], ["containment", "OBSERVATION_MODIFIER", 117, 128]]], ["Firstly, the longer the outbreak persists, the more chains of community transmission and missed cases are present, and the more difficult it will be to link cases and contain spread.", [["spread", "OBSERVATION_MODIFIER", 175, 181]]], ["Contact tracing and quarantine are resource-intensive activities and may not be sustainable in the long run.", [["Contact tracing", "TEST", 0, 15]]], ["Secondly, some individuals who continue to work or attend social functions while symptomatic are driving disease spread, leading to substantial community transmission.", [["driving disease spread", "PROBLEM", 97, 119], ["substantial", "OBSERVATION_MODIFIER", 132, 143], ["community", "OBSERVATION_MODIFIER", 144, 153]]], ["Thirdly, with global spread, the force of infection from imported cases will be substantial, leading to new waves of infection.Success and ChallengesAs Singapore is a travel hub with high reliance on trade, sustained border control measures may not be practical with global disease spread, and it may not be feasible to completely shut a country's borders for a prolonged duration.", [["infection", "DISEASE", 42, 51], ["infection", "DISEASE", 117, 126], ["global spread", "PROBLEM", 14, 27], ["infection", "PROBLEM", 42, 51], ["infection", "PROBLEM", 117, 126], ["sustained border control measures", "TREATMENT", 207, 240], ["global disease spread", "PROBLEM", 267, 288], ["global", "OBSERVATION_MODIFIER", 14, 20], ["spread", "OBSERVATION_MODIFIER", 21, 27], ["infection", "OBSERVATION", 42, 51], ["infection", "OBSERVATION", 117, 126], ["disease", "OBSERVATION", 274, 281]]], ["These factors may result in a rise in cases, and additional measures will be required to achieve a balance between containing disease spread and reducing the overall health and socioeconomic impact due to community transmission.ConclusionEarly detection of cases through surveillance and aggressive contact tracing around known cases has helped to contain spread of the outbreak in Singapore.", [["disease spread", "PROBLEM", 126, 140], ["surveillance", "TEST", 271, 283], ["aggressive contact tracing", "TEST", 288, 314], ["disease", "OBSERVATION", 126, 133]]], ["Countries could consider these measures for a proportionate response to the risk of COVID-19.Author contributions:All authors contributed equally to the literature review, data collection and writing of the manuscript.Declaration of interests:We declare no competing interests.Singapore Other Countries (selected) Surveillance and containment measures Case detectionCase definition was established based on clinical and epidemiological criteria, and continuously updated as the COVID-19 situation evolved.", [["COVID-19", "CHEMICAL", 84, 92], ["these measures", "TREATMENT", 25, 39], ["COVID", "TEST", 84, 89], ["data collection", "TEST", 172, 187], ["the COVID", "TEST", 474, 483]]], ["Surveillance was enhanced to test COVID-19 in all pneumonia patients, ICU patients and deaths from possible infectious cause, and influenza-like illness (ILI) in sentinel primary care sites.", [["pneumonia", "DISEASE", 50, 59], ["deaths", "DISEASE", 87, 93], ["influenza-like illness", "DISEASE", 130, 152], ["ILI", "DISEASE", 154, 157], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 74, 82], ["Surveillance", "TEST", 0, 12], ["test COVID", "TEST", 29, 39], ["infectious cause", "PROBLEM", 108, 124], ["influenza", "PROBLEM", 130, 139], ["pneumonia", "OBSERVATION", 50, 59], ["possible", "UNCERTAINTY", 99, 107], ["infectious", "OBSERVATION_MODIFIER", 108, 118]]], ["Doctors were also allowed to test patients whom they viewed with suspicion for clinical or epidemiological reasons.Singapore Other Countries (selected) Surveillance and containment measures Case detectionAffected countries instituted various case finding activities using WHO's case definition or a modified version.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["a modified version", "TREATMENT", 297, 315]]], ["6 Malaysia, Republic of Korea (ROK) and the United Kingdom incorporated COVID-19 testing for severe acute respiratory illness (SARI) and ILI surveillances.", [["respiratory", "ANATOMY", 106, 117], ["acute respiratory illness", "DISEASE", 100, 125], ["SARI", "DISEASE", 127, 131], ["COVID", "TEST", 72, 77], ["severe acute respiratory illness", "PROBLEM", 93, 125], ["ILI surveillances", "PROBLEM", 137, 154], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory", "ANATOMY", 106, 117], ["illness", "OBSERVATION", 118, 125]]], ["In Japan, Republic of Korea (ROK) and the United States (US), doctors were allowed to test patients at their discretion.Quarantine & phone surveillanceSymptomatic contacts were referred to hospital.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["Asymptomatic close contacts were placed under compulsory quarantine for 14 days, while lower-risk contacts were put on phone surveillance.Quarantine & phone surveillanceMandatory quarantine was required by law in several countries/regions, including Brunei, Hong Kong, Israel, mainland China and ROK.Laboratory testingPCR testing for COVID-19 is available at all public hospital laboratories to increase national diagnostic capacity, and other healthcare institutions can send samples for testing at these facilities.", [["Laboratory testingPCR testing", "TEST", 300, 329], ["COVID", "TEST", 334, 339], ["testing", "TEST", 489, 496]]], ["Serological tests were used to investigate linkages between cases and clusters.Laboratory testingIn Japan and the United States (US), COVID-19 testing was extended to non-public health laboratories.", [["Serological tests", "TEST", 0, 17], ["linkages between cases and clusters", "PROBLEM", 43, 78], ["COVID", "TEST", 134, 139]]], ["Serological testing using IgM and IgG antibodies was described in mainland China.Healthcare measures Clinical management in primary careMedical practitioners were instructed to provide extended medical leave of up to five days for patients with respiratory symptoms, and to refer them for further testing if they do not recover.", [["respiratory", "ANATOMY", 245, 256], ["respiratory symptoms", "DISEASE", 245, 265], ["IgM", "GENE_OR_GENE_PRODUCT", 26, 29], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 34, 48], ["patients", "ORGANISM", 231, 239], ["IgM", "PROTEIN", 26, 29], ["IgG antibodies", "PROTEIN", 34, 48], ["patients", "SPECIES", 231, 239], ["Serological testing", "TEST", 0, 19], ["IgM", "TEST", 26, 29], ["IgG antibodies", "TEST", 34, 48], ["Healthcare measures", "TREATMENT", 81, 100], ["respiratory symptoms", "PROBLEM", 245, 265], ["further testing", "TEST", 289, 304]]], ["Patients were advised to return to the same doctor if symptoms persist.Healthcare measures Clinical management in primary careIn UK, primary care practitioners were advised to avoid face-to-face assessment of suspected cases.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 54, 62], ["face assessment", "TEST", 190, 205]]], ["Instead, patients should be immediately isolated and referred to the local health authorities via a hotline.", [["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17]]], ["7 General practitioners in Australia were similarly advised to refer patients to dedicated health services, undertake remote telemedicine consultation or make safe arrangements to assess possible COVID-19 patients.Healthcare measures Clinical management in primary care8Infection prevention and controlInfection control measures were strengthened at healthcare institutions, including strict visitor controls, cohorting of patients with pneumonia or respiratory infection, and maintenance of strict infection control practices across all settings.", [["respiratory", "ANATOMY", 450, 461], ["pneumonia", "DISEASE", 437, 446], ["respiratory infection", "DISEASE", 450, 471], ["infection", "DISEASE", 499, 508], ["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 205, 213], ["patients", "ORGANISM", 423, 431], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 205, 213], ["patients", "SPECIES", 423, 431], ["Clinical management", "TREATMENT", 234, 253], ["Infection prevention", "TREATMENT", 270, 290], ["controlInfection control measures", "TREATMENT", 295, 328], ["pneumonia", "PROBLEM", 437, 446], ["respiratory infection", "PROBLEM", 450, 471], ["strict infection control practices", "TREATMENT", 492, 526], ["pneumonia", "OBSERVATION", 437, 446], ["respiratory", "ANATOMY", 450, 461], ["infection", "OBSERVATION", 462, 471], ["infection", "OBSERVATION", 499, 508]]], ["Inter-institution movement of patients and doctors was limited.Infection prevention and controlInfection control measures recommended by the US Centers for Disease Control to healthcare institutes included limiting points of entry to facilities, prioritizing triage of patients with respiratory symptoms, exploring alternatives to face-to-face triage, limiting visitor access and movement within facility, and managing exposed healthcare workers 9 .Healthcare servicesOver 800 Public Health Preparedness Clinics (PHPCs) were activated to enhance management of respiratory infections in the primary care setting, with subsidies extended to Singapore residents.Healthcare servicesAustralia and China set up \"fever clinics\" to assess large volume of people for COVID-19 while minimizing risk of transmission to other patients.Designated hospitalMajority of cases were isolated and treated at the National Centre for Infectious Diseases (NCID), a 330-bed purpose built infectious diseases management facility.Designated hospitalWhile most countries managed their cases in existing hospitals, China established at least 14 temporary medical facilities designated to treat COVID-19 patients.", [["respiratory", "ANATOMY", 283, 294], ["respiratory", "ANATOMY", 560, 571], ["respiratory symptoms", "DISEASE", 283, 303], ["respiratory infections", "DISEASE", 560, 582], ["fever", "DISEASE", 706, 711], ["Infectious Diseases", "DISEASE", 913, 932], ["NCID", "DISEASE", 934, 938], ["infectious diseases", "DISEASE", 965, 984], ["COVID", "DISEASE", 1167, 1172], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 269, 277], ["people", "ORGANISM", 747, 753], ["patients", "ORGANISM", 814, 822], ["patients", "ORGANISM", 1176, 1184], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 269, 277], ["people", "SPECIES", 747, 753], ["patients", "SPECIES", 814, 822], ["patients", "SPECIES", 1176, 1184], ["Infection prevention", "TREATMENT", 63, 83], ["controlInfection control measures", "TREATMENT", 88, 121], ["respiratory symptoms", "PROBLEM", 283, 303], ["respiratory infections", "PROBLEM", 560, 582], ["fever", "PROBLEM", 706, 711], ["COVID", "TEST", 758, 763], ["a 330-bed purpose built infectious diseases management", "TREATMENT", 941, 995], ["respiratory", "ANATOMY", 560, 571], ["infections", "OBSERVATION", 572, 582], ["infectious", "OBSERVATION", 965, 975]]], ["Two new hospitals with at least 1,000 beds each were also built in Wuhan city.Border control measures Temperature screeningTemperature and health screening for inbound travelers is being conducted at all land, air, and sea checkpoints.Border control measures Temperature screeningCountries including China are conducting temperature screening of incoming passengers at air, land and sea checkpoints.Travel advisories & border restrictionsSingaporeans are advised to defer nonessential travel to mainland China, ROK, Northern Italy and Iran, and entry restrictions are imposed on visitors from these regions.", [["Border control measures", "TEST", 78, 101], ["Temperature screening", "TEST", 102, 123], ["Temperature", "TEST", 123, 134], ["health screening", "TEST", 139, 155], ["inbound travelers", "TREATMENT", 160, 177], ["Border control measures", "TREATMENT", 235, 258], ["Temperature screening", "TEST", 259, 280], ["temperature screening", "TEST", 321, 342], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["Returning residents with travel history to these areas are subject to a 14-day quarantine.Travel advisories & border restrictionsAt least 45 countries or regions issued partial or complete travel bans on mainland China, Iran, Italy, ROK or other countries.Community and social measures SchoolsSchools have remained open, but implemented precautionary measures such as reduction of mass assemblies, inter-class and inter-school activities, and staggered meal times.Community and social measures SchoolsCountry/region-wide school closures were announced in Albania, Bulgaria, Iran, Iraq, Italy, Japan, mainland China, Hong Kong, Saudi Arabia, Spain and ROK.WorkplacesEmployees are encouraged to monitor their temperature and health regularly, and institutions are encouraged to step up their business continuity plans, such as telecommuting where possible and having segregated teams.WorkplacesHong Kong's Centre for Health Protection encouraged companies to develop comprehensive policies that include business continuity and operational plans to maintain core services 10 .", [["precautionary measures", "TREATMENT", 337, 359], ["mass assemblies", "PROBLEM", 381, 396], ["mass", "OBSERVATION", 381, 385]]], ["In US, employers were recommended to develop contingency plans for situations that may arise during outbreaks 11 .Public communicationsPublic education was done through traditional print and broadcast media, as well as social media.", [["broadcast media", "TREATMENT", 191, 206]]], ["In mainland China, several provinces mandated mask wearing in public spaces.Lockdown of affected areasNo areas have been locked down to date.Lockdown of affected areasMassive lockdowns were reported in mainland China, Palestine, Saudi Arabia, and Italy.", [["affected areas", "PROBLEM", 88, 102], ["affected areas", "PROBLEM", 153, 167], ["Massive lockdowns", "PROBLEM", 167, 184], ["mainland China", "ANATOMY", 3, 17], ["affected", "OBSERVATION_MODIFIER", 88, 96], ["affected", "OBSERVATION_MODIFIER", 153, 161], ["areas", "OBSERVATION_MODIFIER", 162, 167], ["Massive", "OBSERVATION_MODIFIER", 167, 174], ["lockdowns", "OBSERVATION", 175, 184]]], ["Smaller scale lockdowns were reported in ROK, Cyprus and Vietnam.", [["Smaller scale lockdowns", "PROBLEM", 0, 23]]]], "PMC7297191": [["IntroductionEbola virus disease, which was first discovered near Ebola River in Africa in 1976, is a serious disease with rare outbreaks.", [["IntroductionEbola virus disease", "DISEASE", 0, 31], ["Ebola River", "DISEASE", 65, 76], ["IntroductionEbola virus", "ORGANISM", 0, 23], ["Ebola River", "ORGANISM", 65, 76], ["IntroductionEbola virus", "SPECIES", 0, 23], ["IntroductionEbola virus disease", "PROBLEM", 0, 31], ["a serious disease", "PROBLEM", 99, 116], ["virus disease", "OBSERVATION", 18, 31], ["serious", "OBSERVATION_MODIFIER", 101, 108], ["disease", "OBSERVATION", 109, 116], ["rare", "OBSERVATION_MODIFIER", 122, 126], ["outbreaks", "OBSERVATION", 127, 136]]], ["The Ebola virus affects humans and animals like monkeys, gorillas, and chimpanzees.", [["Ebola virus", "DISEASE", 4, 15], ["Ebola virus", "ORGANISM", 4, 15], ["humans", "ORGANISM", 24, 30], ["monkeys", "ORGANISM", 48, 55], ["gorillas", "ORGANISM", 57, 65], ["chimpanzees", "ORGANISM", 71, 82], ["Ebola virus", "SPECIES", 4, 15], ["humans", "SPECIES", 24, 30], ["monkeys", "SPECIES", 48, 55], ["Ebola virus", "SPECIES", 4, 15], ["humans", "SPECIES", 24, 30], ["The Ebola virus", "PROBLEM", 0, 15], ["Ebola virus", "OBSERVATION", 4, 15]]], ["At the initial stage, this virus was affecting people and causing outbreaks in some African countries.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["this virus", "PROBLEM", 22, 32]]], ["The origin of the Ebola virus was not determine exactly.", [["Ebola", "DISEASE", 18, 23], ["Ebola virus", "ORGANISM", 18, 29], ["Ebola virus", "SPECIES", 18, 29], ["Ebola virus", "SPECIES", 18, 29], ["the Ebola virus", "PROBLEM", 14, 29], ["origin", "ANATOMY_MODIFIER", 4, 10], ["Ebola virus", "OBSERVATION", 18, 29]]], ["The bats or other animals are considered as origin for this type of virus.", [["bats", "ORGANISM", 4, 8], ["this type of virus", "PROBLEM", 55, 73], ["virus", "OBSERVATION", 68, 73]]], ["This virus infects the humans by direct contact with the blood in the starting [1,2].IntroductionNow many researchers are working in the area of fractional calculus.", [["blood", "ANATOMY", 57, 62], ["fractional calculus", "DISEASE", 145, 164], ["humans", "ORGANISM", 23, 29], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["humans", "SPECIES", 23, 29], ["humans", "SPECIES", 23, 29], ["fractional calculus", "PROBLEM", 145, 164], ["area", "OBSERVATION_MODIFIER", 137, 141], ["fractional", "OBSERVATION_MODIFIER", 145, 155], ["calculus", "OBSERVATION", 156, 164]]], ["Many analytical and numerical approach have been developed to solve problems in fractional calculus [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13].", [["[4]", "SIMPLE_CHEMICAL", 105, 108], ["[5], [6], [7], [8], [9], [10], [11], [12]", "SIMPLE_CHEMICAL", 110, 151], ["fractional calculus", "TEST", 80, 99], ["calculus", "OBSERVATION", 91, 99]]], ["Fractional calculus has many real life applications like in engineering, epidemiology, fluid mechanics, physics, chemistry, medical and health sciences.", [["Fractional calculus", "DISEASE", 0, 19], ["Fractional calculus", "PROBLEM", 0, 19], ["calculus", "OBSERVATION", 11, 19], ["fluid mechanics", "OBSERVATION", 87, 102]]], ["The mathematical model based on Ebola outbreak in Liberia was studied by Rachah et al. [14] and the results were simulated using existing data provided by the World Health Organization.", [["Ebola", "DISEASE", 32, 37], ["Ebola", "ORGANISM", 32, 37], ["Ebola", "OBSERVATION_MODIFIER", 32, 37]]], ["Area et al. [15] investigated fractional SEIR Ebola outbreak model.", [["Ebola", "DISEASE", 46, 51]]], ["In [16], authors used two models for optimal control of Ebola disease.", [["Ebola disease", "DISEASE", 56, 69], ["Ebola", "ORGANISM", 56, 61], ["Ebola disease", "PROBLEM", 56, 69], ["Ebola disease", "OBSERVATION", 56, 69]]], ["Atangana and Goufo [17], studied generalised version of Ebola virus model and also discussed the endemic equilibrium points.", [["Ebola virus", "DISEASE", 56, 67], ["Ebola virus", "ORGANISM", 56, 67], ["Ebola virus", "SPECIES", 56, 67], ["Ebola virus", "SPECIES", 56, 67], ["Ebola virus model", "TREATMENT", 56, 73], ["Ebola virus", "OBSERVATION", 56, 67]]], ["In [18], authors discussed this model using Atangana Baleanu fractional derivative and also discussed existence and uniqueness of the solutions.", [["Atangana Baleanu fractional derivative", "TREATMENT", 44, 82]]], ["Some other method on Ebola disease can be found in [19], [20], [21].", [["Ebola disease", "DISEASE", 21, 34], ["Ebola", "ORGANISM", 21, 26], ["[19], [20]", "SIMPLE_CHEMICAL", 51, 61], ["Ebola disease", "PROBLEM", 21, 34], ["Ebola", "OBSERVATION", 21, 26]]], ["Some recent developments in the area of numerical methods to solve this type of models can be found in [22,23].IntroductionIn this paper we will use an iterative scheme to solve fractional Ebola virus model as given in [18], [19], [20].", [["Ebola", "DISEASE", 189, 194], ["Ebola virus", "ORGANISM", 189, 200], ["Ebola virus", "SPECIES", 189, 200], ["numerical methods", "TREATMENT", 40, 57], ["an iterative scheme", "TREATMENT", 149, 168], ["fractional Ebola virus model", "TREATMENT", 178, 206]]], ["Proposed iterative scheme is based on the discretization of the domain.", [["Proposed iterative scheme", "TREATMENT", 0, 25]]], ["We are using Gr\u00fcnwald\u2013Letnikov (GL) fractional derivative for the fractional Ebola virus model.", [["Ebola virus", "ORGANISM", 77, 88], ["Ebola virus", "SPECIES", 77, 88], ["Ebola virus", "SPECIES", 77, 88], ["Gr\u00fcnwald\u2013Letnikov (GL) fractional derivative", "TREATMENT", 13, 57], ["the fractional Ebola virus model", "TREATMENT", 62, 94], ["Ebola virus", "OBSERVATION", 77, 88]]], ["Coefficients in the approximation of GL derivative is very easy in computation and provides long time behaviour of solution in the fraction of second.", [["GL derivative", "TREATMENT", 37, 50]]], ["The solution behaviour is shown in long time interval.", [["The solution behaviour", "TREATMENT", 0, 22]]], ["CPU time taken in iterative scheme for different values of iterations are listed.", [["CPU time", "TEST", 0, 8]]], ["Behaviour of approximate solutions for integer and fractional order derivatives are shown using figures.", [["approximate solutions", "TREATMENT", 13, 34], ["integer and fractional order derivatives", "TREATMENT", 39, 79]]]], "b782a1917e2c91df7913834ccb24f2affb8125a5": [["Door de frequente toepassing van echografie, CT en MRI wordt de clinicus regelmatig geconfronteerd met toevalsbevindingen, zogenaamde incidentalomen.", [["CT en MRI", "TEST", 45, 54]]]]}